<SEC-DOCUMENT>0001401914-23-000045.txt : 20230810
<SEC-HEADER>0001401914-23-000045.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810160156
ACCESSION NUMBER:		0001401914-23-000045
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		231159151

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dare-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba,d:1a96c573cb0642a4ab930e77d995671e--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dare="http://darebioscience.com/20230630" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dare-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-25">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-28">0001401914</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-94">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-95">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-96">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-97">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-446">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dare-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dare:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:HennepinLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:HennepinLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:LicensedProductOrProcessForVaginalOrUrologicalUseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:MergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:March2023AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:March2023AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:October2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:October2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dare:TwoThousandTwentyTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CRADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELBT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELBT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:JulyAndAugust2023AtTheMarketSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:NICHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-28</xbrli:startDate><xbrli:endDate>2023-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-18</xbrli:startDate><xbrli:endDate>2023-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-04</xbrli:startDate><xbrli:endDate>2023-07-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1a96c573cb0642a4ab930e77d995671e_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2023</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center;text-indent:47.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36395</ix:nonNumeric></span></div><div style="text-align:center"><img src="dare-20230630_g1.jpg" alt="darebioinlinefullcolorrgba05.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:236px"/></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">DAR&#201; BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">20-4139823</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3655 Nobel Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 260</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">926-7655</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-15">92122</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">DARE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;9, 2023, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">87,785,166</ix:nonFraction> shares of the Registrant&#8217;s Common Stock, par value $0.0001, were issued and outstanding.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of Part I. Financial Information, and the information incorporated by reference herein contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, projected revenue, funding and expenses, prospects, plans and objectives of management, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; "pursue," &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; "project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors described in Part II, Item 1A, "Risk Factors", in this report, and elsewhere in this report. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to raise additional capital, under favorable terms or at all, and continue as a going concern;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to complete development of our product candidates or submit and obtain United States Food and Drug Administration, or FDA, or foreign regulatory authority approval for our product candidates on projected timelines or budgets, or at all; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to demonstrate sufficient safety and efficacy of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The timely supply of XACIATO&#8482; and our clinical trial supplies, including their components as well as the finished product, in the quantities needed in accordance with current good manufacturing practices, our specifications and other applicable requirements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of third parties on which we rely to conduct nonclinical studies and clinical trials of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure, or a failure of a strategic collaborator, to successfully commercialize our product candidates, if approved, or our failure to otherwise monetize our portfolio programs and assets;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The timing and amount of future royalty and milestone payments to us, if any, under our out-license agreements for commercialization of XACIATO and Ovaprene&#174;;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Termination by a collaborator of our respective out-license agreements for commercialization of XACIATO and Ovaprene, or, in the case of Ovaprene, a decision by the collaborator not to make the license grant fully effective following its review of the results of a pivotal clinical trial of Ovaprene; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of third parties on which we rely to commercialize, or assist us in commercializing, XACIATO and any future product;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties with maintaining existing collaborations relating to the development and/or commercialization of our product candidates, or establishing new ones on a timely basis or on acceptable terms, or at all;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The terms and conditions of any future strategic collaborations relating to our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The degree of market acceptance that XACIATO and any future product achieves;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement levels for XACIATO and any future product by government health care programs, private health insurance companies and other third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our loss of, or inability to attract, key personnel;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in the FDA's prior determination that the Center for Devices and Radiological Health would lead the review of a premarket approval application for potential marketing approval of Ovaprene; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable differences between preliminary, interim or topline clinical study data reported by us and final study results;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Communication from the FDA or another regulatory authority, including a complete response letter, that such agency does not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of clinical or nonclinical study data regarding a product candidate, or that such agency interprets or weighs the importance of study data differently than we have in a manner that negatively impacts the candidate's prospects for regulatory approval in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to select product candidates that capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas within women's health including due to our limited financial resources;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or impairment of our in-licensed rights to develop and commercialize XACIATO and our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our payment and other obligations under our in-license and acquisition agreements for XACIATO and our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Developments by our competitors that make XACIATO, or any potential product we develop, less competitive or obsolete;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Macroeconomic factors, including inflation, interest rates and recessionary pressures, geopolitical conflicts and events, public health emergencies such as the COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat or natural disasters;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Weak interest in women's health relative to other healthcare sectors from the investment community or from pharmaceutical companies and other potential development and commercialization collaborators;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyber-attacks, security breaches or similar events compromising our technology systems and data, our financial resources and other assets, or the technology systems and data of third parties on which we rely; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty in introducing branded products in a market made up of generic products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lack of patent protection for the active ingredients in XACIATO and certain of our product candidates that expose them to competition from other formulations using the same active ingredients; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence on grant funding for pre-clinical development of DARE-LARC1;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes or other developments concerning our intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Actual and anticipated fluctuations in our quarterly or annual operating results or results that differ from investors' expectations for such results;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Price and volume fluctuations in the stock market, and in our stock in particular, which could cause investors to experience losses and subject us to securities class-action litigation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to maintain the listing of our common stock on the Nasdaq Capital Market or another nationally recognized exchange;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Development of safety, efficacy or quality concerns related to our product or product candidates (or third-party products or product candidates that share similar characteristics or drug substances), whether or not scientifically justified, leading to delays in or discontinuation of product development, product recalls or withdrawals, diminished sales, and/or other significant negative consequences;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability claims or governmental investigations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in government laws and regulations in the United States and other jurisdictions, including laws and regulations governing the research, development, approval, clearance, manufacturing, supply, distribution, pricing and/or marketing of our products, product candidates and related intellectual property, health care information and data privacy and security laws, transparency laws and fraud and abuse laws, and the enforcement thereof affecting our business; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_16">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_64">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_64">21</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_88">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_91">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_94">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_97">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_100">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_103">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_106">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_109">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_112">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_115">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_115">41</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_118">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a96c573cb0642a4ab930e77d995671e_118">42</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_16"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i1a96c573cb0642a4ab930e77d995671e_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-30">13,329,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-31">34,669,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-32">572,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-33">1,703,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-34">8,069,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-35">6,665,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-36">272,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:fixed-zero" scale="0" id="f-37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-38">22,243,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-39">43,038,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-40">45,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-41">64,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-42">920,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-43">722,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-44">23,209,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-45">43,826,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-46">6,541,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-47">2,027,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-48">4,193,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-49">10,894,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-50">13,694,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">18,303,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-52">271,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-53">398,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">24,700,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">31,623,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">1,205,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">23,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">90,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-60">25,929,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-61">32,714,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-62"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-63"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-64"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-65">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-66"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-67">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-71">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-77">240,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-79">86,633,588</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-81">84,825,481</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-82">8,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-83">8,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-84">404,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-85">351,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-86">155,555,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-87">152,529,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-88">157,879,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-89">141,074,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-90">2,719,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-91">11,112,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-92">23,209,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-93">43,826,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-94"><span style="-sec-ix-hidden:f-95"><span style="-sec-ix-hidden:f-96"><span style="-sec-ix-hidden:f-97">License fee revenue</span></span></span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-99">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-101">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="f-103">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="f-105">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-106">2,920,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-107">2,792,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-108">6,258,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-109">5,362,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-110">6,043,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-111">6,797,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-112">11,063,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-113">12,603,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="dare:LicenseFeeExpense" format="ixt:num-dot-decimal" scale="0" id="f-114">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="dare:LicenseFeeExpense" format="ixt:num-dot-decimal" scale="0" id="f-115">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="dare:LicenseFeeExpense" format="ixt:num-dot-decimal" scale="0" id="f-116">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="dare:LicenseFeeExpense" format="ixt:num-dot-decimal" scale="0" id="f-117">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-118">8,989,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-119">9,615,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-120">17,372,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-121">18,016,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-122">8,989,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-123">384,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-124">17,372,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-125">8,016,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-126">227,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-127">29,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-128">567,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-129">31,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-130">8,762,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-131">413,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-132">16,804,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-133">7,984,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-134">31,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-135">135,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-136">53,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-137">145,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-138">8,793,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-139">278,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-140">16,857,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-141">8,129,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" scale="0" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-144">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-145">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-146">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" scale="0" id="f-147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-150">86,403,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151">84,682,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-152">86,976,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-153">84,682,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-154">86,403,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">85,369,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156">86,976,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">84,682,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.889%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity (deficit)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-158">84,825,481</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-159">8,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-160">152,529,579</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-161">351,311</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-162">141,074,640</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-163">11,112,110</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-164">624,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-165">624,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-166">1,353,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="f-167">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-168">1,299,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-169">1,299,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-170">8,042,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-171">8,042,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-172">22,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-173">22,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-174">86,178,996</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-175">8,618</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-176">154,453,439</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-177">373,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-178">149,117,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-179">4,971,600</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-180">650,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-181">650,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-182">454,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="f-183">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-184">452,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-185">452,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-186">8,762,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-187">8,762,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-188">31,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-189">31,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-190">86,633,588</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-191">8,663</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-192">155,555,775</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-193">404,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-194">157,879,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-195">2,719,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-196">83,944,119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-197">8,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-198">149,027,802</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-199">154,973</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-200">110,126,902</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-201">38,754,321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-202">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-203">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-204">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-205">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-206">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-207">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-208">83,944,119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-209">8,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-210">149,560,211</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-211">164,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-212">118,525,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-213">30,878,910</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-214">537,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-215">537,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-216">751,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="f-217">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-218">1,218,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-219">1,218,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-220">125,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="f-221">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-222">120,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-223">120,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-224">413,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-225">413,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-226">135,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-227">135,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-228">84,820,858</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-229">8,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-230">151,436,543</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-231">299,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-232">118,111,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-233">33,033,459</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-234">16,804,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-235">7,984,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-236">19,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-237">10,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-238">1,274,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-239">1,069,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="dare:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-240">11,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="dare:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-241">9,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="0" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-243">10,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="f-244">1,130,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="f-245">992,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="f-246">1,403,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="f-247">3,427,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-248">272,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:fixed-zero" scale="0" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-250">44,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-251">91,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-252">4,513,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-253">988,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-254">6,700,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-255">3,211,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="dare:IncreaseDecreaseInDeferredGrantFunding" format="ixt:num-dot-decimal" scale="0" id="f-256">4,609,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="dare:IncreaseDecreaseInDeferredGrantFunding" format="ixt:num-dot-decimal" scale="0" id="f-257">1,791,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="f-258">205,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-260">22,703,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-261">20,791,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-263">5,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-265">5,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-266">452,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-267">1,218,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-268">1,299,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-269">120,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-270">1,751,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-271">1,338,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-272">53,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-273">145,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-274">21,005,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-275">19,603,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-276">34,669,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-277">51,674,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-278">13,664,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-279">32,070,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the condensed consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-280">13,329,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-281">32,070,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-282">335,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:fixed-zero" scale="0" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-284">13,664,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-285">32,070,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use assets obtained in exchange for new operating lease liabilities, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-287">1,043,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i1a96c573cb0642a4ab930e77d995671e_34"></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-288" continuedAt="f-288-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-288-1"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-289">one</ix:nonFraction> segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, vaginal health, reproductive health, menopause, sexual health, and fertility, and aim to expand treatment options, enhance outcomes and improve ease of use for women.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio includes one FDA-approved product, drug and drug/device product candidates and potential product candidates in various stages of development.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's product, XACIATO&#8482; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. That agreement became effective in June 2022, and in July 2022, the Company received the $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-290">10.0</ix:nonFraction>&#160;million non-refundable and non-creditable payment due upon the effectiveness of the agreement.</span></div></ix:continuation><div id="i1a96c573cb0642a4ab930e77d995671e_37"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-291" continuedAt="f-291-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-291-1" continuedAt="f-291-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-292" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, or the 2022 10-K.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-293" continuedAt="f-293-1" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-293-1">The Company considers cash and all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-294">0.3</ix:nonFraction> million in restricted cash related to (i) letters of credit established under real property leases for the Company's wholly owned subsidiary, Dare MB Inc., that serve as security for potential future default of lease payments, and (ii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or for usage for general obligations and are included in other non-current assets on the Company's consolidated balance sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-2" continuedAt="f-291-3"><ix:nonNumeric contextRef="c-1" name="dare:GoingConcernPolicyTextBlock" id="f-295" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-296">157.9</ix:nonFraction> million, cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-297">13.3</ix:nonFraction> million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="f-298">13.7</ix:nonFraction> million, and a working capital deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="dare:WorkingCapitalIncreaseDeficit" format="ixt:num-dot-decimal" scale="6" id="f-299">2.5</ix:nonFraction> million. Substantially all of the Company's cash and cash equivalents at June&#160;30, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the six months ended June&#160;30, 2023, the Company incurred a net loss of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-300">16.8</ix:nonFraction> million and had negative cash flow from operations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-301">22.7</ix:nonFraction> million. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next <ix:nonNumeric contextRef="c-1" name="dare:PeriodofInsufficientCashandLiquidityRequirements" format="ixt-sec:durmonth" id="f-302">12</ix:nonNumeric> months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2 to the consolidated financial statements included in the 2022 10-K. Since the date on which the 2022 10-K was filed with the U.S. Securities and Exchange Commission, or the SEC, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-303" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-3" continuedAt="f-291-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-304" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of June&#160;30, 2023 and December&#160;31, 2022. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of June&#160;30, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"></td><td style="width:216.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-305">10,837,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-308">10,837,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-309">33,238,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-312">33,238,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-313" continuedAt="f-313-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification Topic 606, or ASC 606, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products. As of June&#160;30, 2023, the Company has not recognized any collaboration revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-314">10.0</ix:nonFraction> million in license fee revenue, all of which represents the upfront payment due under its license agreement for XACIATO. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-291-4"><ix:continuation id="f-313-1"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of June&#160;30, 2023, the Company has not recognized any royalty revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. As of June&#160;30, 2023, the Company has not recognized any revenue associated with product supply arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. As of June&#160;30, 2023, the Company has not recognized any milestone revenue.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer License. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-315">1.0</ix:nonFraction> million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-316">20.0</ix:nonFraction> million. The Company concluded that there was one significant performance obligation related to the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-317">1.0</ix:nonFraction>&#160;million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-318">20.0</ix:nonFraction> million fee. The $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-319">1.0</ix:nonFraction> million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-320">20.0</ix:nonFraction> million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-321">1.0</ix:nonFraction> million payment is recorded as deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also be entitled to receive (a) milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-322">310.0</ix:nonFraction> million related to the commercial sales of Ovaprene, if all such milestones are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, Strategic Agreements.)</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-323" continuedAt="f-323-1" escape="true">STRATEGIC AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-323-1" continuedAt="f-323-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Agreements for Product Commercialization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organon Exclusive License Agreement</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an exclusive license agreement with Organon, which became effective in June 2022, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. In July 2022, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-324">10.0</ix:nonFraction> million non-refundable and non-creditable payment from Organon, which was recorded as license fee revenue. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement in effect as of June 30, 2023, the Company is entitled to receive tiered double-digit royalties based on net sales and up to $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-325">182.5</ix:nonFraction> million in milestone payments as follows: $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount" format="ixt:num-dot-decimal" scale="6" id="f-326">2.5</ix:nonFraction> million following the first commercial sale of a licensed product in the United States; and up to $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="f-327">180.0</ix:nonFraction> million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. Subsequent to June 30, 2023, the Company and Organon entered into an amendment to the license agreement, which changed some of the payment terms. (See Note 10, Subsequent Events.)</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the agreement, the Company concluded that the transaction price was $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-328">10.0</ix:nonFraction> million and should not include the variable consideration related to unachieved development, regulatory, commercial milestones and future sales-based royalty payments. This consideration was determined to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal in cumulative revenue. The Company re-evaluates the transaction price at each reporting period as uncertain events are resolved and other changes in circumstances occur. For the quarter ended June&#160;30, 2023, no adjustments were made to the transaction price. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize any consideration related to sales-based payments, including milestones and royalties which relate predominantly to the license granted, at the later of (i) when or as the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-323-2" continuedAt="f-323-3"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer HealthCare License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-329">1.0</ix:nonFraction> million upfront non-refundable license fee payment from Bayer and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-330">20.0</ix:nonFraction> million, referred to as the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-331">20.0</ix:nonFraction> million fee. After payment of the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-332">20.0</ix:nonFraction> million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S. Such license would be exclusive as to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there was one significant performance obligation related to the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-333">1.0</ix:nonFraction> million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-334">20.0</ix:nonFraction> million fee. The $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-335">1.0</ix:nonFraction> million upfront payment will be recorded as license revenue at the earlier of either the point in time the Company receives the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-336">20.0</ix:nonFraction> million fee, the license is transferred to Bayer and Bayer is able to use and benefit from the license or the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="f-337">1.0</ix:nonFraction> million payment is recorded as long-term deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023  and December&#160;31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-338">310.0</ix:nonFraction> million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S. or 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-339">20.0</ix:nonFraction> million fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Strategic Agreements for Pipeline Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hennepin License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a license agreement with Hennepin Life Sciences LLC, or Hennepin, under which the Company acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of health conditions including bacterial, fungal, and viral infections. Under the agreement, the Company received an exclusive, worldwide, royalty-bearing license to research, develop and commercialize the licensed technology. The Company is entitled to sublicense the rights granted to it under the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company agreed to make potential future payments and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-4" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-340">6.25</ix:nonFraction> million in the aggregate upon achieving certain development and regulatory milestones, and of up to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-341">45.0</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones for each product covered by the licenses granted under the agreement, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Hennepin is eligible to receive tiered royalties in low single-digit to low double-digit percentages based on worldwide net sales of products and processes covered by the licenses granted under the agreement.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, no payments have been made under this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Dare MB Inc., or MBI, to secure the rights to develop a long-acting reversible contraception method, that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-323-3" continuedAt="f-323-4"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the merger agreement, the Company agreed to pay former MBI stockholders: (a) up to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-342">46.5</ix:nonFraction> million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="dare:AssetAcquisitionContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="f-343">55.0</ix:nonFraction> million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property the Company acquired in the merger; and (c) tiered royalty payments ranging from low single-digit to low double-digit percentages based on annual net sales of such products sold by the Company (but not by sublicensee) and a percentage of sublicense revenue related to such products. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, a total of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-4" name="dare:PaymentOfAdditionalConsiderationInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-344">1.25</ix:nonFraction> million of the contingent consideration became payable upon the achievement of certain of the funding and product development milestone events. In accordance with the terms of the merger agreement, the Company&#8217;s board of directors elected to pay a portion of these milestone payments in shares of the Company&#8217;s common stock, and in September 2021, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-345">700,000</ix:nonFraction> shares of its common stock to former stockholders of MBI and paid $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="dare:PaymentsToStockholdersRepresentativeInBusinessCombination" format="ixt:num-dot-decimal" scale="0" id="f-346">75,000</ix:nonFraction> in cash to the stockholders&#8217; representative in satisfaction of the $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-4" name="dare:PaymentOfAdditionalConsiderationInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-347">1.25</ix:nonFraction> million in milestone payments associated with milestones achieved in June 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TriLogic and MilanaPharm License Agreement / Hammock Assignment Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into an assignment agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and a first amendment to license agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. In December 2019, the Company entered into amendments to each of the Assignment Agreement and License Amendment. In September 2021, the Company entered into a second amendment to the License Agreement. In March 2022, the Company entered into a Consent, Waiver and Stand-By License Agreement with TriLogic, MilanaPharm and Organon, which further amended the License Agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License Agreement, the Company paid clinical and regulatory development milestones in the aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="f-348">300,000</ix:nonFraction> to MilanaPharm, the final payment of $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="dare:AssetAcquisitionContingentConsideration" format="ixt:num-dot-decimal" scale="0" id="f-349">250,000</ix:nonFraction> was expensed in 2021. The Company may also pay MilanaPharm up to $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="dare:AssetAcquisitionContingentConsideration" format="ixt:num-dot-decimal" scale="0" id="f-350">500,000</ix:nonFraction> upon the first commercial sale in the United States of the first licensed product for each vaginal and urological use, and up to $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="f-351">250,000</ix:nonFraction> upon the first commercial sale in the United States of each successive licensed products for each vaginal or urological use. In addition, upon achievement of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-352">50.0</ix:nonFraction> million in cumulative worldwide net sales of licensed products the Company must pay MilanaPharm $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-353">1.0</ix:nonFraction> million. MilanaPharm is also eligible to receive (a) a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions, and (b) high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm license agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan. Hammock is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-354">1.1</ix:nonFraction> million in the aggregate upon achievement of certain clinical and regulatory development milestones, $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="f-355">850,000</ix:nonFraction> of which has been paid as of June&#160;30, 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company acquired Pear Tree Pharmaceuticals, Inc., or Pear Tree, to secure exclusive, sublicensable, worldwide rights under certain patents and know-how to develop and commercialize a proprietary formulation of tamoxifen for vaginal administration. This acquisition led to the Company's DARE-VVA1 program. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-323-4" continuedAt="f-323-5"><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the merger agreement, the Company agreed to pay the former stockholders of Pear Tree: (a) up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-356">15.5</ix:nonFraction> million in the aggregate upon achieving certain clinical development and regulatory milestones by licensed products, and (b) up to $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-357">47.0</ix:nonFraction> million in the aggregate upon achieving certain commercial milestones by licensed products. Additionally, the former stockholders of Pear Tree are eligible to receive tiered royalties based on single-digit to low double-digit percentages of annual net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, and a portion of royalties the Company receives from sublicensees. Both the milestone and royalty payments may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the merger agreement. Under the merger agreement, in addition to customary royalty reductions and offsets, royalty payments and payments based on income received from sublicensees of licensed products made by the Company to Pear Tree's licensors are creditable against all royalty and sublicense revenue share payments payable to the former stockholders of Pear Tree.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay licensors of Pear Tree (a) up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-358">3.2</ix:nonFraction> million in the aggregate upon achieving certain clinical development, regulatory and commercial milestones by each licensed product, and (b) semi-annual royalties based on a single-digit percentage of net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, or a portion of any royalties the Company or its affiliates receives from sublicensees, and a low double-digit percentage of all sublicensing fees or other lump sum payments or compensation the Company receives from sublicensees, subject to customary exclusions. The milestone payments to the licensors of Pear Tree may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the license agreements. Portions of certain milestone payments made to Pear Tree's licensors may be creditable against royalty payments due to Pear Tree's licensors. </span></div><div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc., or Catalent, under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="0" id="f-359">250,000</ix:nonFraction> non-creditable upfront license fee to Catalent in connection with the execution of the agreement and will pay a $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" format="ixt:num-dot-decimal" scale="0" id="f-360">100,000</ix:nonFraction> annual license maintenance fee on each anniversary of the date of the agreement. The annual maintenance fee will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. Catalent is eligible to receive up to (a) $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-361">13.5</ix:nonFraction> million in the aggregate in payments based on the achievement of specified development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-362">1.0</ix:nonFraction>&#160;million of which has been paid as of June&#160;30, 2023; and (b) up to $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-363">30.3</ix:nonFraction> million in the aggregate in payments based on the achievement of specified commercial sales milestones for each product or process covered by the licenses granted under the agreement. Additionally, Catalent is eligible to receive mid single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals USA, Inc., or Adare, for the development and potential exclusive worldwide license of injectable formulations of etonogestrel for contraceptive protection over 6-month and 12-month periods (which the Company refers to as DARE-204 and DARE-214, respectively). The agreement, as amended, provides the Company with an option to negotiate an exclusive, worldwide, royalty-bearing license, with rights to sublicense, for the programs if the Company funds the conduct of specified development work. The Company has no obligation to exercise its option. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-323-5"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SST License and Collaboration Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder and/or female sexual interest/arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SST will be eligible to receive payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-364">18.0</ix:nonFraction> million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and up to $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-365">100.0</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST. Additionally, SST is eligible to receive tiered royalties based on percentages of annual net sales of licensed products in the single-digit to mid double-digits subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company will pay ADVA-Tec (a) up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-366">14.6</ix:nonFraction> million in the aggregate based on the achievement of specified development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="f-367">1.2</ix:nonFraction>&#160;million of which has been paid; and (b) up to $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-368">20.0</ix:nonFraction> million in the aggregate based on the achievement of certain worldwide net sales milestones. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, ADVA-Tec is eligible to receive royalties based on aggregate annual net sales of Ovaprene in specified regions at a royalty rate that will vary between <ix:nonFraction unitRef="number" contextRef="c-92" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="f-369">1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-93" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="f-370">10</ix:nonFraction>% and will increase based on various net sales thresholds, subject to customary reductions and offsets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company sublicenses its rights under the agreement, in lieu of royalty payments to ADVA-Tec, ADVA-Tec is eligible to receive a double-digit percentage of sublicense revenue received by the Company during the royalty term; provided, however, that for sublicense revenue the Company receives prior to the first commercial sale of a licensed product that represents an upfront payment or license fee due on or around the effective date of the sublicense, ADVA-Tec is eligible to receive a single-digit percentage of that sublicense revenue.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-371" continuedAt="f-371-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-371-1" continuedAt="f-371-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Increase in Authorized Shares of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, following the approval of the Company's stockholders at its annual meeting of stockholders, the Company amended its restated certificate of incorporation to increase the Company's authorized shares of common stock to <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-372">240,000,000</ix:nonFraction>. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2023 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a sales agreement with Stifel, Nicolaus &amp; Company, Incorporated, or Stifel, and Cantor Fitzgerald &amp; Co., or Cantor, to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which Stifel and Cantor act as the Company's agent. The Company agreed to pay a commission equal to <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="dare:PercentageOfAggregateCommission" scale="-2" id="f-373">3</ix:nonFraction>% of the gross proceeds of any common stock sold under the agreement or such lower amount as the Company and Stifel and Cantor agree, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862), the base prospectus included therein, originally filed with the SEC on March 30, 2021 and declared effective by the SEC on April 7, 2021, the prospectus supplement dated March 31, 2023 relating to the offering of up to $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="dare:SaleOfStockProspectusOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-374">50.0</ix:nonFraction>&#160;million of shares of the Company's common stock under the sales agreement, and any subsequent prospectus supplement related to the offering of shares of the Company's common stock under the sales agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-375">454,592</ix:nonFraction> shares of common stock under this agreement and received aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-376">463,000</ix:nonFraction> and incurred sales agent commissions and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="dare:SaleOfStockBrokerageCommissionsExpense" format="ixt:num-dot-decimal" scale="0" id="f-377">11,000</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2021 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a sales agreement with SVB Securities LLC (formerly known as SVB Leerink LLC) to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-378"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-379">no</ix:nonFraction></ix:nonFraction> shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2021 ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a sales agreement with SVB Securities LLC to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-380"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-381">no</ix:nonFraction></ix:nonFraction> shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwritten public offering in February 2018, the Company issued to the investors in that offering, warrants exercisable through February 2023 with an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-382">3.00</ix:nonFraction> per share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="dare:EstimatedFairValueOfWarrantsRecordedInEquity" format="ixt:num-dot-decimal" scale="6" id="f-383">3.0</ix:nonFraction> million which was recorded in equity as of the grant date. The warrants included a price-based anti-dilution provision, which provided that, subject to certain limited exceptions, the exercise price of the warrants would be reduced each time the Company issued or sold (or was deemed to have issued or sold) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issued, sold or entered into any agreement to issue or sell securities at a price which varied or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders had the right to substitute such variable price for the exercise price of the warrant then in effect. In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="2" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="f-384">0.98</ix:nonFraction> per share and to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="f-385">0.96</ix:nonFraction> per share, respectively. During the six months ended June&#160;30, 2023, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="dare:NumberOfCommonStockWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-386">1,353,515</ix:nonFraction> shares of common stock were exercised for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="f-387">1.3</ix:nonFraction> million and the remaining unexercised warrants expired on February 15, 2023. <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dare:NumberOfCommonStockWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-388">No</ix:nonFraction> warrants were exercised during the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-389" continuedAt="f-389-1" escape="true">As of June&#160;30, 2023, the Company had the following warrants outstanding:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="f-371-2"><ix:continuation id="f-389-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-390">6,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-391">10.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-107" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" format="ixt:date-month-day-year" id="f-392">04/04/2026</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-393">6,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div id="i1a96c573cb0642a4ab930e77d995671e_46"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-394" continuedAt="f-394-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-394-1" continuedAt="f-394-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-395"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-396">no</ix:nonFraction></ix:nonFraction> stock-based compensation related to the ESPP for the six months ended June&#160;30, 2023 or June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, provided for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-397">2,046,885</ix:nonFraction> shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increased annually on the first day of each fiscal year by the least of (i) <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-398">2,000,000</ix:nonFraction>, (ii) <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-399">4</ix:nonFraction>% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2022, the number of authorized shares increased by <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-400">2,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-401">2,201,855</ix:nonFraction>. As a result of the approval of the 2022 Plan (as defined below) by the Company's stockholders on June 23, 2022, no further awards have been or will be granted under the Amended 2014 Plan. Outstanding awards previously granted under the Amended 2014 Plan continue to remain outstanding in accordance with their terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company's board of directors approved the Dar&#233; Bioscience, Inc. 2022 Stock Incentive Plan, or the 2022 Plan, which was subsequently approved by the Company's stockholders on June 23, 2022, and became effective as of that date. The 2022 Plan provides for the grant of stock-based incentive awards to employees, consultants, advisors, and directors. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock authorized for issuance under the 2022 Plan is (a) <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-402">10,117,305</ix:nonFraction>; plus (b) up to <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-403">6,144,682</ix:nonFraction> shares subject to awards granted under the Amended 2014 Plan or the 2007 Stock Incentive Plan that expire, terminate or are otherwise forfeited on or after June 23, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-394-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-404" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Company's stock incentive plans and related information for the six months ended June&#160;30, 2023. The exercise price of all options granted during the six months ended June&#160;30, 2023 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of June&#160;30, 2023, unamortized stock-based compensation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-405">5.6</ix:nonFraction>&#160;million will be amortized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="dare:WeightedAverageAmortizationPeriod" format="ixt-sec:duryear" id="f-406">2.47</ix:nonNumeric> years. The number of shares of common stock available for future awards granted under the 2022 Plan at June&#160;30, 2023 was <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-407">6,718,916</ix:nonFraction>. </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:376.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-408">6,612,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-409">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-410">2,857,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-411">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-413"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-415"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-417"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-418">9,470,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-419">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-420">4,769,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-421">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:13pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-422" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-423">210,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-424">171,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-425">410,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-426">346,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-427">439,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-428">365,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-429">864,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-430">723,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-431">650,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-432">537,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-433">1,274,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-434">1,069,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1a96c573cb0642a4ab930e77d995671e_49"></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-435" continuedAt="f-435-1" escape="true">LEASED PROPERTIES</ix:nonNumeric></span></div><ix:continuation id="f-435-1" continuedAt="f-435-2"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (<ix:nonFraction unitRef="sqft" contextRef="c-130" decimals="0" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-436">3,169</ix:nonFraction> square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for <ix:nonNumeric contextRef="c-131" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-437">two years</ix:nonNumeric> such that the term now expires on August 31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts. The lease for that space commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for <ix:nonNumeric contextRef="c-132" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-438">three years</ix:nonNumeric> to December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The extension of the lease in February 2022 resulted in an increase in operating lease liabilities and ROU assets of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-439">1.0</ix:nonFraction>&#160;million. In September 2022, the landlord exercised its option to terminate the lease, resulting in the new lease term ending on December 31, 2023. The termination of the lease resulted in a reduction of operating lease liabilities and ROU assets of approximately $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-440">504,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" sign="-" name="dare:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-441">458,000</ix:nonFraction>, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="0" id="f-442">46,000</ix:nonFraction> gain on the modification of the lease which was included as a reduction to research and development expense for the year ended December 31, 2022. MBI entered into a new lease for general office space in June 2023 that will commence on December 1, 2023 and will create an obligation to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-443">1.4</ix:nonFraction>&#160;million over the lease period of <ix:nonNumeric contextRef="c-135" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-444">three years</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI previously leased warehouse space in Billerica, Massachusetts, under a lease that commenced on October 1, 2016 and terminated on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-435-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate consisting of the current prime rate plus <ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="dare:OperatingLeaseIncrementalBorrowingRatePrimeRate" scale="-4" id="f-445">200</ix:nonFraction> basis points for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, the Company reported operating lease <span style="-sec-ix-hidden:f-446">ROU assets</span> of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-447">276,000</ix:nonFraction> in other non-current assets, approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-448">272,000</ix:nonFraction> in current portion of lease liabilities, and approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-449">23,000</ix:nonFraction> in lease liabilities long-term in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-450">145,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-451">284,000</ix:nonFraction> for the three and six months ended&#160;June&#160;30, 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-452">150,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-453">340,000</ix:nonFraction> for the three and six months ended  June&#160;30, 2022, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-454">105,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-455">209,000</ix:nonFraction> for the three and six months ended&#160;June&#160;30, 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-456">80,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-457">203,000</ix:nonFraction> for the three and six months ended June&#160;30, 2022, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. At June&#160;30, 2023, operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-458">0.83</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-459" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, future minimum lease payments under the Company's operating leases are as follows (does not include any minimum lease payments under the lease MBI entered in June 2023 because the lease does not commence until December 1, 2023):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:445.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-460">213,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-461">93,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-462">306,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-463">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-464">296,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1a96c573cb0642a4ab930e77d995671e_52"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-465" continuedAt="f-465-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="f-465-1" continuedAt="f-465-2">CRADA with NICHD for the Pivotal Phase 3 Study of Ovaprene</ix:continuation></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-465-2">In July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#8217;s Contraceptive Clinical Trial Network with NICHD's contract research organization providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="dare:ResearchAndDevelopmentAgreementCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-466">5.5</ix:nonFraction>&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD is responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="f-467">5.0</ix:nonFraction>&#160;million to NICHD, $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="f-468">3.5</ix:nonFraction>&#160;million of which was paid in 2022. The Company's remaining obligation under the CRADA at June&#160;30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-469">0.5</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dare:GrantAwardTextBlock" id="f-470" continuedAt="f-470-1" escape="true">GRANT AWARDS</ix:nonNumeric></span></div><ix:continuation id="f-470-1" continuedAt="f-470-2"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of DARE-PTB1, DARE-LARC1 and DARE-204/214. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-PTB1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="f-471">300,000</ix:nonFraction> was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="dare:AdditionalPotentialFundingRelatedToGrantAward" format="ixt:num-dot-decimal" scale="6" id="f-472">2.0</ix:nonFraction>&#160;million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NICHD award of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="f-473"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="0" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="f-474">721</ix:nonFraction></ix:nonFraction> during the three and six months ended June&#160;30, 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-2" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-475">2,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-2" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-476">19,500</ix:nonFraction> during the three and six months ended June&#160;30, 2022, respectively. At June&#160;30, 2023 the Company recorded a receivable for expenses incurred through such date that it believes are reimbursable under the grant of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="dare:ReceivableForExpensesEligibleForReimbursement" scale="0" id="f-477">721</ix:nonFraction>. <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:fixed-zero" scale="0" id="f-478">No</ix:nonFraction> receivable was recorded at December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="f-479">300,000</ix:nonFraction> was to be used to explore device insertion and removal in nonclinical studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="f-480">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-481">32,000</ix:nonFraction> for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-2" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-482">27,800</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-483">193,000</ix:nonFraction> for the three and six months ended June&#160;30, 2022, respectively. The Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-484">33,000</ix:nonFraction> at December&#160;31, 2022 for expenses incurred through such date that were subsequently reimbursed under the grant. <ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:fixed-zero" scale="0" id="f-485">No</ix:nonFraction> receivable was recorded at June&#160;30, 2023. The Company received aggregate reimbursements under the NICHD award of approximately $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="f-486">278,000</ix:nonFraction> during the grant period, which ended in June 2023. No further funds are available under this award.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-204 and DARE-214</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company received a notice of award of a grant from NICHD of approximately $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="f-487">249,000</ix:nonFraction> to support end-user research to better understand women's preferences for a long-acting injectable contraceptive method. The findings from the research will inform the Company's target product profile and guide its development priorities for DARE-204 and DARE-214. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-2" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-488">32,700</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-2" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="f-489">81,500</ix:nonFraction> for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, with no such credits recorded in the same periods of the prior year. The Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-1" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-490">33,040</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-491">24,000</ix:nonFraction> at June&#160;30, 2023 and December&#160;31, 2022, respectively, for expenses incurred through such date that it believes is eligible for reimbursement under the grant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-470-2" continuedAt="f-470-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Dilutive Grant Funding</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 DARE-LBT Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company entered into an agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation, under which the Company was awarded $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-492">585,000</ix:nonFraction> to support the development of DARE-LBT. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LBT, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the full amount of the award in November 2022. As of June&#160;30, 2023, the Company has recorded a deferred grant funding liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-493">544,000</ix:nonFraction> in the Company's condensed consolidated balance sheets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 DARE-LARC1 Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into an agreement with the Foundation under which the Company was awarded up to $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-494">49.0</ix:nonFraction>&#160;million to support the development of DARE-LARC1. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LARC1, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The agreement supports technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in nonclinical proof of principle studies. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-470-3">The Company received an initial payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="6" id="f-495">11.5</ix:nonFraction> million in 2021, and aggregate payments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="6" id="f-496">12.4</ix:nonFraction> million in 2022. As of June&#160;30, 2023, the Company has received a cumulative total of approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="6" id="f-497">23.9</ix:nonFraction> million in non-dilutive funding under the agreement and recorded a deferred grant funding liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="f-498">13.1</ix:nonFraction> million in the Company's condensed consolidated balance sheets. Additional payments are contingent upon the DARE-LARC1 program&#8217;s achievement of specified development and reporting milestones.</ix:continuation> </span></div><div id="i1a96c573cb0642a4ab930e77d995671e_58"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-499" continuedAt="f-499-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-499-1"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share, or EPS, using the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted EPS is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Dilutive securities include the dilutive effect of in-the-money options and warrants, which is calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an option or warrant, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option or warrant is exercised are assumed to be used to repurchase shares in the current period</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities are excluded from the diluted EPS calculation if their effect is anti-dilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-500" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:541.50pt"><tr><td style="width:1.0pt"></td><td style="width:251.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-501">9,470,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-502">6,053,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-503">9,470,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-504">6,417,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-505">6,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-506">1,058,733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-507">6,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-508">1,381,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-509">9,476,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-510">7,111,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-511">9,476,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-512">7,798,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-513" continuedAt="f-513-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-513-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Sales</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July and August 2023, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-514">1,151,578</ix:nonFraction> shares of common stock under its ATM equity offering program and received aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-515">946,000</ix:nonFraction> and incurred sales agent commissions and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="dare:SaleOfStockBrokerageCommissionsExpense" format="ixt:num-dot-decimal" scale="0" id="f-516">22,000</ix:nonFraction> (See Note 4, Stockholders' Equity).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Award</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2023, the Company received a notice of award of a grant from NICHD of approximately $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="f-517">385,000</ix:nonFraction> to support preclinical development of a potential new therapeutic for the prevention of idiopathic preterm birth. The grant funds will support activities related to the conduct and completion of proof-of-concept target validation studies in collaboration with the University of South Florida, or USF, which are to occur over a 12-month period. The Company will track expenses eligible for reimbursement under the grant award and submit a detailed accounting of such expenses to receive payment of the grant funds. The amounts of any such payments will be recognized in the Company's statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the project period. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Financing</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Company obtained financing for certain director and officer and other liability insurance premiums. The agreement for such financing assigns to the lender a first priority lien on and a security interest in the financed insurance policies and any additional premium required in the financed insurance policies including (a) all returned or unearned premiums, (b) all additional cash contributions or collateral amounts assessed by the insurance companies in relation to the financed insurance policies and financed by the lender, (c) any credits generated by the financed insurance policies, (d) dividend payments, and (e) loss payments which reduce unearned premiums. If any circumstances exist in which premiums related to any financed insurance policy could become fully earned in the event of loss, the lender will be named a loss-payee with respect to such policy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total premiums, taxes and fees financed is approximately $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="dare:InsuranceFinancingPremiumsTaxesAndFeesAmount" format="ixt:num-dot-decimal" scale="6" id="f-518">0.8</ix:nonFraction> million with an annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="c-177" decimals="3" name="dare:InsuranceFinancingInterestRate" scale="-2" id="f-519">8.0</ix:nonFraction>%. In consideration of the premium payment by the lender to the insurance companies or the agent or broker, the Company unconditionally promises to pay the lender the amount financed plus interest and other charges permitted under the agreement. The Company will pay the insurance financing through monthly installment payments through April 20, 2024. The amount financed will be recognized as an insurance financing payable in the Company's consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Exclusive License Agreement with Organon</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2023, the Company entered into an amendment to its exclusive license agreement with Organon to commercialize XACIATO. Under the amendment, Organon agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="dare:MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-520">1.0</ix:nonFraction>&#160;million to the Company as reimbursement for fees paid to the FDA in connection with the submission of the new drug application for XACIATO (known as PDUFA fees) and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, which will be recognized as license fee revenue in the third quarter of 2023. The Company received such amount in July 2023. The amount payable by Organon to the Company following the first commercial sale of a licensed product in the United States was revised to $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount" format="ixt:num-dot-decimal" scale="6" id="f-521">1.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, or our 2022 10-K, filed with the Securities and Exchange Commission, or SEC, on March 30, 2023. Past operating results are not necessarily indicative of results that may occur in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> The following discussion includes forward-looking statements.&#160;See &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS,&#8221; above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors of our 2022 10-K, and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading &#8220;Risk Factors,&#8221; which are incorporated herein by reference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dar&#233;&#8221; or the &#8220;Company&#8221; refer collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Dar&#233; Bioscience, Inc. and XACIATO&#8482; is a trademark of Dar&#233; Bioscience, Inc. with registration pending. Ovaprene</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark licensed to Dar&#233; Bioscience, Inc. All other trademarks, service marks or trade names appearing in this report are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, service marks or trade names is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, service mark or trade name owners.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_67"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Our business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid to late-stage clinical development or regulatory approval, and to establish and leverage strategic collaborations to achieve commercialization. We and our wholly owned subsidiaries operate in one business segment.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our first product, XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2%, was approved by the FDA in December 2021 as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, we entered into an agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, which became fully effective in June 2022, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO. Accordingly, our potential future revenue from the commercialization of XACIATO will consist of royalties based on net sales and milestone payments from Organon, and, for an interim period, payments from Organon for commercial supply of XACIATO. We anticipate the first commercial sale of XACIATO in the U.S. in 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product pipeline includes diverse programs that target unmet needs in women's health in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility, and aim to expand treatment options, enhance outcomes and improve ease of use for women. We are primarily focused on progressing the development of our existing portfolio of product candidates. However, we also explore opportunities to expand our portfolio by leveraging assets to which we hold rights or obtaining rights to new assets, with continued focus solely on women's health.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current portfolio includes four product candidates in advanced clinical development (Phase 2 to Phase 3):</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ovaprene&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly intravaginal contraceptive;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sildenafil Cream, 3.6%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder (FSAD) and/or female sexual interest/arousal disorder (FSIAD);</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-HRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring designed to deliver both bio-identical estradiol and progesterone together, continuously over a 28-day period, for the treatment of moderate-to-severe vasomotor symptoms, as part of menopausal hormone therapy; and</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-VVA1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary formulation of tamoxifen for intravaginal administration being developed as a hormone-free alternative to estrogen-based therapies for the treatment of moderate to severe vulvovaginal atrophy.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio also includes five product candidates in Phase 1 clinical development or that we believe are Phase 1-ready:</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-PDM1, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for primary dysmenorrhea;</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively;</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-FRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring designed to deliver bio-identical progesterone continuously for up to 14 days for luteal phase support as part of an in vitro fertilization treatment plan; and</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-PTB1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring designed to deliver bio-identical progesterone continuously for up to 14 days for the prevention of preterm birth.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our portfolio includes five pre-clinical stage programs: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a contraceptive implant delivering levonorgestrel with a woman-centered design that has the potential to be a long-acting, yet convenient and user-controlled contraceptive option;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-GML</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate (GML), which has shown broad antimicrobial activity, killing bacteria and viruses; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-LBT</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-RH1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-PTB2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product candidates and potential product candidates in our portfolio will require review and approval from the FDA, or a comparable foreign regulatory authority, prior to being marketed or sold. See below and ITEM 1. "BUSINESS," in Part I of our 2022 10-K for additional information regarding our product and product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary operations have consisted of research and development activities to advance our portfolio of product candidates through late-stage clinical development and/or regulatory approval. We expect our research and development expenses will continue to represent the majority of our operating expenses for at least the next twelve months. For the remainder of 2023, we expect to focus our resources on advancement of Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1 and our other product candidates that have reached the human clinical study development phase. In addition, we expect to incur significant research and development expenses for the DARE-LARC1 program for the next several years, but we also expect such expenses will be supported by non-dilutive funding provided under a grant agreement we entered into in June 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of developing and obtaining regulatory approvals for prescription drug and drug/device products in the United States and in foreign jurisdictions is inherently uncertain and requires the expenditure of substantial financial resources without any guarantee of success. As discussed below, we will need to raise substantial additional capital to continue to fund our operations and execute our current business strategy. To the extent we receive regulatory approvals, such as the FDA&#8217;s approval of XACIATO, the commercialization of any product and compliance with subsequently applicable laws and regulations requires the expenditure of further substantial financial resources without any guarantee of commercial success. The amount of post-approval financial resources required for commercialization and the potential revenue we may receive from sales of any product will vary significantly depending on many factors, including whether, and the extent to which, we establish our own sales and marketing capabilities and/or enter into and maintain commercial collaborations with third parties with established commercialization infrastructure. We are also subject to a number of other risks common to biopharmaceutical companies, including, but not limited to, dependence on key employees, reliance on third-party collaborators, service providers and suppliers, being able to develop commercially viable products in a timely and cost-effective manner, dependence on intellectual property we own or in-license and the need to protect that intellectual property and maintain those license agreements, uncertainty of market acceptance of products, uncertainty of third-party payor coverage, pricing and reimbursement for products, rapid technology change, intense competition, compliance with government regulations, product liability claims, and exposure to cybersecurity threats and incidents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XACIATO</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activities in preparation for commercial launch of XACIATO (clindamycin phosphate) vaginal gel, 2% in the United States, including manufacturing-related activities, are ongoing and the first commercial sale is expected in 2023. In July 2023, we entered into an amendment to our exclusive global license agreement with Organon and received $1.0 million from Organon as reimbursement for fees paid to the FDA in connection with submission of the new drug application (NDA) for XACIATO (known as PDUFA fees) and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, which will be recognized as license fee revenue in the third quarter of 2023. Following the first commercial sale of XACIATO, we are entitled to receive a $1.8 million milestone payment from Organon and a $0.5 million payment from us to a third-party licensor will become payable. Under our agreement with Organon, we are also entitled to receive tiered double-digit royalties based on net sales and up to $180.0 million in tiered commercial sales milestones and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreement with Organon, for an interim period, we will remain the holder of the FDA&#8217;s marketing approval for XACIATO and be responsible for providing commercial product supply. Upon Organon's request, we will assist with the transfer of the NDA by the FDA to Organon, as well as the transfer of manufacturing responsibilities to Organon. As the current NDA holder, we will continue to be responsible for regulatory and compliance matters following commercial launch, though Organon is responsible for commercializing, promoting, determining pricing, and negotiating reimbursement matters related to XACIATO. Organon will purchase all of its product requirements of XACIATO from us at a transfer price equal to our manufacturing costs plus a single-digit percentage markup. We will fulfill our commercial supply obligations through the contract manufacturer that provided clinical supplies of XACIATO for our pivotal Phase 3 DARE-BVFREE clinical study of XACIATO. We will not be responsible for other costs of commercializing XACIATO.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical-Stage Program Updates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Ovaprene</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that the FDA approved an Investigational Device Exemption, or IDE, application allowing us to conduct a single arm, open-label pivotal contraceptive efficacy study of Ovaprene. The multi-center, non-comparative pivotal Phase 3 clinical study will evaluate Ovaprene&#8217;s effectiveness as a contraceptive device along with its safety and usability. We will target having approximately 250 women complete approximately 12-months (13 menstrual cycles) of use of Ovaprene. Based on typical dropout rates for contraceptive efficacy studies, we will seek to enroll more than double the number of subjects we target to complete 13 menstrual cycles of use. We have been working with our collaborators at the National Institutes of Health, or NIH, and at Bayer to review and implement study design considerations provided by the FDA with its IDE approval letter, which we believe will further position the Phase 3 study to collect safety and effectiveness data to enable the preparation of, and to support the submission of, a premarket approval, or PMA, application for Ovaprene. The primary objective of the study is to assess the typical use pregnancy rate over 13 menstrual cycles, or the estimated Pearl Index for Ovaprene. Secondary objectives are to assess Ovaprene's 13-cycle use cumulative pregnancy rate, safety, acceptability, product fit/ease of use, and assessments of vaginal health. If successful, we expect the study to support a PMA application to the FDA, as well as regulatory filings in Europe and other countries worldwide, to allow for marketing approvals of Ovaprene. Subject enrollment in the study is targeted to begin in the fourth quarter of 2023. </span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 study will be conducted under our Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NICHD, part of the NIH, and within NICHD&#8217;s Contraceptive Clinical Trial Network. We and NICHD will each provide medical oversight and final data review and analysis for the study and will work together to prepare the final report of the results of the study. We are responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5 million to NICHD to be applied toward the costs of conducting the Phase 3 study, $5.0 million of which has been paid. NICHD is responsible for the other costs related to the conduct of the Phase 3 study and for managing the payment of expenses to the contract research organization for the study, the clinical sites, and other parties involved with the study. We and NICHD are in discussions regarding an amendment to the CRADA, which we expect will delay the due date of our remaining $0.5 million payment to NICHD to the fourth quarter of 2023. In the future, depending on the duration of the enrollment period and number of subjects enrolled in the Phase 3 study, there may be costs associated with the study that are not reflected in the current budget under the CRADA, in which case, we and NICHD would discuss the mechanism to potentially provide for additional future payments by us in support of the Phase 3 study. We do not expect any such potential additional amounts to be payable in 2023. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Sildenafil Cream, 3.6%</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we announced topline results from our exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, or Sildenafil Cream, in premenopausal women with FSAD, and in July 2023, we announced additional data from the study. During the multi-center, double-blind, randomized, placebo-controlled study, subjects used Sildenafil Cream and placebo cream in their home setting over 12 weeks following a 4-week non-drug run-in period and a 4-week, single-blind placebo run-in period. The study was a first of its kind Phase 2b clinical study that included patient reported outcome instruments to screen for eligible women with FSAD and measure efficacy endpoints. There are no treatments approved by the FDA for FSAD, as described in the fourth edition of the Diagnostic and Statistical Manual (DSM), or for FSIAD, as described in the fifth edition of the DSM, and thus, there are no efficacy endpoints that have been previously validated in a Phase 3 pivotal study for potential treatments for FSAD or FSIAD. </span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 252 subjects were enrolled in the 4-week single-blind placebo run-in period and a total of 200 subjects were randomized to the 12-week double-blind dosing period. A total of seven subjects were randomized but not treated in the double-blind dosing period. In the intent to treat (ITT) population, 99 subjects were randomized to the Sildenafil Cream group and 94 subjects were randomized to the placebo cream group. A co-primary endpoint of the study evaluated the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to end of study (the assessment 12 weeks after randomization) in the Arousal-Sensation Domain of the 28-item Sexual Function Questionnaire. The endpoint did not achieve statistical significance. However, the change at end of study in the Sildenafil Cream group was consistent with how women reported meaningful improvement in an exit interview at the end of the study. The other co-primary endpoint evaluated the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to end of study in the score for feeling concerned by difficulties with sexual arousal. The change was assessed using one question from the previously validated Female Sexual Distress Scale &#8211; Desire, Arousal and Orgasm Survey. This assessment did not differentiate Sildenafil Cream from placebo. The secondary endpoint evaluated the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to end of study in the number of satisfactory sexual events based on the subjects&#8217; response to a question answered and recorded via electronic diary within 24 hours after each sexual event. When measured at the 4- and 8-week mark after randomization, subjects in the Sildenafil Cream group had a higher proportion of satisfying sexual events during the prior four weeks (68.6% and 74.1% at the 4- and 8-week mark, respectively) compared to subjects in the placebo group (47.9% and 67.9% at the 4- and 8-week mark, respectively) (week 4 P value = 0.04).</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subjects in the Sildenafil Cream group showed improvements in multiple pre-specified exploratory endpoints that evaluated various aspects of the sexual experience, including concerns about difficulties with sexual arousal, arousal lubrication, achievement and pleasure of orgasm, and sexual desire. In an exploratory endpoint regarding concerns about difficulties with sexual arousal, when asked about their overall impression of change regarding their concerns about difficulties with sexual arousal, women treated with Sildenafil Cream were more likely to report an overall improvement. Based on responses to the question at the 4-, 8- and 12-week mark after randomization, 44% to 49% of the subjects treated with Sildenafil Cream reported an overall improvement compared to 37% to 44% of the subjects treated with placebo (P value &lt; 0.01). Exploratory endpoints related to arousal lubrication, orgasm, and sexual desire demonstrated important differences between subjects in the Sildenafil Cream group compared to the placebo group as measured by change from baseline to the 8-week mark after randomization, at P value = 0.059, P value = 0.066, and P value = 0.022, respectively. Improvements in arousal lubrication, orgasm, and sexual desire in the Sildenafil Cream group achieved maximum separation from placebo at the 8-week mark after randomization and these improvements were maintained through end of study, demonstrating persistence while on treatment. In the placebo group, no such trends were observed, with no such improvements achieved at the 8-week mark. While improvements achieved in the Sildenafil Cream group in arousal lubrication, orgasm, and sexual desire by the 8-week mark persisted through end of study, no endpoint achieved statistical significance at end of study. Sildenafil Cream was generally safe and well-tolerated in the study for both the female subjects and their male partners enrolled in the study. There were no treatment related serious adverse events and the majority of treatment related adverse events were mild in severity. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe data from the Phase 2b RESPOND study support Sildenafil Cream&#8217;s potential to improve female genital arousal and orgasm, as well as sexual desire, suggesting that FSAD and/or FSIAD are potential indications to pursue, and we plan to advance clinical development of Sildenafil Cream into a Phase 3 pivotal study. Phase 3 clinical study design, including primary and secondary efficacy endpoints, study duration, timing for efficacy endpoint assessment, use of endpoints that reduce burden on study subjects (e.g., 28-day recall assessments as opposed to recall assessments within 24 hours after each sexual event), and inclusion/exclusion criteria for study subjects, will be determined following psychometric analyses we are conducting of the Phase 2b RESPOND study data and future discussions with the FDA, including an end of Phase 2 meeting with the FDA.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced the initiation of subject enrollment in a Phase 1, single-dose, double-blind, placebo-controlled, 3-way crossover clinical study of Sildenafil Cream using thermography to assess the pharmacodynamic (PD) and pharmacokinetic (PK) characterization of Sildenafil Cream. We expect this study will enroll approximately 15 women and be completed in 2023. Data from the study will expand our existing clinical and nonclinical data for Sildenafil Cream and are expected to support the ongoing development of Sildenafil Cream as a potential treatment for FSAD and/or FSIAD.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-HRT1</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 and January 2023, we announced topline results of our Phase 1/2 clinical study of DARE-HRT1 conducted by our wholly owned subsidiary in Australia. The randomized, open-label, two arm, parallel group study evaluated the PK of two versions of DARE-HRT1 (estradiol 80 &#181;g/progesterone 4 mg intravaginal ring (IVR) and estradiol 160 &#181;g/progesterone 8 mg IVR) in approximately 20 healthy, post-menopausal women over approximately three consecutive months of use. The study also collected safety, usability, acceptability and symptom-relief data including the vasomotor symptoms, or VMS, as well as the vaginal symptoms of menopause. Based on pre-IND communications with the FDA and the topline PK data from the Phase 1/2 study, we plan to advance DARE-HRT1 directly into a Phase 3 clinical trial. We believe FDA approval of DARE-HRT1 for the treatment of moderate to severe VMS due to menopause in women with intact uteri is achievable via the FDA's 505(b)(2) pathway supported by a single, placebo-controlled Phase 3 clinical trial and a scientifically justified PK &#8220;bridge&#8221; (via a relative bioavailability trial) between DARE-HRT1 and the selected listed estradiol and progesterone drugs. Ongoing activities to support progressing DARE-HRT1 directly into a Phase 3 clinical study to support registration include manufacturing and non-clinical studies to support an investigational new drug, or IND, submission to the FDA and the IND-opening Phase 3 study. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-VVA1</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced topline results from of our Phase 1/2 clinical study of DARE-VVA1 conducted by our wholly owned subsidiary in Australia. The randomized, multi-center, double-blind, parallel-arm, placebo-controlled, dose-ranging study enrolled 17 postmenopausal women with vulvovaginal atrophy (VVA), and evaluated the safety, tolerability, plasma PK and PD of DARE-VVA1. We believe the results of the Phase 1/2 study support ongoing development of DARE-VVA1 as a potential hormone-free treatment for moderate to severe VVA. We are conducting activities to support an IND submission to the FDA and an IND-opening Phase 2 clinical study. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">DARE-PDM1</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced the start of a Phase 1 clinical study of DARE-PDM1, which is being conducted by our wholly owned subsidiary in Australia. The DARE-PDM1 Phase 1 study, DARE-PDM1-001, is a multi-center, randomized, placebo-controlled, double-blind, three-arm parallel group study expected to enroll approximately 36 healthy, premenopausal women with primary dysmenorrhea. This study is designed to assess the systemic (plasma) and local mucosal (vaginal fluid) diclofenac PK and safety after a single dose and during three daily doses of vaginally administered DARE-PDM1, given in two different strengths (1% or 3% diclofenac in 2.5 mL of hydrogel) versus placebo. The study will also assess, as an exploratory endpoint, the preliminary dysmenorrhea treatment efficacy of DARE-PDM1, when dosed in three daily doses at the onset of dysmenorrhea symptoms, compared to a no-treatment, baseline, control cycle. The study observation period will encompass approximately three menstrual cycles. We anticipate announcing topline data from the study in 2023. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">DARE-204 and DARE-214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting development activities in preparation for Phase 1 clinical studies of DARE-204 and DARE-214 by our wholly-owned subsidiary in Australia. We do not expect to commence the Phase 1 studies in 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">DARE-FRT1 and DARE-PTB1</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting development activities in preparation for Phase 1 clinical studies of DARE-FRT1 and DARE-PTB1. We do not expect to commence clinical development activities of these product candidates in 2023. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div id="i1a96c573cb0642a4ab930e77d995671e_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Positive Topline Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in June 2023, we announced topline data from our exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, and in July 2023, we announced additional data from the study. See "Clinical-Stage Program Updates-Sildenafil Cream, 3.6%," above.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Amendment to Exclusive License Agreement with Organon</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above, in July 2023, we entered into an amendment to our exclusive license agreement with Organon to commercialize XACIATO. See "XACIATO," above.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Receipt of Cash Rebate under Australian Research and Development Tax Incentive Program</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we received a cash rebate from the government of Australia in the amount of approximately $1.6 million for research and development expenditures incurred in Australia in 2022. The rebate is accounted for as a reduction to research and development expenses.</span></div><div style="margin-bottom:10pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">NICHD Non-Dilutive Grant Award</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we received a notice of award of a grant from NICHD of approximately $385,000 to support preclinical development of a potential new therapeutic for the prevention of idiopathic preterm birth. The grant funds will support activities related to the conduct and completion of proof-of-concept target validation studies in collaboration with the University of South Florida, or USF, which are to occur over a 12-month period. We previously entered into an option agreement with the University of South Florida Research Foundation, Inc., or USFRF, a nonprofit Florida corporation that is a direct support organization of USF, pursuant to which we have an exclusive right, and not an obligation, to elect to negotiate to acquire the exclusive worldwide rights in the field of human reproduction to patents and know-how controlled by USFRF relating to the potential therapeutic whose development is being supported by the NICHD award.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have generated $11.0 million in revenue, $10.0 million of which represents the upfront payment under our license agreement with Organon to commercialize XACIATO, which is recognized as license fee revenue, and $1.0 million of which represents the reimbursement for PDUFA fees and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, which will be recognized as license fee revenue in the third quarter of 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from royalties and commercial milestones based on the net sales of XACIATO, from product sales of other approved products, if any, and from license fees, milestone payments, and research and development payments in connection with strategic collaborations. In the future and for an interim period, we may also generate revenue from commercial supply of XACIATO to Organon. Our ability to generate such revenue, with respect to XACIATO, will depend on the extent to which its commercialization is successful, and with respect to our product candidates, will depend on their successful clinical development, the receipt of regulatory approvals to market such product candidates and the eventual successful commercialization of products. If the commercialization of XACIATO is not successful or we fail to complete the development of our product candidates in a timely manner, or to receive regulatory approval for such product candidates, our ability to generate future revenue and our results of operations would be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our operating expenses during a fiscal year are research and development expenses, a significant portion of which, excluding those funded by non-dilutive grants, are associated with the clinical development for our product candidates that have reached the human clinical study development phase. Research and development expenses include research and development costs for our product candidates and transaction costs related to our acquisitions. We recognize all research and development expenses as they are incurred. Research and development expenses consist primarily of:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses incurred under agreements with clinical trial sites and consultants that conduct research and development and regulatory affairs activities on our behalf;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">laboratory and vendor expenses related to the execution of nonclinical studies and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">contract manufacturing expenses, primarily for the production of clinical supplies; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">transaction costs related to acquisitions of companies, technologies and related intellectual property, and other assets;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">milestone payments due to third parties under acquisition and in-licensing arrangements we incur, or the incurrence of which we deem probable; and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">internal costs associated with activities performed by our research and development organization and generally benefit multiple programs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in the development of and seeking regulatory approval for our clinical-stage and Phase 1-ready product candidates and the development of any other potential product candidates we may advance into and through clinical trials in the pursuit of regulatory approvals, will increase our research and development expenses. Activities associated with the foregoing will require a significant increase in investment in regulatory support, clinical supplies, inventory build-up related costs, and the payment of success-based milestones to licensors. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to, among other factors, license fee and/or milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the Australian Research and Development Tax Incentive Program, or the Tax Incentive, as a reduction of research and development expenses. The amounts are determined based on our eligible research and development expenditures and are non-refundable, provided that in order to qualify for the Tax Incentive the filing entity must have revenue of less than AUD $20.0 million during the tax year for which a reimbursement claim is made and cannot be controlled by an income tax exempt entity. The Tax Incentive is recognized when there is reasonable assurance that the Tax Incentive will be received, the relevant expenditure has been incurred, and the amount can be reliably measured or reliably estimated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive funding through grants that support activities related to the development of certain of our product candidates. As we incur eligible expenses under those grants, we recognize grant funding in the statements of operations as a reduction to research and development expense (contra-research and development expense). For more information, see Note 2, Basis of Presentation and Summary of Significant Accounting Policies &#8211; Grant Funding, to our consolidated financial statements contained in our 2022 10-K and Note 8, Grant Awards, to our condensed consolidated financial statements contained in this report. For the three and six months ended June&#160;30, 2023 and 2022, we recognized contra-research and development expenses of approximately $2.2 million and $4.7 million, respectively, and $1.0 million and $2.0 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may not obtain regulatory approval for any product candidate on a timely or cost-effective basis, or at all. The probability of success of our product candidates may be affected by numerous factors, including clinical results and data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we cannot accurately determine the duration and completion costs of development projects or when and to what extent we will generate revenue from the commercialization of any of our product candidates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fee Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee expenses consist of up-front license fees and annual license fees due under our in-licensing arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of personnel costs, facility expenses, expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. Facility expenses consist of rent and other related costs. </span></div><div id="i1a96c573cb0642a4ab930e77d995671e_76"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations is based on our interim condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our accompanying condensed consolidated financial statements, refer to Item 7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 2 to our financial statements contained in our 2022 10-K, and Note 2 to our condensed consolidated financial statements contained in this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended June&#160;30, 2023 and 2022 (Unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:225.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,920,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,797,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626,322)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,989,356)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,678)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2439)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,762,232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,176,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,793,383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,071,512)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue for the three months ended June 30, 2022 relates to our license agreement with Organon to commercialize XACIATO. We earned $10.0 million in license fee revenue related to the transfer of the license and related know-how to Organon upon effectiveness of the agreement on June 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately $128,000 in general and administrative expenses&#160;for the three months ended June&#160;30, 2023 as compared to the three months ended June&#160;30, 2022 was primarily attributable to increases in (i) professional services expense of approximately $148,000, (ii) personnel costs of approximately $104,000, and (iii) stock-based compensation expense of approximately $74,000. These increases were partially offset by decreases in general corporate overhead, including rent and facilities expenses, of approximately $158,000.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of approximately $754,000 in research and development expenses for the three months ended June&#160;30, 2023 as compared to the three months ended June&#160;30, 2022 was primarily attributable to decreases in expenses related to our Sildenafil Cream Phase 2b RESPOND clinical study of approximately $1.2 million, and decreases in expenses related to clinical trial and manufacturing and regulatory affairs activities for our clinical-stage product candidate Ovaprene of approximately $831,000, partially offset by increases in costs related to development activities for our Phase 1 and Phase 1-ready programs of approximately $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License fee expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended June&#160;30, 2023 and June&#160;30, 2022, we accrued $25,000 of the $100,000 annual license maintenance fee payable under our license agreement related to DARE-HRT1.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of these license fees, see Note 3 to our condensed consolidated financial statements contained in this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $0.2 million in other income for the three months ended June&#160;30, 2023 as compared to the three months ended June&#160;30, 2022 was primarily due to an increase in interest earned on cash balances in the current period.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Six Months Ended June&#160;30, 2023 and 2022 (Unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:225.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,063,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,603,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,539,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,372,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,016,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,372,005)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,016,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,355,877)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,804,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,984,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,820,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,857,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,129,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,728,198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue relates to our license agreement with Organon to commercialize XACIATO. See "&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of Three Months Ended June 30, 2023 and 2022 (Unaudited)&#8212;Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately $895,000 in general and administrative expenses&#160;for the six months ended June&#160;30, 2023 as compared to the six months ended June&#160;30, 2022 was primarily attributable to (i) a one-time fraud loss of approximately $230,000, net of proceeds we received under an insurance policy, related to criminal fraud commonly referred to as "business email compromise fraud" to which we were subject, and (ii) increases in (a) professional services expense of approximately $226,000, (b) commercial-readiness expenses of approximately $199,000, (c) personnel costs of approximately $153,000, and (d) stock-based compensation expense of approximately $141,000. These increases were partially offset by decreases in general corporate overhead, including rent and facilities expenses, of approximately $54,000.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of approximately $1.5 million in research and development expenses for the six months ended June&#160;30, 2023 as compared to the six months ended June&#160;30, 2022 was primarily attributable to decreases in (i) expenses related to clinical trial and manufacturing and regulatory affairs activities for our clinical-stage product candidate Ovaprene of approximately $1.9&#160;million, (ii) costs related to our Sildenafil Cream exploratory Phase 2b RESPOND clinical study of approximately $1.5 million, and (iii) costs related to our pre-clinical development activities of approximately $219,000, partially offset by increases in costs related to development activities for our Phase 1 and Phase 1-ready programs of approximately $2.1 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License fee expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the six months ended June&#160;30, 2023 and June&#160;30, 2022, we accrued $50,000 of the $100,000 annual license maintenance fee payable under our license agreement related to DARE-HRT1.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of these license fees, see Note 3 to our condensed consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately $0.5 million in other income for the six months ended June&#160;30, 2023 as compared to the six months ended June&#160;30, 2022 was primarily due to an increase in interest earned on cash balances in the current period.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_82"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operations and Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, our accumulated deficit was approximately $157.9 million, our cash and cash equivalents were approximately $13.3 million, our deferred grant funding liabilities under our grant agreements related to DARE-LARC1 and DARE-LBT were approximately $13.1 million and $0.6 million, respectively, and our working capital deficit was approximately $2.5 million. Substantially all of our cash and cash equivalents at June&#160;30, 2023 represented funds received under such grant agreements and such funds may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support our entire operations. We incurred a loss from operations of approximately $16.8 million and had negative cash flow from operations of approximately $22.7 million during the six months ended June&#160;30, 2023. </span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant losses from operations and negative cash flows from operations for the foreseeable future as we continue to develop and seek to bring to market our existing product candidates and as we seek to potentially acquire, license and develop additional product candidates. We expect our primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to our product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments to third-party licensors upon the occurrence of commercial milestones for XACIATO and development milestones for our product candidates pursuant to terms of the agreements under which we acquired or in-licensed rights to those programs, legal expenses, other regulatory expenses and general overhead costs. Our future funding requirements could also include significant costs related to commercialization of our product candidates, if approved, depending on the type, nature and terms of commercial collaborations we establish, and in particular, if we determine to engage in commercialization activities directly as opposed to through a third-party collaborator. The amount and timing of our capital needs have and will continue to depend highly on many factors, including the pace at which our clinical development programs proceed and the expenses associated therewith. In large part, we can control the pace of advancement of our development programs and, therefore, we can control the timing of when we incur most of our research and development expenses.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our sources of potential license fee revenue are our license agreements relating to XACIATO and Ovaprene. If the first commercial sale of XACIATO in the U.S. occurs in 2023 as expected, we will receive a $1.8 million milestone payment and we will be eligible to receive royalty payments at rates in the tiered double-digits based on annual net sales of XACIATO. We do not expect royalty payments for 2023 net sales of XACIATO to materially impact our cash resources or requirements. In regard to our license agreement relating to the commercialization of Ovaprene in the U.S., if approved, we are not eligible to receive any additional payments from our collaborator until after we complete the planned pivotal Phase 3 clinical study of Ovaprene. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate our general and administrative expenses to increase in 2023 compared to 2022 primarily due to increased personnel costs and other general corporate overhead. General and administrative expenses have included and are expected to include additional costs related to commercial-readiness activities and obtaining commercial supply of XACIATO from our contract manufacturer. Under the terms of our license agreement with Organon, Organon will purchase XACIATO from us at a price equal to our manufacturing costs plus a single digit percentage markup. As a result, we do not anticipate our costs for providing XACIATO to Organon will have a material impact on our cash resources and requirements. Following commercial launch of XACIATO, we expect our general and administrative expenses will include payments by us under our in-license agreement for XACIATO, including a $500,000 milestone payment upon first commercial sale of XACIATO in the U.S. and royalty payments at rates in the high single-digit to low double-digits based on annual net sales of XACIATO. </span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our operating expenses during a fiscal year are research and development expenses, a significant portion of which, excluding those funded by non-dilutive grants, are associated with the clinical development for our product candidates that have reached the human clinical study development phase. The amount of our research and development expenses for the remainder of 2023 is difficult to predict with certainty and will depend on the pace and extent of our research and development activities. Factors that impact the pace and extent of our research and development activities and, therefore our research and development spend include, without limitation, our cash resources, reprioritization of development programs and activities, the scope, timing of commencement, and rate of progress of our clinical trials and preclinical studies, the cost and timing of manufacture and receipt of clinical supplies, timing of regulatory approval of a clinical study or alignment on study design, the results of our clinical trials and preclinical studies, and the extent to which we establish strategic collaborations or other arrangements and the terms of such arrangements. We currently anticipate our research and development expenses for 2023 will be less than our research and development expenses for 2022, in part due to cost-savings measures we have implemented. Our research and development expenses for the remainder of 2023 will be primarily associated with our exploratory Phase 2b RESPOND clinical study and ongoing Phase 1 thermography clinical study of Sildenafil Cream, manufacturing activities in connection with our pivotal Phase 3 clinical study of Ovaprene, and variable expenses for our other programs, the timing of when we incur the majority of such expenses we can control. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor our cash resources and we have implemented cost-savings measures, primarily by controlling our spend on research and development activities related to clinical-stage programs other than Ovaprene and Sildenafil Cream. These cost-savings measures may impact anticipated development timelines for our clinical-stage programs, including DARE-HRT1, DARE-VVA1 and DARE-204/214. We will need additional capital to fund our operating needs into the fourth quarter of 2023 and to meet our current obligations as they become due.  We are in ongoing discussions with multiple potential third-party sources of additional capital, including non-dilutive sources of capital, and we believe that we will be able to obtain sufficient capital when needed in a manner that will not materially impact the development of our product candidates. However, many aspects of our ability to obtain additional capital are not entirely within our control and there can be no assurance that we will receive additional capital when needed, on favorable terms, or at all. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. See the risk factor in Item 1A of Part II of this report titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will need to raise substantial additional capital to continue our operations and execute our business strategy, and we may not be able to raise adequate capital on a timely basis, on favorable terms, or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the cash used to fund our operations has come from a variety of sources and predominantly from sales of shares of our common stock. We have also received a significant amount of cash through non-dilutive grants and strategic collaborations. We will continue to evaluate and may pursue a variety of capital raising options on an on-going basis, including sales of equity (including sales of our common stock in ATM offerings), debt financings, government or other grant funding, collaborations, structured financings, and strategic alliances or other similar types of arrangements, to cover our operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to us and our stockholders. Our ability to raise capital through sales of our common stock will depend on a variety of factors including, among others, market conditions, the trading price and volume of our common stock, our clinical and commercial developments, and investor sentiment. In addition, macroeconomic factors and volatility in the financial market, which may be exacerbated in the short term by concerns over inflation, rising interest rates, economic recession, adverse developments affecting financial institutions or the financial services industry, impacts of the war in Ukraine, strained relations between the U.S. and several other countries, and social and political discord and unrest in the U.S., among other things, may make equity or debt financings more difficult, more costly or more dilutive to our stockholders, and may increase competition for, or limit the availability of, funding from other potential third-party sources of capital, such as strategic collaborators and sources of grant funding.</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders, and debt financings may subject us to restrictive covenants, operational restrictions and security interests in our assets. If we raise capital through collaborations, structured financings, strategic alliances or other similar types of arrangements, we may be required to relinquish some or all of our rights to potential revenue or to intellectual property rights for our product candidates on terms that are not favorable to us. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. As discussed above, there is substantial doubt about our ability to continue as a going concern because we do not have sufficient cash to satisfy our working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of our ability to remain a going concern.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated:</span></div><div style="margin-bottom:7pt;margin-top:10pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:520.50pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,703,918)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,791,986)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,005,504)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,603,475)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in operating activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June&#160;30, 2023 included the net loss of $16.8 million, decreased by non-cash stock-based compensation expense of approximately $1.3 million. Components providing operating cash were an increase in accounts payable of approximately $4.5 million, a decrease in other receivables of approximately $1.1 million, and an increase in deferred revenue of approximately $0.2 million related to XACIATO commercial product supply. Components reducing operating cash were a decrease in accrued expenses of approximately $6.7 million, a decrease in deferred grant funding of approximately $4.6 million, an increase in prepaid expenses of approximately $1.4 million, and a one-time fraud loss of $0.2 million related to a "business email compromise fraud" to which we were subject, net of insurance reimbursement, which was recognized in general and administrative expenses. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June 30, 2022 included the net loss of $8.0 million, decreased by non-cash stock-based compensation expense of approximately $1.1 million. A component providing operating cash was an increase in accrued expenses of approximately $3.2 million. Components reducing operating cash were an increase in accounts receivable of $10.0 million related to our exclusive license agreement for XACIATO, an increase in prepaid expenses of approximately $3.4 million, a decrease in deferred grant funding of approximately $1.8 million, an increase in other receivables of approximately $1.0 million, and a decrease in accounts payable of approximately $1.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in investing activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No cash was used in investing activities for the six months ended June&#160;30, 2023. Net cash used in investing activities for the six months ended June&#160;30, 2022 was de minimis. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by financing activities </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the six months ended June&#160;30, 2023 and June&#160;30, 2022 of approximately $1.8 million and $1.2 million in the aggregate, respectively, primarily consisted of sales of our common stock under our ATM sales agreement and upon the exercise of warrants.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Royalty Agreements</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to make royalty and milestone payments under the license and development agreements related to XACIATO, Ovaprene, and Sildenafil Cream, and under other agreements related to our other clinical and preclinical candidates.&#160;During the remainder of 2023, based on our current expectations regarding the development of our product candidates and sales of XACIATO, we expect to pay approximately $2.7 million in royalty and milestone payments under the license and development agreements, which is significantly less than our previously reported expected amount, primarily due to lesser anticipated royalty payments we may owe with respect to sales of XACIATO resulting from the delay of its commercial launch from earlier expectations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;For further discussion of these potential payments, see Note 3 to our condensed consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with various third parties for research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and we do not believe that our non-cancelable obligations under these agreements are material.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_85"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_91"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of June&#160;30, 2023 at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_97"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. As of the date of filing this report, there is no material pending legal proceeding to which we are a party or to which any of our property is subject, and management is not aware of any contemplated proceeding by any governmental authority against us.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_100"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2022 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. Except as discussed below, there have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in our 2022 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional capital to continue our operations and execute our business strategy, and we may not be able to raise adequate capital on a timely basis, on favorable terms, or at all. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for the foreseeable future as we develop and seek to bring to market our existing product candidates and as we seek to potentially acquire or license and develop additional product candidates. These circumstances raise substantial doubt about our ability to continue as a going concern. Our financial statements as of December 31, 2022 and June 30, 2023 were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. At June 30, 2023, our accumulated deficit was approximately $157.9 million, our cash and cash equivalents were approximately $13.3 million, our deferred grant funding liabilities under our grant agreements related to DARE-LARC1 and DARE-LBT were approximately $13.7 million, and we had a working capital deficit of approximately $2.5 million. Substantially all of our cash and cash equivalents at June&#160;30, 2023 represented funds received under such grant agreements and such funds may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support our entire operations. We will require additional capital to fund our operating needs into the fourth quarter of 2023 and to meet our current obligations as they become due. Advancing our investigational women's health products through clinical development and pursuing regulatory approval and commercialization will require substantial additional investment. We will need to raise substantial additional capital to continue to fund our operations and execute our current business strategy. The amount and timing of our capital needs have and will continue to depend highly on many factors, as discussed further below as well as under "ITEM 2. MANAGEMENT'S DISCUSSION OF AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS&#8212;Liquidity and Capital Resources&#8212;Plan of Operations and Future Funding Requirements" in Part I of this report. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has devoted, and may continue to devote, significant time and we may incur substantial costs in pursuing, evaluating and negotiating potential capital-raising transactions and those efforts may not prove successful on a timely basis, or at all. If we cannot raise adequate additional capital when needed, we may be forced to reduce, or even terminate our operations. We may delay, scale back or eliminate one or more of our product development programs; delay, limit or terminate activities in support of our third-party collaborator&#8217;s commercialization of XACIATO in the U.S.; relinquish rights under our license agreements with third parties relating to our product and product candidates; forgo opportunities to expand our product portfolio; take other measures to reduce our expenses; reorganize or merge with another entity; or file for bankruptcy or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and our stockholders may lose all or part of their investment in our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital needs have depended on, and will continue to depend on, many factors that are highly variable and difficult to predict, including:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product development programs we choose to pursue;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and pace of preclinical and clinical development;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical activities and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of obtaining clinical supplies of product candidates and commercial supplies of products;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of regulatory submissions and decisions by the FDA and other regulatory authorities on our applications to commence and advance clinical development of and to market our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of payments to third parties required under acquisition, in-license and other agreements relating our rights to develop and commercialize our product and product candidates;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of commercialization activities we undertake or engage third parties to undertake for any approved product;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of future royalty, milestone or other payments, if any, we receive under our commercial collaboration agreements for XACIATO and Ovaprene;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, and establish new, strategic collaborations relating to the development and/or commercialization of our product and product candidates;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire, in-license, or otherwise invest in new product candidates or technologies and the terms of any such transaction; and</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we add product candidates to our portfolio, should our existing product candidates require testing or other capital-intensive development activities that we do not anticipate, should the duration of our clinical trials be longer than anticipated, should manufacturing and supply be disrupted, or should regulatory approvals be delayed, our cash resources will be further strained. Should our product development efforts succeed, we will need to develop a commercialization plan for each product, which may also require significant resources to create and implement. In addition, the terms of any collaboration agreements for development and/or commercialization of our product and product candidates may significantly impact our need for additional capital. Because of these uncertainties and the other risks and uncertainties discussed in the &#8220;Risk Factors&#8221; sections of this report and our 2022 10-K, we cannot reasonably estimate the amount funding necessary to successfully complete development of and seek regulatory approval for our product candidates or to commercialize any approved products. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our planned operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to raise additional capital through a variety of means, including equity, equity-linked or debt securities offerings, government or other grant funding, strategic collaborations or alliances, debt, royalty monetization or other structured financings, or other similar types of arrangements. Our past success in raising capital through equity offerings, grant funding and collaboration agreements should not be viewed as an indication we will be successful in raising capital through those or any other means in the future. We expect that our ability to raise additional capital and the amount of capital available to us will depend not only on progress we and our collaborators make toward successfully developing, obtaining regulatory approval for and commercializing our product and product candidates, but also on factors outside of our control, such as macroeconomic and financial market conditions. To the extent we seek to obtain additional capital before achieving clinical, regulatory and/or sales milestones or when our stock price or trading volume or both are low, or when the general market for biopharmaceutical or women&#8217;s health companies is weak, additional capital may not be available to us on favorable terms, or at all.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unstable and unfavorable market and economic conditions may harm our ability to raise additional capital. An economic downturn, recession or recessionary concerns, increased inflation, rising interest rates, adverse developments affecting financial institutions or the financial services industry, or the occurrence or continued occurrence of events similar to those in recent years, such as the COVID-19 pandemic or other public health emergencies, geopolitical conflict (such as the war in Ukraine), natural/environmental disasters, supply-chain disruptions, terrorist attacks, strained relations between the U.S. and a number of other countries, social and political discord and unrest in the U.S. and other countries, and government shutdowns, among others, increase market volatility and have long-term adverse effects on the U.S. and global economies and financial markets. Volatility and deterioration in the financial markets and liquidity constraints or other adverse developments affecting financial institutions may make equity or debt financings more difficult, more costly or more dilutive and may increase competition for, or limit the availability of, funding from other third-party sources, such as from strategic collaborations and government and other grants.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is no assurance that we will continue to satisfy the listing requirements of the Nasdaq Capital Market.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market. As previously reported, on July 19, 2023, we received a letter from the Listing Qualifications Department (the &#8220;Nasdaq Staff&#8221;) of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;), and that we have initial period of 180 calendar days, or until January 16, 2024 (the &#8220;Compliance Date&#8221;), to regain compliance. We will regain compliance if the closing bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business days during such 180-day period, unless the Nasdaq Staff exercises its discretion to extend such 10-day period. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have not regained compliance by the Compliance Date, we may be eligible for an additional 180 calendar day compliance period. To qualify for this additional compliance period, we would have to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, including having stockholders&#8217; equity of at least $5.0 million under the &#8220;Equity Standard&#8221; or of at least $4.0 million under the &#8220;Market Value of Listed Securities Standard&#8221; or &#8220;Net Income Standard,&#8221; and we would need to provide written notice of our intention to cure the minimum bid price deficiency during the additional compliance period, by effecting a reverse stock split, if necessary. If we are not granted the additional compliance period for any reason, the Nasdaq Staff will provide written notice to us that our common stock will be subject to delisting. At that time, we may appeal the Nasdaq Staff&#8217;s delisting determination to a Nasdaq Hearing Panel.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Nasdaq Capital Market requires that companies have: (x) stockholders' equity of at least $2.5 million; (y) a market value of listed securities of at least $35 million; or (z) net income from continuing operations of $500,000 in the company's most recently completed fiscal year or in two of the three most recently completed fiscal years. Our stockholders' equity at June&#160;30, 2023 was negative $2.7 million and we do not currently meet either of the two alternative compliance standards described in clause (y) and (z). Accordingly, we expect to receive a separate notice from Nasdaq informing us that we do not meet the foregoing continued listing requirements. If we receive such a notice, we expect to be afforded 45 days to submit a plan to regain compliance with the stockholders' equity requirement for Nasdaq's consideration, and if the plan is accepted, to be granted an extension period of up to 180 calendar days from the date of the deficiency notice to regain compliance. If the plan is not accepted or if we are unable to regain compliance within any extension period granted by Nasdaq, Nasdaq would be required to issue a delisting determination, which we expect we would be entitled to request a hearing before a Nasdaq Hearings Panel to present a plan to regain compliance and to request a further extension period to regain compliance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance we will regain compliance with the Minimum Bid Price Requirement or continue to satisfy the other continued listing requirements of The Nasdaq Capital Market. The delisting of our common stock, or the commencement of delisting proceedings, for whatever reason could, among other things, substantially impair our ability to raise additional capital; result in the loss of interest from institutional investors, the loss of confidence in our company by investors and employees, and in fewer financing, strategic and business development opportunities; and result in potential breaches of agreements under which we made representations or covenants relating to our compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of our management&#8217;s time and attention and could have a material adverse effect on our financial condition, business and results of operations. In addition, the suspension or delisting of our common stock, or the commencement of delisting proceedings, for whatever reason may materially impair our stockholders&#8217; ability to buy and sell shares of our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_103"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;None</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_106"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_109"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1a96c573cb0642a4ab930e77d995671e_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item in this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">File No.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex31_by-laws.htm">Third Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311_20230630.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312_20230630.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321_20230630.htm">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit322_20230630.htm">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. This certification is being furnished solely to accompany this report pursuant to U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i1a96c573cb0642a4ab930e77d995671e_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:45.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dar&#233; Bioscience, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex31_by-laws.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIRD AMENDED AND RESTATED BY-LAWS</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OF</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DAR&#201; BIOSCIENCE, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(as amended through January 24, 2023)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.340%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE I STOCKHOLDERS</a></font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.1&#160;&#160;&#160;&#160;Place of Meetings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.2&#160;&#160;&#160;&#160;Annual Meeting</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.3&#160;&#160;&#160;&#160;Special Meetings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.4&#160;&#160;&#160;&#160;Notice of Meetings</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.5&#160;&#160;&#160;&#160;Voting List</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.6&#160;&#160;&#160;&#160;Quorum</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.7&#160;&#160;&#160;&#160;Adjournments</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.8&#160;&#160;&#160;&#160;Voting and Proxies</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.9&#160;&#160;&#160;&#160;Action at Meeting</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.10&#160;&#160;&#160;&#160;Nomination of Directors</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.11&#160;&#160;&#160;&#160;Additional Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.12&#160;&#160;&#160;&#160;Business at Annual Meetings Other than Election of Directors</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.13&#160;&#160;&#160;&#160;Conduct of Meetings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.14&#160;&#160;&#160;&#160;No Action by Consent in Lieu of a Meeting</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_64" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE II DIRECTORS</a></font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.1&#160;&#160;&#160;&#160;General Powers</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.2&#160;&#160;&#160;&#160;Number, Election and Qualification</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.3&#160;&#160;&#160;&#160;Chair of the Board&#59; Vice Chair of the Board</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.4&#160;&#160;&#160;&#160;Classes of Directors</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.5&#160;&#160;&#160;&#160;Terms of Office</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.6&#160;&#160;&#160;&#160;Quorum</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.7&#160;&#160;&#160;&#160;Action at Meeting</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.8&#160;&#160;&#160;&#160;Removal</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.9&#160;&#160;&#160;&#160;Vacancies</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.10&#160;&#160;&#160;&#160;Resignation</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.11&#160;&#160;&#160;&#160;Regular Meetings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.12&#160;&#160;&#160;&#160;Special Meetings</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.13&#160;&#160;&#160;&#160;Notice of Special Meetings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.14&#160;&#160;&#160;&#160;Meetings by Conference Communications Equipment</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.15&#160;&#160;&#160;&#160;Action by Consent</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.16&#160;&#160;&#160;&#160;Committees</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.17&#160;&#160;&#160;&#160;Compensation of Directors</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_79" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE III OFFICERS</a></font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.1&#160;&#160;&#160;&#160;Titles</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.2&#160;&#160;&#160;&#160;Election</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.3&#160;&#160;&#160;&#160;Qualification</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.4&#160;&#160;&#160;&#160;Tenure</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.5&#160;&#160;&#160;&#160;Resignation and Removal</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.6&#160;&#160;&#160;&#160;Vacancies</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.7&#160;&#160;&#160;&#160;President&#59; Chief Executive Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.8&#160;&#160;&#160;&#160;Chief Financial Officer</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.9&#160;&#160;&#160;&#160;Vice Presidents</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.10&#160;&#160;&#160;&#160;Secretary and Assistant Secretaries</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.11&#160;&#160;&#160;&#160;Treasurer and Assistant Treasurers</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.12&#160;&#160;&#160;&#160;Salaries</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.13&#160;&#160;&#160;&#160;Delegation of Authority</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_94" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE IV CAPITAL STOCK</a></font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.1&#160;&#160;&#160;&#160;Issuance of Stock</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.2&#160;&#160;&#160;&#160;Stock Certificates&#59; Uncertificated Shares</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.3&#160;&#160;&#160;&#160;Transfers</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.4&#160;&#160;&#160;&#160;Lost, Stolen or Destroyed Certificates</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.5&#160;&#160;&#160;&#160;Record Date</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4.6&#160;&#160;&#160;&#160;Regulations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_109" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE V GENERAL PROVISIONS</a></font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.1&#160;&#160;&#160;&#160;Fiscal Year</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.2&#160;&#160;&#160;&#160;Corporate Seal</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.3&#160;&#160;&#160;&#160;Waiver of Notice</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.4&#160;&#160;&#160;&#160;Voting of Securities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.5&#160;&#160;&#160;&#160;Evidence of Authority</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.6&#160;&#160;&#160;&#160;Certificate of Incorporation</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.7&#160;&#160;&#160;&#160;Severability</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.8&#160;&#160;&#160;&#160;Pronouns</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5.9&#160;&#160;&#160;&#160;Forum Selection By-law</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_124" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE</a><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_124" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> VI AMENDMENTS</a></font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i730b9ba60ebf4922b76cc6e01a4cbfab_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">24</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-ii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE I</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STOCKHOLDERS</font></div><div style="text-indent:18pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.95pt;text-decoration:underline">Place of Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All meetings of stockholders shall be held at such place as may be designated from time to time by the Board of Directors, the Chair of the Board, the Chief Executive Officer or the President or, if not so designated, at the principal office of the corporation.  The Board of Directors may, in its sole discretion, determine that any meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized under General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Annual Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The annual meeting of stockholders for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly be brought before the meeting shall be held on a date and at a time designated by the Board of Directors, the Chair of the Board, the Chief Executive Officer or the President (which date shall not be a legal holiday in the place where the meeting is to be held).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Special Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Special meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chair of the Board or the Chief Executive Officer, and may not be called by any other person or persons.  The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders.  Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Notice of Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Except as otherwise provided by law, notice of each meeting of stockholders, whether annual or special, shall be delivered by the corporation to each stockholder entitled to vote at such meeting not less than 10 nor more than 60 days before the date of the meeting, either personally, by mail, by courier service, or, in accordance with any applicable requirements of the DGCL, by electronic transmission (as such term is defined in the DGCL).  Without limiting the manner by which notice otherwise may be given to stockholders, any written, printed, or electronic notice of all meetings shall state the place, if any, date and time of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), and shall specify the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at any such meeting.  The notice of a special meeting shall state, in addition, the purpose or purposes for which the meeting is called.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">If notice is given by mail, such notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the corporation.  If notice is delivered by courier service, such notice shall be deemed given on the earlier of when the notice is received or left at the stockholder&#8217;s address.  If notice is delivered by electronic mail (as such term is defined in the DGCL), such notice shall be deemed given when directed to such stockholder&#8217;s electronic mail address (unless the stockholder has notified the corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by the DGCL to be given by electronic transmission).  A notice by electronic mail must include a prominent legend that the communication is an important notice regarding the corporation, and will be deemed to include any files attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information of an officer or agent of the corporation who is available to assist with accessing such files or information.  Notice given by electronic transmission (other than electronic mail) shall be effective if it is given by a form of electronic transmission consented to by the stockholder (in a manner consistent with the DGCL) to whom the notice is directed.  Such notice shall be deemed given at the time specified in Section 232 of the DGCL.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Whenever any notice is required to be given to any stockholder under the provisions of the DGCL or these amended By-laws, a waiver thereof in writing, signed by the person or persons entitled to such notice, or a waiver by electronic transmission by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Voting List</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The corporation shall prepare, no later than the 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder.  Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of 10 days ending on the day before the meeting date&#58;  (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the corporation.  In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation.  The list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided by law, the Certificate of Incorporation or these By-laws, the holders of a majority in voting power of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum for the transaction of business&#59; provided, however, that where a separate vote by a class or classes or series of capital stock is required by law or the Certificate of Incorporation, the holders of a majority in voting power of the shares of such class or classes or series of the capital stock of the corporation issued and outstanding and entitled to vote on such matter, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum entitled to take action with respect to the vote on such matter.  A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Adjournments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any meeting of stockholders may be adjourned from time to time to any other time and to any other place at which a meeting of stockholders may be held under these By-laws (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), by the chair of the meeting or by the stockholders present or represented at the meeting and entitled to vote, although less than a quorum.  It shall not be necessary to notify any stockholder of any adjournment of less than 30 days if the time, place, date, and means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken&#59; (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxyholders to participate in the meeting by means of remote communication&#59; or (iii) provided in any other manner permitted by the DGCL.  At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting.  If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.  If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with the DGCL, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Voting and Proxies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder and a proportionate vote for each fractional share so held, unless otherwise provided by law or the Certificate of Incorporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Each stockholder of record entitled to vote at a meeting of stockholders may vote in person (including by means of remote communications, if any, by which stockholders may be deemed to be present in person and vote at such meeting) or may authorize another person or persons to vote for such stockholder by a proxy executed or transmitted in a manner permitted by the DGCL by the stockholder or such stockholder&#8217;s authorized agent and delivered (including by electronic transmission) to the Secretary of the corporation.  No such proxy shall be voted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a form of appointment of proxy (i.e., a proxy card) that is a color other than white.  A white-colored proxy card shall be reserved for the exclusive use by the Board of Directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Action at Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  When a quorum is present at any meeting, any matter other than the election of directors to be voted upon by the stockholders at such meeting shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented at the meeting and voting affirmatively or negatively on such matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority in voting power of the shares of stock of that class or series present or represented at the meeting and voting affirmatively or negatively on such matter), except when a different or minimum vote is required by any law applicable to the corporation or its securities, the Certificate of Incorporation or these By-laws, in which case such different or minimum vote shall be the applicable vote on the matter.  When a quorum is present at any meeting, any election by stockholders of directors shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Nomination of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for (1) any directors entitled to be elected by the holders of preferred stock, (2) any directors elected in accordance with Section 2.9 hereof by the Board of Directors to fill a vacancy or newly-created directorship or (3) as otherwise required by applicable law or stock exchange regulation, at any meeting of stockholders, only persons who are nominated in accordance with this Section 1.10 shall be eligible to be elected as directors at an annual or special meeting of stockholders.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Nominations of Candidates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nominations of any person for election to the Board of Directors at an annual meeting or special meeting of the stockholders of the corporation (but, with respect to a special meeting, only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i) by or at the direction of the Board of Directors, including by any committee or persons authorized to do so by the Board of Directors or these By-laws, or (ii) by a stockholder present in person who (A) was a stockholder of record of the corporation both at the time of giving the notice provided for in this Section 1.10 and at the time of the meeting, (B) is entitled to vote at the meeting, and (C) has complied with this Section 1.10 and Section 1.11 with respect to such notice and nomination.  The foregoing clause (ii) shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board of Directors at an annual meeting or special meeting of the stockholders of the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Section 1.10, &#8220;present in person&#8221; shall mean that the stockholder proposing to nominate one or more candidates for election to the Board of Directors at the meeting, or a qualified representative of such stockholder, appears in person at such meeting if such meeting is held solely at a physical location or, in the event that such meeting permits stockholder attendance by means of remote communication, appears by such means of remote communication&#59; a &#8220;qualified representative&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must provide such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, to the Secretary of the corporation prior to or at the time of the meeting of stockholders.  For the avoidance of doubt, notwithstanding anything to the contrary in these By-laws, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) nominating a candidate for election as a director at a meeting is not present in person at the meeting, such candidate shall not be considered for election as a director, and any proxies or votes cast in favor of or for the election of such candidate shall be disregarded (provided, however, that such proxies and&#47;or votes will be counted for the purposes of establishing a quorum).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Stockholder Advance Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.24pt">For a stockholder to make any nomination of a person or persons for election to the Board of Directors at an annual meeting of the stockholders of the corporation, the stockholder must (1) provide Timely Notice (as defined below) thereof in writing and in proper form to the Secretary of the corporation, (2) provide the information, agreements and questionnaires with respect to such stockholder and its candidate(s) for nomination as required to be set forth by this Section 1.10 and Section 1.11 and (3) provide any updates or supplements to such notice at the times and in the forms required by this Section 1.10 and Section 1.11.  To be timely, a stockholder&#8217;s notice </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">must be received in writing by the Secretary of the corporation at the principal executive offices of the corporation not later than the close of business on the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day or earlier than the 120</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to the first anniversary of the preceding year&#8217;s annual meeting&#59; provided, however, that in the event that the date of the annual meeting is advanced by more than 20 days, or delayed by more than 60 days, from the first anniversary of the preceding year&#8217;s annual meeting, a stockholder&#8217;s notice must be so received not earlier than the 120</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such annual meeting and not later than the close of business on the later of (A) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such annual meeting and (B) the 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day following the day on which public disclosure (as defined below) of the date of such annual meeting is first made (such notice within such time periods, &#8220;Timely Notice&#8221;).  In no event shall the adjournment, recess, postponement, judicial stay or rescheduling of an annual meeting (or the public disclosure thereof) commence a new time period (or extend any time period) for the giving of Timely Notice as described above.  For purposes of these By-laws, &#8220;public disclosure&#8221; means disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting of the stockholders of the corporation, then for a stockholder to make any nomination of a person or persons for election to the Board of Directors at such special meeting, the stockholder must (i) provide Timely Notice thereof in writing and in proper form to the Secretary of the corporation at the principal executive offices of the corporation, (ii) provide the information with respect to such stockholder and its candidate(s) for nomination as required by this Section 1.10 and Section 1.11 and (iii) provide any updates or supplements to such notice at the times and in the forms required by this Section 1.10.  To be timely, a stockholder&#8217;s notice for nominations to be made at such special meeting must be received in writing by the Secretary of the corporation at the principal executive offices of the corporation not earlier than the 120</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such special meeting and not later than the close of business on the later of (x) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such special meeting and (y) the 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day following the day on which public disclosure of the date of such special meeting was first made (solely for purposes of special meetings of stockholders of the corporation, the term &#8220;Timely Notice&#8221; shall mean such notice within the time periods set forth in this sentence).  In no event shall the adjournment, recess, postponement, judicial stay or rescheduling of a special meeting (or the public disclosure thereof) commence a new time period (or extend any time period) for the giving of Timely Notice as described above.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">In no event may a Nominating Person (as defined below) provide Timely Notice with respect to a greater number of director candidates than are subject to election by stockholders at the applicable meeting.  If the corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such notice as to any additional nominees shall be due on the later of (A) the conclusion of the time period for Timely Notice, (B) the date set forth in 1.10(c)(ii) or (C) the 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day following the date of public disclosure of such increase.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Contents of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To be in proper form for purposes of this Section&#160;1.10, a stockholder&#8217;s notice to the Secretary of the corporation shall set forth&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.24pt">As to each Nominating Person, (A) the name and address of such Nominating Person (including, if applicable, the name and address that appear on the corporation&#8217;s books and records) and (B) the class and series and number of shares of stock of the corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by each Nominating Person (specifying the type of ownership for the class and&#47;or series and the number of shares of stock of the corporation that are, directly or indirectly, owned of record or beneficially owned by each Nominating Person), except that such Nominating Person shall in all events be deemed to beneficially own any shares of any class or series of the corporation as to which such Nominating Person has a right to acquire beneficial ownership at any time in the future&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As to each Nominating Person, (A) the full notional amount of any securities that, directly or indirectly, underlie any &#8220;derivative security&#8221; (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a &#8220;call equivalent position&#8221; (as such term is defined in Rule 16a-1(b) under the Exchange Act) (&#8220;Synthetic Equity Position&#8221;) and that is, directly or indirectly, held or maintained by such Nominating Person with respect to any shares of any class or series of shares of the corporation&#59; provided that, for the purposes of the definition of &#8220;Synthetic Equity Position,&#8221; the term &#8220;derivative security&#8221; shall also include any security or instrument that would not otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">constitute a &#8220;derivative security&#8221; as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination&#59; and, provided, further, that any Nominating Person satisfying the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than a Nominating Person that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely by reason of Rule 13d-1(b)(1)(ii)(E)) shall not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic Equity Position held by such Nominating Person as a hedge with respect to a bona fide derivatives trade or position of such Nominating Person arising in the ordinary course of such Nominating Person&#8217;s business as a derivatives dealer, (B) any rights to dividends on the shares of any class or series of shares of the corporation owned beneficially by such Nominating Person that are separated or separable from the underlying shares of the corporation, (C) any material pending or threatened legal proceeding in which such Nominating Person is a party or material participant involving the corporation, any affiliate of the corporation, or any of their respective officers or directors, (D) any other material relationship between such Nominating Person, on the one hand, and the corporation, any affiliate of the corporation, or any of their respective officers or directors, on the other hand, (E) any direct or indirect material interest in any material contract or agreement of such Nominating Person with the corporation or any affiliate of the corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), and (F) any other information relating to such Nominating Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the election of directors by such Nominating Person pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A) through (E) are referred to as &#8220;Disclosable Interests&#8221;)&#59; provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Nominating Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these By-laws on behalf of a beneficial owner&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">As to each Nominating Person, a reasonably detailed description of all agreements, arrangements and understandings (A) between or among any of the Nominating Persons and (B) between or among any Nominating Person and any other person or entity (including their names) in connection with the nomination of such candidate&#59; provided, however, that the disclosures required by this paragraph (iii) shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Nominating Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these By-laws on behalf of a beneficial owner&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">As to each Nominating Person, a representation that the Nominating Person will or is part of a group that will (A) solicit proxies from holders of the corporation&#8217;s outstanding capital stock representing at least 67% of the voting power of shares of capital stock entitled to vote on the election of directors, (B) include a statement to that effect in its proxy statement and&#47;or its form of proxy, (C) otherwise comply with Rule 14a-19 under the Exchange Act and (D) provide the Secretary of the corporation not less than five business days prior to the applicable meeting, or any adjournment or postponement thereof, with reasonable documentary evidence that such Nominating Person complied with such representations&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">As to each candidate whom a Nominating Person proposes to nominate for election as a director, (A) all information with respect to such candidate for nomination that would be required to be set forth in a stockholder&#8217;s notice pursuant to this Section 1.10 and Section 1.11 if such candidate for nomination were a Nominating Person, (B) all information relating to such candidate for nomination that is required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14(a) under the Exchange Act (including such candidate&#8217;s written consent to being named in any proxy statement for the applicable meeting and any associated proxy card as a nominee and to serving as a director if elected), (C) a description of any direct or indirect material interest in any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information that would be required to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">disclosed pursuant to Item 404 under Regulation S-K of the SEC if such Nominating Person were the &#8220;registrant&#8221; for purposes of such Item 404 and the candidate for nomination were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (A) through (C) are referred to as &#8220;Nominee Information&#8221;), and (D) a completed and signed questionnaire, representation and agreement as required by Section 1.11(a).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Section 1.10, the term &#8220;Nominating Person&#8221; shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting of the stockholders of the corporation, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made, and (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A under the Exchange Act) with such stockholder in such solicitation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Updating of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A stockholder providing notice of any nomination proposed to be made at a meeting of the stockholders of the corporation shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 1.10 shall be true and correct as of the record date for stockholders entitled to vote at such meeting and as of the date that is 10 business days prior to the date of such meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the corporation at the principal executive offices of the corporation (or any other office specified by the corporation in any public disclosure) not later than five business days after the record date for stockholders entitled to vote at such meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for such meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to such meeting or any adjournment or postponement thereof).  Notwithstanding the foregoing, if a Nominating Person no longer intends to solicit proxies pursuant to Section 1.10(d)(iv), such Nominating Person shall inform the corporation of this change by delivering a writing to the Secretary of the corporation at the principal executive offices of the corporation (or any other office specified by the corporation in any public disclosure) no later than two business days after the occurrence of such change.  For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these By-laws shall not limit the corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nomination.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Required Compliance with the Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the requirements of this Section 1.10 with respect to any nomination proposed to be made at a meeting of the stockholders of the corporation, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations.  Notwithstanding the foregoing provisions of this Section 1.10, unless otherwise required by law, (i) no Nominating Person shall solicit proxies in support of the election of director nominees at such meeting other than the Board of Directors&#8217; nominees unless such Nominating Person has complied with Rule 14a-19 under the Exchange Act in connection with the solicitation of such proxies with respect to such meeting, including the provision to the corporation of notices required thereunder in a timely manner and (ii) if any Nominating Person (1) provides notice pursuant to Rules 14a-19(a)(1) and (b) under the Exchange Act and (2) subsequently fails to comply with the requirements of Rule 14a&#8209;19 under the Exchange Act (including the provision to the corporation of notices required thereunder in a timely manner and evidence that the Nominating Person on whose behalf a nomination is made complied with such Nominating Person&#8217;s representation as to whether the Nominating Person solicited (or is part of a group which solicited) proxies in support of such nomination as required by clause (A) of Section 1.10(d)(iv)), then the corporation shall disregard any proxies or votes solicited for the Nominating Person&#8217;s candidates, notwithstanding that proxies or votes with respect to such nominations may have been received by the corporation (provided, however, that such proxies and&#47;or votes will be counted for the purposes of establishing a quorum).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Means of Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any written notice, supplement, update or other information required to be delivered to the corporation pursuant to this Section 1.10 must be given by personal delivery, by overnight courier or by registered or certified mail, postage prepaid, to the Secretary at the corporation&#8217;s principal executive offices.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">6</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Additional Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Candidate to Provide Questionnaire, Representation and Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To be eligible to be a candidate for election as a director of the corporation at an annual meeting or special meeting of the stockholders of the corporation, a candidate must be nominated in the manner prescribed in Section 1.10 and a candidate nominated by a stockholder must have previously delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on behalf of the Board of Directors), to the Secretary of the corporation at the principal executive offices of the corporation, (i) a completed written questionnaire with respect to the background, qualifications, stock ownership and independence of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the corporation upon written request of a stockholder therefor) and (ii) a written representation and agreement (in a form provided by the corporation upon written request of a stockholder therefor) that such candidate for nomination (A) is not and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question if such agreement, arrangement or understanding has not been disclosed to the corporation, or if such agreement, arrangement or understanding could limit or interfere with such person&#8217;s ability to comply, if elected as a director of the corporation, with such person&#8217;s fiduciary duties under applicable law, (B) may not be, and may not become, a party to any compensatory, payment, indemnification or other financial agreement, arrangement or understanding with any person or entity other than the corporation in connection with service or action as a director that has not been disclosed to the corporation, and (C) will comply with all of the corporation&#8217;s corporate governance, conflict of interest, confidentiality, and stock ownership and trading policies and guidelines, and any other corporation policies and guidelines applicable to directors (and, if requested by any candidate for nomination, the Secretary of the corporation shall provide to such candidate for nomination all such policies and guidelines then in effect).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Candidate to Furnish Certain Other Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The corporation may request such additional information as necessary to permit the Board of Directors to determine if each candidate for election as a director of the corporation is independent under any applicable listing standards, any applicable rules of the SEC and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the corporation&#8217;s directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Updating Candidate Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A candidate for nomination as a director shall further update and supplement the materials delivered pursuant to this Section 1.11, if necessary, so that the information provided or required to be provided pursuant to this Section 1.11 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the corporation at the principal executive offices of the corporation (or any other office specified by the corporation in any public disclosure) not later than five business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten business days prior to the meeting or any adjournment or postponement thereof).  For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these By-laws shall not limit the corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed to be brought before a meeting of the stockholders.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Rejection of Nominee for Non-compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No candidate shall be eligible for nomination as a director of the corporation, or be seated as a director, unless such candidate and the Nominating Person seeking to place such candidate&#8217;s name in nomination has complied with Section 1.10 and with this Section 1.11.  The chair of the meeting shall, if the facts warrant, determine that a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">7</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">nomination was not properly made in accordance with Section 1.10 and with this Section 1.11, and if he or she should so determine, he or she shall so declare such determination to the meeting and the defective nomination shall be disregarded, notwithstanding that proxies or votes in respect of such nomination may have been received by the corporation (provided, however, that such proxies and&#47;or votes will be counted for the purposes of establishing a quorum). </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Business at Annual Meetings Other than Election of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At any annual meeting of the stockholders of the corporation, only such business shall be conducted as shall have been properly brought before the meeting.  To be properly brought before an annual meeting of the stockholders of the corporation, business must be (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (ii) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (iii) properly brought before the meeting by a stockholder of the corporation present in person who (A) (1) was a stockholder of record of the corporation both at the time of giving the notice provided for in this Section 1.12 and at the time of the meeting, (2) is entitled to vote at the meeting, and (3) has complied with this Section 1.12 in all applicable respects or (B) properly made such proposal in accordance with Rule 14a-8 under the Exchange Act.  The foregoing clause (iii) shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders of the corporation.  Stockholders seeking to nominate persons for election to the Board of Directors must comply with Section 1.10 and Section 1.11, and this Section 1.12 shall not be applicable to such nominations.  Furthermore, for any business to be properly brought before the meeting by a stockholder, such business must constitute a proper matter under Delaware law for stockholder action.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Section 1.12, &#8220;present in person&#8221; means that the stockholder proposing that the business be brought before the annual meeting of the stockholders of the corporation, or a qualified representative of such proposing stockholder, appears in person at such annual meeting if the annual meeting of the stockholders of the corporation is held solely at a physical location or, in the event that the annual meeting permits stockholder attendance by means of remote communication, appears by such means of remote communication&#59; and a &#8220;qualified representative&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the annual meeting of stockholders and such person must provide such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, to the Secretary of the corporation prior to or at the time of such annual meeting.  For the avoidance of doubt, notwithstanding anything to the contrary in these By-laws, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) proposing business to be conducted at a meeting is not present in person at the annual meeting, such business shall not be considered, and no vote shall be taken with respect to such proposed business, notwithstanding that proxies in respect of such business may have been received by the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Timeliness of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For business to be properly brought before an annual meeting of the stockholders of the corporation by a stockholder, the stockholder must (i)&#160;provide Timely Notice (as defined in Section 1.10) thereof in writing and in proper form to the Secretary of the corporation and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 1.12.  In no event shall the adjournment, recess, postponement, judicial stay or rescheduling of an annual meeting (or the public disclosure thereof) commence a new time period (or extend any time period) for the giving of Timely Notice.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Contents of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To be in proper form for purposes of this Section&#160;1.12, a stockholder&#8217;s notice to the Secretary of the corporation shall set forth&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.24pt">As to each item of business that the Proposing Person (as defined below) proposes to bring before such annual meeting&#58; (A) a brief description of the business desired to be brought before the annual meeting, (B) the text of the proposal or business (including the exact text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend the By-laws, the exact text of the proposed amendment), (C) the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (D) a reasonably detailed description of all agreements, arrangements and understandings (x) between or among any of the Proposing Persons or (y) between or among any Proposing Person and any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">person or entity (including their names) in connection with the proposal of such business by the Proposing Persons and (E) all other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act&#59; provided, however, that the disclosures required by this paragraph (i) shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these By-laws on behalf of a beneficial owner&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As to each Proposing Person, (A) the name and address of such Proposing Person (including, if applicable, the name and address that appear on the corporation&#8217;s books and records)&#59; and (B) the class and series and number of shares of stock of the corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by each Proposing Person (specifying the type of ownership for the class and&#47;or series and the number of shares of stock of the corporation that are, directly or indirectly, owned of record or beneficially owned by each Proposing Person), except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">As to each Proposing Person, (A) any Disclosable Interests (as defined in Section 1.10(d)(ii), except that for purposes of this Section 1.12, the term &#8220;Proposing Person&#8221; shall be substituted for the term &#8220;Nominating Person&#8221; in all places it appears in Section 1.10(d)(ii))), (B) a representation that such Proposing Person intends or is part of a group that intends to deliver a proxy statement or form of appointment of proxy to holders of at least the percentage of the corporation&#8217;s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal, and (C) any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Section 1.12, the term &#8220;Proposing Person&#8221; shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting of stockholders of the corporation, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before such annual meeting is made, and (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A under the Exchange Act) with such stockholder in such solicitation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Required Updating of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Proposing Person shall update and supplement its notice to the corporation of its intent to propose business at an annual meeting of stockholders of the corporation, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 1.12 shall be true and correct as of the record date for stockholders entitled to vote at such annual meeting and as of the date that is 10 business days prior to such annual meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the corporation at the principal executive offices of the corporation (or any other office specified by the corporation in any public disclosure) not later than five business days after the record date for stockholders entitled to vote at such annual meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for such annual meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which such annual meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to the meeting or any adjournment or postponement thereof).  For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these By-laws shall not limit the corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding matters, business or resolutions proposed to be brought before a meeting of the stockholders.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Requirement for Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything in these By-laws to the contrary, no business shall be conducted at an annual meeting of the stockholders of the corporation that is not properly brought before such annual meeting in accordance with this Section 1.12.  The chair </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of any annual meeting of stockholders of the corporation shall have the power and duty to determine whether business was properly brought before the annual meeting in accordance with the provisions of this Section 1.12 (including whether the Proposing Person solicited (or is part of a group which solicited) or did not so solicit, as the case may be, proxies in support of such Proposing Person&#8217;s proposal in compliance with the representation with respect thereto required by this Section 1.12), and if the chair should determine that business was not properly brought before the annual meeting in accordance with the provisions of this Section 1.12, the chair shall so declare to the meeting and such business shall not be brought before the annual meeting, in each case, notwithstanding that proxies or votes with respect to such business may have been received by the corporation (provided, however, that such proxies and&#47;or votes will be counted for the purposes of establishing a quorum).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Applicability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Section 1.12 is expressly intended to apply to any business proposed to be brought before an annual meeting of the stockholders of the corporation other than any proposal made in accordance with Rule 14a-8 under the Exchange Act and included in the corporation&#8217;s proxy statement.  In addition to the requirements of this Section 1.12 with respect to any business proposed to be brought before an annual meeting of stockholders of the corporation, each Proposing Person shall comply with all applicable requirements of state law and of the Exchange Act, and the rules and regulations thereunder, with respect to any such business.  Nothing in this Section 1.12 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Other</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise required by law, nothing in this Section 1.12 shall obligate the corporation or the Board of Directors to include in any proxy statement (or other stockholder communication distributed on behalf of the corporation or the Board of Directors) information with respect to any proposal submitted by a stockholder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt;text-decoration:underline">Means of Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any written notice, supplement, update or other information required to be delivered to the corporation pursuant to this Section 1.12 must be given by personal delivery, by overnight courier or by registered or certified mail, postage prepaid, to the Secretary of the corporation at the corporation&#8217;s principal executive offices.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Conduct of Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Meetings of stockholders of the corporation shall be presided over by the Chief Executive Officer of the corporation or the Chair of the Board, if any, or in their absence, by the Vice Chair of the Board, if any, or in the Vice Chair&#8217;s absence, by the President of the corporation (if different than the Chief Executive Officer), or in the President&#8217;s absence, by a Vice President of the corporation, or in the absence of all of the foregoing persons, by a chair designated by the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Board of Directors may adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders of the corporation as it shall deem appropriate, including, without limitation, such guidelines and procedures as it may deem appropriate regarding the participation by means of remote communication of stockholders and proxyholders not physically present at a meeting.  Except to the extent inconsistent with such rules, regulations and procedures as adopted by the Board of Directors, the chair of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chair, are appropriate for the proper conduct of the meeting.  Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chair of the meeting, may include, without limitation, the following&#58;  (i) the establishment of an agenda or order of business for the meeting&#59; (ii) rules and procedures for maintaining order at the meeting and the safety of those present&#59; (iii) limitations on attendance at or participation in the meeting to stockholders of record of the corporation, their duly authorized and constituted proxies or such other persons as shall be determined&#59; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof&#59; and (v) limitations on the time allotted to questions or comments by participants.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The chair of the meeting shall announce at the meeting when the polls for each matter to be voted upon at the meeting will be opened and closed.  After the polls close, no ballots, proxies or votes or any revocations or changes thereto may be accepted.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">In advance of any meeting of stockholders of the corporation, the Board of Directors, the Chair of the Board, the Chief Executive Officer or the President shall appoint one or more inspectors of election to act at the meeting and make a written report thereof.  One or more other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">persons may be designated as alternate inspectors to replace any inspector who fails to act.  If no inspector or alternate is present, ready and willing to act at a meeting of stockholders of the corporation, the chair of the meeting shall appoint one or more inspectors to act at the meeting.  Unless otherwise required by law, inspectors may be officers, employees or agents of the corporation.  Each inspector, before entering upon the discharge of such inspector&#8217;s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability.  The inspector shall have the duties prescribed by law and shall take charge of the polls and, when the vote is completed, shall make a certificate of the result of the vote taken and of such other facts as may be required by law.  Every vote taken by ballots shall be counted by a duly appointed inspector or duly appointed inspectors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">No Action by Consent in Lieu of a Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Stockholders of the corporation may not take any action by written consent in lieu of a meeting.</font></div><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">11</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DIRECTORS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">General Powers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The business and affairs of the corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the corporation except as otherwise provided by law or the Certificate of Incorporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Number, Election and Qualification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights of holders of any series of Preferred Stock to elect directors, the number of directors of the corporation shall be established by the Board of Directors.  The election of directors need not be by written ballot.  Directors need not be stockholders of the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Chair of the Board&#59; Vice Chair of the Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Board of Directors may appoint from its members a Chair of the Board and a Vice Chair of the Board, neither of whom need be an employee or officer of the corporation.  If the Board of Directors appoints a Chair of the Board, such Chair shall perform such duties and possess such powers as are assigned by the Board of Directors and, if the Chair of the Board is also designated as the corporation&#8217;s Chief Executive Officer, shall have the powers and duties of the Chief Executive Officer prescribed in Section 3.7 of these By-laws.  If the Board of Directors appoints a Vice Chair of the Board, such Vice Chair shall perform such duties and possess such powers as are assigned by the Board of Directors.  Unless otherwise provided by the Board of Directors, the Chair of the Board or, in the Chair&#8217;s absence, the Vice Chair of the Board, if any, shall preside at all meetings of the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Classes of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be and is divided into three classes&#58;  Class I, Class II and Class III.  Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors.  The allocation of directors among classes shall be determined by resolution of the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Terms of Office</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected&#59; provided that the term of each director shall continue until the election and qualification of his or her successor and be subject to his or her earlier death, resignation or removal.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The greater of (a) a majority of the directors at any time in office and (b) one-third of the number of directors established by the Board of Directors pursuant to Section&#160;2.2 of these By-laws shall constitute a quorum of the Board of Directors.  If at any meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Action at Meeting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or by the Certificate of Incorporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights of holders of any series of Preferred Stock, directors of the corporation may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly-created directorship on the Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and shall not be filled by the stockholders.  A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor or until such director&#8217;s earlier death, resignation or removal.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any director may resign by delivering a resignation in writing or by electronic transmission to the corporation at its principal office or to the Chair of the Board, the Chief Executive Officer, the President or the Secretary.  Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">12</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Regular Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Regular meetings of the Board of Directors may be held without notice at such time and place as shall be determined from time to time by the Board of Directors&#59; provided that any director who is absent when such a determination is made shall be given notice of the determination.  A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders of the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Special Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Special meetings of the Board of Directors may be held at any time and place designated in a call by the Chair of the Board, the Chief Executive Officer, the President, two or more directors, or by one director in the event that there is only a single director in office.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Notice of Special Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notice of the date, place and time of any special meeting of directors shall be given to each director by the Secretary of the corporation or by the officer or one of the directors calling the meeting.  Notice shall be duly given to each director (a) in person or by telephone at least 24 hours in advance of the meeting, (b) by sending written notice by reputable overnight courier, telecopy, facsimile or electronic transmission, or delivering written notice by hand, to such director&#8217;s last known business, home or electronic transmission address at least 48 hours in advance of the meeting, or (c) by sending written notice by first-class mail to such director&#8217;s last known business or home address at least 72 hours in advance of the meeting.  A notice or waiver of notice of a meeting of the Board of Directors need not specify the purposes of the meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Meetings by Conference Communications Equipment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Directors may participate in meetings of the Board of Directors or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Action by Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing or by electronic transmission.  After an action is taken, the consent or consents relating thereto shall be filed with the minutes of proceedings of the Board of Directors or committee.  Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Committees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the corporation with such lawfully delegable powers and duties as the Board of Directors thereby confers, to serve at the pleasure of the Board of Directors.  The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.  In the absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.  Any such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation and may authorize the seal of the corporation to be affixed to all papers which may require it.  Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request.  Except as the Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-laws for the Board of Directors.  Except as otherwise provided in the Certificate of Incorporation, these By-laws, or the resolution of the Board of Directors designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Compensation of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Directors may be paid such compensation for their services and such reimbursement for expenses of attendance at meetings as the Board of Directors may from time to time determine.  No such payment shall preclude any director from serving the corporation or any of its parent or subsidiary entities in any other capacity and receiving compensation for such service.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">13</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFFICERS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The officers of the corporation shall consist of a Chief Executive Officer, a President, and a Secretary, and such other officers with such other titles as the Board of Directors shall determine, including a Chief Financial Officer, a Treasurer, and one or more Vice Presidents, Assistant Treasurers and Assistant Secretaries.  The Board of Directors may appoint such other officers as it may deem appropriate to carry on the business of the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each officer of the corporation shall be elected by the Board of Directors and shall hold office for such term as may be prescribed by the Board of Directors and until such person&#8217;s successor shall have been duly elected and qualified, or until such person&#8217;s earlier death, disqualification, resignation or removal.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Qualification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No officer need be a stockholder or director of the corporation.  Any two or more offices may be held by the same person.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Tenure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided by law, by the Certificate of Incorporation or by these By-laws, each officer shall hold office until such officer&#8217;s successor is elected and qualified, unless a different term is specified in the resolution electing or appointing such officer, or until such officer&#8217;s earlier death, resignation or removal.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Resignation and Removal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any officer may resign by delivering a written resignation to the corporation at its principal office or to the Chief Executive Officer, the President or the Secretary.  Such resignation shall be effective upon receipt unless it is specified to be effective at some later time or upon the happening of some later event.  Any officer may be removed at any time, with or without cause, by vote of a majority of the directors then in office.  Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to any compensation as an officer for any period following such officer&#8217;s resignation or removal, or any right to damages on account of such removal, whether such officer&#8217;s compensation be by the month or by the year or otherwise, unless such compensation is expressly provided for in a duly authorized written agreement with the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Board of Directors may fill any vacancy occurring in any office for any reason and may, in its discretion, leave unfilled for such period as it may determine any offices other than those of Chief Executive Officer, President, and Secretary.  Each such successor shall hold office for the unexpired term of such officer&#8217;s predecessor and until a successor is elected and qualified, or until such officer&#8217;s earlier death, resignation or removal.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">President&#59; Chief Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Unless the Board of Directors has designated another person as the corporation&#8217;s Chief Executive Officer, the President shall be the Chief Executive Officer of the corporation.  The Chief Executive Officer shall have general charge and supervision of the business of the corporation subject to the direction of the Board of Directors, and shall perform all duties and have all powers that are commonly incident to the office of chief executive or that are delegated to such officer by the Board of Directors.  The President shall perform such other duties and shall have such other powers as the Board of Directors or the Chief Executive Officer (if the President is not the Chief Executive Officer) may from time to time prescribe.  In the event of the absence, inability or refusal to act of the Chief Executive Officer or the President (if the President is not the Chief Executive Officer), the Vice President (or if there shall be more than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the Chief Executive Officer and when so performing such duties shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Chief Financial Officer shall exercise all the powers and perform the duties of the office of the chief financial officer and in general have overall supervision of the financial operations of the corporation.  The Chief Financial Officer shall, when requested, counsel with and advise the other officers of the corporation and shall perform such other duties as the Board of Directors or the Chief Executive Officer may from time to time prescribe.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Vice Presidents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Vice President shall perform such duties and possess such powers as the Board of Directors or the Chief Executive Officer may from time to time prescribe.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">14</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Board of Directors may assign to any Vice President the title of Executive Vice President, Senior Vice President or any other title selected by the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Secretary and Assistant Secretaries</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Secretary shall perform such duties and shall have such powers as the Board of Directors or the Chief Executive Officer may from time to time prescribe.  In addition, the Secretary shall perform such duties and have such powers as are incident to the office of the secretary, including without limitation the duty and power to give notices of all meetings of stockholders and special meetings of the Board of Directors, to attend all meetings of stockholders and the Board of Directors and keep a record of the proceedings (or designate any other person to serve as secretary of the meeting to keep a record of the proceedings), to maintain a stock ledger and prepare lists of stockholders and their addresses as required, to be custodian of corporate records and the corporate seal and to affix and attest to the same on documents.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Any Assistant Secretary shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the Secretary may from time to time prescribe.  In the event of the absence, inability or refusal to act of the Secretary, the Assistant Secretary (or if there shall be more than one, the Assistant Secretaries in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the Secretary.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the absence of the Secretary or any Assistant Secretary at any meeting of stockholders or directors, the chair of the meeting shall designate a secretary for the meeting to keep a record of the proceedings of the meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Treasurer and Assistant Treasurers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned by the Board of Directors or the Chief Executive Officer.  In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation the duty and power to keep and be responsible for all funds and securities of the corporation, to deposit funds of the corporation in depositories selected in accordance with these By-laws, to disburse such funds as ordered by the Board of Directors, to make proper accounts of such funds, and to render as required by the Board of Directors statements of all such transactions and of the financial condition of the corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Assistant Treasurers shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the Treasurer may from time to time prescribe.  In the event of the absence, inability or refusal to act of the Treasurer, the Assistant Treasurer (or if there shall be more than one, the Assistant Treasurers in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the Treasurer.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Salaries</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Officers of the corporation shall be entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.62pt;text-decoration:underline">Delegation of Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.  To the extent not set forth in these By-laws, the officers of the corporation shall have such authority and perform such duties as shall be prescribed by the Board of Directors or by officers authorized by the Board of Directors to prescribe their duties.  To the extent that such duties are not so prescribed, such officers shall have such authority and perform the duties which generally pertain to their respective offices, subject to the control of the Chief Executive Officer or the Board of Directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">15</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE IV</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CAPITAL STOCK</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the provisions of the Certificate of Incorporation, the whole or any part of any unissued balance of the authorized capital stock of the corporation or the whole or any part of any shares of the authorized capital stock of the corporation held in the corporation&#8217;s treasury may be issued, sold, transferred or otherwise disposed of by vote of the Board of Directors in such manner, for such lawful consideration and on such terms as the Board of Directors may determine.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Stock Certificates&#59; Uncertificated Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The shares of the corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of the corporation&#8217;s stock shall be uncertificated shares.  Every holder of stock of the corporation represented by certificates shall be entitled to have a certificate, in such form as may be prescribed by law and by the Board of Directors, representing the number of shares held by such holder registered in certificate form.  Each such certificate shall be signed in a manner that complies with Section 158 of the DGCL.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Each certificate for shares of stock which are subject to any restriction on transfer pursuant to the Certificate of Incorporation, these By-laws, applicable securities laws or any agreement among any number of stockholders or among such holders and the corporation shall have conspicuously noted on the face or back of the certificate either the full text of the restriction or a statement of the existence of such restriction.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If the corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and&#47;or rights shall be set forth in full or summarized on the face or back of each certificate representing shares of such class or series of stock, provided that in lieu of the foregoing requirements there may be set forth on the face or back of each certificate representing shares of such class or series of stock a statement that the corporation will furnish without charge to each stockholder who so requests a copy of the full text of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and&#47;or rights.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Within a reasonable time after the issuance or transfer of uncertificated shares, the corporation shall send to the registered owner thereof a notice, in writing or by electronic transmission, containing the information required to be set forth or stated on certificates pursuant to Sections 151, 202(a) or 218(a) of the DGCL or, with respect to Section&#160;151 of DGCL, a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and&#47;or rights.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Shares of stock of the corporation shall be transferable in the manner prescribed by law and in these By-laws.  Transfers of shares of stock of the corporation shall be made only on the books of the corporation or by transfer agents designated to transfer shares of stock of the corporation.  Subject to applicable law, shares of stock represented by certificates shall be transferred only on the books of the corporation by the surrender to the corporation or its transfer agent of the certificate representing such shares properly endorsed or accompanied by a written assignment or power of attorney properly executed, and with such proof of authority or the authenticity of signature as the corporation or its transfer agent may reasonably require.  Except as may be otherwise required by law, by the Certificate of Incorporation or by these By-laws, the corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect to such stock, regardless of any transfer, pledge or other disposition of such stock until the shares have been transferred on the books of the corporation in accordance with the requirements of these By-laws.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Lost, Stolen or Destroyed Certificates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The corporation may issue a new certificate of stock in place of any previously issued certificate alleged to have been lost, stolen or destroyed, upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">16</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such terms and conditions as the Board of Directors may prescribe, including the presentation of reasonable evidence of such loss, theft or destruction and the giving of such indemnity and posting of such bond as the Board of Directors may require for the protection of the corporation or any transfer agent or registrar.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Record Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Board of Directors may fix in advance a date as a record date for the determination of the stockholders entitled to notice of or to vote at any meeting of stockholders, or entitled to receive payment of any dividend or other distribution or allotment of any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action.  Such record date shall not precede the date on which the resolution fixing the record date is adopted, and such record date shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 60 days prior to any other action to which such record date relates.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">If no record date is fixed, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day before the day on which notice is given, or, if notice is waived, at the close of business on the day before the day on which the meeting is held.  If no record date is fixed, the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating to such purpose.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting&#59; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The issue, transfer, conversion and registration of shares of stock of the corporation shall be governed by such other regulations as the Board of Directors may establish.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">17</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_109"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE V</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GENERAL PROVISIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the corporation shall begin on the first day of January of each year and end on the last day of December in each year.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Corporate Seal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The corporate seal shall be in such form as shall be approved by the Board of Directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Waiver of Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever notice is required to be given by law, by the Certificate of Incorporation, by these By-laws, or in accordance with the provisions of the DGCL, a written waiver signed by the person entitled to such notice, or a waiver by electronic transmission by the person entitled to such notice, whether before, at or after the time of the event for which notice is to be given, shall be deemed equivalent to the giving of such notice.  Neither the business nor the purpose of any meeting need be specified in any such waiver.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Voting of Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as the Board of Directors may otherwise designate, the Chief Executive Officer, the President or the Treasurer may waive notice of, vote, or appoint any person or persons to vote, on behalf of the corporation at, and act as, or appoint any person or persons to act as, proxy or attorney-in-fact for this corporation (with or without power of substitution) at, any meeting of stockholders or securityholders of any other entity, the securities of which may be held by this corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Evidence of Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A certificate by the Secretary, or an Assistant Secretary, or a temporary Secretary, as to any action taken by the stockholders, directors, a committee or any officer or representative of the corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All references in these By-laws to the Certificate of Incorporation shall be deemed to refer to the certificate of incorporation of the corporation, as amended and in effect from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any determination that any provision of these By-laws is for any reason inapplicable, illegal or ineffective shall not affect or invalidate any other provision of these By-laws.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Pronouns</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All pronouns used in these By-laws shall be deemed to refer to the masculine, feminine or neuter, singular or plural, as the identity of the person or persons may require.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Forum Selection By-law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law&#58; (i) any derivative action or proceeding brought on behalf of the corporation&#59; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of the corporation, to the corporation or the corporation&#8217;s stockholders&#59; (iii) any action or proceeding asserting a claim against the corporation or any current or former director, officer or other employee of the corporation, arising out of or pursuant to any provision of the DGCL, the Certificate of Incorporation or these By-laws (as each may be amended from time to time)&#59; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or these By-laws (including any right, obligation, or remedy thereunder)&#59; (v) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware&#59; and (vi) any action asserting a claim against the corporation or any director, officer or other employee of the corporation, governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants.  This Section 5.9(a) shall not apply to suits brought to enforce a duty or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">18</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liability created by the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If any action the subject matter of which is within the scope of subparagraph (a) of this Section 5.9 is filed in a court other than a court located within the State of Delaware (a &#8220;Foreign Action&#8221;) in the name of any stockholder, such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce subparagraph (a) of this Section 5.9 (an &#8220;Enforcement Action&#8221;) and (ii) having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">If any provision of this Section 5.9 shall be held to be invalid, illegal or unenforceable as applied to any person, entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Section 5.9, and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">For the avoidance of doubt, any person or entity purchasing or otherwise acquiring or holding any interest in any security of the corporation shall be deemed to have notice of and consented to the provisions of this Section 5.9.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">19</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i730b9ba60ebf4922b76cc6e01a4cbfab_124"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE VI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENTS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These By-laws may be altered, amended or repealed, in whole or in part, or new By-laws may be adopted by the Board of Directors or by the stockholders as provided in the Certificate of Incorporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">20</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311_20230630.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i50c318e5ade9432587c5a105312b0116_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sabrina Martucci Johnson, certify that&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  August&#160;10, 2023 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312_20230630.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc88825563e74d8e8272591aaff0be2a_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lisa Walters-Hoffert, certify that&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;10, 2023 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321_20230630.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic5a3618d20fd4a44959a2f2a7917bce4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended June&#160;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Sabrina Martucci Johnson, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;10, 2023 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322_20230630.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if38f59106ed24412a235eee8d621d14c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended June&#160;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Lisa Walters-Hoffert, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;10, 2023 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dare-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dare="http://darebioscience.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://darebioscience.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAgreements" roleURI="http://darebioscience.com/role/StrategicAgreements">
        <link:definition>0000009 - Disclosure - Strategic Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://darebioscience.com/role/StockholdersEquity">
        <link:definition>0000010 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://darebioscience.com/role/StockBasedCompensation">
        <link:definition>0000011 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedProperties" roleURI="http://darebioscience.com/role/LeasedProperties">
        <link:definition>0000012 - Disclosure - Leased Properties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://darebioscience.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwards" roleURI="http://darebioscience.com/role/GrantAwards">
        <link:definition>0000014 - Disclosure - Grant Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://darebioscience.com/role/NetLossPerShare">
        <link:definition>0000015 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://darebioscience.com/role/SubsequentEvents">
        <link:definition>0000016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954701 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954702 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://darebioscience.com/role/StockholdersEquityTables">
        <link:definition>9954703 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://darebioscience.com/role/StockBasedCompensationTables">
        <link:definition>9954704 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesTables" roleURI="http://darebioscience.com/role/LeasedPropertiesTables">
        <link:definition>9954705 - Disclosure - Leased Properties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://darebioscience.com/role/NetLossPerShareTables">
        <link:definition>9954706 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>9954707 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954708 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails">
        <link:definition>9954709 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAgreementsDetails" roleURI="http://darebioscience.com/role/StrategicAgreementsDetails">
        <link:definition>9954710 - Disclosure - Strategic Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>9954711 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails">
        <link:definition>9954712 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9954713 - Disclosure - Stock Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails">
        <link:definition>9954714 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails">
        <link:definition>9954715 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesAdditionalInformationDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails">
        <link:definition>9954716 - Disclosure - Leased Properties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails">
        <link:definition>9954717 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954717 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954718 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwardsDetails" roleURI="http://darebioscience.com/role/GrantAwardsDetails">
        <link:definition>9954719 - Disclosure - Grant Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://darebioscience.com/role/NetLossPerShareDetails">
        <link:definition>9954720 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://darebioscience.com/role/SubsequentEventsDetails">
        <link:definition>9954721 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dare_MilanaPharmMember" abstract="true" name="MilanaPharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_April2021AtTheMarketSalesAgreementMember" abstract="true" name="April2021AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" abstract="false" name="MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AdditionalPotentialFundingRelatedToGrantAward" abstract="false" name="AdditionalPotentialFundingRelatedToGrantAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_DARELARC1Member" abstract="true" name="DARELARC1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" abstract="false" name="InsuranceFinancingPremiumsTaxesAndFeesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MergerAgreementMember" abstract="true" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmount" abstract="false" name="MilestonePaymentsContingentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NICHDMember" abstract="true" name="NICHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_JulyAndAugust2023AtTheMarketSalesMember" abstract="true" name="JulyAndAugust2023AtTheMarketSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_March2023AtTheMarketSalesAgreementMember" abstract="true" name="March2023AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" abstract="false" name="MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" abstract="true" name="WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_OrganonMember" abstract="true" name="OrganonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_PeriodofInsufficientCashandLiquidityRequirements" abstract="false" name="PeriodofInsufficientCashandLiquidityRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_BayerHealthcareLicenseAgreementMember" abstract="true" name="BayerHealthcareLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_WeightedAverageAmortizationPeriod" abstract="false" name="WeightedAverageAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_ADVATecAgreementMember" abstract="true" name="ADVATecAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_CatalentAndMilanaPharmMember" abstract="true" name="CatalentAndMilanaPharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" abstract="false" name="MilestonePaymentsContingentAmountFirstCommercialSaleAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MicrochipsBiotechInc.Member" abstract="true" name="MicrochipsBiotechInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_PaymentOfAdditionalConsiderationInBusinessCombination" abstract="false" name="PaymentOfAdditionalConsiderationInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="NetProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PercentageOfRoyaltyRate" abstract="false" name="PercentageOfRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dare_ReceivableForExpensesEligibleForReimbursement" abstract="false" name="ReceivableForExpensesEligibleForReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UpfrontLicenseFeeAmountPaid" abstract="false" name="UpfrontLicenseFeeAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" abstract="true" name="StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_SaleOfStockProspectusOfferingAmount" abstract="false" name="SaleOfStockProspectusOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CRADAMember" abstract="true" name="CRADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_AssignmentAgreementMember" abstract="true" name="AssignmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_WorkingCapitalIncreaseDeficit" abstract="false" name="WorkingCapitalIncreaseDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LicenseFeeExpense" abstract="false" name="LicenseFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_EstimatedFairValueOfWarrantsRecordedInEquity" abstract="false" name="EstimatedFairValueOfWarrantsRecordedInEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_HammockPharmaceuticalsInc.Member" abstract="true" name="HammockPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" abstract="true" name="UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_HennepinLicenseAgreementMember" abstract="true" name="HennepinLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" abstract="false" name="PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainCommercialMilestonesMember" abstract="true" name="UponAchievingCertainCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_PercentageOfAggregateCommission" abstract="false" name="PercentageOfAggregateCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dare_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsideration" abstract="false" name="AssetAcquisitionContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_IncreaseDecreaseInDeferredGrantFunding" abstract="false" name="IncreaseDecreaseInDeferredGrantFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_ResearchAndDevelopmentMilestonePayment" abstract="false" name="ResearchAndDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_GoingConcernPolicyTextBlock" abstract="false" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dare_GrantDAREPTB1Member" abstract="true" name="GrantDAREPTB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_MBIMember" abstract="true" name="MBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_ProceedsFromAwardOfGrant" abstract="false" name="ProceedsFromAwardOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ClinicalAndRegulatoryMilestonesMember" abstract="true" name="ClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_NumberOfCommonStockWarrantsExercised" abstract="false" name="NumberOfCommonStockWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_GrantAwardTextBlock" abstract="false" name="GrantAwardTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dare_MaximumPotentialMilestonePayments" abstract="false" name="MaximumPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponReachingCertainWorldwideNetSalesMilestonesMember" abstract="true" name="UponReachingCertainWorldwideNetSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_October2021AtTheMarketSalesAgreementMember" abstract="true" name="October2021AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsiderationCurrent" abstract="false" name="AssetAcquisitionContingentConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_SaleOfStockBrokerageCommissionsExpense" abstract="false" name="SaleOfStockBrokerageCommissionsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" abstract="true" name="LicensedProductOrProcessForVaginalOrUrologicalUseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_DARELBT1Member" abstract="true" name="DARELBT1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_ClassOfWarrantOrRightsWarrantsExpirationDate" abstract="false" name="ClassOfWarrantOrRightsWarrantsExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_GrantADARE204AndADARE214Member" abstract="true" name="GrantADARE204AndADARE214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_InsuranceFinancingInterestRate" abstract="false" name="InsuranceFinancingInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dare_PaymentsToStockholdersRepresentativeInBusinessCombination" abstract="false" name="PaymentsToStockholdersRepresentativeInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ResearchAndDevelopmentAgreementCommitmentAmount" abstract="false" name="ResearchAndDevelopmentAgreementCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PearTreePharmaceuticalsIncMember" abstract="true" name="PearTreePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_JuniperPharmaceuticalsInc.Member" abstract="true" name="JuniperPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_TwoThousandTwentyTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwentyTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRatePrimeRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>dare-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bffa66fc-345c-4707-9273-1e71690fe91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_fefc4f78-aa3f-4d54-935e-52ae7ffd8aa3" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bffa66fc-345c-4707-9273-1e71690fe91e" xlink:to="loc_dare_DeferredGrantFundingCurrent_fefc4f78-aa3f-4d54-935e-52ae7ffd8aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_69b0438e-64dd-484d-8636-acd597cbcc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bffa66fc-345c-4707-9273-1e71690fe91e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_69b0438e-64dd-484d-8636-acd597cbcc0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cabb682b-e95a-4b00-aa39-e9209df6c1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bffa66fc-345c-4707-9273-1e71690fe91e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cabb682b-e95a-4b00-aa39-e9209df6c1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1f158396-bbd9-4856-b76a-01cbda74e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bffa66fc-345c-4707-9273-1e71690fe91e" xlink:to="loc_us-gaap_AccountsPayableCurrent_1f158396-bbd9-4856-b76a-01cbda74e3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a388086b-0a61-4e51-8ff6-5609c839dbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:to="loc_us-gaap_PreferredStockValue_a388086b-0a61-4e51-8ff6-5609c839dbdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_82b4eecd-8773-4f04-afd9-3750af12062f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:to="loc_us-gaap_CommonStockValue_82b4eecd-8773-4f04-afd9-3750af12062f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5101a450-8d1c-4c32-9622-40cb99a72dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5101a450-8d1c-4c32-9622-40cb99a72dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94c3bd49-afbd-4ba1-9955-21501ae7ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94c3bd49-afbd-4ba1-9955-21501ae7ecb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fb2c734-aee3-458f-b532-ae5886619db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af35f521-95d8-47a9-91ad-ff929a87bb4e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fb2c734-aee3-458f-b532-ae5886619db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4102f5d-d347-4ed9-a59a-ee081f33f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_78dc60d0-6392-4e88-a4c5-bc1477fc4fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4102f5d-d347-4ed9-a59a-ee081f33f72a" xlink:to="loc_us-gaap_Liabilities_78dc60d0-6392-4e88-a4c5-bc1477fc4fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6febc6c2-1e98-4c98-997e-ba8d20ebc608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4102f5d-d347-4ed9-a59a-ee081f33f72a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6febc6c2-1e98-4c98-997e-ba8d20ebc608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d35ec640-2cec-42c4-9094-f70bece03a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4102f5d-d347-4ed9-a59a-ee081f33f72a" xlink:to="loc_us-gaap_StockholdersEquity_d35ec640-2cec-42c4-9094-f70bece03a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ea34c6f-0eb5-45f6-9b67-bc339e3e71a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4276b72a-7cbc-4eac-9839-ba1c1846e641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ea34c6f-0eb5-45f6-9b67-bc339e3e71a0" xlink:to="loc_us-gaap_AssetsCurrent_4276b72a-7cbc-4eac-9839-ba1c1846e641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b24ee40-727a-46e2-9aba-6818463cfc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ea34c6f-0eb5-45f6-9b67-bc339e3e71a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b24ee40-727a-46e2-9aba-6818463cfc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1396a493-baff-4cbf-81f4-9d2190541287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ea34c6f-0eb5-45f6-9b67-bc339e3e71a0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1396a493-baff-4cbf-81f4-9d2190541287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01f681d6-146a-432b-bb26-bd66e5c814c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1c3a07f0-1112-484e-8cfd-4f2db767b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01f681d6-146a-432b-bb26-bd66e5c814c3" xlink:to="loc_us-gaap_LiabilitiesCurrent_1c3a07f0-1112-484e-8cfd-4f2db767b0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b9f70b78-1e0f-4379-871b-ffdcd90a5ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01f681d6-146a-432b-bb26-bd66e5c814c3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b9f70b78-1e0f-4379-871b-ffdcd90a5ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0b84ede-3c9e-4ef1-8814-211d5cca1b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01f681d6-146a-432b-bb26-bd66e5c814c3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0b84ede-3c9e-4ef1-8814-211d5cca1b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7cc84a12-2d8c-43b9-928b-0bd19ca7e5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a774bd0-507a-43ab-94a9-b10512ee68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cc84a12-2d8c-43b9-928b-0bd19ca7e5e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a774bd0-507a-43ab-94a9-b10512ee68fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_e4c1fe02-641e-436c-b302-0f39f04deab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cc84a12-2d8c-43b9-928b-0bd19ca7e5e4" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_e4c1fe02-641e-436c-b302-0f39f04deab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4c5edf88-3156-4619-9214-99786d67b291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cc84a12-2d8c-43b9-928b-0bd19ca7e5e4" xlink:to="loc_us-gaap_OtherAssetsCurrent_4c5edf88-3156-4619-9214-99786d67b291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_deaeb3b8-8c8a-4356-bbe8-c89488b7996f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cc84a12-2d8c-43b9-928b-0bd19ca7e5e4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_deaeb3b8-8c8a-4356-bbe8-c89488b7996f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b872d0a6-5576-47b5-aa32-4b12c7ad1ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87d54e3d-892c-43bc-a028-a71ed27cf809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_b872d0a6-5576-47b5-aa32-4b12c7ad1ed7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87d54e3d-892c-43bc-a028-a71ed27cf809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0899e1d0-f691-47b3-8945-3fb693b73cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_275bd92e-7937-4f07-8085-6edfb306ba03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0899e1d0-f691-47b3-8945-3fb693b73cf3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_275bd92e-7937-4f07-8085-6edfb306ba03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_91aae4eb-8192-441a-bf6b-4d9035c8732f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0899e1d0-f691-47b3-8945-3fb693b73cf3" xlink:to="loc_us-gaap_OperatingIncomeLoss_91aae4eb-8192-441a-bf6b-4d9035c8732f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_051a7ac1-bff0-4019-af7f-a8226aa69449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7016ab0-cea4-4c04-8399-a6f1373e6531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_051a7ac1-bff0-4019-af7f-a8226aa69449" xlink:to="loc_us-gaap_NetIncomeLoss_e7016ab0-cea4-4c04-8399-a6f1373e6531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_04eaab38-5a57-421f-9c7e-779d40a00400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_051a7ac1-bff0-4019-af7f-a8226aa69449" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_04eaab38-5a57-421f-9c7e-779d40a00400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ef1b1759-ebbc-44c5-bbaf-fb599894d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3dbcb9bd-38e3-421f-b7bb-9844da1ee47a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ef1b1759-ebbc-44c5-bbaf-fb599894d5d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3dbcb9bd-38e3-421f-b7bb-9844da1ee47a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6cc38497-ee1d-4ec3-9da9-49c7f2a907c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ef1b1759-ebbc-44c5-bbaf-fb599894d5d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6cc38497-ee1d-4ec3-9da9-49c7f2a907c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeExpense_5324218e-a4d1-4ff5-b0ce-a4b252dfafde" xlink:href="dare-20230630.xsd#dare_LicenseFeeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ef1b1759-ebbc-44c5-bbaf-fb599894d5d1" xlink:to="loc_dare_LicenseFeeExpense_5324218e-a4d1-4ff5-b0ce-a4b252dfafde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8e5254a7-bb89-428f-9b75-4a3c580b39bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8e5254a7-bb89-428f-9b75-4a3c580b39bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c092e5f7-ed46-4214-8868-74a64d9c37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c092e5f7-ed46-4214-8868-74a64d9c37c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9361042f-f1ad-4429-9608-f2985a4ce5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9361042f-f1ad-4429-9608-f2985a4ce5a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ae2717a7-2b96-4f76-b712-62681d29ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ae2717a7-2b96-4f76-b712-62681d29ce20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5211cd95-f47d-4c3b-8b28-6efa67842acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_NetIncomeLoss_5211cd95-f47d-4c3b-8b28-6efa67842acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_201f9203-94b3-4aa2-bc43-62f3b8f73355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_201f9203-94b3-4aa2-bc43-62f3b8f73355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aee3be4f-cccb-43f1-ba6a-bc088d0715f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_ShareBasedCompensation_aee3be4f-cccb-43f1-ba6a-bc088d0715f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_998a145c-a130-44b9-bb36-97c28b9102c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_Depreciation_998a145c-a130-44b9-bb36-97c28b9102c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_39a32005-ddad-4aef-b941-23bfa50d0d2e" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_39a32005-ddad-4aef-b941-23bfa50d0d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb19ddff-88e8-46ff-8e28-b7abf08f60d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb19ddff-88e8-46ff-8e28-b7abf08f60d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2b32e376-ecac-4ec0-ab07-3c3f54beb490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2b32e376-ecac-4ec0-ab07-3c3f54beb490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_786e8aca-64a0-4330-9cfc-46987dedb13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_786e8aca-64a0-4330-9cfc-46987dedb13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_18591e82-302a-487e-8f40-b997ebc1a6a1" xlink:href="dare-20230630.xsd#dare_NonCashLeaseExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db46a83c-9ceb-40a4-a6a8-788e52519bb2" xlink:to="loc_dare_NonCashLeaseExpense_18591e82-302a-487e-8f40-b997ebc1a6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfcef313-37f8-40ff-992c-c894ffafefcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_42a10a24-265c-4630-802e-ba4882ea2c28" xlink:href="dare-20230630.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfcef313-37f8-40ff-992c-c894ffafefcf" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_42a10a24-265c-4630-802e-ba4882ea2c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_8d681f00-0496-4227-a7a1-ea5df5007db4" xlink:href="dare-20230630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfcef313-37f8-40ff-992c-c894ffafefcf" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_8d681f00-0496-4227-a7a1-ea5df5007db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88ae5101-b5fa-4cc8-bc0b-a82f8b89bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e4449e22-e405-40b6-946f-1941be802154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88ae5101-b5fa-4cc8-bc0b-a82f8b89bad1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e4449e22-e405-40b6-946f-1941be802154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe0affe0-2d87-4e1d-86c9-639936696ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5ae7c92-f8a9-499c-b385-72faa83adc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe0affe0-2d87-4e1d-86c9-639936696ca1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5ae7c92-f8a9-499c-b385-72faa83adc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f8ad0e0-b135-4b81-9faa-82758369b260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe0affe0-2d87-4e1d-86c9-639936696ca1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f8ad0e0-b135-4b81-9faa-82758369b260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f37131c-4ef4-4efa-b6c9-fa1fc9a92815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe0affe0-2d87-4e1d-86c9-639936696ca1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f37131c-4ef4-4efa-b6c9-fa1fc9a92815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ebcd07d0-f222-48c6-86fc-eb15fe930f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fe0affe0-2d87-4e1d-86c9-639936696ca1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ebcd07d0-f222-48c6-86fc-eb15fe930f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42aa9185-9cfe-4a5c-8561-2da53f679061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_34c8f806-1a92-4a2a-8a2e-517ffd174766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42aa9185-9cfe-4a5c-8561-2da53f679061" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_34c8f806-1a92-4a2a-8a2e-517ffd174766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d1c1506-1b49-4a9a-8a5a-a6f57453deaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42aa9185-9cfe-4a5c-8561-2da53f679061" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d1c1506-1b49-4a9a-8a5a-a6f57453deaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3ae0830-9b8b-42d0-9068-3d306bc37741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f470429a-de25-4450-bc3c-25a7f0078684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3ae0830-9b8b-42d0-9068-3d306bc37741" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f470429a-de25-4450-bc3c-25a7f0078684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f020b7c-6e27-43c5-a281-c61fc4cc35d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3ae0830-9b8b-42d0-9068-3d306bc37741" xlink:to="loc_us-gaap_OperatingLeaseLiability_7f020b7c-6e27-43c5-a281-c61fc4cc35d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecdbc83a-d2be-4d66-8e82-40e381313508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ee69d6fa-2e67-4916-a391-30118c6276f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecdbc83a-d2be-4d66-8e82-40e381313508" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ee69d6fa-2e67-4916-a391-30118c6276f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dad24d36-2640-4ec8-accb-5c915a863a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecdbc83a-d2be-4d66-8e82-40e381313508" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dad24d36-2640-4ec8-accb-5c915a863a41" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>dare-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_283216d6-568a-4722-8820-f30b2af1742c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_SharesOutstanding_283216d6-568a-4722-8820-f30b2af1742c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1fa36a73-a682-4dfe-a905-011c62e12596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockholdersEquity_1fa36a73-a682-4dfe-a905-011c62e12596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d013afd3-e7b8-44c0-aef2-1b01e1a356a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d013afd3-e7b8-44c0-aef2-1b01e1a356a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_c988fd09-adb2-4b0b-877c-5243f0deea3f" xlink:href="dare-20230630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_c988fd09-adb2-4b0b-877c-5243f0deea3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d1fa0baa-e792-40b3-a870-13cfd9c91bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d1fa0baa-e792-40b3-a870-13cfd9c91bd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52f490a4-5c2d-4bf4-91f4-da981a6fcfca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52f490a4-5c2d-4bf4-91f4-da981a6fcfca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d4c39299-2f10-4b2e-895c-6e1ef6f03400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d4c39299-2f10-4b2e-895c-6e1ef6f03400" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dec6553d-19be-432d-9ad5-a9d462c3ab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_NetIncomeLoss_dec6553d-19be-432d-9ad5-a9d462c3ab5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0792ac1-457f-44f6-8dc3-7c706195fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0792ac1-457f-44f6-8dc3-7c706195fa20" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_68532d30-1128-454c-8fb4-78b5d160c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75dbd575-eb31-41c0-b341-14f4792330d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:to="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e71546f8-da06-406a-a9a4-38a8c1f07500_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:to="loc_us-gaap_EquityComponentDomain_e71546f8-da06-406a-a9a4-38a8c1f07500_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:to="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_71ab158c-d178-42ca-924e-c65b943a7e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_CommonStockMember_71ab158c-d178-42ca-924e-c65b943a7e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6fc7245b-9852-4b07-b2a7-e6452076d8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6fc7245b-9852-4b07-b2a7-e6452076d8c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2105a692-817f-4f95-b919-470c97209b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2105a692-817f-4f95-b919-470c97209b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7444302c-ee45-4f0f-8a5b-d26f36497159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_RetainedEarningsMember_7444302c-ee45-4f0f-8a5b-d26f36497159" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_421b6263-d44d-4304-8ea5-ab8a429f261e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:to="loc_us-gaap_NumberOfOperatingSegments_421b6263-d44d-4304-8ea5-ab8a429f261e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14bda9fd-3a4a-45ed-aae0-7d8418e25231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14bda9fd-3a4a-45ed-aae0-7d8418e25231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:to="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_106c1418-c580-4493-a8d2-e1e7742b943c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:to="loc_srt_ProductsAndServicesDomain_106c1418-c580-4493-a8d2-e1e7742b943c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:to="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f1c1394e-ceee-4ba3-80a7-de0e749d82ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:to="loc_us-gaap_LicenseMember_f1c1394e-ceee-4ba3-80a7-de0e749d82ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ff1f30e9-7229-4220-8501-cf60394c4e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ff1f30e9-7229-4220-8501-cf60394c4e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b7e8469-75a1-498b-b3d7-c1af5c9c9ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b7e8469-75a1-498b-b3d7-c1af5c9c9ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194a8bb-924e-433e-8be2-1ea6eba2f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194a8bb-924e-433e-8be2-1ea6eba2f72f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_8f98c246-1b69-4f6e-976c-5cddb59468b3" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_DeferredGrantFundingCurrent_8f98c246-1b69-4f6e-976c-5cddb59468b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit_7da405e1-4949-4452-bb1c-6a4b85bcbf5c" xlink:href="dare-20230630.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_WorkingCapitalIncreaseDeficit_7da405e1-4949-4452-bb1c-6a4b85bcbf5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6ae8fae-1078-461b-a636-6b951880d694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_NetIncomeLoss_b6ae8fae-1078-461b-a636-6b951880d694" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3c4bfeab-afce-4ab2-b7d4-3f333427e8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3c4bfeab-afce-4ab2-b7d4-3f333427e8c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_e8874335-b47b-49c3-9190-f8dc59c747c1" xlink:href="dare-20230630.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_e8874335-b47b-49c3-9190-f8dc59c747c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_1b1e73e4-2cf5-4335-984a-510155c08373" xlink:href="dare-20230630.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_1b1e73e4-2cf5-4335-984a-510155c08373" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b0befe-5278-437d-8794-6dbfc710b1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b0befe-5278-437d-8794-6dbfc710b1ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_e7e08943-cfb7-4b30-9ef6-a21a2de42e73" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_MilestonePaymentsContingentAmount_e7e08943-cfb7-4b30-9ef6-a21a2de42e73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:to="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef375c05-f941-4d1e-a217-963df1e6bb6f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef375c05-f941-4d1e-a217-963df1e6bb6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_45ad3bee-cd61-4db4-a0a8-c5361ab961b0" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:to="loc_dare_OrganonMember_45ad3bee-cd61-4db4-a0a8-c5361ab961b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5172bb22-e8fb-4d4c-8592-55b8b7f21f30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5172bb22-e8fb-4d4c-8592-55b8b7f21f30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_da5146ed-7a84-4769-8774-26e37edfbe24" xlink:href="dare-20230630.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_da5146ed-7a84-4769-8774-26e37edfbe24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7f4e6742-cd9b-40be-8315-0e62600b9fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7f4e6742-cd9b-40be-8315-0e62600b9fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2724398c-0632-44e5-8c0c-f6823cdb645d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2724398c-0632-44e5-8c0c-f6823cdb645d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_63e0ef3c-8baa-4519-a4dc-f01eea4f7151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_63e0ef3c-8baa-4519-a4dc-f01eea4f7151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e00d807-d2ed-4ade-9758-ed4ad4f2c754_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e00d807-d2ed-4ade-9758-ed4ad4f2c754_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d5e1b4a-be24-4a3f-a7ab-54f335a29250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d5e1b4a-be24-4a3f-a7ab-54f335a29250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fc9ec216-a13a-452a-9d84-0825ee913b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fc9ec216-a13a-452a-9d84-0825ee913b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4294503-5d89-4783-a4c1-76fb22bd1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4294503-5d89-4783-a4c1-76fb22bd1de6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StrategicAgreementsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_b197e276-cb14-412b-a7b6-09fb8a157ff8" xlink:href="dare-20230630.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_b197e276-cb14-412b-a7b6-09fb8a157ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_2953beb4-fb4f-44d7-ac5c-9ff4b5fc6945" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_2953beb4-fb4f-44d7-ac5c-9ff4b5fc6945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_ff062909-1e9d-432c-8a88-cc6c0ec562b4" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmount_ff062909-1e9d-432c-8a88-cc6c0ec562b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_26676f92-2bbf-44b9-b17b-548f96cee3d7" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_26676f92-2bbf-44b9-b17b-548f96cee3d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3254b6d6-c48c-4bac-87d4-adc298c412f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3254b6d6-c48c-4bac-87d4-adc298c412f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_ce1bfdae-eb94-49f6-8b76-9ff54cdf77de" xlink:href="dare-20230630.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MaximumPotentialMilestonePayments_ce1bfdae-eb94-49f6-8b76-9ff54cdf77de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_f7c387bd-d631-4d29-bf3a-432cb1a3acb6" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_f7c387bd-d631-4d29-bf3a-432cb1a3acb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_e0894d5b-d0b4-4feb-bf08-0949a1bf2d12" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_e0894d5b-d0b4-4feb-bf08-0949a1bf2d12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_5f4db773-4c9f-4bff-9aaa-220f404acb7a" xlink:href="dare-20230630.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_5f4db773-4c9f-4bff-9aaa-220f404acb7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_011eca6b-ca2b-44b5-9ea5-3c0ec4218391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_011eca6b-ca2b-44b5-9ea5-3c0ec4218391" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_6393181c-47f1-4da6-9fc5-e870afd44fc9" xlink:href="dare-20230630.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_6393181c-47f1-4da6-9fc5-e870afd44fc9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration_3d9a402b-c433-4443-80bc-bbf6b51c016d" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_AssetAcquisitionContingentConsideration_3d9a402b-c433-4443-80bc-bbf6b51c016d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3c335b17-2121-402b-9618-f3b48da46551" xlink:href="dare-20230630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3c335b17-2121-402b-9618-f3b48da46551" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_7f0d2973-1cde-4c49-aa07-c67ec61461cd" xlink:href="dare-20230630.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PercentageOfRoyaltyRate_7f0d2973-1cde-4c49-aa07-c67ec61461cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbe93c95-b687-4995-8695-24d955b28d82_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbe93c95-b687-4995-8695-24d955b28d82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_192d86fb-0688-49ec-919b-94b05399b091" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:to="loc_dare_OrganonMember_192d86fb-0688-49ec-919b-94b05399b091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember_99aef380-a469-4d57-9428-cff835d72f1c" xlink:href="dare-20230630.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:to="loc_dare_CatalentAndMilanaPharmMember_99aef380-a469-4d57-9428-cff835d72f1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba43179e-2a7a-4833-bfee-75279eec94ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba43179e-2a7a-4833-bfee-75279eec94ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_ff4a8bf8-7612-4835-b83b-c7ccb8b57a25" xlink:href="dare-20230630.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_ff4a8bf8-7612-4835-b83b-c7ccb8b57a25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HennepinLicenseAgreementMember_6a9bb6b0-ba09-4ff5-95de-a7412726ce73" xlink:href="dare-20230630.xsd#dare_HennepinLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_HennepinLicenseAgreementMember_6a9bb6b0-ba09-4ff5-95de-a7412726ce73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b38590c1-ec30-49a7-a87e-36b58a9badd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_us-gaap_LicensingAgreementsMember_b38590c1-ec30-49a7-a87e-36b58a9badd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_9da5650a-0820-4f35-aced-16ec483f88c8" xlink:href="dare-20230630.xsd#dare_AssignmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_AssignmentAgreementMember_9da5650a-0820-4f35-aced-16ec483f88c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MergerAgreementMember_4fe42a00-00bd-458e-a953-e7733ca53bee" xlink:href="dare-20230630.xsd#dare_MergerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_MergerAgreementMember_4fe42a00-00bd-458e-a953-e7733ca53bee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_bc970fed-f2ea-40c2-bef2-7959fe08ee31" xlink:href="dare-20230630.xsd#dare_PearTreePharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_bc970fed-f2ea-40c2-bef2-7959fe08ee31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_9c34be44-b518-42f7-aa35-647288e1f024" xlink:href="dare-20230630.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_9c34be44-b518-42f7-aa35-647288e1f024" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_f22fa45b-e56a-4f6a-841c-e3a02da81620" xlink:href="dare-20230630.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_f22fa45b-e56a-4f6a-841c-e3a02da81620" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_659f3e3d-fa82-4cf9-ab73-6eb41e9148da" xlink:href="dare-20230630.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_659f3e3d-fa82-4cf9-ab73-6eb41e9148da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_d22cb811-d759-49fe-806b-41c2ec214dc4" xlink:href="dare-20230630.xsd#dare_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_SalesMilestonesMember_d22cb811-d759-49fe-806b-41c2ec214dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_1f868035-ef25-4f34-a3d1-d13a18ebb61d" xlink:href="dare-20230630.xsd#dare_ADVATecAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_ADVATecAgreementMember_1f868035-ef25-4f34-a3d1-d13a18ebb61d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_847bca7f-abf0-4164-a017-f6f62143291f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_847bca7f-abf0-4164-a017-f6f62143291f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_7a9c045b-3ea6-4af1-8e39-3e0711c28548" xlink:href="dare-20230630.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:to="loc_dare_MicrochipsBiotechInc.Member_7a9c045b-3ea6-4af1-8e39-3e0711c28548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b98cfcf6-13b6-4d47-bc35-3e9adeccb469_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b98cfcf6-13b6-4d47-bc35-3e9adeccb469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_f701f709-eb65-4278-9aa3-90e27b60538d" xlink:href="dare-20230630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_f701f709-eb65-4278-9aa3-90e27b60538d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d359a63-956a-4347-9b7f-2e8632fc85a7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:to="loc_srt_RangeMember_5d359a63-956a-4347-9b7f-2e8632fc85a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:to="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a1fd0b8-ab79-493c-af25-74a60b1c4a5a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:to="loc_srt_MaximumMember_4a1fd0b8-ab79-493c-af25-74a60b1c4a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dc02f05c-495a-4434-83f2-a9e79c3e454a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:to="loc_srt_MinimumMember_dc02f05c-495a-4434-83f2-a9e79c3e454a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_951e42e3-c2ce-4f67-9032-5bbf4bbd6420_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_951e42e3-c2ce-4f67-9032-5bbf4bbd6420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_aaecccc5-922a-446c-b40a-7b095d3182cb" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_aaecccc5-922a-446c-b40a-7b095d3182cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_a1593f0d-b94f-4888-b4df-226f6e15aff6" xlink:href="dare-20230630.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_a1593f0d-b94f-4888-b4df-226f6e15aff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_31af5abb-33ab-405b-9802-da97814d623c" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_31af5abb-33ab-405b-9802-da97814d623c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_f2ade201-3663-42dc-90f8-3c3b46ff5fad" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_f2ade201-3663-42dc-90f8-3c3b46ff5fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_3166c6da-538c-4a95-8bc2-10cdbf597cc1" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_3166c6da-538c-4a95-8bc2-10cdbf597cc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_316a5760-451d-45b7-9d3a-24b57cc1e53e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:to="loc_us-gaap_RelatedPartyDomain_316a5760-451d-45b7-9d3a-24b57cc1e53e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:to="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_00230da3-9659-4cb3-b1e6-9464ccc06307" xlink:href="dare-20230630.xsd#dare_MilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_MilanaPharmMember_00230da3-9659-4cb3-b1e6-9464ccc06307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_fe876d2e-503e-464a-bcfa-74dbfcd3a848" xlink:href="dare-20230630.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_fe876d2e-503e-464a-bcfa-74dbfcd3a848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_8b438c19-4052-4fd3-b962-57ef9481e09c" xlink:href="dare-20230630.xsd#dare_PearTreePharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_8b438c19-4052-4fd3-b962-57ef9481e09c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_81a1444c-9cd7-4d29-be83-a0c542fe33a0" xlink:href="dare-20230630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_81a1444c-9cd7-4d29-be83-a0c542fe33a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8c5e6cd0-dff3-4909-92a4-408923b68acc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:to="loc_us-gaap_ProjectMember_8c5e6cd0-dff3-4909-92a4-408923b68acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:to="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_7e50c534-ec71-49e7-b706-73ae6630bcc0" xlink:href="dare-20230630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_7e50c534-ec71-49e7-b706-73ae6630bcc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_33449447-cc1b-4c70-896c-efbc012d2741" xlink:href="dare-20230630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_33449447-cc1b-4c70-896c-efbc012d2741" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:href="dare-20230630.xsd#dare_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ddfd2dfa-44a7-4389-aa54-8aa7fe1593da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ddfd2dfa-44a7-4389-aa54-8aa7fe1593da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_a13f21b1-3173-4951-be1a-6529825c9ba5" xlink:href="dare-20230630.xsd#dare_PercentageOfAggregateCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_PercentageOfAggregateCommission_a13f21b1-3173-4951-be1a-6529825c9ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockProspectusOfferingAmount_ac59515e-bc72-4051-a356-ba73840f64a1" xlink:href="dare-20230630.xsd#dare_SaleOfStockProspectusOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_SaleOfStockProspectusOfferingAmount_ac59515e-bc72-4051-a356-ba73840f64a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8e6c91bf-9d7c-44ce-b186-f54aac4e00d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8e6c91bf-9d7c-44ce-b186-f54aac4e00d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cbed89bf-fd37-4714-aaf4-8de7cc54d36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cbed89bf-fd37-4714-aaf4-8de7cc54d36a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockBrokerageCommissionsExpense_162d1896-cdb5-4262-9daa-b57f583d0a14" xlink:href="dare-20230630.xsd#dare_SaleOfStockBrokerageCommissionsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_SaleOfStockBrokerageCommissionsExpense_162d1896-cdb5-4262-9daa-b57f583d0a14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00270529-a644-4968-81f6-f0f76f5636d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00270529-a644-4968-81f6-f0f76f5636d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_04516277-f56b-48a1-9908-510a37df5b4c" xlink:href="dare-20230630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_04516277-f56b-48a1-9908-510a37df5b4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_2d9437cc-c4ba-4524-97cd-66fe31825a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_2d9437cc-c4ba-4524-97cd-66fe31825a29" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_9b64d1e1-1744-4124-ba4f-f8ca924e9d5a" xlink:href="dare-20230630.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_9b64d1e1-1744-4124-ba4f-f8ca924e9d5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_2360f638-3dce-4f08-819a-cc2e445a81fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_2360f638-3dce-4f08-819a-cc2e445a81fa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:href="dare-20230630.xsd#dare_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:to="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47693198-9026-4244-89e0-dd1541eeab70_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:to="loc_srt_RangeMember_47693198-9026-4244-89e0-dd1541eeab70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:to="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e91c227f-533b-417c-9fa8-fbaa0076324e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:to="loc_srt_MaximumMember_e91c227f-533b-417c-9fa8-fbaa0076324e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b629d90-919f-4017-adcf-d23d7231f259_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b629d90-919f-4017-adcf-d23d7231f259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_March2023AtTheMarketSalesAgreementMember_fabf6b06-5d76-4861-85de-570cea6a89e2" xlink:href="dare-20230630.xsd#dare_March2023AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_March2023AtTheMarketSalesAgreementMember_fabf6b06-5d76-4861-85de-570cea6a89e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_October2021AtTheMarketSalesAgreementMember_8a5e271a-7dd5-4b9a-84c9-5eabd0ca5b93" xlink:href="dare-20230630.xsd#dare_October2021AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_October2021AtTheMarketSalesAgreementMember_8a5e271a-7dd5-4b9a-84c9-5eabd0ca5b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember_8580374b-4efb-4ea7-ace9-49dd278acd0d" xlink:href="dare-20230630.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_April2021AtTheMarketSalesAgreementMember_8580374b-4efb-4ea7-ace9-49dd278acd0d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e1a8dfc0-d37c-4048-b718-a685f86b4871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e1a8dfc0-d37c-4048-b718-a685f86b4871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d68e84c8-4379-4aeb-8fb1-e268b2daafcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d68e84c8-4379-4aeb-8fb1-e268b2daafcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0ec128a1-756f-4bbe-a780-e55884ba271f" xlink:href="dare-20230630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0ec128a1-756f-4bbe-a780-e55884ba271f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_9c205c52-e873-4b2a-9354-ad280a21397e" xlink:href="dare-20230630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_9c205c52-e873-4b2a-9354-ad280a21397e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6d2d94b8-22c5-4d4e-8d24-66b7cb3617fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6d2d94b8-22c5-4d4e-8d24-66b7cb3617fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edadbeaa-1b23-4414-9353-39d722bccfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edadbeaa-1b23-4414-9353-39d722bccfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6847db5a-8255-48c6-92ce-b13754c49c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6847db5a-8255-48c6-92ce-b13754c49c9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_9b666232-2dee-4135-b9bf-2b5b8309790a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_9b666232-2dee-4135-b9bf-2b5b8309790a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_2a905231-0b16-43ea-b18f-097486526a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_2a905231-0b16-43ea-b18f-097486526a10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_540c6b55-dcd1-4488-a7a3-bc0847a3e8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_540c6b55-dcd1-4488-a7a3-bc0847a3e8db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_283cf6d7-7e6d-43a1-afdb-f0fbc12de657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_283cf6d7-7e6d-43a1-afdb-f0fbc12de657" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_72fc56ac-a8c4-43bb-83a7-fe24c0f8a3b1" xlink:href="dare-20230630.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_72fc56ac-a8c4-43bb-83a7-fe24c0f8a3b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:to="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8e33e89a-3389-4e30-99e6-b9d1c6c145ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:to="loc_us-gaap_PlanNameDomain_8e33e89a-3389-4e30-99e6-b9d1c6c145ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:to="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_6c2a3ca0-e075-45db-83d8-9107be9a4f1c" xlink:href="dare-20230630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_6c2a3ca0-e075-45db-83d8-9107be9a4f1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_e2e15af2-963d-4e28-8123-76dfb0263e3e" xlink:href="dare-20230630.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_e2e15af2-963d-4e28-8123-76dfb0263e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:to="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b05ef6a-181e-48cf-9919-32ee3f634786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b05ef6a-181e-48cf-9919-32ee3f634786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5691660-43b5-4c14-b134-0d242c2e7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5691660-43b5-4c14-b134-0d242c2e7bbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember_dae432ed-a0f1-4a8e-ab70-a080da00eb0a" xlink:href="dare-20230630.xsd#dare_TwoThousandTwentyTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:to="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember_dae432ed-a0f1-4a8e-ab70-a080da00eb0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa404912-3819-4051-83af-1283886025f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa404912-3819-4051-83af-1283886025f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23c7e1c6-48b4-46c2-83d6-bad2fa878167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23c7e1c6-48b4-46c2-83d6-bad2fa878167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_438b90d7-949d-415f-8879-993b73787e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_438b90d7-949d-415f-8879-993b73787e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_492176a6-0038-49ab-9ec2-6de096ef4f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_492176a6-0038-49ab-9ec2-6de096ef4f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_55483329-6d23-46bf-8973-76e589018a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_55483329-6d23-46bf-8973-76e589018a4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4fe99fb-22c3-4514-a621-dd4b95b21c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_38b89c99-b9e8-47be-b285-23ce3bdb56af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_38b89c99-b9e8-47be-b285-23ce3bdb56af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a34b4a46-2ddd-4c68-9322-2fb0c36f7774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a34b4a46-2ddd-4c68-9322-2fb0c36f7774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_defb3185-2558-4d77-91d3-b4cb9c9445a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_defb3185-2558-4d77-91d3-b4cb9c9445a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42c85a6f-9c71-4c3a-89e6-8e70ee9b75d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42c85a6f-9c71-4c3a-89e6-8e70ee9b75d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b7e2d43a-dcb3-4658-b934-c49b5e6e148e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b7e2d43a-dcb3-4658-b934-c49b5e6e148e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dc2f2402-5068-4082-a3d0-36bedef1a769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dc2f2402-5068-4082-a3d0-36bedef1a769" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88361e72-62dc-451e-8ffa-7438c1d59611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c1d1903a-57ad-41b2-bd4c-d660034953cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c1d1903a-57ad-41b2-bd4c-d660034953cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:to="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d75bf8e0-db25-4153-96eb-60065d9b339a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:to="loc_us-gaap_PlanNameDomain_d75bf8e0-db25-4153-96eb-60065d9b339a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:to="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_99d47d47-6273-47c1-a2ce-eb6f3340b37f" xlink:href="dare-20230630.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_99d47d47-6273-47c1-a2ce-eb6f3340b37f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:to="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0041fa5a-3519-479d-a2ed-b28bc4fe2207_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0041fa5a-3519-479d-a2ed-b28bc4fe2207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0d2eb2a-b455-4cce-87cd-28fab50e6487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0d2eb2a-b455-4cce-87cd-28fab50e6487" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5b7917d-a0eb-496c-bdbf-bc782750ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5b7917d-a0eb-496c-bdbf-bc782750ef60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:to="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3073b24f-2bf6-404e-919a-26785429ac1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3073b24f-2bf6-404e-919a-26785429ac1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_279ce9fb-85f7-4bbd-a17a-8d76fadd4634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_279ce9fb-85f7-4bbd-a17a-8d76fadd4634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_66ca83ce-80f8-4cfa-a899-872935f1681f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_66ca83ce-80f8-4cfa-a899-872935f1681f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7161d38c-e3e1-402c-a8b6-087251bf15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7161d38c-e3e1-402c-a8b6-087251bf15dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9bc2d9-5264-47d2-9797-d070513ab240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9bc2d9-5264-47d2-9797-d070513ab240" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_1f14c576-8a30-4e80-a578-9af4d61a040d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_NetRentableArea_1f14c576-8a30-4e80-a578-9af4d61a040d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5e320818-71e9-4b18-afe2-80bfa9b120c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5e320818-71e9-4b18-afe2-80bfa9b120c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45c7fe1-5c98-444d-ac01-045e43ab3cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45c7fe1-5c98-444d-ac01-045e43ab3cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_676844e5-8576-47c0-91ae-8a27789b8074" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_676844e5-8576-47c0-91ae-8a27789b8074" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_f12b6322-0c8a-46e4-ab81-9966b136fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_f12b6322-0c8a-46e4-ab81-9966b136fb6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b13969a6-d0a4-4fc1-9062-00309fd18e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b13969a6-d0a4-4fc1-9062-00309fd18e65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_41587a28-c1a2-450e-a299-49cd72395c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_41587a28-c1a2-450e-a299-49cd72395c8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_00b45fa7-9790-45c0-9b69-ff653377662a" xlink:href="dare-20230630.xsd#dare_OperatingLeaseIncrementalBorrowingRatePrimeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_00b45fa7-9790-45c0-9b69-ff653377662a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_782e0b33-8cd3-4eef-8466-b1d38a293c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_782e0b33-8cd3-4eef-8466-b1d38a293c7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa037eda-dfb1-410e-9149-0d3f234f55dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa037eda-dfb1-410e-9149-0d3f234f55dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e206a18-3462-44a4-b795-49719e5adefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e206a18-3462-44a4-b795-49719e5adefc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ab2acd-2cfe-4e2c-9181-7631515fc807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ab2acd-2cfe-4e2c-9181-7631515fc807" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_22182c70-bc6c-4fd2-84cb-004b232b0998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseCost_22182c70-bc6c-4fd2-84cb-004b232b0998" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a6c7080a-9c88-4fed-b9ab-1523eaec580c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeasePayments_a6c7080a-9c88-4fed-b9ab-1523eaec580c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_209ac699-ea46-44b0-8fab-787e2f500174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_209ac699-ea46-44b0-8fab-787e2f500174" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:to="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6a20f1d3-1d92-478b-98a2-8357d7570af7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:to="loc_dei_EntityDomain_6a20f1d3-1d92-478b-98a2-8357d7570af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:to="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember_79d7da3a-d039-41eb-8bf6-bc18d5af7156" xlink:href="dare-20230630.xsd#dare_MBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:to="loc_dare_MBIMember_79d7da3a-d039-41eb-8bf6-bc18d5af7156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:to="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_612ace9b-c8b3-4b81-b11b-fe8eda2809da_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:to="loc_srt_RangeMember_612ace9b-c8b3-4b81-b11b-fe8eda2809da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:to="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_62230aab-8037-4d8d-b9bb-097b4507b650" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:to="loc_srt_MaximumMember_62230aab-8037-4d8d-b9bb-097b4507b650" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_8902944c-d0bf-484d-af89-f25d86b83d75" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_8902944c-d0bf-484d-af89-f25d86b83d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_54cce785-a63c-434c-a9dd-9ceb2dcfb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_54cce785-a63c-434c-a9dd-9ceb2dcfb7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a2af4135-1858-4f15-889d-51e30d347aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a2af4135-1858-4f15-889d-51e30d347aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:to="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_208fe9df-a706-4f28-aa85-35b310f73bd4" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:to="loc_dare_NICHDMember_208fe9df-a706-4f28-aa85-35b310f73bd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember_972779b9-a47e-4a5f-b0c6-bf2b76846bd6" xlink:href="dare-20230630.xsd#dare_CRADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:to="loc_dare_CRADAMember_972779b9-a47e-4a5f-b0c6-bf2b76846bd6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#GrantAwardsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_69a98f4b-e246-4ce5-97e7-1b34188db55d" xlink:href="dare-20230630.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_ProceedsFromAwardOfGrant_69a98f4b-e246-4ce5-97e7-1b34188db55d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_50f0465e-f2e6-4e17-9e71-09c5659586b1" xlink:href="dare-20230630.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_50f0465e-f2e6-4e17-9e71-09c5659586b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_843ac9fa-2bc2-4936-800d-ba7185035398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_843ac9fa-2bc2-4936-800d-ba7185035398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_070616e4-2825-4b55-92f2-1827f270e677" xlink:href="dare-20230630.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_070616e4-2825-4b55-92f2-1827f270e677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_7a1d63f1-e816-423b-9722-107ccdf20956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_us-gaap_GrantsReceivable_7a1d63f1-e816-423b-9722-107ccdf20956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_af73ee64-0d4a-4f24-8944-fe9d1e543a8e" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_DeferredGrantFundingCurrent_af73ee64-0d4a-4f24-8944-fe9d1e543a8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:to="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c6a8158-2200-4fe1-ae64-16614e855045_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:to="loc_srt_ProductsAndServicesDomain_2c6a8158-2200-4fe1-ae64-16614e855045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:to="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member_74b44d03-aea1-4320-bdb1-146889c06c8c" xlink:href="dare-20230630.xsd#dare_GrantDAREPTB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_GrantDAREPTB1Member_74b44d03-aea1-4320-bdb1-146889c06c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member_3cdd28b7-d382-4013-91ec-c18dead75f9b" xlink:href="dare-20230630.xsd#dare_DARELARC1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_DARELARC1Member_3cdd28b7-d382-4013-91ec-c18dead75f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantADARE204AndADARE214Member_df71a9ea-1c09-4513-9e78-31b680486d6c" xlink:href="dare-20230630.xsd#dare_GrantADARE204AndADARE214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_GrantADARE204AndADARE214Member_df71a9ea-1c09-4513-9e78-31b680486d6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELBT1Member_33f36284-88f6-4c27-952d-295b0e42772e" xlink:href="dare-20230630.xsd#dare_DARELBT1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_DARELBT1Member_33f36284-88f6-4c27-952d-295b0e42772e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_65e40b3e-5bcc-4cae-a72b-7ac80a55d16b" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_NICHDMember_65e40b3e-5bcc-4cae-a72b-7ac80a55d16b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f188e72c-1835-42e8-b556-26ea1ecd5256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f188e72c-1835-42e8-b556-26ea1ecd5256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4acd57bf-9116-474b-9396-414a8cc77bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4acd57bf-9116-474b-9396-414a8cc77bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_67c5901b-b3d9-4d69-af3d-b2008cf85c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:to="loc_us-gaap_EmployeeStockOptionMember_67c5901b-b3d9-4d69-af3d-b2008cf85c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2b2563fc-0cc5-461d-b39d-b6b15189a824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:to="loc_us-gaap_WarrantMember_2b2563fc-0cc5-461d-b39d-b6b15189a824" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8bb5d3c7-65a8-4377-a917-8ac92b53d863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8bb5d3c7-65a8-4377-a917-8ac92b53d863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf91af06-782e-4ba3-a6c6-f9801159fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf91af06-782e-4ba3-a6c6-f9801159fff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockBrokerageCommissionsExpense_c4ca2d05-fdc2-47a6-a206-76d9e9f9e8fd" xlink:href="dare-20230630.xsd#dare_SaleOfStockBrokerageCommissionsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_SaleOfStockBrokerageCommissionsExpense_c4ca2d05-fdc2-47a6-a206-76d9e9f9e8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_c8e165f2-1777-424a-8b95-e7229dcdd4e9" xlink:href="dare-20230630.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_ProceedsFromAwardOfGrant_c8e165f2-1777-424a-8b95-e7229dcdd4e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_085f7212-efc2-4652-b8e2-33242e40f9cf" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_085f7212-efc2-4652-b8e2-33242e40f9cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_c5cd9382-b33d-4b43-b2e8-9642ebcc2e29" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_c5cd9382-b33d-4b43-b2e8-9642ebcc2e29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_51d3186f-d963-44cb-9069-1f7c0847f903" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingPremiumsTaxesAndFeesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_51d3186f-d963-44cb-9069-1f7c0847f903" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingInterestRate_05178023-01e0-41b6-b4e2-6a3d248f692e" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_InsuranceFinancingInterestRate_05178023-01e0-41b6-b4e2-6a3d248f692e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_51176175-ef06-46f2-b5f4-10d1f3a9143d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_51176175-ef06-46f2-b5f4-10d1f3a9143d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f02389f5-9cf5-4a66-ab6b-dc0fb58041f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:to="loc_us-gaap_SubsequentEventMember_f02389f5-9cf5-4a66-ab6b-dc0fb58041f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JulyAndAugust2023AtTheMarketSalesMember_b1de4668-80ff-4298-bd41-6d967d0828f5" xlink:href="dare-20230630.xsd#dare_JulyAndAugust2023AtTheMarketSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:to="loc_dare_JulyAndAugust2023AtTheMarketSalesMember_b1de4668-80ff-4298-bd41-6d967d0828f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_037927d9-8b55-4bab-b792-04c41ce4abfa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:to="loc_srt_ProductsAndServicesDomain_037927d9-8b55-4bab-b792-04c41ce4abfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:to="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_b82fe8c2-9cf7-4f2c-9b7d-6940435c393e" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:to="loc_dare_NICHDMember_b82fe8c2-9cf7-4f2c-9b7d-6940435c393e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_deadad28-61fb-46fe-87b5-3f98cf36713a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_deadad28-61fb-46fe-87b5-3f98cf36713a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_bb1f4c02-cb18-45f8-937d-4cda19cb6748" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:to="loc_dare_OrganonMember_bb1f4c02-cb18-45f8-937d-4cda19cb6748" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>dare-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9fea0917-035d-4178-852a-2a718d70296d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1b0de68a-24bd-4f3a-a891-0eaf514ab9f9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d0cd08c8-b7e5-4842-9b65-250585a59d69_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f019d17a-90f7-4a2d-aab1-86d178dc7cde_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f2bf0ea-fc06-46f5-b48c-4bfadbff23f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_aa69a189-2b0d-453a-8bda-c4b0538643b2_terseLabel_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc.</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_label_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_documentation_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member" xlink:href="dare-20230630.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MicrochipsBiotechInc.Member" xlink:to="lab_dare_MicrochipsBiotechInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_942f706f-b777-48d1-9cc3-3fc5e5969648_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a3045bc-a190-4f59-8ec0-16f65f2c6cec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9851737c-4078-4b30-ae68-aa093aff0f6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0c494498-6e9a-4953-9e2b-7b2749b65a3b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dd440fb4-0651-4b93-a1cf-61a4bc986986_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DARELARC1Member_ecd2d96d-ac67-4760-87a1-f287627cf643_terseLabel_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1</link:label>
    <link:label id="lab_dare_DARELARC1Member_label_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1 [Member]</link:label>
    <link:label id="lab_dare_DARELARC1Member_documentation_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member" xlink:href="dare-20230630.xsd#dare_DARELARC1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DARELARC1Member" xlink:to="lab_dare_DARELARC1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_fa063ca5-f32c-42f7-b164-9400fa5fcaa1_terseLabel_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and Regulatory Milestones</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:href="dare-20230630.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:to="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_43905f5d-caec-4c50-b89e-d51574e2a9e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b11bbeb8-c62e-4342-a60c-25000a5805d2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07144595-b83d-4c28-b85c-5d72af3f0a70_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_d863710a-7022-4c76-8b16-0635e52d06dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cost</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_70e259f6-f7e2-4e08-bfa7-cfe692a34bc5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_d59a8857-d8da-4635-b83e-425b7ac077d1_terseLabel_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional potential grant funding</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_label_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_documentation_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:href="dare-20230630.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:to="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7572d9c3-adbe-4c91-bf98-014821292a45_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying Outstanding Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_dcd56cc3-601b-4d6b-b666-39864ebad07c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_e93a821a-7e6e-4ea2-adea-3f31ee23a3aa_terseLabel_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrants exercised (in shares)</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_label_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_documentation_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:href="dare-20230630.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:to="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_e6616182-5405-465e-b941-5cc7028ff7fc_terseLabel_en-US" xlink:label="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate, amount over prime rate</link:label>
    <link:label id="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_label_en-US" xlink:label="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate, Prime Rate</link:label>
    <link:label id="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_documentation_en-US" xlink:label="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate, Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:href="dare-20230630.xsd#dare_OperatingLeaseIncrementalBorrowingRatePrimeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:to="lab_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b3de7aee-b194-4db5-b170-0162d3ad43d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a38c59b3-b83e-4783-bd84-6ef5f4e1b67a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f5bd4540-93e8-42a4-b24d-a1dc06c2aa23_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_9eb9c9fb-44ed-4994-826a-1e752ad535be_terseLabel_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember" xlink:href="dare-20230630.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAndCollaborationAgreementMember" xlink:to="lab_dare_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_d5e8404e-15ed-4d16-a3ba-03de594872a9_terseLabel_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Two Thousand Fourteen Stock Incentive Plan</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_label_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:href="dare-20230630.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:to="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f6655926-56e7-4b19-bc1c-5f5429a0af33_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_70434a11-d67a-4a78-bdee-6e469a2be36e_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_fce2e0bb-4a90-41a1-99c4-f5ee6d7b0cf3_terseLabel_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_label_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon reaching certain worldwide net sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:to="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_5a6b98bb-d78e-4334-94bb-c6e90130838d_negatedTerseLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in operating lease ROU assets</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-of-Use Asset</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1dff82f6-18a8-4961-9a81-ff518fd70188_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_45e1c1ef-61ee-4a5d-b113-729b50850232_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2624e455-065b-4de4-8996-7207212b6891_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_0f53d30b-7962-4233-9d4b-4db3b1b9620f_terseLabel_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member" xlink:href="dare-20230630.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HammockPharmaceuticalsInc.Member" xlink:to="lab_dare_HammockPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_454e865b-771c-412a-8200-6831c518ade7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7cd521d2-9bb7-4aa4-93d4-5e9ffdc21f52_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_e9b10d0a-e7dd-4179-b4d2-c835b2d7bb21_terseLabel_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_label_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember" xlink:href="dare-20230630.xsd#dare_PearTreePharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PearTreePharmaceuticalsIncMember" xlink:to="lab_dare_PearTreePharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f56014c3-aae2-4285-a41d-058fe2117d37_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other non-current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_62135b82-b652-418f-a80c-5a77668e9a99_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_02b5ea91-f3de-41f6-b072-7c937050dcc6_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcf7e8cb-e9ad-4127-998e-26887ce31550_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SaleOfStockBrokerageCommissionsExpense_b7a7ff26-6761-4762-9145-d7405fcbc5ce_terseLabel_en-US" xlink:label="lab_dare_SaleOfStockBrokerageCommissionsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_dare_SaleOfStockBrokerageCommissionsExpense_label_en-US" xlink:label="lab_dare_SaleOfStockBrokerageCommissionsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Brokerage Commissions Expense</link:label>
    <link:label id="lab_dare_SaleOfStockBrokerageCommissionsExpense_documentation_en-US" xlink:label="lab_dare_SaleOfStockBrokerageCommissionsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Brokerage Commissions Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockBrokerageCommissionsExpense" xlink:href="dare-20230630.xsd#dare_SaleOfStockBrokerageCommissionsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SaleOfStockBrokerageCommissionsExpense" xlink:to="lab_dare_SaleOfStockBrokerageCommissionsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_89120bff-7c37-4802-8380-88060e97ae7a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cfbb6dcd-12c7-4339-8e3d-1afc8a7a2f59_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_02667d46-9cb5-4a67-81fb-ed39cf76ab00_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercises, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_March2023AtTheMarketSalesAgreementMember_c5dbea1a-7104-4c3c-8eeb-4277734268f4_terseLabel_en-US" xlink:label="lab_dare_March2023AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2023 At The Market Sales Agreement</link:label>
    <link:label id="lab_dare_March2023AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_dare_March2023AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2023 At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_dare_March2023AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_dare_March2023AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2023 At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_March2023AtTheMarketSalesAgreementMember" xlink:href="dare-20230630.xsd#dare_March2023AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_March2023AtTheMarketSalesAgreementMember" xlink:to="lab_dare_March2023AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1c95910f-0f03-4487-b7a7-bf12bcd0837f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_662754cb-fcc0-446f-9ec5-05ed268ad949_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fcbcac39-c3c5-498c-85fc-484e6dd65314_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9850ddba-1973-40c9-abd6-28e5e4ced351_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a9679b0c-759f-4e21-ac2c-fdd14319270b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3bd42d4b-a540-4aeb-9285-c13661c86bf5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_87fec26f-13eb-4c63-b3a1-df0d266f806a_terseLabel_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_label_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_documentation_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments" xlink:href="dare-20230630.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MaximumPotentialMilestonePayments" xlink:to="lab_dare_MaximumPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86ba5897-679a-4f28-9148-e6b24109fdc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_31454080-2a87-4aa4-9d67-dc6f97f62a9f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per common share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_2af735d4-57a7-4a8f-8a55-6ace599734c2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_39ebb5e0-008f-487f-beba-ae0d67e85cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_eaa7d5a8-3e6c-42df-bec3-c24bc3751e60_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20230630.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_507e4a11-ef7d-4b83-b17c-ec324b3e8b96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_271dd33d-c6fe-4a7c-87cb-a5cc762bed1b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7c141198-5b74-438c-a2bd-e32664e6f401_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_8054037b-bbfe-4965-a162-864349bbf94e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MBIMember_894d3f52-9ac7-4500-8211-b93663d9fa71_terseLabel_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI</link:label>
    <link:label id="lab_dare_MBIMember_label_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI [Member]</link:label>
    <link:label id="lab_dare_MBIMember_documentation_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember" xlink:href="dare-20230630.xsd#dare_MBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MBIMember" xlink:to="lab_dare_MBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantDAREPTB1Member_9724d929-49c7-4274-bb62-3a9ff5fd44b2_terseLabel_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1</link:label>
    <link:label id="lab_dare_GrantDAREPTB1Member_label_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1 [Member]</link:label>
    <link:label id="lab_dare_GrantDAREPTB1Member_documentation_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member" xlink:href="dare-20230630.xsd#dare_GrantDAREPTB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantDAREPTB1Member" xlink:to="lab_dare_GrantDAREPTB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8dee999d-e54a-4039-8d47-f50e20cc1887_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7627e239-0e20-43f4-8d58-79fb15142662_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf0db375-7333-457a-9bad-877f3a263fbc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_InsuranceFinancingInterestRate_35fe481b-9380-4a8d-9404-cc8005649915_terseLabel_en-US" xlink:label="lab_dare_InsuranceFinancingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on insurance financing</link:label>
    <link:label id="lab_dare_InsuranceFinancingInterestRate_label_en-US" xlink:label="lab_dare_InsuranceFinancingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing, Interest Rate</link:label>
    <link:label id="lab_dare_InsuranceFinancingInterestRate_documentation_en-US" xlink:label="lab_dare_InsuranceFinancingInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingInterestRate" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_InsuranceFinancingInterestRate" xlink:to="lab_dare_InsuranceFinancingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_0048baf7-bbb7-4b39-be50-c218b14a4e13_terseLabel_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm</link:label>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_label_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_documentation_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember" xlink:href="dare-20230630.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CatalentAndMilanaPharmMember" xlink:to="lab_dare_CatalentAndMilanaPharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_24a32726-c3f8-4219-bbfa-d5a479d3487b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4efe478c-d7ec-42d4-936c-106e33ccbc6c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5a01922e-05f7-404f-a7fb-ce8c6ade7614_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_9e9557c3-0bab-450d-86bd-fa22659bc2d7_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit related to lease of real property</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_54804adb-e4ce-4643-b632-7f328f80cfa7_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual license maintenance fee payments, thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:href="dare-20230630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2145ecf7-bf4a-4810-9d48-d8c2a177651f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ce4070be-2b3b-4c87-9a80-dbbca7167447_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1331f3c2-3f06-499d-90bd-9dfb0ee2cbb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_327a173e-f92f-4cda-bbe3-e1612028d1da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d1109c91-525c-4390-8bf2-bcdf3cb3d993_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_04c2e67f-3b8e-4b3e-bbd6-9fcda7135c76_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b3bae2db-324b-459b-8130-9822402e6b25_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6a08faa4-4066-4f05-ae1d-dd70d26396e7_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_89142aab-6838-446e-bd17-5481e42c559a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8f66c215-0238-4de3-b396-3fb15a4752ea_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_51de4647-7e35-4382-bd84-633fc1a7b065_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASED PROPERTIES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b637e48e-d15e-44f9-b2fa-3b0b0ff14c67_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ac8c0a5-c8b3-4365-b54e-80638868abdd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6fa43b10-2767-43ca-9263-a94632454c6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6c983313-cf4e-479b-baaf-38e12066a42e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68437a9f-dbd0-4f0a-9908-4bd89391b530_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_af473378-519f-4236-ad51-387fb7a323a0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1891cb1d-0449-4e41-92bf-5511d41d076d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9ee6954c-9a63-4ba4-a823-59b3788ad47c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71adc53f-e4c7-4bfc-a58c-0c399133412c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_309299fc-49e9-43c6-a2dd-b0158fbf8438_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_adb0298c-4023-4fcc-87e5-97bf91d7bd5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_41b7a167-e634-4d2e-9981-b4b01f8a138a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1074e788-969e-45ff-942a-a6f2af3ea492_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9395aaf-a4de-4fac-895f-03d1487d0bc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_68eeb98e-b643-41a0-bad2-42fe31c347c5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, exercise price, decrease (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_label_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Exercise Price, Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5da65043-deb6-4e9e-867e-ae4a9f084b98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_49abedb4-2c3d-4b2c-a0ca-57be9461d6b9_terseLabel_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use</link:label>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_label_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use [Member]</link:label>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_documentation_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:href="dare-20230630.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:to="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8eed6d05-2804-4a38-877c-6b9570558c82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1f035bc9-c7bf-4923-b3e6-69fbd362c40b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d120ee5b-c65c-46e1-abd0-00aa9b3afec7_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_52ca12d7-5331-41ea-b037-2b4ea3cdd641_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_dc951467-6b1b-4e43-a48b-3ae18952f253_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3d86a95f-e2ab-43aa-9978-b5201ce0a7df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_793f2605-8878-4a25-b3e7-024bde0c518e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_07d69619-01d7-44b8-992e-8324a981a75d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SaleOfStockProspectusOfferingAmount_71d1842b-19dc-41ba-803b-0aaea32ccb06_verboseLabel_en-US" xlink:label="lab_dare_SaleOfStockProspectusOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued shares</link:label>
    <link:label id="lab_dare_SaleOfStockProspectusOfferingAmount_label_en-US" xlink:label="lab_dare_SaleOfStockProspectusOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Prospectus Offering Amount</link:label>
    <link:label id="lab_dare_SaleOfStockProspectusOfferingAmount_documentation_en-US" xlink:label="lab_dare_SaleOfStockProspectusOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Prospectus Offering Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockProspectusOfferingAmount" xlink:href="dare-20230630.xsd#dare_SaleOfStockProspectusOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SaleOfStockProspectusOfferingAmount" xlink:to="lab_dare_SaleOfStockProspectusOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_08be00ab-f3a6-4b01-8b89-c5011bfb4e3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bd47ec62-27dd-4b4a-9bd7-88831e3b8e7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_336515c5-ae39-4c92-967a-01d5f8d854f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9f5a05ca-9bd5-433c-959c-8edd69f261a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_10a31e23-f63c-435e-92cb-3e13930704b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f6001904-e446-4244-a8e2-ab5677e05eec_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_7b03f422-beb3-4b01-8e68-b5993fa455ed_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_35bb0097-68e2-40e9-a88f-29e1060ced3c_terseLabel_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_label_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Warrants Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_documentation_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or rights warrants expiration date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:href="dare-20230630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:to="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a05a3f46-d0b3-415b-8279-85a327c6ab9d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7b401d35-6696-4a19-bbce-f9dfd34e33bc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_813fc4ec-97d7-472f-93a2-42243e851a0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b78005fa-114f-44f2-8f87-617e81d7c048_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_40d62d20-099f-4bcd-a28f-3a8e9984cf1e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_ba764746-2c6b-499b-b267-cba2831eb069_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a0806be4-aad3-4a5d-8cc1-f4b168f8b310_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_747eec27-e618-4546-ad65-d45d54670e1a_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_label_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_documentation_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate" xlink:href="dare-20230630.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRoyaltyRate" xlink:to="lab_dare_PercentageOfRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ddb8e143-8937-4eab-b612-38952bc435c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_34fe7e11-917a-4d09-a6ad-4d47693c7b16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_090a5ac6-ee69-43cf-b401-983f452c1591_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8288b8cf-5da6-4fca-92b8-3533cdfb0976_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember_45db17ec-257b-41b8-aee0-0fe2bacaccc8_terseLabel_en-US" xlink:label="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Stock Incentive Plan</link:label>
    <link:label id="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:href="dare-20230630.xsd#dare_TwoThousandTwentyTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:to="lab_dare_TwoThousandTwentyTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1af57baf-fd69-41d7-a0b0-789de18947e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a2728679-9c1b-4a59-a919-814023f6d92b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SalesMilestonesMember_1d60a9e9-ad71-4c8b-85d2-ce01158254c7_terseLabel_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_label_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember" xlink:href="dare-20230630.xsd#dare_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SalesMilestonesMember" xlink:to="lab_dare_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_85d7853a-5491-4768-969c-43f1d7a3b5e3_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:href="dare-20230630.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:to="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_88ab3057-6c5d-4a87-a809-8b0d7bdba53f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_8df261b3-c863-4d81-9524-7899795ff598_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_23a511ee-df77-4067-91ba-7d17aef34422_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c63d62e2-cd42-43e3-845a-233505c3cfc3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f0532a5-0182-4638-9fb0-e5a6edc279b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_a81ba3da-c59a-4bd8-9fe5-5dee2c3e2f31_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Agreement, Commitment, Amount</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Agreement, Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:to="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7a48163d-5028-4f5b-b535-bd53133cb89c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_334c064d-00a4-47bb-a009-f95ce6f5ca64_negatedTerseLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:to="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b21460fc-6540-4960-8a10-7137f745f384_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_3f2ada86-eaf7-44d0-9ffb-5dbad8fda5df_terseLabel_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20230630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d5da909d-338f-4424-be1a-e8f36de2cdf6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a6f0e74-b3f3-40ff-9ea7-c9fa26030543_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_27952e54-343a-4fa5-932b-79a88bcfb862_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_54f6b493-5e72-44ca-861a-6006b6941a9b_terseLabel_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to stockholders' representative</link:label>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_label_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Stockholders' Representative in Business Combination</link:label>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_documentation_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Stockholders' Representative in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:href="dare-20230630.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:to="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_db51f5f2-c859-4800-972a-9392e162ec90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_00213082-ad07-447e-99b8-6f4aaf8c3f46_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_1a43b3af-5536-492a-bee3-4e54d6db2b46_terseLabel_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GoingConcernPolicyTextBlock" xlink:href="dare-20230630.xsd#dare_GoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GoingConcernPolicyTextBlock" xlink:to="lab_dare_GoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_90f69dd1-827a-440a-ad53-dda8d7574c81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_6591ca77-3155-4b7b-b28d-3fa8f8a4e07c_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:to="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_302c25f1-ba25-466b-a2e9-d4462ad38d8c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b8c9e4b-6f26-49ea-9468-da925bff881e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_02f6176a-d500-4af3-af60-2c56d19a5780_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b2c2c42d-7079-4e36-8b98-f8bec2e24238_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per common share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8a89bd42-180b-423e-a75f-7f3159db6ed2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantADARE204AndADARE214Member_b7869385-1fe5-4148-970e-3084e9f67e9c_terseLabel_en-US" xlink:label="lab_dare_GrantADARE204AndADARE214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, ADARE-204 and ADARE-214</link:label>
    <link:label id="lab_dare_GrantADARE204AndADARE214Member_label_en-US" xlink:label="lab_dare_GrantADARE204AndADARE214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, ADARE-204 and ADARE-214 [Member]</link:label>
    <link:label id="lab_dare_GrantADARE204AndADARE214Member_documentation_en-US" xlink:label="lab_dare_GrantADARE204AndADARE214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, ADARE-204 and ADARE-214</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantADARE204AndADARE214Member" xlink:href="dare-20230630.xsd#dare_GrantADARE204AndADARE214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantADARE204AndADARE214Member" xlink:to="lab_dare_GrantADARE204AndADARE214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_668e3970-27b8-4665-b35b-86fe19d77817_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1cdf4e1b-c395-4918-8b25-abdb4fccf4e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfAggregateCommission_db573452-3516-4f61-906c-75017a5537da_terseLabel_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission percent</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_label_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Aggregate Commission</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_documentation_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of aggregate commission.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission" xlink:href="dare-20230630.xsd#dare_PercentageOfAggregateCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfAggregateCommission" xlink:to="lab_dare_PercentageOfAggregateCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_5172a2f7-0d18-4934-8541-3e2704c7fe5b_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:to="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6a4452e5-2545-43ab-8a55-9b6beef2d01e_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9f17d348-f3ca-46dd-886d-5524f5e357dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_359c02c8-0283-4e49-872c-a03821663829_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c175bee1-3985-4dac-aca3-0e595acdb01f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1cac778b-4649-41b2-a40c-956c89d7464d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4bef0ac8-1e6c-42e3-94e7-7933e1125174_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_69684025-2632-4336-814b-217ffc6696cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CRADAMember_68524e2a-40b8-43c5-a546-e8adff637c10_terseLabel_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA</link:label>
    <link:label id="lab_dare_CRADAMember_label_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA [Member]</link:label>
    <link:label id="lab_dare_CRADAMember_documentation_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember" xlink:href="dare-20230630.xsd#dare_CRADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CRADAMember" xlink:to="lab_dare_CRADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_d8739be2-e5b7-464c-ae64-97b5502f9742_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b8a68f8f-38bb-4858-9fa2-aae88d376999_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_66191dfa-8a1c-4f83-a04f-640e86da8261_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a9eb3ffc-b323-4385-85f6-630acf9d8f1b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_159e5bc5-011f-494d-8143-55a8f00e3a8d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_605b294a-0c7d-414a-a0b5-047a3b657e9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_143c382e-841b-4325-887c-f960c0c0e084_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c63047d2-9fe2-4f2c-90dd-a473e081e422_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d3c0b766-331d-4250-9b5a-6babb9aeb27d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase number of outstanding shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_541154eb-573a-491d-82ea-1ac53e2a5bb4_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical and Regulatory Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a367724f-f9e7-46a2-9bdc-36dab1a3d7b7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets obtained in exchange for new operating lease liabilities, net</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_deb52c72-58da-4c05-afc9-94e1ab1e448d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ad03b7a6-1ab9-4f4f-9cdd-cb09b12bc2d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2ed6534e-f550-44f1-9e4c-f558fc03382a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_52e9dbc6-e2f6-4cc2-b287-569eb1894659_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75e86223-87a5-4fc2-99f3-b9f3e53f4190_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_October2021AtTheMarketSalesAgreementMember_de489eb4-a189-4499-8f1e-b03c18769f67_terseLabel_en-US" xlink:label="lab_dare_October2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 At The Market Sales Agreement</link:label>
    <link:label id="lab_dare_October2021AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_dare_October2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_dare_October2021AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_dare_October2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_October2021AtTheMarketSalesAgreementMember" xlink:href="dare-20230630.xsd#dare_October2021AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_October2021AtTheMarketSalesAgreementMember" xlink:to="lab_dare_October2021AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f3c958fa-a8d6-48cc-9e4b-e8e1483e4bca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3654788d-fbc2-4488-a81f-b5746ac7b1e0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f5aac03-3cde-40eb-b8ec-f7405b74aca9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_25fbffec-2b77-4bc9-86e6-d6e9109a3e38_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_48105117-5c74-4ae8-addf-29d4a519f0d3_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales based milestones amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, Sales Based Milestones Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, Sales Based Milestones Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5421e492-834b-4555-906c-0e8f9bec88b1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3d67d23f-2cf2-4c5f-aa74-5e03376287db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_910c32a0-6cc7-4538-a371-2aa18bb1fe98_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityLineItems_e3b7ab81-caaa-4625-88f6-a6fae077a065_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_label_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems" xlink:href="dare-20230630.xsd#dare_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityLineItems" xlink:to="lab_dare_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_21f6d2bb-201b-45e8-a014-c6717c56cc1e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0b5a3a0a-4cdd-4404-a82e-4d6c02c500c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d232ca3a-4765-412f-bb4f-19768864a6c3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4aef9857-be11-4caa-afb6-978ff3f26d79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in outstanding number of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fabf5be-33a3-4560-ae0e-985e91ca621b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d074d4aa-b365-4eb9-9c76-fc89bf5419ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa6e0796-5886-44bf-8115-948c67428f11_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbd378a8-653a-402a-95e0-597d5996b44f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_9bcfa122-847f-469a-ac9e-06fa7dd09678_terseLabel_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_label_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_documentation_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:href="dare-20230630.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:to="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a034369f-acb4-47a2-84f8-502ae4b191d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityTable_0a72778b-9d51-4d98-9a5b-a50b75d01a25_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_label_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_documentation_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable" xlink:href="dare-20230630.xsd#dare_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityTable" xlink:to="lab_dare_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_218b5e32-7b6d-4013-9285-d6014ca3b58b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on early termination of lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c0ff85d9-cc26-470b-8f59-86801135f310_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a16f386d-3386-4971-bae2-7024b0a1d4bc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9ba7a76-9d44-4d47-9e4e-e62c7f28c17b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0a405dfe-35f1-402b-a940-f68eaab9254e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1da4c203-010a-4e5e-8ab6-97c4e4451ebb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock for net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8fd93432-8477-4d92-8e1c-0a8a8e2f8c45_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_31446035-2b92-46e8-9259-772e00421028_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_25e41908-216f-43bc-a18c-3e88f04aa136_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STRATEGIC AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_ffa87c58-2204-4502-b830-06e7369a752d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b2225171-f364-403f-b8f1-7f986c00fd8e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2883fb88-779b-459a-b778-f0c23dbd17fe_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f78631f9-cf06-41f3-8e27-871388a6e3ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0e5ff46d-c35d-4237-8a23-122912b6e6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_daf4bc2f-ecfb-4d3b-aea4-7564d2a25dfc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued to microchips capital stock holders (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5adb27c4-46ef-49d8-abbc-29b1ad06fe42_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b5c839cb-8983-4e53-a664-310f65735a1f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3332719c-e65b-468c-a13c-43424343b4e5_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilanaPharmMember_8967649e-da51-49cd-9f71-32e3d10fd4d4_terseLabel_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm</link:label>
    <link:label id="lab_dare_MilanaPharmMember_label_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_documentation_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember" xlink:href="dare-20230630.xsd#dare_MilanaPharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilanaPharmMember" xlink:to="lab_dare_MilanaPharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba4f12db-d267-4d40-9297-53b4d66b8bb6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fc1e7299-119a-4090-9fac-0749ee96c619_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DARELBT1Member_2b73e489-7e02-492f-94ab-d89abbfa0efa_terseLabel_en-US" xlink:label="lab_dare_DARELBT1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LBT1</link:label>
    <link:label id="lab_dare_DARELBT1Member_label_en-US" xlink:label="lab_dare_DARELBT1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LBT1 [Member]</link:label>
    <link:label id="lab_dare_DARELBT1Member_documentation_en-US" xlink:label="lab_dare_DARELBT1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LBT1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELBT1Member" xlink:href="dare-20230630.xsd#dare_DARELBT1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DARELBT1Member" xlink:to="lab_dare_DARELBT1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c7a97811-4a14-4e27-895d-862ccfc8e043_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_df76fc6a-c2cc-4405-8bcc-0c1b4378fd1e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_2e8ea0c4-51c7-4af9-86e9-fd787a8deeee_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee, Amount Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee, Amount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid" xlink:href="dare-20230630.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeeAmountPaid" xlink:to="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_efae3323-5ff4-4ac3-86e6-3a7d826f34f1_verboseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_fab9275e-02a6-422c-97a7-1a4d96b958d0_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, contingent consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsideration" xlink:to="lab_dare_AssetAcquisitionContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9ceaf3bf-1bd2-4513-b654-8f7164f0d6d2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4c717c5e-e0ac-4ddb-8f50-f79e43d9800b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d8d62a8b-6556-4437-985c-97bc0fe7eb5f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e81cd74-0169-4ba2-b3b4-7d5406e23f5e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_da71a2d0-653c-4285-ac45-e4e1ad379b8d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce36116c-7325-46c8-9e8b-4b613a47c256_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bf49dd4c-ac49-4b7f-9ea0-a8f40eed7934_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_ccfa7ce2-2e0d-4d9c-b133-3221d1c206bd_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on April 4, 2026</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On April Four Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiring on april four two thousand twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:href="dare-20230630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:to="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3cd48ee9-2ded-4c4b-bf65-db1e18705621_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8aeebd2b-fe66-45f5-8684-57acd882defd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_e4dd95f4-84c9-4fb4-af40-6f177705e31f_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesTable" xlink:to="lab_dare_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_15f11874-1759-4508-8ace-5cd3c9c7f627_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_82596498-a984-44cd-87e9-0bae90991bbe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MergerAgreementMember_2761d94c-d820-4013-aa23-c92f012fd1c0_terseLabel_en-US" xlink:label="lab_dare_MergerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement</link:label>
    <link:label id="lab_dare_MergerAgreementMember_label_en-US" xlink:label="lab_dare_MergerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement [Member]</link:label>
    <link:label id="lab_dare_MergerAgreementMember_documentation_en-US" xlink:label="lab_dare_MergerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MergerAgreementMember" xlink:href="dare-20230630.xsd#dare_MergerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MergerAgreementMember" xlink:to="lab_dare_MergerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_3693bf88-9d07-47d3-89a4-c46b5269e902_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_8bc585dd-6fad-4d0c-8e52-344572a64e62_terseLabel_en-US" xlink:label="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums, taxes and fees</link:label>
    <link:label id="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_label_en-US" xlink:label="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing, Premiums, Taxes And Fees, Amount</link:label>
    <link:label id="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_documentation_en-US" xlink:label="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Financing, Premiums, Taxes And Fees, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingPremiumsTaxesAndFeesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:to="lab_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b1b2f634-ef4b-4c45-abe4-cba9942c9d78_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4a95d805-931e-4283-9785-fd1c6365d873_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f93cba4e-d6d1-4126-917c-209ea8e19067_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5191b0d4-f8eb-4697-b779-3e3d13186304_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9171602a-55b2-4095-b9cf-65037ba09c3a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_2163479f-7fc3-46bd-9c14-fb41ab360e2d_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9ea95fc-8e8d-417a-97d3-98d691257f58_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_97724daa-8a4f-449c-84b3-db5ab3fdb732_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_8492bb7d-36b1-42dd-b89b-60850e26cfd9_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems" xlink:to="lab_dare_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_HennepinLicenseAgreementMember_27a4d265-7234-4867-af30-33e8b330eb3e_terseLabel_en-US" xlink:label="lab_dare_HennepinLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hennepin License Agreement</link:label>
    <link:label id="lab_dare_HennepinLicenseAgreementMember_label_en-US" xlink:label="lab_dare_HennepinLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hennepin License Agreement [Member]</link:label>
    <link:label id="lab_dare_HennepinLicenseAgreementMember_documentation_en-US" xlink:label="lab_dare_HennepinLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hennepin License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HennepinLicenseAgreementMember" xlink:href="dare-20230630.xsd#dare_HennepinLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HennepinLicenseAgreementMember" xlink:to="lab_dare_HennepinLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantAwardTextBlock_115b9477-bc2d-44a1-bf1c-6a8e35d9b97d_terseLabel_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRANT AWARDS</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_label_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_documentation_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock" xlink:href="dare-20230630.xsd#dare_GrantAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantAwardTextBlock" xlink:to="lab_dare_GrantAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NICHDMember_811be69c-a0a9-4246-8ad5-a59278f1bca4_terseLabel_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD</link:label>
    <link:label id="lab_dare_NICHDMember_label_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD [Member]</link:label>
    <link:label id="lab_dare_NICHDMember_documentation_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NICHDMember" xlink:to="lab_dare_NICHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_e906b60c-0a03-420a-b304-9f97cfeb0846_negatedLabel_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital deficit</link:label>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_label_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Increase (Deficit)</link:label>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_documentation_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Increase (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit" xlink:href="dare-20230630.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WorkingCapitalIncreaseDeficit" xlink:to="lab_dare_WorkingCapitalIncreaseDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d6f15b70-92d6-4039-bccf-3055d9276cfc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be7be8d0-c5fe-403f-973a-fe15d7108c4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_98b7a006-07b4-4622-9f0e-029020296449_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_7b625149-27db-4719-99a1-9fbc5687be16_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First commercial sale amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, First Commercial Sale Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, First Commercial Sale Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cff6e290-7888-40a8-8299-8321531d8d2d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2923786e-e8dc-490b-89dd-70854ef4cb8b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_5a4af815-11af-41d6-9311-40d79b82a092_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_492ad074-5d07-410e-928f-3d84f01f7b46_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_1040e3e6-57e2-41e5-be76-c12e105dd526_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of office space</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0a808ffa-2692-4aba-a1dd-69057898bf3f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_ae4d53b2-3472-43e1-8cbd-9aec8ddacc6e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_178c8cf9-c30a-48f3-8ef0-ee901f0b3e0e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6d1fe17a-b5e2-4d87-a9e9-025107398586_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_98a946a9-4773-4bfb-8d7e-2c1c83cb5506_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimburse amount, PDUFA fees and other manufacturing expenses</link:label>
    <link:label id="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_label_en-US" xlink:label="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses</link:label>
    <link:label id="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:to="lab_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a9a56ec-7187-4f3a-bcb6-8e3d1e7984e8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_f6b1a832-8f99-4b07-8cf2-ac51529a3f55_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f1571ebc-80c2-4e0b-8a90-c089c83bcaf9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_e55ee10c-71ea-4132-806e-f11fbfaf6909_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits recorded to research and development expense for costs related to award</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7a039303-feec-4fb6-84dd-d5f1f15c58ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_32fc68a4-d59e-4173-988c-cc53edec16e2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_9a4d561e-1926-46f0-adbd-7eb7f3d6d40a_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="dare-20230630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_ccbd254c-f46c-4e80-9171-75fd85b97330_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement of Specified Development and Regulatory Milestones</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon achievement of specified development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:href="dare-20230630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_d4f797ca-839c-4bda-baae-641bfbe01127_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c87c5155-3d21-460d-a683-f5b65e00cf34_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the condensed consolidated balance sheets:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d3b152b1-20e7-436b-9878-ba138fae81f7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93a382f8-0950-4f6c-ac3f-f3658c62062b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_326a59cd-fe51-4343-b58d-0ad911ede220_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa25d4d0-d8b7-4a3c-ae81-36c6d0c90624_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_0994b17e-76ad-44af-8183-c4a569b05d9b_terseLabel_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_label_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_documentation_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod" xlink:href="dare-20230630.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WeightedAverageAmortizationPeriod" xlink:to="lab_dare_WeightedAverageAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cb7e96ee-b7e0-462f-b5c1-190d8fdd0639_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_23efbe95-a2db-475f-b13c-d8f9cb165f88_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44e07396-316f-4e14-a366-9643e99f2c09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_452defa2-d8c4-49be-a473-bb1b742a0b28_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_eaa896b8-9638-485c-977f-284f1502e97b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60b0ad19-9216-434f-aac4-a1a4853ca031_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c7ad101c-6d90-45c2-8083-259bef263200_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_471b56ee-ea4f-42ae-91ac-7515678dc5d6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f9b2d60d-6cf9-4046-8d2b-a6b5efe5d9dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8df969ed-a646-4876-b150-8227b423aec5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_9b94aeab-0d86-4661-a9cd-de6a69474182_terseLabel_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of warrants recorded in equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_label_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_documentation_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:href="dare-20230630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:to="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a5e8b0a4-d834-49d1-af12-ce537b8bb3f3_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_JulyAndAugust2023AtTheMarketSalesMember_00e2df21-51b4-42c6-ba25-4260f2fbfdb8_terseLabel_en-US" xlink:label="lab_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July and August 2023 At The Market Sales</link:label>
    <link:label id="lab_dare_JulyAndAugust2023AtTheMarketSalesMember_label_en-US" xlink:label="lab_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July and August 2023 At The Market Sales [Member]</link:label>
    <link:label id="lab_dare_JulyAndAugust2023AtTheMarketSalesMember_documentation_en-US" xlink:label="lab_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July and August 2023 At The Market Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:href="dare-20230630.xsd#dare_JulyAndAugust2023AtTheMarketSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:to="lab_dare_JulyAndAugust2023AtTheMarketSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_edfdcd7f-ab54-4904-afb8-4a68c31d0c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_dc2ae8df-b3cb-402d-a715-74d3239754c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3eeaccf9-4fc1-486f-bb76-2a6b38b819c8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_40f51124-68e8-47f0-939e-97fd7e818513_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1cff6f5c-31a1-48b4-a1dc-074b400ba081_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_b90f06fa-c9f0-4c7a-a969-a5b44edca518_terseLabel_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_label_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_documentation_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:href="dare-20230630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:to="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NonCashLeaseExpense_b42a5e64-a484-4f89-974d-f47a4b21b7c9_terseLabel_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease cost</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_label_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense" xlink:href="dare-20230630.xsd#dare_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NonCashLeaseExpense" xlink:to="lab_dare_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_97844967-935d-4f88-9f3c-3515e9f40cfa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ede8db8a-4592-4407-a1dd-bb8214ac6912_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_2918d138-c8b9-4b23-a3d0-ea7086290cec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3275dce0-a72b-4e28-a7b2-25921c09445d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_777cf560-12a6-4bf4-a208-af420efbf467_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e5b8ae87-25bc-4a8c-8b0e-c3fc5741a74b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_889f64c8-1396-4995-b3f6-099ee3d5be40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_31dac645-03ef-4b89-8a5e-fbd630164569_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83cbc016-d384-4167-8dc7-3b4a2b3ae6ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_82739b59-53bc-4f96-b0dc-498914ef3f15_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_e5c1ffc9-6de8-4313-9c5e-66c4c489d2dc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_d88505e2-ac07-4308-9887-ace56444a76a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_1bdf95eb-cf5f-41d6-afe0-96157e820918_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Milestone Payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:to="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_26ae7042-896a-4210-91de-830ac279fb6c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8cdfda60-b2c3-4a07-a910-41d0d5a9b097_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_75b5238a-271e-45ee-8d4f-13606e6f88f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ea62149-303d-4540-995c-3a98585f65c6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_53ad049d-443d-4093-a5e8-2af734fd1823_terseLabel_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeferredGrantFundingCurrent" xlink:to="lab_dare_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc6f7d8c-98b7-43bf-8bef-9b39253e1b3e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1ade2855-1c07-452f-bdb7-c3d05f843344_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_633bee3d-47f0-45d4-a1c8-b41cb95ac5ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d7407a5b-2677-42f2-bf99-5ba201430c8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b74a7d97-faff-4ab9-b6ab-b8e7e9593eac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86cb37eb-a829-4c9e-88d7-54642a4848bc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9941554-56f3-4155-aaed-a358ce7af26a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_4609553b-deeb-41a5-8683-8b050f9f71da_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems" xlink:to="lab_dare_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_62947644-af2b-4e8d-9fea-73a5b47c1260_terseLabel_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of insufficient cash and liquidity requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_label_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_documentation_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:href="dare-20230630.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:to="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4675907-4803-45fa-af72-d73e455a7291_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_03ab7c78-94b4-4391-8d8a-55b720dd1f0f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b6e1f355-9fb1-4553-889e-72af81cdcdfb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a1a23fe8-da3f-491f-b8b4-7a6610a2f4b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_93c36b89-c84e-4068-af35-1b5745c9ee3b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_47e1a1e1-a39d-4892-b4dc-2e2be46b01b2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ADVATecAgreementMember_dc9ea75c-43ad-4a16-ae4b-0373541cb786_terseLabel_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec Agreement</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_label_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A D V A Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_documentation_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember" xlink:href="dare-20230630.xsd#dare_ADVATecAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ADVATecAgreementMember" xlink:to="lab_dare_ADVATecAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssignmentAgreementMember_939966f6-8db5-4349-9841-cb8013a5f94b_terseLabel_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_label_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_documentation_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember" xlink:href="dare-20230630.xsd#dare_AssignmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssignmentAgreementMember" xlink:to="lab_dare_AssignmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6fd75979-9462-4aa4-beaf-5e264b6919bd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4b907319-0e40-489d-8ff6-2718ffc8cfc1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d2106166-97cf-45bb-8fc5-7abb15e63446_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_7ba3471b-2e05-40f2-9a6d-0baee358c8c5_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants (in shares)</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:href="dare-20230630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5bdc785a-5032-4ea9-b55d-0ffd35b23763_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a8c1be86-1f9b-4f5c-ab41-d94d715db0cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e6efc404-ec03-410a-a586-a749cb068b36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_3d66393a-17f0-45de-bd87-32494b33f5ea_terseLabel_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement</link:label>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember" xlink:href="dare-20230630.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_April2021AtTheMarketSalesAgreementMember" xlink:to="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3198bf40-0f09-42ed-bac9-c45f3b053820_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a845341b-0195-4447-85e7-061d6fb04079_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1cba5739-9d87-4d53-a3f7-681708b491f6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_239315e6-f6e1-412b-adfb-a7653fc8a811_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dfe2fb84-7d61-426b-a820-bd484494172b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_ce98d67c-2a2e-43ff-ba29-b7730a543192_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesTable" xlink:to="lab_dare_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseFeeExpense_ea5c649e-174e-448b-abd2-0c0d15ded225_terseLabel_en-US" xlink:label="lab_dare_LicenseFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee expense</link:label>
    <link:label id="lab_dare_LicenseFeeExpense_label_en-US" xlink:label="lab_dare_LicenseFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Expense</link:label>
    <link:label id="lab_dare_LicenseFeeExpense_documentation_en-US" xlink:label="lab_dare_LicenseFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeExpense" xlink:href="dare-20230630.xsd#dare_LicenseFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFeeExpense" xlink:to="lab_dare_LicenseFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_9960472d-57be-469d-bfec-231f88f31144_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_7c8bc4c3-d24b-4109-b987-950d456b2b1f_terseLabel_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for expenses eligible for reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_label_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_documentation_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:href="dare-20230630.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:to="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_0ee029c6-e99e-4f14-9570-afec790f6319_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded for grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_label_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_documentation_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant" xlink:href="dare-20230630.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromAwardOfGrant" xlink:to="lab_dare_ProceedsFromAwardOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8c60feb0-34f5-462f-ab6f-88660da8f69f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c34d7188-97ad-4da0-88ae-cfe4e5565a70_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_OrganonMember_a1a4a722-1fa1-4ae8-b283-d9ea31ef55ee_terseLabel_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon</link:label>
    <link:label id="lab_dare_OrganonMember_label_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon [Member]</link:label>
    <link:label id="lab_dare_OrganonMember_documentation_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OrganonMember" xlink:to="lab_dare_OrganonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_505fd26e-6b3e-434c-85c1-a4646e8d05f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 240,000,000 shares authorized; 86,633,588 and 84,825,481 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_d0414a2b-fe1d-4022-ade5-1aaca2188372_terseLabel_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of additional consideration</link:label>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_label_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Additional Consideration in Business Combination</link:label>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_documentation_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Additional Consideration in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:href="dare-20230630.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:to="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ac5110f7-cfd1-4080-8983-78684218f7e5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc5af4a0-f202-45dc-9249-93463ecde286_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>dare-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:496c6c3f-9f6f-492e-8493-032079d4ee9f,g:84a23fc5-0c0f-4355-b860-ff432ee8c6ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="dare-20230630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6d3ddbab-0202-454d-82f2-7eca2cc96759" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentType_6d3ddbab-0202-454d-82f2-7eca2cc96759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7db26139-47e7-4d4a-aa7a-cfeb30152ae4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentQuarterlyReport_7db26139-47e7-4d4a-aa7a-cfeb30152ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fbd6c19a-431c-422f-9940-f6cc60238fd6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentPeriodEndDate_fbd6c19a-431c-422f-9940-f6cc60238fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_26fe2001-f08d-492d-ab3e-b4466e4a3a62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentTransitionReport_26fe2001-f08d-492d-ab3e-b4466e4a3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7ef27431-a58d-407d-8cab-a0e4a961809b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityFileNumber_7ef27431-a58d-407d-8cab-a0e4a961809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a3f34fc8-d093-4218-84c5-b32627212200" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityRegistrantName_a3f34fc8-d093-4218-84c5-b32627212200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d2e4586a-f7ef-4b21-afcd-e8d01be8a74a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d2e4586a-f7ef-4b21-afcd-e8d01be8a74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_be815068-1eab-4f6a-93fd-983310b6bd80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityTaxIdentificationNumber_be815068-1eab-4f6a-93fd-983310b6bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e68d8993-d8cf-4c27-a6d0-7c5dad16ba05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityAddressAddressLine1_e68d8993-d8cf-4c27-a6d0-7c5dad16ba05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_13d08525-460c-4176-867c-ed578f3bfe8e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityAddressAddressLine2_13d08525-460c-4176-867c-ed578f3bfe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e7e6966a-331c-4251-b5d9-21a549e6aa4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityAddressCityOrTown_e7e6966a-331c-4251-b5d9-21a549e6aa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_360810c4-241d-42ab-8f9f-c467867b1b80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityAddressStateOrProvince_360810c4-241d-42ab-8f9f-c467867b1b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ec18fc1-9587-4f57-9692-05692081e08f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_CityAreaCode_8ec18fc1-9587-4f57-9692-05692081e08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de0945fb-e156-4830-b13c-8e6773b787f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_LocalPhoneNumber_de0945fb-e156-4830-b13c-8e6773b787f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_baa29bbe-a3a3-4e81-9473-9d986b1e0065" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityAddressPostalZipCode_baa29bbe-a3a3-4e81-9473-9d986b1e0065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_86b41f6f-85be-4a91-bb4a-6e3125b22f76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_Security12bTitle_86b41f6f-85be-4a91-bb4a-6e3125b22f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e93e093-e675-4980-9b40-bb85b6e91de0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_TradingSymbol_2e93e093-e675-4980-9b40-bb85b6e91de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d45e3dae-d155-4442-b24e-357a5d424e5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityCurrentReportingStatus_d45e3dae-d155-4442-b24e-357a5d424e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4f0a4c32-e5c0-4642-aac9-c38fe7be4321" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityInteractiveDataCurrent_4f0a4c32-e5c0-4642-aac9-c38fe7be4321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ba65ca6c-bb43-42a0-b50e-6e570b0f1fc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityFilerCategory_ba65ca6c-bb43-42a0-b50e-6e570b0f1fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_886a8bee-5044-4ca0-bd48-d07de239c3d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntitySmallBusiness_886a8bee-5044-4ca0-bd48-d07de239c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_51032fdb-e02e-4c04-97f1-8adb982efb92" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityEmergingGrowthCompany_51032fdb-e02e-4c04-97f1-8adb982efb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f652fc20-58cc-4d1b-a5c2-3262460f5f9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityShellCompany_f652fc20-58cc-4d1b-a5c2-3262460f5f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0867e4a1-653a-4997-bb37-eee162fb5d3d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0867e4a1-653a-4997-bb37-eee162fb5d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9bad3e5b-840e-474b-9800-5969adaf92fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_AmendmentFlag_9bad3e5b-840e-474b-9800-5969adaf92fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_099ba16c-9481-4754-b3bf-d2c12e8b86c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentFiscalYearFocus_099ba16c-9481-4754-b3bf-d2c12e8b86c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_464a8740-280e-4fc8-a66d-834cc462806d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_464a8740-280e-4fc8-a66d-834cc462806d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e81f8f04-9d6f-4e53-b4da-a5ab8a333d91" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_EntityCentralIndexKey_e81f8f04-9d6f-4e53-b4da-a5ab8a333d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2e73441e-7134-4c23-a44a-03428f0eee69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ebc95b5-6108-4305-a7f0-d7d53c9d5fdf" xlink:to="loc_dei_CurrentFiscalYearEndDate_2e73441e-7134-4c23-a44a-03428f0eee69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e041e4a-f38f-4406-8ae6-4c227c561b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e041e4a-f38f-4406-8ae6-4c227c561b87" xlink:to="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72b117d8-0f5f-49bc-82ae-213b965563e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72b117d8-0f5f-49bc-82ae-213b965563e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_0edf2a81-57ed-4fc2-87d6-4cb5a75e77c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_0edf2a81-57ed-4fc2-87d6-4cb5a75e77c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9dc35f04-d45f-4106-91ea-8876f6ea0638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9dc35f04-d45f-4106-91ea-8876f6ea0638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_30d281ee-e788-4b87-928a-fdbe7484100a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:to="loc_us-gaap_OtherAssetsCurrent_30d281ee-e788-4b87-928a-fdbe7484100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_47dcc784-5ad6-493e-b9b9-fb03156a41d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6acb5edc-4016-4eec-9f3d-372d1b9f53e2" xlink:to="loc_us-gaap_AssetsCurrent_47dcc784-5ad6-493e-b9b9-fb03156a41d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4706c590-5a18-41c4-be34-41dc1b63a2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4706c590-5a18-41c4-be34-41dc1b63a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0f4c5d96-819a-4836-9d81-dabfd25aa538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0f4c5d96-819a-4836-9d81-dabfd25aa538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c67ea556-00dc-481e-8d53-73b010ef75c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d59d6606-9d2a-446c-bed2-b437a7e8ab05" xlink:to="loc_us-gaap_Assets_c67ea556-00dc-481e-8d53-73b010ef75c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e041e4a-f38f-4406-8ae6-4c227c561b87" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_07bcb21f-4113-4453-a9fb-42bf08b9ba92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:to="loc_us-gaap_AccountsPayableCurrent_07bcb21f-4113-4453-a9fb-42bf08b9ba92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9278afab-0a5c-4aa5-993e-4f1b91b41fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9278afab-0a5c-4aa5-993e-4f1b91b41fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_b321e8e4-2258-4bea-9ace-9a0d2ebf4287" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:to="loc_dare_DeferredGrantFundingCurrent_b321e8e4-2258-4bea-9ace-9a0d2ebf4287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0a95b0b-635f-41e4-b13a-e58664a2ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0a95b0b-635f-41e4-b13a-e58664a2ed3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d8c45814-6435-48d3-b5ed-c43c50a9ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_358250dd-7665-4791-be46-926be3d62c19" xlink:to="loc_us-gaap_LiabilitiesCurrent_d8c45814-6435-48d3-b5ed-c43c50a9ca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b21606d2-c4c6-4dc4-926a-e29d134ad0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b21606d2-c4c6-4dc4-926a-e29d134ad0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6f141b43-60de-4968-92d6-324b04825e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6f141b43-60de-4968-92d6-324b04825e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5e09a057-dddc-4c99-80aa-8201e0127978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_Liabilities_5e09a057-dddc-4c99-80aa-8201e0127978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e2270b00-02d2-41c3-a19b-ae2c1544c880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e2270b00-02d2-41c3-a19b-ae2c1544c880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a609b514-1db8-448c-bd66-2df47e4aa931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_PreferredStockValue_a609b514-1db8-448c-bd66-2df47e4aa931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_826d9f3d-5542-4c10-9044-d99f794b96e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_CommonStockValue_826d9f3d-5542-4c10-9044-d99f794b96e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5ce7a7b8-ad66-4870-8c08-d32e2ef6bf94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5ce7a7b8-ad66-4870-8c08-d32e2ef6bf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5f922b6c-8f93-4d57-9fa2-785d147f07b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5f922b6c-8f93-4d57-9fa2-785d147f07b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dac960c-0ee7-4189-adf4-7cbcb20e2c65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dac960c-0ee7-4189-adf4-7cbcb20e2c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b0aa152-4760-4d75-8538-606c87381fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_78c7b3da-83bd-4d08-b525-328a92a1e139" xlink:to="loc_us-gaap_StockholdersEquity_9b0aa152-4760-4d75-8538-606c87381fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3bb3ea4-ccc0-4d9e-91cb-26f66858118c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e85541fb-a591-4a97-bbcd-fe2fe4aa000d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3bb3ea4-ccc0-4d9e-91cb-26f66858118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73710333-6545-4251-bc33-3da1fa9799fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73710333-6545-4251-bc33-3da1fa9799fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c3cf0b7c-df5f-4823-9607-93fdc9ee3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c3cf0b7c-df5f-4823-9607-93fdc9ee3ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_32a783b8-7062-499d-a6a9-2fd5d482f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_PreferredStockSharesIssued_32a783b8-7062-499d-a6a9-2fd5d482f8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1055d922-c387-450a-86a1-e751c0d0155d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1055d922-c387-450a-86a1-e751c0d0155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_79d28cec-3445-4f2a-931e-bc43e527de4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_79d28cec-3445-4f2a-931e-bc43e527de4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b3a38401-cf54-4ad6-9703-88af382b0ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b3a38401-cf54-4ad6-9703-88af382b0ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a7b9d58f-432b-43cf-a83e-74f37ae84891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_CommonStockSharesIssued_a7b9d58f-432b-43cf-a83e-74f37ae84891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8e68b85b-8fd7-4c4c-8847-29a24017ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_107345fb-4f23-4fcd-8d98-e7be5fc00b79" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8e68b85b-8fd7-4c4c-8847-29a24017ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_f036acdd-36fa-44f0-bf8e-f8f1ec5758d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_f036acdd-36fa-44f0-bf8e-f8f1ec5758d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bd1b4fa3-034a-439f-a0e4-fdd92c0ef7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_RevenuesAbstract_bd1b4fa3-034a-439f-a0e4-fdd92c0ef7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ec2a974-8a55-4822-b049-7f5e2bd4525c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bd1b4fa3-034a-439f-a0e4-fdd92c0ef7c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ec2a974-8a55-4822-b049-7f5e2bd4525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_baf945b8-a48e-4ef0-85a4-1d75e5144966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bd1b4fa3-034a-439f-a0e4-fdd92c0ef7c2" xlink:to="loc_us-gaap_Revenues_baf945b8-a48e-4ef0-85a4-1d75e5144966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95074056-6d6d-423e-8829-a7b30346c486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95074056-6d6d-423e-8829-a7b30346c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8afb99cf-c870-4f89-8b98-79fa91712b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8afb99cf-c870-4f89-8b98-79fa91712b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeExpense_30992ae3-8ec3-4a20-b49a-60b749f2efa4" xlink:href="dare-20230630.xsd#dare_LicenseFeeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:to="loc_dare_LicenseFeeExpense_30992ae3-8ec3-4a20-b49a-60b749f2efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3583dbc7-4a7d-4fa6-8be9-1886c588a9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1c91bb75-2880-476d-81c2-2016f558b5dd" xlink:to="loc_us-gaap_OperatingExpenses_3583dbc7-4a7d-4fa6-8be9-1886c588a9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_77677340-0bc2-4269-ad39-bde605c62e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_OperatingIncomeLoss_77677340-0bc2-4269-ad39-bde605c62e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b4bc00fb-00ce-4c1c-a603-0d286e045d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b4bc00fb-00ce-4c1c-a603-0d286e045d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_78928a1a-b43d-42d8-b4b5-b56031b0f188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_NetIncomeLoss_78928a1a-b43d-42d8-b4b5-b56031b0f188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a82a2e1c-b81e-42bd-b2c9-fa70ae32132d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a82a2e1c-b81e-42bd-b2c9-fa70ae32132d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f81ded70-6a77-45d7-8737-e08689009de5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f81ded70-6a77-45d7-8737-e08689009de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d03bb7d-d890-4bf1-a249-a89ae20eb226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d03bb7d-d890-4bf1-a249-a89ae20eb226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_14bd4e3d-894b-495f-895b-57132e382885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_14bd4e3d-894b-495f-895b-57132e382885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9e839820-757f-430f-8fa8-1398dd7d3c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45afc1b0-5fd9-4613-bd75-2aa3317e4cab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9e839820-757f-430f-8fa8-1398dd7d3c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93bd27ad-8252-44e5-853e-5333795364a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9e839820-757f-430f-8fa8-1398dd7d3c83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93bd27ad-8252-44e5-853e-5333795364a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d619abfc-d78f-4560-9168-6aeb9732107a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9e839820-757f-430f-8fa8-1398dd7d3c83" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d619abfc-d78f-4560-9168-6aeb9732107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7355592-8ec6-40d7-86a3-d421f5954ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7355592-8ec6-40d7-86a3-d421f5954ffa" xlink:to="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e71546f8-da06-406a-a9a4-38a8c1f07500" xlink:to="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_71ab158c-d178-42ca-924e-c65b943a7e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_CommonStockMember_71ab158c-d178-42ca-924e-c65b943a7e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6fc7245b-9852-4b07-b2a7-e6452076d8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6fc7245b-9852-4b07-b2a7-e6452076d8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2105a692-817f-4f95-b919-470c97209b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2105a692-817f-4f95-b919-470c97209b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7444302c-ee45-4f0f-8a5b-d26f36497159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b650b303-fa4d-45f4-9e90-80716696e3e5" xlink:to="loc_us-gaap_RetainedEarningsMember_7444302c-ee45-4f0f-8a5b-d26f36497159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2d82b49-0cdb-432f-86f6-6ac7690345b2" xlink:to="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c1ea0bd-03fb-4cb3-8cba-b236225b26e2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_283216d6-568a-4722-8820-f30b2af1742c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_SharesOutstanding_283216d6-568a-4722-8820-f30b2af1742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1fa36a73-a682-4dfe-a905-011c62e12596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockholdersEquity_1fa36a73-a682-4dfe-a905-011c62e12596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d013afd3-e7b8-44c0-aef2-1b01e1a356a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d013afd3-e7b8-44c0-aef2-1b01e1a356a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_c988fd09-adb2-4b0b-877c-5243f0deea3f" xlink:href="dare-20230630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_c988fd09-adb2-4b0b-877c-5243f0deea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d1fa0baa-e792-40b3-a870-13cfd9c91bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d1fa0baa-e792-40b3-a870-13cfd9c91bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52f490a4-5c2d-4bf4-91f4-da981a6fcfca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52f490a4-5c2d-4bf4-91f4-da981a6fcfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d4c39299-2f10-4b2e-895c-6e1ef6f03400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d4c39299-2f10-4b2e-895c-6e1ef6f03400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dec6553d-19be-432d-9ad5-a9d462c3ab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_NetIncomeLoss_dec6553d-19be-432d-9ad5-a9d462c3ab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0792ac1-457f-44f6-8dc3-7c706195fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e0792ac1-457f-44f6-8dc3-7c706195fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_68532d30-1128-454c-8fb4-78b5d160c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_SharesOutstanding_68532d30-1128-454c-8fb4-78b5d160c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75dbd575-eb31-41c0-b341-14f4792330d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69eecf8-d3c0-4b5d-a819-e54ba7a1d986" xlink:to="loc_us-gaap_StockholdersEquity_75dbd575-eb31-41c0-b341-14f4792330d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dare-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a1f3e23c-fe9f-449b-8ab1-cf5cb27484f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a1f3e23c-fe9f-449b-8ab1-cf5cb27484f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a55e31a-15b3-411b-9ef8-914aa01baa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a1f3e23c-fe9f-449b-8ab1-cf5cb27484f4" xlink:to="loc_us-gaap_NetIncomeLoss_2a55e31a-15b3-411b-9ef8-914aa01baa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a1f3e23c-fe9f-449b-8ab1-cf5cb27484f4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2e4d4a5b-167f-428d-9666-ac1639b0f043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:to="loc_us-gaap_Depreciation_2e4d4a5b-167f-428d-9666-ac1639b0f043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_475d3ea9-205a-4414-80d1-1fed96a90b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:to="loc_us-gaap_ShareBasedCompensation_475d3ea9-205a-4414-80d1-1fed96a90b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_ade2aad0-df62-49d4-8381-7ad226671082" xlink:href="dare-20230630.xsd#dare_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:to="loc_dare_NonCashLeaseExpense_ade2aad0-df62-49d4-8381-7ad226671082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e42a08c5-c0bf-464e-a4d8-a15f7b9e6922" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28e572f0-108c-443d-923d-2b82e24b0f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28e572f0-108c-443d-923d-2b82e24b0f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e84cd687-7c7e-4cab-bbba-53ffc27b4e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e84cd687-7c7e-4cab-bbba-53ffc27b4e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f586628a-d896-4e7d-9eac-0ee743740815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f586628a-d896-4e7d-9eac-0ee743740815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71e9b236-8a5a-486d-8842-d1fb9afe4086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71e9b236-8a5a-486d-8842-d1fb9afe4086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0bb08a6c-eec5-4de7-a4cc-c35acac6eb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0bb08a6c-eec5-4de7-a4cc-c35acac6eb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9edece83-848f-4c72-a76f-7a0fd150b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9edece83-848f-4c72-a76f-7a0fd150b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e39c5328-1973-4ec9-880f-ff141b7520eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e39c5328-1973-4ec9-880f-ff141b7520eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_02d76d89-dc58-48ca-9e9e-977ce57412bf" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_02d76d89-dc58-48ca-9e9e-977ce57412bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7f1aa4d-077b-4d71-8c61-5b1b394cfb79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_479a29bc-f510-48d0-b06b-6f956b01dc68" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7f1aa4d-077b-4d71-8c61-5b1b394cfb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb85f8d8-24d6-495c-ada0-94540c5d1849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a1f3e23c-fe9f-449b-8ab1-cf5cb27484f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb85f8d8-24d6-495c-ada0-94540c5d1849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de9218f-5129-4465-b6b4-9ea58d723771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de9218f-5129-4465-b6b4-9ea58d723771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3bb9b59b-d6e7-4fc0-8502-4f18f296679a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de9218f-5129-4465-b6b4-9ea58d723771" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3bb9b59b-d6e7-4fc0-8502-4f18f296679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_916509c0-d98a-419e-bee5-af5b7e45eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de9218f-5129-4465-b6b4-9ea58d723771" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_916509c0-d98a-419e-bee5-af5b7e45eb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_787d9f9f-0e7d-4de2-9c60-63601780dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_787d9f9f-0e7d-4de2-9c60-63601780dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_ceea3aa4-9be4-40b6-ad6c-70836f6e5f66" xlink:href="dare-20230630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_787d9f9f-0e7d-4de2-9c60-63601780dd4e" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_ceea3aa4-9be4-40b6-ad6c-70836f6e5f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_80b7d9ef-5833-447b-a72e-90faed5bd720" xlink:href="dare-20230630.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_787d9f9f-0e7d-4de2-9c60-63601780dd4e" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_80b7d9ef-5833-447b-a72e-90faed5bd720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a534f94-c2fd-4fbb-ae60-080f4bd48f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_787d9f9f-0e7d-4de2-9c60-63601780dd4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a534f94-c2fd-4fbb-ae60-080f4bd48f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e485166a-5d7d-4a88-aba6-c47b5b958241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e485166a-5d7d-4a88-aba6-c47b5b958241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6a9db004-3798-471a-8c1c-276a6d9d1260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6a9db004-3798-471a-8c1c-276a6d9d1260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3db9f21f-6964-40fc-afeb-1c48b30217d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3db9f21f-6964-40fc-afeb-1c48b30217d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92726058-929e-4e59-9f66-2d12076d9bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92726058-929e-4e59-9f66-2d12076d9bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2d06205a-df93-4504-b72a-69d00f24efd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2d06205a-df93-4504-b72a-69d00f24efd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14b7d130-0e73-427e-a60d-287e93f48179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2d06205a-df93-4504-b72a-69d00f24efd4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14b7d130-0e73-427e-a60d-287e93f48179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145d18fd-75d2-486b-8555-ad27edf10fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2d06205a-df93-4504-b72a-69d00f24efd4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145d18fd-75d2-486b-8555-ad27edf10fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9a7cad5-50ea-4c45-9ad7-f2bfbe0034bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2d06205a-df93-4504-b72a-69d00f24efd4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9a7cad5-50ea-4c45-9ad7-f2bfbe0034bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_258f26be-2208-4c3c-b075-c67ae9722853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e96fee8f-4bfb-41a6-bbd7-eb4e82747bdf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_258f26be-2208-4c3c-b075-c67ae9722853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2c3f2ba5-8996-4f7a-b908-d2fddc74bec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_258f26be-2208-4c3c-b075-c67ae9722853" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2c3f2ba5-8996-4f7a-b908-d2fddc74bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="dare-20230630.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c283e124-a475-4219-8c59-52dcd7c86cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3cb405ec-23ff-4036-b9a6-96c524b6c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c283e124-a475-4219-8c59-52dcd7c86cf9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3cb405ec-23ff-4036-b9a6-96c524b6c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_803f8ee8-84bc-4484-bf96-237fe37e5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_405341d1-95ec-4340-823e-9e0a63473add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_803f8ee8-84bc-4484-bf96-237fe37e5dd1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_405341d1-95ec-4340-823e-9e0a63473add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreements" xlink:type="simple" xlink:href="dare-20230630.xsd#StrategicAgreements"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StrategicAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07d17fc7-3ee6-405f-9009-9a2c630a29a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0aad9506-1652-4641-999a-c7cfc8b097f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07d17fc7-3ee6-405f-9009-9a2c630a29a4" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0aad9506-1652-4641-999a-c7cfc8b097f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5f861d6d-b3fb-4b9c-8f9e-60f7f788cf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cd734236-015c-4a15-ba03-54ca9957ecee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5f861d6d-b3fb-4b9c-8f9e-60f7f788cf6d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cd734236-015c-4a15-ba03-54ca9957ecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f8f511-e9e7-4047-aa48-9d97b7bf0354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ae47b5cb-d0c4-4afc-967b-935ed7e1f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f8f511-e9e7-4047-aa48-9d97b7bf0354" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ae47b5cb-d0c4-4afc-967b-935ed7e1f3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedProperties"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5ba51e9d-4f4b-45b4-a950-1c90443f9765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_00e354ee-6e37-4f51-a279-668062b51682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ba51e9d-4f4b-45b4-a950-1c90443f9765" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_00e354ee-6e37-4f51-a279-668062b51682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dare-20230630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d02f923a-7d07-40ab-ac40-70de63435773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_b0ea1107-20e2-4e60-ad79-a49560c1d530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d02f923a-7d07-40ab-ac40-70de63435773" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_b0ea1107-20e2-4e60-ad79-a49560c1d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwards" xlink:type="simple" xlink:href="dare-20230630.xsd#GrantAwards"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_3ca47124-a61f-4779-8e9a-b046dc941206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock_d6e3415d-00e0-446d-8c1e-a03cebe8b4db" xlink:href="dare-20230630.xsd#dare_GrantAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_3ca47124-a61f-4779-8e9a-b046dc941206" xlink:to="loc_dare_GrantAwardTextBlock_d6e3415d-00e0-446d-8c1e-a03cebe8b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dare-20230630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3b83b54b-ed78-48ba-aef4-fd66c6bd09fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_53b40c81-c580-4940-92e9-70508091cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b83b54b-ed78-48ba-aef4-fd66c6bd09fc" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_53b40c81-c580-4940-92e9-70508091cd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dare-20230630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_78dfefa4-e950-424f-aac5-003183c41599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_904ba2a0-4652-43b5-9d6f-7b39549fd8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_78dfefa4-e950-424f-aac5-003183c41599" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_904ba2a0-4652-43b5-9d6f-7b39549fd8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b6439fa2-149c-458b-bf42-75c7dd4fccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b6439fa2-149c-458b-bf42-75c7dd4fccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_41d4c2b8-38a3-41f3-8640-bc672b063065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_41d4c2b8-38a3-41f3-8640-bc672b063065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GoingConcernPolicyTextBlock_55d07fc9-e50b-42c1-97c1-a247c5fda2a9" xlink:href="dare-20230630.xsd#dare_GoingConcernPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:to="loc_dare_GoingConcernPolicyTextBlock_55d07fc9-e50b-42c1-97c1-a247c5fda2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7b635a25-2cba-4075-844f-9347665bb950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7b635a25-2cba-4075-844f-9347665bb950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b04bbdcd-cada-49ae-96f6-8f7f0d3fe45c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad57bff7-e376-48a8-971b-ed1d26793f06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b04bbdcd-cada-49ae-96f6-8f7f0d3fe45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d2d76543-a9f8-404b-819e-a7ca70a639f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3b570b88-86b8-4a6c-b5fd-f105a81bbaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2d76543-a9f8-404b-819e-a7ca70a639f3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3b570b88-86b8-4a6c-b5fd-f105a81bbaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_75712f25-2f70-4128-b506-a021d6409217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8ff0268b-8dd3-45ba-b92b-5fe3b77ab7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_75712f25-2f70-4128-b506-a021d6409217" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8ff0268b-8dd3-45ba-b92b-5fe3b77ab7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79264a25-15f0-4b53-a932-ce4ca90ec987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f6d99031-b952-492a-8ae2-c3c6f6aa6b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79264a25-15f0-4b53-a932-ce4ca90ec987" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f6d99031-b952-492a-8ae2-c3c6f6aa6b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_13b47a80-3403-42b9-bab3-4098c53e7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79264a25-15f0-4b53-a932-ce4ca90ec987" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_13b47a80-3403-42b9-bab3-4098c53e7fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_981921a4-ef01-4402-875c-9f672d32b22e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7b71de09-19e0-4bbb-9a40-046e3da40b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_981921a4-ef01-4402-875c-9f672d32b22e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7b71de09-19e0-4bbb-9a40-046e3da40b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dare-20230630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d637168f-1526-4b61-9248-e1b029a578d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8af61634-5531-4e4a-870e-dd0840559943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d637168f-1526-4b61-9248-e1b029a578d9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8af61634-5531-4e4a-870e-dd0840559943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45e70d2c-bea1-4b71-9406-c581ec7c9d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45e70d2c-bea1-4b71-9406-c581ec7c9d8f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:to="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_106c1418-c580-4493-a8d2-e1e7742b943c" xlink:to="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f1c1394e-ceee-4ba3-80a7-de0e749d82ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1855272a-f887-4ecf-8de6-378fe4ecc4ba" xlink:to="loc_us-gaap_LicenseMember_f1c1394e-ceee-4ba3-80a7-de0e749d82ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a424ad6b-66fc-4a3f-8baa-58132dcab903" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_421b6263-d44d-4304-8ea5-ab8a429f261e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:to="loc_us-gaap_NumberOfOperatingSegments_421b6263-d44d-4304-8ea5-ab8a429f261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14bda9fd-3a4a-45ed-aae0-7d8418e25231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_132bc851-ec61-48b3-89be-2a3b99af3b79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14bda9fd-3a4a-45ed-aae0-7d8418e25231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6b1cf6a-6bae-46f8-96cd-bc120a471f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6b1cf6a-6bae-46f8-96cd-bc120a471f00" xlink:to="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:to="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ef375c05-f941-4d1e-a217-963df1e6bb6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_45ad3bee-cd61-4db4-a0a8-c5361ab961b0" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_204a810c-e4fd-47b0-8323-47b03643a81f" xlink:to="loc_dare_OrganonMember_45ad3bee-cd61-4db4-a0a8-c5361ab961b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5172bb22-e8fb-4d4c-8592-55b8b7f21f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_da5146ed-7a84-4769-8774-26e37edfbe24" xlink:href="dare-20230630.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6161a5c2-19ef-4977-9e09-2c31a41dc5a1" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_da5146ed-7a84-4769-8774-26e37edfbe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:href="dare-20230630.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_fe7c7d9b-cfda-453f-91d4-955fa94e3969" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ff1f30e9-7229-4220-8501-cf60394c4e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ff1f30e9-7229-4220-8501-cf60394c4e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b7e8469-75a1-498b-b3d7-c1af5c9c9ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b7e8469-75a1-498b-b3d7-c1af5c9c9ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194a8bb-924e-433e-8be2-1ea6eba2f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194a8bb-924e-433e-8be2-1ea6eba2f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_8f98c246-1b69-4f6e-976c-5cddb59468b3" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_DeferredGrantFundingCurrent_8f98c246-1b69-4f6e-976c-5cddb59468b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit_7da405e1-4949-4452-bb1c-6a4b85bcbf5c" xlink:href="dare-20230630.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_WorkingCapitalIncreaseDeficit_7da405e1-4949-4452-bb1c-6a4b85bcbf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6ae8fae-1078-461b-a636-6b951880d694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_NetIncomeLoss_b6ae8fae-1078-461b-a636-6b951880d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3c4bfeab-afce-4ab2-b7d4-3f333427e8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3c4bfeab-afce-4ab2-b7d4-3f333427e8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_e8874335-b47b-49c3-9190-f8dc59c747c1" xlink:href="dare-20230630.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_e8874335-b47b-49c3-9190-f8dc59c747c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_1b1e73e4-2cf5-4335-984a-510155c08373" xlink:href="dare-20230630.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_1b1e73e4-2cf5-4335-984a-510155c08373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b0befe-5278-437d-8794-6dbfc710b1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b0befe-5278-437d-8794-6dbfc710b1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_e7e08943-cfb7-4b30-9ef6-a21a2de42e73" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_a53a09ce-63c4-447e-b172-16d75a4a8971" xlink:to="loc_dare_MilestonePaymentsContingentAmount_e7e08943-cfb7-4b30-9ef6-a21a2de42e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bec506be-4b41-4699-ad77-3f2ce902ea9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bec506be-4b41-4699-ad77-3f2ce902ea9d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2724398c-0632-44e5-8c0c-f6823cdb645d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_63e0ef3c-8baa-4519-a4dc-f01eea4f7151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_433da4ee-f57b-48c9-8911-9ca731c52330" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_63e0ef3c-8baa-4519-a4dc-f01eea4f7151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e00d807-d2ed-4ade-9758-ed4ad4f2c754" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d5e1b4a-be24-4a3f-a7ab-54f335a29250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d5e1b4a-be24-4a3f-a7ab-54f335a29250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fc9ec216-a13a-452a-9d84-0825ee913b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fc9ec216-a13a-452a-9d84-0825ee913b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4294503-5d89-4783-a4c1-76fb22bd1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f447a1ed-0ba0-4b65-b50b-1a139eac1231" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4294503-5d89-4783-a4c1-76fb22bd1de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b35b62b1-4320-4a80-8961-40d510e882c2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7f4e6742-cd9b-40be-8315-0e62600b9fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90dc5aed-a775-4611-87d7-cc21bc65e44a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7f4e6742-cd9b-40be-8315-0e62600b9fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StrategicAgreementsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_539fd014-dc9d-4d70-9baa-334b21ca7857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_539fd014-dc9d-4d70-9baa-334b21ca7857" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cbe93c95-b687-4995-8695-24d955b28d82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_192d86fb-0688-49ec-919b-94b05399b091" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:to="loc_dare_OrganonMember_192d86fb-0688-49ec-919b-94b05399b091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember_99aef380-a469-4d57-9428-cff835d72f1c" xlink:href="dare-20230630.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b034838-660d-4923-b67c-a9d5b1086391" xlink:to="loc_dare_CatalentAndMilanaPharmMember_99aef380-a469-4d57-9428-cff835d72f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba43179e-2a7a-4833-bfee-75279eec94ff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_ff4a8bf8-7612-4835-b83b-c7ccb8b57a25" xlink:href="dare-20230630.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_ff4a8bf8-7612-4835-b83b-c7ccb8b57a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HennepinLicenseAgreementMember_6a9bb6b0-ba09-4ff5-95de-a7412726ce73" xlink:href="dare-20230630.xsd#dare_HennepinLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_HennepinLicenseAgreementMember_6a9bb6b0-ba09-4ff5-95de-a7412726ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b38590c1-ec30-49a7-a87e-36b58a9badd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_us-gaap_LicensingAgreementsMember_b38590c1-ec30-49a7-a87e-36b58a9badd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_9da5650a-0820-4f35-aced-16ec483f88c8" xlink:href="dare-20230630.xsd#dare_AssignmentAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_AssignmentAgreementMember_9da5650a-0820-4f35-aced-16ec483f88c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MergerAgreementMember_4fe42a00-00bd-458e-a953-e7733ca53bee" xlink:href="dare-20230630.xsd#dare_MergerAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_MergerAgreementMember_4fe42a00-00bd-458e-a953-e7733ca53bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_bc970fed-f2ea-40c2-bef2-7959fe08ee31" xlink:href="dare-20230630.xsd#dare_PearTreePharmaceuticalsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_bc970fed-f2ea-40c2-bef2-7959fe08ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_9c34be44-b518-42f7-aa35-647288e1f024" xlink:href="dare-20230630.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_9c34be44-b518-42f7-aa35-647288e1f024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_f22fa45b-e56a-4f6a-841c-e3a02da81620" xlink:href="dare-20230630.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9437f3d2-a544-4247-815a-003c31144686" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_f22fa45b-e56a-4f6a-841c-e3a02da81620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5dcb3aad-53ec-47df-b8d2-c1d846d0c53f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_659f3e3d-fa82-4cf9-ab73-6eb41e9148da" xlink:href="dare-20230630.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_659f3e3d-fa82-4cf9-ab73-6eb41e9148da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_d22cb811-d759-49fe-806b-41c2ec214dc4" xlink:href="dare-20230630.xsd#dare_SalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_SalesMilestonesMember_d22cb811-d759-49fe-806b-41c2ec214dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_1f868035-ef25-4f34-a3d1-d13a18ebb61d" xlink:href="dare-20230630.xsd#dare_ADVATecAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cb6c7efd-670f-4c04-8bdc-351ffc2b1683" xlink:to="loc_dare_ADVATecAgreementMember_1f868035-ef25-4f34-a3d1-d13a18ebb61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847bca7f-abf0-4164-a017-f6f62143291f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_7a9c045b-3ea6-4af1-8e39-3e0711c28548" xlink:href="dare-20230630.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_73fb14ec-8dfb-485b-ab4c-5d63f6030ec4" xlink:to="loc_dare_MicrochipsBiotechInc.Member_7a9c045b-3ea6-4af1-8e39-3e0711c28548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b98cfcf6-13b6-4d47-bc35-3e9adeccb469" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_f701f709-eb65-4278-9aa3-90e27b60538d" xlink:href="dare-20230630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2b605b2a-c006-431f-8d04-aa0c73864ab2" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_f701f709-eb65-4278-9aa3-90e27b60538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d359a63-956a-4347-9b7f-2e8632fc85a7" xlink:to="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a1fd0b8-ab79-493c-af25-74a60b1c4a5a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:to="loc_srt_MaximumMember_4a1fd0b8-ab79-493c-af25-74a60b1c4a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dc02f05c-495a-4434-83f2-a9e79c3e454a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f45af421-c338-41d4-ada9-c061e3f2996e" xlink:to="loc_srt_MinimumMember_dc02f05c-495a-4434-83f2-a9e79c3e454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_951e42e3-c2ce-4f67-9032-5bbf4bbd6420" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_aaecccc5-922a-446c-b40a-7b095d3182cb" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_aaecccc5-922a-446c-b40a-7b095d3182cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_a1593f0d-b94f-4888-b4df-226f6e15aff6" xlink:href="dare-20230630.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_a1593f0d-b94f-4888-b4df-226f6e15aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_31af5abb-33ab-405b-9802-da97814d623c" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_31af5abb-33ab-405b-9802-da97814d623c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_f2ade201-3663-42dc-90f8-3c3b46ff5fad" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_f2ade201-3663-42dc-90f8-3c3b46ff5fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_3166c6da-538c-4a95-8bc2-10cdbf597cc1" xlink:href="dare-20230630.xsd#dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_f370e4a8-d2c2-4810-8fa5-3e1046968520" xlink:to="loc_dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember_3166c6da-538c-4a95-8bc2-10cdbf597cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_316a5760-451d-45b7-9d3a-24b57cc1e53e" xlink:to="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_00230da3-9659-4cb3-b1e6-9464ccc06307" xlink:href="dare-20230630.xsd#dare_MilanaPharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_MilanaPharmMember_00230da3-9659-4cb3-b1e6-9464ccc06307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_fe876d2e-503e-464a-bcfa-74dbfcd3a848" xlink:href="dare-20230630.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_fe876d2e-503e-464a-bcfa-74dbfcd3a848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_8b438c19-4052-4fd3-b962-57ef9481e09c" xlink:href="dare-20230630.xsd#dare_PearTreePharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_8b438c19-4052-4fd3-b962-57ef9481e09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_81a1444c-9cd7-4d29-be83-a0c542fe33a0" xlink:href="dare-20230630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_97e1a9ac-70b5-4195-817d-2a23d2594932" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_81a1444c-9cd7-4d29-be83-a0c542fe33a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8c5e6cd0-dff3-4909-92a4-408923b68acc" xlink:to="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_7e50c534-ec71-49e7-b706-73ae6630bcc0" xlink:href="dare-20230630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_7e50c534-ec71-49e7-b706-73ae6630bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_33449447-cc1b-4c70-896c-efbc012d2741" xlink:href="dare-20230630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_b24806e2-416e-4877-a1d4-5fc3464ebf08" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_33449447-cc1b-4c70-896c-efbc012d2741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d31b522f-3b59-421d-b6a3-360c6ee8e85b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_b197e276-cb14-412b-a7b6-09fb8a157ff8" xlink:href="dare-20230630.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_b197e276-cb14-412b-a7b6-09fb8a157ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_2953beb4-fb4f-44d7-ac5c-9ff4b5fc6945" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_2953beb4-fb4f-44d7-ac5c-9ff4b5fc6945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_ff062909-1e9d-432c-8a88-cc6c0ec562b4" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmount_ff062909-1e9d-432c-8a88-cc6c0ec562b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_26676f92-2bbf-44b9-b17b-548f96cee3d7" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_26676f92-2bbf-44b9-b17b-548f96cee3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3254b6d6-c48c-4bac-87d4-adc298c412f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3254b6d6-c48c-4bac-87d4-adc298c412f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_ce1bfdae-eb94-49f6-8b76-9ff54cdf77de" xlink:href="dare-20230630.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_MaximumPotentialMilestonePayments_ce1bfdae-eb94-49f6-8b76-9ff54cdf77de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_f7c387bd-d631-4d29-bf3a-432cb1a3acb6" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_f7c387bd-d631-4d29-bf3a-432cb1a3acb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_e0894d5b-d0b4-4feb-bf08-0949a1bf2d12" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_e0894d5b-d0b4-4feb-bf08-0949a1bf2d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_5f4db773-4c9f-4bff-9aaa-220f404acb7a" xlink:href="dare-20230630.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_5f4db773-4c9f-4bff-9aaa-220f404acb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_011eca6b-ca2b-44b5-9ea5-3c0ec4218391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_011eca6b-ca2b-44b5-9ea5-3c0ec4218391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_6393181c-47f1-4da6-9fc5-e870afd44fc9" xlink:href="dare-20230630.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_6393181c-47f1-4da6-9fc5-e870afd44fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration_3d9a402b-c433-4443-80bc-bbf6b51c016d" xlink:href="dare-20230630.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_AssetAcquisitionContingentConsideration_3d9a402b-c433-4443-80bc-bbf6b51c016d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3c335b17-2121-402b-9618-f3b48da46551" xlink:href="dare-20230630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3c335b17-2121-402b-9618-f3b48da46551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_7f0d2973-1cde-4c49-aa07-c67ec61461cd" xlink:href="dare-20230630.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_75b18507-9ce2-4ca0-9e63-b2bb199ddf17" xlink:to="loc_dare_PercentageOfRoyaltyRate_7f0d2973-1cde-4c49-aa07-c67ec61461cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_126254e5-88c8-48f6-aecc-c31d0e1120f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:href="dare-20230630.xsd#dare_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_126254e5-88c8-48f6-aecc-c31d0e1120f3" xlink:to="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:to="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_47693198-9026-4244-89e0-dd1541eeab70" xlink:to="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e91c227f-533b-417c-9fa8-fbaa0076324e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff545944-29f1-4a38-a0f1-259777f847ca" xlink:to="loc_srt_MaximumMember_e91c227f-533b-417c-9fa8-fbaa0076324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7b629d90-919f-4017-adcf-d23d7231f259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_March2023AtTheMarketSalesAgreementMember_fabf6b06-5d76-4861-85de-570cea6a89e2" xlink:href="dare-20230630.xsd#dare_March2023AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_March2023AtTheMarketSalesAgreementMember_fabf6b06-5d76-4861-85de-570cea6a89e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_October2021AtTheMarketSalesAgreementMember_8a5e271a-7dd5-4b9a-84c9-5eabd0ca5b93" xlink:href="dare-20230630.xsd#dare_October2021AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_October2021AtTheMarketSalesAgreementMember_8a5e271a-7dd5-4b9a-84c9-5eabd0ca5b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember_8580374b-4efb-4ea7-ace9-49dd278acd0d" xlink:href="dare-20230630.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f14a349-b386-4c59-9635-817c0b9df915" xlink:to="loc_dare_April2021AtTheMarketSalesAgreementMember_8580374b-4efb-4ea7-ace9-49dd278acd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:href="dare-20230630.xsd#dare_StockholdersEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_00385343-66db-43ad-966b-98d4df275370" xlink:to="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ddfd2dfa-44a7-4389-aa54-8aa7fe1593da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ddfd2dfa-44a7-4389-aa54-8aa7fe1593da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_a13f21b1-3173-4951-be1a-6529825c9ba5" xlink:href="dare-20230630.xsd#dare_PercentageOfAggregateCommission"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_PercentageOfAggregateCommission_a13f21b1-3173-4951-be1a-6529825c9ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockProspectusOfferingAmount_ac59515e-bc72-4051-a356-ba73840f64a1" xlink:href="dare-20230630.xsd#dare_SaleOfStockProspectusOfferingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_SaleOfStockProspectusOfferingAmount_ac59515e-bc72-4051-a356-ba73840f64a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8e6c91bf-9d7c-44ce-b186-f54aac4e00d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8e6c91bf-9d7c-44ce-b186-f54aac4e00d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cbed89bf-fd37-4714-aaf4-8de7cc54d36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cbed89bf-fd37-4714-aaf4-8de7cc54d36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockBrokerageCommissionsExpense_162d1896-cdb5-4262-9daa-b57f583d0a14" xlink:href="dare-20230630.xsd#dare_SaleOfStockBrokerageCommissionsExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_SaleOfStockBrokerageCommissionsExpense_162d1896-cdb5-4262-9daa-b57f583d0a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00270529-a644-4968-81f6-f0f76f5636d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00270529-a644-4968-81f6-f0f76f5636d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_04516277-f56b-48a1-9908-510a37df5b4c" xlink:href="dare-20230630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_04516277-f56b-48a1-9908-510a37df5b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_2d9437cc-c4ba-4524-97cd-66fe31825a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_2d9437cc-c4ba-4524-97cd-66fe31825a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_9b64d1e1-1744-4124-ba4f-f8ca924e9d5a" xlink:href="dare-20230630.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_9b64d1e1-1744-4124-ba4f-f8ca924e9d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_2360f638-3dce-4f08-819a-cc2e445a81fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_83513383-0580-497d-b68e-cc7c60fa7ded" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_2360f638-3dce-4f08-819a-cc2e445a81fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec8e3715-f098-446b-ae99-d43caaab7342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec8e3715-f098-446b-ae99-d43caaab7342" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef58b767-7a1c-41dd-9bb5-6ad8d4ce80b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_9c205c52-e873-4b2a-9354-ad280a21397e" xlink:href="dare-20230630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_036669cc-554e-4b5d-9a12-2e6cd53d47f1" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_9c205c52-e873-4b2a-9354-ad280a21397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bbcc45b4-67ec-4eb0-baed-2a18e502cc17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e1a8dfc0-d37c-4048-b718-a685f86b4871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e1a8dfc0-d37c-4048-b718-a685f86b4871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d68e84c8-4379-4aeb-8fb1-e268b2daafcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d68e84c8-4379-4aeb-8fb1-e268b2daafcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0ec128a1-756f-4bbe-a780-e55884ba271f" xlink:href="dare-20230630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_79f5bf07-23f3-478c-aabc-bf328fd159a8" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0ec128a1-756f-4bbe-a780-e55884ba271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcd3b8a-401c-4037-8658-f38fd1ec45be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcd3b8a-401c-4037-8658-f38fd1ec45be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:to="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8e33e89a-3389-4e30-99e6-b9d1c6c145ca" xlink:to="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_6c2a3ca0-e075-45db-83d8-9107be9a4f1c" xlink:href="dare-20230630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_6c2a3ca0-e075-45db-83d8-9107be9a4f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_e2e15af2-963d-4e28-8123-76dfb0263e3e" xlink:href="dare-20230630.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5cd51dc3-cab7-4280-89d3-10a0b6fc33d7" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_e2e15af2-963d-4e28-8123-76dfb0263e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:to="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9b05ef6a-181e-48cf-9919-32ee3f634786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5691660-43b5-4c14-b134-0d242c2e7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5691660-43b5-4c14-b134-0d242c2e7bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember_dae432ed-a0f1-4a8e-ab70-a080da00eb0a" xlink:href="dare-20230630.xsd#dare_TwoThousandTwentyTwoStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c82fd1f0-f5d1-403a-b248-9df4d9e38e7d" xlink:to="loc_dare_TwoThousandTwentyTwoStockIncentivePlanMember_dae432ed-a0f1-4a8e-ab70-a080da00eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44e610a5-aaf2-460e-bd75-24e6dff89c44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6d2d94b8-22c5-4d4e-8d24-66b7cb3617fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6d2d94b8-22c5-4d4e-8d24-66b7cb3617fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edadbeaa-1b23-4414-9353-39d722bccfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edadbeaa-1b23-4414-9353-39d722bccfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6847db5a-8255-48c6-92ce-b13754c49c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6847db5a-8255-48c6-92ce-b13754c49c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_9b666232-2dee-4135-b9bf-2b5b8309790a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_9b666232-2dee-4135-b9bf-2b5b8309790a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_2a905231-0b16-43ea-b18f-097486526a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_2a905231-0b16-43ea-b18f-097486526a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_540c6b55-dcd1-4488-a7a3-bc0847a3e8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_540c6b55-dcd1-4488-a7a3-bc0847a3e8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_283cf6d7-7e6d-43a1-afdb-f0fbc12de657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_283cf6d7-7e6d-43a1-afdb-f0fbc12de657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_72fc56ac-a8c4-43bb-83a7-fe24c0f8a3b1" xlink:href="dare-20230630.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bd106b0-77b2-4257-942d-b3dcd7abc11b" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_72fc56ac-a8c4-43bb-83a7-fe24c0f8a3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d88ef3d-7b4a-482d-85bc-8813e85736dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d88ef3d-7b4a-482d-85bc-8813e85736dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:to="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d75bf8e0-db25-4153-96eb-60065d9b339a" xlink:to="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_99d47d47-6273-47c1-a2ce-eb6f3340b37f" xlink:href="dare-20230630.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c1cb3037-8fd0-48cf-bb1c-6764c5950323" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_99d47d47-6273-47c1-a2ce-eb6f3340b37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:to="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0041fa5a-3519-479d-a2ed-b28bc4fe2207" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0d2eb2a-b455-4cce-87cd-28fab50e6487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49aad699-85d7-4571-8cdd-0d6eb5cfeadf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0d2eb2a-b455-4cce-87cd-28fab50e6487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93e9b0b6-8d4d-41e7-bf3a-ea594d608aa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa404912-3819-4051-83af-1283886025f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa404912-3819-4051-83af-1283886025f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23c7e1c6-48b4-46c2-83d6-bad2fa878167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23c7e1c6-48b4-46c2-83d6-bad2fa878167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_438b90d7-949d-415f-8879-993b73787e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_438b90d7-949d-415f-8879-993b73787e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_492176a6-0038-49ab-9ec2-6de096ef4f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_492176a6-0038-49ab-9ec2-6de096ef4f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_55483329-6d23-46bf-8973-76e589018a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_55483329-6d23-46bf-8973-76e589018a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4fe99fb-22c3-4514-a621-dd4b95b21c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee606bb3-bb05-4f0d-bf91-8b3eb774b59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4fe99fb-22c3-4514-a621-dd4b95b21c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_38b89c99-b9e8-47be-b285-23ce3bdb56af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_38b89c99-b9e8-47be-b285-23ce3bdb56af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a34b4a46-2ddd-4c68-9322-2fb0c36f7774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a34b4a46-2ddd-4c68-9322-2fb0c36f7774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_defb3185-2558-4d77-91d3-b4cb9c9445a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_defb3185-2558-4d77-91d3-b4cb9c9445a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42c85a6f-9c71-4c3a-89e6-8e70ee9b75d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42c85a6f-9c71-4c3a-89e6-8e70ee9b75d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b7e2d43a-dcb3-4658-b934-c49b5e6e148e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b7e2d43a-dcb3-4658-b934-c49b5e6e148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dc2f2402-5068-4082-a3d0-36bedef1a769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dc2f2402-5068-4082-a3d0-36bedef1a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88361e72-62dc-451e-8ffa-7438c1d59611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cd0f29d2-2189-4cce-a5dd-849100fe5243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88361e72-62dc-451e-8ffa-7438c1d59611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c1d1903a-57ad-41b2-bd4c-d660034953cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3155c2e2-bab6-4005-aeff-6c0157962c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c1d1903a-57ad-41b2-bd4c-d660034953cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c768551-a975-4add-bfda-03bfe9feabec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c768551-a975-4add-bfda-03bfe9feabec" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:to="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3073b24f-2bf6-404e-919a-26785429ac1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_279ce9fb-85f7-4bbd-a17a-8d76fadd4634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0a61e19-aeb2-46f5-b691-bd68d82bdf08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_279ce9fb-85f7-4bbd-a17a-8d76fadd4634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66ca83ce-80f8-4cfa-a899-872935f1681f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7161d38c-e3e1-402c-a8b6-087251bf15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7161d38c-e3e1-402c-a8b6-087251bf15dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9bc2d9-5264-47d2-9797-d070513ab240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_293708c8-737e-4795-9c95-cb0cca811497" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c9bc2d9-5264-47d2-9797-d070513ab240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5400b745-c6c4-48d2-971b-49960a8e55d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5b7917d-a0eb-496c-bdbf-bc782750ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_95bf5c09-e205-4548-aa1f-448fb63460c5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5b7917d-a0eb-496c-bdbf-bc782750ef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b56ada41-d777-4fca-a27a-24e15077629d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b56ada41-d777-4fca-a27a-24e15077629d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:to="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6a20f1d3-1d92-478b-98a2-8357d7570af7" xlink:to="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember_79d7da3a-d039-41eb-8bf6-bc18d5af7156" xlink:href="dare-20230630.xsd#dare_MBIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_90ac2c3d-3005-48c0-95b2-f418922b72b8" xlink:to="loc_dare_MBIMember_79d7da3a-d039-41eb-8bf6-bc18d5af7156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:to="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_612ace9b-c8b3-4b81-b11b-fe8eda2809da" xlink:to="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_62230aab-8037-4d8d-b9bb-097b4507b650" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85d7de6c-1d76-4b79-89b4-7943a51df231" xlink:to="loc_srt_MaximumMember_62230aab-8037-4d8d-b9bb-097b4507b650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_123ec2f1-46fd-487d-ba3f-9c54333cd88d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_1f14c576-8a30-4e80-a578-9af4d61a040d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_NetRentableArea_1f14c576-8a30-4e80-a578-9af4d61a040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5e320818-71e9-4b18-afe2-80bfa9b120c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5e320818-71e9-4b18-afe2-80bfa9b120c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45c7fe1-5c98-444d-ac01-045e43ab3cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45c7fe1-5c98-444d-ac01-045e43ab3cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_676844e5-8576-47c0-91ae-8a27789b8074" xlink:href="dare-20230630.xsd#dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_676844e5-8576-47c0-91ae-8a27789b8074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_f12b6322-0c8a-46e4-ab81-9966b136fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_f12b6322-0c8a-46e4-ab81-9966b136fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b13969a6-d0a4-4fc1-9062-00309fd18e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b13969a6-d0a4-4fc1-9062-00309fd18e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_41587a28-c1a2-450e-a299-49cd72395c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_41587a28-c1a2-450e-a299-49cd72395c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_00b45fa7-9790-45c0-9b69-ff653377662a" xlink:href="dare-20230630.xsd#dare_OperatingLeaseIncrementalBorrowingRatePrimeRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate_00b45fa7-9790-45c0-9b69-ff653377662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_782e0b33-8cd3-4eef-8466-b1d38a293c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_782e0b33-8cd3-4eef-8466-b1d38a293c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa037eda-dfb1-410e-9149-0d3f234f55dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa037eda-dfb1-410e-9149-0d3f234f55dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e206a18-3462-44a4-b795-49719e5adefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e206a18-3462-44a4-b795-49719e5adefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ab2acd-2cfe-4e2c-9181-7631515fc807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ab2acd-2cfe-4e2c-9181-7631515fc807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_22182c70-bc6c-4fd2-84cb-004b232b0998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseCost_22182c70-bc6c-4fd2-84cb-004b232b0998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a6c7080a-9c88-4fed-b9ab-1523eaec580c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeasePayments_a6c7080a-9c88-4fed-b9ab-1523eaec580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_209ac699-ea46-44b0-8fab-787e2f500174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ee2e4637-4b42-48e4-9129-bde337b4769a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_209ac699-ea46-44b0-8fab-787e2f500174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7792f44c-291d-4813-9c73-9fa285cdcf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7792f44c-291d-4813-9c73-9fa285cdcf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d241d066-3019-4988-9a35-7734754cf9de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d241d066-3019-4988-9a35-7734754cf9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a37279d5-75a1-4e13-b193-86bf2479f668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a37279d5-75a1-4e13-b193-86bf2479f668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_588997b9-a110-4559-9bbf-522cf9acf14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_588997b9-a110-4559-9bbf-522cf9acf14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_35065a61-1db7-46b4-9935-7b57fe58261b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db87297-9cb1-4183-a685-f9b1efb88ffb" xlink:to="loc_us-gaap_OperatingLeaseLiability_35065a61-1db7-46b4-9935-7b57fe58261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20230630.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cad5e6bc-cce5-40c7-831a-98e93a9219f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cad5e6bc-cce5-40c7-831a-98e93a9219f5" xlink:to="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:to="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c2cd4560-47cc-4faa-86eb-c17a1b2a7a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_208fe9df-a706-4f28-aa85-35b310f73bd4" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:to="loc_dare_NICHDMember_208fe9df-a706-4f28-aa85-35b310f73bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember_972779b9-a47e-4a5f-b0c6-bf2b76846bd6" xlink:href="dare-20230630.xsd#dare_CRADAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2e91eaa-d23c-4dee-b905-7de22601f294" xlink:to="loc_dare_CRADAMember_972779b9-a47e-4a5f-b0c6-bf2b76846bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:href="dare-20230630.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_5edbf06f-0f19-46e2-97da-39ba20e16f82" xlink:to="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_8902944c-d0bf-484d-af89-f25d86b83d75" xlink:href="dare-20230630.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_8902944c-d0bf-484d-af89-f25d86b83d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_54cce785-a63c-434c-a9dd-9ceb2dcfb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_54cce785-a63c-434c-a9dd-9ceb2dcfb7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a2af4135-1858-4f15-889d-51e30d347aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_09e9afff-6694-40c5-a078-99b19eec0bcd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a2af4135-1858-4f15-889d-51e30d347aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#GrantAwardsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_d8746874-8bd4-463d-871a-34463f6bc4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_d8746874-8bd4-463d-871a-34463f6bc4a1" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:to="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c6a8158-2200-4fe1-ae64-16614e855045" xlink:to="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member_74b44d03-aea1-4320-bdb1-146889c06c8c" xlink:href="dare-20230630.xsd#dare_GrantDAREPTB1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_GrantDAREPTB1Member_74b44d03-aea1-4320-bdb1-146889c06c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member_3cdd28b7-d382-4013-91ec-c18dead75f9b" xlink:href="dare-20230630.xsd#dare_DARELARC1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_DARELARC1Member_3cdd28b7-d382-4013-91ec-c18dead75f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantADARE204AndADARE214Member_df71a9ea-1c09-4513-9e78-31b680486d6c" xlink:href="dare-20230630.xsd#dare_GrantADARE204AndADARE214Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_GrantADARE204AndADARE214Member_df71a9ea-1c09-4513-9e78-31b680486d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELBT1Member_33f36284-88f6-4c27-952d-295b0e42772e" xlink:href="dare-20230630.xsd#dare_DARELBT1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_DARELBT1Member_33f36284-88f6-4c27-952d-295b0e42772e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_65e40b3e-5bcc-4cae-a72b-7ac80a55d16b" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb45d91-829b-41f8-aa5d-817348ae17bc" xlink:to="loc_dare_NICHDMember_65e40b3e-5bcc-4cae-a72b-7ac80a55d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ce10afd2-a30b-43dc-9d13-080ef2e54728" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_69a98f4b-e246-4ce5-97e7-1b34188db55d" xlink:href="dare-20230630.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_ProceedsFromAwardOfGrant_69a98f4b-e246-4ce5-97e7-1b34188db55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_50f0465e-f2e6-4e17-9e71-09c5659586b1" xlink:href="dare-20230630.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_50f0465e-f2e6-4e17-9e71-09c5659586b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_843ac9fa-2bc2-4936-800d-ba7185035398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_843ac9fa-2bc2-4936-800d-ba7185035398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_070616e4-2825-4b55-92f2-1827f270e677" xlink:href="dare-20230630.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_070616e4-2825-4b55-92f2-1827f270e677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_7a1d63f1-e816-423b-9722-107ccdf20956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_us-gaap_GrantsReceivable_7a1d63f1-e816-423b-9722-107ccdf20956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_af73ee64-0d4a-4f24-8944-fe9d1e543a8e" xlink:href="dare-20230630.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_41e02798-c4cd-4b54-81f5-1be9d7ec9b97" xlink:to="loc_dare_DeferredGrantFundingCurrent_af73ee64-0d4a-4f24-8944-fe9d1e543a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5990751a-3025-4c12-b399-73ef86e7c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5990751a-3025-4c12-b399-73ef86e7c8fb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4acd57bf-9116-474b-9396-414a8cc77bef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_67c5901b-b3d9-4d69-af3d-b2008cf85c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:to="loc_us-gaap_EmployeeStockOptionMember_67c5901b-b3d9-4d69-af3d-b2008cf85c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2b2563fc-0cc5-461d-b39d-b6b15189a824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b713d1-84b8-484a-936c-d38781634303" xlink:to="loc_us-gaap_WarrantMember_2b2563fc-0cc5-461d-b39d-b6b15189a824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b45e2abe-82a2-4f69-99ba-7a35888f1e4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f188e72c-1835-42e8-b556-26ea1ecd5256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c38bf85-7754-4999-a0c6-24b0d813d2a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f188e72c-1835-42e8-b556-26ea1ecd5256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20230630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f0f24742-45da-4329-809b-20a58c18fd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f0f24742-45da-4329-809b-20a58c18fd70" xlink:to="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_51176175-ef06-46f2-b5f4-10d1f3a9143d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f02389f5-9cf5-4a66-ab6b-dc0fb58041f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_364179ed-a574-44a8-aeeb-9633adc8af49" xlink:to="loc_us-gaap_SubsequentEventMember_f02389f5-9cf5-4a66-ab6b-dc0fb58041f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69409cd7-3ba2-450c-ac6e-c4e5a4c41eb9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JulyAndAugust2023AtTheMarketSalesMember_b1de4668-80ff-4298-bd41-6d967d0828f5" xlink:href="dare-20230630.xsd#dare_JulyAndAugust2023AtTheMarketSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee1b745-7323-4a4d-accb-a18688f08598" xlink:to="loc_dare_JulyAndAugust2023AtTheMarketSalesMember_b1de4668-80ff-4298-bd41-6d967d0828f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_037927d9-8b55-4bab-b792-04c41ce4abfa" xlink:to="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_b82fe8c2-9cf7-4f2c-9b7d-6940435c393e" xlink:href="dare-20230630.xsd#dare_NICHDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35d4708a-7ea3-43fe-8fb8-be348eea6009" xlink:to="loc_dare_NICHDMember_b82fe8c2-9cf7-4f2c-9b7d-6940435c393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_deadad28-61fb-46fe-87b5-3f98cf36713a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_bb1f4c02-cb18-45f8-937d-4cda19cb6748" xlink:href="dare-20230630.xsd#dare_OrganonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb919-58ca-4e09-b2e1-d1549a7b7eb7" xlink:to="loc_dare_OrganonMember_bb1f4c02-cb18-45f8-937d-4cda19cb6748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3f16695-08b6-4330-acec-bdd35445eb48" xlink:to="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8bb5d3c7-65a8-4377-a917-8ac92b53d863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8bb5d3c7-65a8-4377-a917-8ac92b53d863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf91af06-782e-4ba3-a6c6-f9801159fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf91af06-782e-4ba3-a6c6-f9801159fff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleOfStockBrokerageCommissionsExpense_c4ca2d05-fdc2-47a6-a206-76d9e9f9e8fd" xlink:href="dare-20230630.xsd#dare_SaleOfStockBrokerageCommissionsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_SaleOfStockBrokerageCommissionsExpense_c4ca2d05-fdc2-47a6-a206-76d9e9f9e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_c8e165f2-1777-424a-8b95-e7229dcdd4e9" xlink:href="dare-20230630.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_ProceedsFromAwardOfGrant_c8e165f2-1777-424a-8b95-e7229dcdd4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_085f7212-efc2-4652-b8e2-33242e40f9cf" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses_085f7212-efc2-4652-b8e2-33242e40f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_c5cd9382-b33d-4b43-b2e8-9642ebcc2e29" xlink:href="dare-20230630.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_c5cd9382-b33d-4b43-b2e8-9642ebcc2e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_51d3186f-d963-44cb-9069-1f7c0847f903" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingPremiumsTaxesAndFeesAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount_51d3186f-d963-44cb-9069-1f7c0847f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_InsuranceFinancingInterestRate_05178023-01e0-41b6-b4e2-6a3d248f692e" xlink:href="dare-20230630.xsd#dare_InsuranceFinancingInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_880a73f0-4aa7-44eb-ac21-3392fe8935d6" xlink:to="loc_dare_InsuranceFinancingInterestRate_05178023-01e0-41b6-b4e2-6a3d248f692e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>dare-20230630_g1.jpg
<TEXT>
begin 644 dare-20230630_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP
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M&?_:  P# 0 "$0,1 #\ W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?SS7_K7_LUG_LX_VP_(W^T3_P"D=%_ZL#^[_2/_ ,)_UM;^,']_/-?^M?\
MLUG_ +.7.Z)DKN9T?3<QDIOK.1RNJ:[DK]CVXH?K%V]B*=JU-[->.*"+W9Y7
M.[6-:QO7HB(G1"O&9T:=OF5Q;T5A1IUZD8K:\%&;26+Q;P2Z7B7_ --7=QF&
MG,OO[N7'=U[*A4G+!+BG.E&4GA%)+%MO!))="2/5GPGM@
M
M
M
M                                           BIYQ?A+YV^X]K]=HD
M3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_P"%5O[ :;U:
M ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N-J7V!CRI>=?/%
MW\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                          $5/.+\)?.WW'M?KM$B;GK]D6?_ ""7I1)L
M\./VY::^DH^A,R-&/QNH   ;%.6?PV;G_"JW]@--ZM ?.&4>ZM_P1/YEN='U
M3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1M
MM\# ]R>8=(
M
M
M
M        "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,?C=
M0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
M#1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
M
M
M
M                                                  !%3SB_"7SM
M]Q[7Z[1(FYZ_9%G_ ,@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_P *
MK?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#
M'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                  (J><7X2^=ON/:_7:)$W/7[(L_^
M02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_X56_L!IO5H#YPRCW5O^")
M_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531W
MU0RKZ-MO@8'N3S#I
M
M
M
M               14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3
M,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\ !$_F6YT?5/4OR:\_+*&R
MVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                                         (J>
M<7X2^=ON/:_7:)$W/7[(L_\ D$O2B39X<?MRTU])1]"9D:,?C=0   V*<L_A
MLW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N
M-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                                       $5/.+\)?.WW'M?KM$B;GK
M]D6?_()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[
MJW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].
M1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                    (J><7X2^=ON/:_7:)$W/7[(L_P#D$O2B39X<?MRT
MU])1]"9D:,?C=0   V*<L_ALW/\ A5;^P&F]6@/G#*/=6_X(G\RW.CZIZE^3
M7GY90V6W,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>
MY/,.D
M
M
M
M   !%3SB_"7SM]Q[7Z[1(FYZ_9%G_P @EZ42;/#C]N6FOI*/H3,C1C\;J
M&Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP
M_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2
M
M
M
M                                              BIYQ?A+YV^X]K]
M=HD3<]?LBS_Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X;-S_A5;^P&F]6
M@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\
M\7?RFKZ<C531WU0RKZ-MO@8'N3S#I
M
M
M
M                            14\XOPE\[?<>U^NT2)N>OV19_P#()>E$
MFSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN
M='U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5
M?1MM\# ]R>8=(
M
M
M
M           "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,
M?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP
M  -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
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M;Y=94<OM$XVM"E"G!-MX0A%1BL7M>"2VO:^D^@?J/J
M
M
M
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MN83IUEOC).+7E3P:)GL[ZRS&WC>9?6I5[2:QC.G.,X279*+<7ZC/H'ZCZ@
M
M
M
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MTEQ13PJ0QZ*E.6$X=G%%)]#:/>'F'2@
M
M
M
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M6E._RZK3KV56/%"<)*49)]*DL4_U-Q](_2?6
M
M
M
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M_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
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M0GC!=I.=)!
M
M
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MX*/::6O.+\)?.WW'M?KM$TYYZ_9%G_R"7I1,@_#C]N6FOI*/H3,C1C\;J
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MN$-L-T*ZBMM2ECN>]RI8N44G*+E%/AEH<(3>
M
M
M
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M[\F^;]#6UI'(\]G&&K:47MP48W,5[."6"51+\Y326YU(+AXHTYBD?D]
M
M
M
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M'.@
M    J]YY^:1Q3Q#OEW1-3U2[RO+A4=7V#/878Z.)P-++L?VRXC'7'8W+)F9J
M:(J6)8T9#'+^C:Y[FO1E6-?^*O2>CL_GD&46D\WG0V5:M*M&G2C4QVTX2X*G
M>./LY+",9>:G)J7#<OEEX,-;:[TS3U+G=]3R2G<>=0HUJ$ZM:=)K95G!5*7=
M*>^G&6,Y1\YJ*<>+BO\ OE=:_L$SG_>!0_ZJ'#_XT\L_L_7_ -;A_LY(?_\
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MYPD,
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MIOV-6-D.3?V4Z>^B;;X-&#//G[:-4?3=W\+(D<241*
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M,O/7GWJ7G1G?O[G:Z/MJK=I9I[([.%5J[6RI7E'';MC24I0I['.4YADS$"
M       &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2
M_#[QK_DS)_UAS!7W7'UKO/=Q^#@7VY*?9=E'[S4^'JDA3DR4P
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M5-QE3J)8X<7!449..[SHIQ3:3:;P.J'AG:
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M;B>'KD_:\GM T<KK1@]47O#7OZBVXUFO-HQETT[>+X(]#FZE18=XT1#(>)V
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M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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MT=J-91F-3#3N83C">+\VE6?FTZW4D]D*KV+A:E)X4TBZ4KJ:"@
M                   &1KS@_%GSM]^;?ZG2,?N>OVNY_P#+Y>C$W4\./V&Z
M:^C8^G,BH1,38; O$#\+? /\*=-^QJQLAR;^RG3WT3;?!HP9Y\_;1JCZ;N_A
M9$CB2B)0
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MNHOTOGLNYRNCC&UM(2;HV\'Y<..K/!.K6:4IM))0IQA3C)4DXB$
M &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2_#[QK_
M ),R?]8<P5]UQ]:[SW<?@X%]N2GV791^\U/AZI(4Y,E,
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MT*Y%:\>L-)JPOI\6>9;PTJC;\Z=/!]S5?6VDX2>UN<')^N1+$X4FX
M                     &1KS@_%GSM]^;?ZG2,?N>OVNY_\OEZ,3=3PX_8;
MIKZ-CZ<R*A$Q-AL"\0/PM\ _PITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^
M%D2.)*(E
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MHZKYLZEJ:CU16<GBU0H1;[BVI-K"G1@W@E@EQS]?4DN*;;W=O.Y(Y
M     ,]?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'
MWC7_ "9D_P"L.8*^ZX^M=Y[N/P<"^W)3[+LH_>:GP]4D*<F2F
M                >/W/0-,Y#QD>(W77<;L5"&;ZQ7BOQ.]VK/T[5FIVX7Q6
MZ<KV?1<Z*1BN;Z+U3T/0R[-<QRFL[C+JTZ-5K!N+WKJ:>*:\J9X6H-,9!JJS
M5CJ&TI75K&7%%36V+ZX234H-K8W%K%;'L/PZ/Q=Q]QM%;BT?5<7KWU]6K=GJ
M,EENVFL7K'%/?N2V;TD$;O5L:R>VU5541%53]F99WFN<2C+,J\ZO#N3P27:H
MI)8];PQ9\VG-&Z7TE"<-.65&U[WU[BFYRPW)SDY3:71'BP70CWQY9TP
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MS2UG=ZQSV35:O+AI4DVX6]"+?=4(8X>;!/:TEQU)3J-<4Y'9#M#@
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M.:Y$<US516N:J=45%3T5%0J^UAL>\TO336*VIG_0?Z
M         9&O.#\6?.WWYM_J=(Q^YZ_:[G_R^7HQ-U/#C]ANFOHV/IS(J$3$
MV&P+Q _"WP#_  ITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^%D2.)*(E
M                                                    !X_=^/\
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M?9=E'[S4^'JDA3DR4P
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M\:RL]4].U+$J)\>J_ A[,?&E>2FXY1D%.$$]DJUU*;:[8PHPX?)QR\I.V5>
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M; O$#\+? /\ "G3?L:L;(<F_LIT]]$VWP:,&>?/VT:H^F[OX61(XDHB4
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M6MKI73UU=W=.KEM.YJ2KNFY1G4K5Z:@N[A!)<-)2VK'SEMPW3,)J*_
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MD5_1J7;7YF>-.MLWX4YJ,I8=+@I1[3K1X1W
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M3=.K%QJ1>#3333ZFGM1,U"XH75&-Q:SA4MYK&,HM2C)/I4DVFNU,_2?@?N
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MWA=_QIHW_<WRA_LKIO\ W99?Q!<?\I;D_DKDC_7_ /ZP^0]YWW]C?ZJOV/\
MTTVW/[3^ROVC_K(_:'[-_;F0O?4?KWU&#WO:[?=]EG=U[&]+H>$/5.I]2_\
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M.NQWH^>5S(6*O17=RM:ONY%IW,]07'<6$/>UZZ<MD(>5]?5%8M]6&+.)UMS
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M,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
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MG)MK$S:YE:NCKW7N;:QITYT:.87M2K"G)IRA!O"$9..";C!13:Z4=8.N.'
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MGL79%;HKLBDBXN0Z;R+3%BLNR"UHVMHL,5".#DULXIRVRG+VTW*7:>K/A/;
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M&6O>:F>:H4N*UKWTX47C_P"[T,*%#L6-*G"3PV<3;V[SOY(1%P
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MD^3%+*J5'6&K*2EFLTIV]O-;*">ZI4BUMK-;8Q:PI+:_?,.[L((H+1@
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MGX?^74-3YW+4V;4U+),OFN",ML:MS@I1BUTQI)JI)/8Y.FFI1<D7#$ %\0
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MO>"Q[<"I_C1SEY7R,NK-2P>8YA:6^]+'";NFMKQ>RV>*6+PQQ6&)IY-23&\
M            $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$FSPX_;EIKZ2CZ$S(T
M8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN='U3U+\FO/RRALMN9
M8   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(
M         "A3R:PR8'GGDZBC48D^QOS/1.GJNQTZFPN=]'TZO=E.[\_KZ^I:
M'1MQ\:TO95.JCP?P;=/\DS/YOY>LMYEYQ;I8<5VZO\/"-?'U>\Q.%'3$;@
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MR3.ZY#Z1AJG75*XNX\66Y='XS-/=*<6E1@_+4:FT]DHTY)[R[<K@:'@
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M0>EJ&C=)V>GZ27>T:2=62]G6GYU67;C-M1VO"*BMR1TP\8Z\
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M=U2^[Y#-#Q^Z?A3S/3NJJ<?/K4+FTJ/#HI3IUJ*Q[>^KO#L>'278EX3.X
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MW$\'[:1IQX!-/0I9!J#5<HXU*]Y0M(O#<J%-UJB3W><[BFY+VL>M%+A28T(
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M_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\
M\%2_7'^/O5_]G\M_AJWZP_W.7&O]LN\?Y@P'^$'^##3']=7_ /!4OUQ_C[U?
M_9_+?X:M^L/]SEQK_;+O'^8,!_A!_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#
M_<Y<:_VR[Q_F# ?X0?X,-,?UU?\ \%2_7'^/O5_]G\M_AJWZP_W.7&O]LN\?
MY@P'^$'^##3']=7_ /!4OUQ_C[U?_9_+?X:M^L/]SEQK_;+O'^8,!_A!_@PT
MQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\ \%2_
M7'^/O5_]G\M_AJWZP_W.7&O]LN\?Y@P'^$'^##3']=7_ /!4OUQ_C[U?_9_+
M?X:M^L/]SEQK_;+O'^8,!_A!_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<
M:_VR[Q_F# ?X0?X,-,?UU?\ \%2_7'^/O5_]G\M_AJWZQ-?Q.\2<#XH8K<\3
MK^YY[;JVY9##Y&9,U3ITFXZ?$UKU;K5BI/=&YUR.XGN.5$5?:8GP3TG#E'RA
MR_E):7MGEU[<7E*]J4YOO8QCP.FI1\U1V><I;7[5%=^=_//,^=][E]]FF7VM
MC6R^E5IKN93GWBJRA+SG-8^8XOA2V>=+K)<$OD%@    SU\T_OCY9_B9OG]:
M<J6NT[]7[#Y'0^#B9;<P?K[GGTQ>?TBH7"^(]2*GX]<=LB1/T];.VY7=K4<^
M6UM&;F<KU:B=ZL1R,:J]5[&HGY" ->5)5-67;ET."7D5."_Y?*R^'(VA"ARM
MRJ,/90K2?:Y7%9[>O#<NQ)$CSD"60                4R^<].*MSI)-&B(
M_(:CKUR;HUK565CK]!%<K417K[-%GJOKT]/@B%AN6=24],J+W0N*B7D\V7X6
MR@/B/H0H\QW4CZZK8T)/9TKCAZNR"VOR;D2?^7U=63CK=\=U?VU=U9=1%Z>V
MBW\%C8'*W^=WJF-3NZ^G1$Z?E.+YJTTLVMJW3*VP_:SD_P HF/PO7#EI3,;7
M;A#,%/L\^C37W?>]OJ$^R+2S8     !5Y\P[_'/%O^3-J_6L&35RG_F][[NE
M^"93?Q3_ #ADW[S<^E1.9>"'[[K7W&SWVA@SV>9WU;C\IAZ,SD/#7]HD_HVM
MZ=$N0*^%]P     "NGYAEB1NN\9U$Z>S/FMBL/3UZ^Y5HXR.+HO7IT1MM_7T
M_,2WRG@G=WE3V2ITU]V4L?P(JGXIJLUE63T%ZR5Q7D_+&%-+TF<8\!*#;',&
MP77QHYN.X_RCHGJY$6*U:SVMP,5&]>KNZJLR?F3K_<.BYI5>#(*5-/;.ZCZJ
M4*C_  X$?^&2V577EU<26*I974P?5*5:A%?Y/$BWT@(O8
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MIL)YKIG,<KIQ4ZES87%)1>U2=2E."323>#;P>Q^0VQ&X1_.X
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MRZA+RNIWGJ>;47X3&WQH6=2UYZWE>?K;FPLZD?(J2I>KYU*75U=!8F6/*H@
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M<.4O,.3$+Z*VV.<6U9OI49PKV[6Y['*O'%8K:D\=F#TLFG)D&
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MIXUU&:OCZTE5C?9#KNC%NA.E4L*LL-D90E*XMXX]<U.Y:71W;ZR[<O(9T@
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M^C:D_P#)4EZI5?DOG4,CYE99<59<-"M5E;RZO?X2IPQ[%4E!^H7N%8S28
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MV)56WV(ASQ!Z=EJGDMJ/*8+BK++9UX+>W.T<;J,5OVRE145VOH->1L081
M           BIYQ?A+YV^X]K]=HD3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1H
MQ^-U   #8IRS^&S<_P"%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<R
MP   -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
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M*N9VB."2/OQVB8FZLL$-E.OO0R;)GZ;&Q*WT?!1LL=Z/3K3[Q;\PZ63Z9I:
ML*G_ 'IF;C4KI-8PM:<L4I=*=:K%*.&QPI54]C6-ZO!#RMK9[JZMS,S*G_W-
ME"E2MFT\*EY5AA)QZ&K>A-N6.U3K491VQ>&>(SF-5B>'RXN)).4_*+3;EFM[
MV!XS;+R1F7N9UC;8P,D+-9B1R_02=VTVJ<J-7JKHH)%1/HJJ3[X:](2U7S4L
MJU6/%E^5XWE1X;,:32H+JQ[^5.6'3&,L-Q6?Q::YCHODSF%O1GPYGG#5A26.
MWAK)NX>&_#XM&K''HE.&._;J@-73%<   CAY;\32<V>._)^@4Z[K6;NZ_)F-
M8BC;UFEV?6IHL_@ZL*HCE8[)7L<VHY415]N=R?E(UYOZ1EKCEQFNGJ,7*^G;
MNI02WNO1:JTHKW<H*F^R;):Y%ZXCR[YK9-JBXFH9=3NE2N&]RM[A.A6D^ONX
M3=5>V@F9 '-<QSF/:YCV.5KV.16N:YJ]'-<U>BM<U4Z*B_ QP:<6XR6$D;RQ
MDI)2BTXM8IKI/><6\B9WB7D73>2=:>B9G3,_0SE6)[WQPW8ZLJ?7<7:?&BO2
MEEZ#Y:LZ)ZK#,Y$/?TIJ._TAJ2RU-EC_ );97$*L5C@I*+\Z$L-O#4AQ0EA[
M&3.9UII3+=<Z4S#2.;K_ +OS"UG1DTDW!R7F5(I[..E-1J0QV<<4;'>.=^US
ME+1=5Y#U*VEW7MOPM/-8V7JWW8X[4?Z:E;8USDAOXZTU]>Q'UZQ3Q/8OJU39
M_3>H,MU7D-IJ/*)\>77E"-2#Z4I+;&75.$L83C[&46GM1@/JS3&;:+U+>Z5S
MR'=YK87$Z51=#<7LG%O?"I'"=.6Z4)1DMC/:GMG/           \[MVUX'1=
M7V#<MGOQ8O7M8Q%_.9F_,Y$96H8ZO)9L/:BJBR2N9'VQL3Z4DBHUJ*Y40\W.
M,VL,ARJXSK-*BI9=:T9U:DWT0@G)^5X+!+>W@EM9ZN19)F>I,YM=/Y-2E6S6
M\KPHTH+?*=22C%=BQ>,F]D4FWL3,=?.W+&5YPY<WSE/,-DAFV[.V+E*C+(V5
MV*P=9D>/U[#K(QK62+B<'4KUU>B)[CHU?TZN4QFU[JV[UUK#,-5WB<9WEPY1
MBWCW=*.$*-/%;'W=*,(8]+6/2;Y<M=$67+C0N6:+L&I4[&VC"<TL%4K2;G7J
MX/%KO:TIS2;?"I*.Y')3D#N2U;Y0/XE=W_@;LO\ 7[C,MEX.?M-OOH&M_2[(
MI/X\?LARW_\ )+?^A9@:.C2@R7    !3A\XW]VO#7WXS_P!@1E,/&?\ 5C)?
ME]7X)%_/ )];]0?1M'X9F?XST-1"\CY,7_F1_P"Q[_Q2+V^"C_S-_P"'?_7&
M;_\ Z@O_ )1_\4_^W%Y!>TS?         (#_ #)>)9>4O%W:KF.J.M9[C2[3
MY'QC(VN65U+#1V:FSLZLZN6*+5\C;LJSHJ/DK,]$5$5*_>)C2$M5\J[NM;0X
M\PRN<;R&&_AIIQKK9T*A.I/#I<(]C5G/"-KF&B^<UE;W<U#+,XIRL*C>[CJN
M,K=[=F+N*=*GCL:C4EUM/+.93&TA(?Q6YNL>/G.FC<E=9GX6C?=B=NIP][G7
M=0S;/J&=8V&-46S8HUY4N5HU7M=;K1=?0D;E/KFIR[UY8:F\YV-.IW=Q%8^=
M;U?,J[%ZYQ3[R"W.I"&)%7.OEU2YI\MLRTAYJS&I2[VUD\/,NJ+XZ+Q?K8SD
MNZJ2WJE4GAM-?6*RF.SF+QN:P]VODL3F*%/*8O(U)&S5+^.R%>.W2NU9F]6R
MU[5:9KV.3T<UR*;&6EW;7]K2OK.<:MG6IQJ4YQ>,9PFE*,HOI4HM-/I3,'KV
MRN\MO*V77].=&^MZLZ=2$EA*%2$G&<)+HE&2::Z&C]Y]!\H          .>\
MI<IZ-PSI65Y!Y$S4>!U?#NJ1V[BP6+EB2Q?MPTJ=2E0IQSW;]N>>9.D<3'N1
MB.>J(QKG)SNJ]5Y%HK(ZVHM25U;Y51X5*6#DVYR48QC"*<I2;>Z*;PQ;V)M=
M5HO1>I.8.HJ&EM*6[N<ZN%)QAC&,5&$7.4ISFU"$8Q3QE)I8X16,FDX@_P"\
MZ\//_G_.?] MR_T,0W_BDY-?UA<?ZK<_Q9/'^#CGW_5=M_KMI_&GT<1\R7Q,
MSV6Q>#Q&Z[#>RN:R-+$XRE#H.Y.FN9#(V8J=*K$W]C?2DL69FL:GY54^FS\3
M'*+,+NE86=]<U+NO4C3A%6ESC*<Y*,8KWO>Y-)'R7_A&YXY98ULROLNM:=E;
MTIU:DW>VF$84XN4Y/WW=&*;?8B=Y/I6@      KO\_\ 0I+^NZCR+2@5[\!<
MGUW-R,9U<F-RZML8NQ,[^9!4R4$D2?GDN(2SRLS14KNXRBH]E6*J0]U'9)+M
M<6GY(%5O$]IF5SE5CJNWCC*UJ.A6:7[G5\ZG)]2C44H^6JB+GAUR1'H/,&/H
M7YDBPN\U_P"BMUSWM;%!D+$\<V!N.[E:WN;D8TK]55$;':>[UZ(=KS R=YID
M$ZM)8W-L^]76XI837[7SNUQ2(:Y"ZMCIG7E*VN9<.7YE'XM/%[%.33HR_A$H
M;]D:DGT%V97$T.               .3<X\B0\6\7[7MRR-9D*U!]' QNZ*LV
M?R?6GBD:Q>ONMKV)??D:GK[,3U_(>[IK*99WG5"PP]Z<^*?9".V7DQ7FKM:.
M(YC:JAHS1M[GN*5U"DX45UUJGF4]G3PR?')?B1D4)8#"9/:]@Q&OXR-UK+;!
ME:6+I,<KG++=R-J.O$Z5Z(YR-]V7N>Y>O1O55+0W5S1L;6I=UGPT*4')]BBL
M7A]S89G99E]YG6:4,KLTYWUU7A3@MNV=22BL7MZ7BWT+%FBC5M>I:GK6OZOC
M4Z4->PV-PM15:C'/@QM.&I'+(B*OZ65(NYZ]557*JJJKZE2[V[J7]Y5O:WYV
MK4E-^63;P\BQP1JMDV5V^1Y1:Y-:?S:UMZ=*/1BJ<5%-]KPQ?6VS[Q\IZ0
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M)4=OJ=*+H>!K4:ROFU<Y%5:5+-,JJPBNNM0G"O'[E*-?9OZ=R9FY,T#7
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M\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\
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MS&7LL%>+D9RREHO)GG6<0PU+?06*:VT*.R4:76IR>$ZN[!J$&L:;;F&1^3R
M                    9#?,KBMW#ODIRII\4#H,1-L4^SZW]!60KKVVM;L&
M.@K*O_&Q8OZ^^DKORR5G)\4,=^=.DWHSF;FV30CPV<KEUZ.S!=S<>_04>M4^
M-TL>N#-W/#_K5:^Y19)GTY*5_&T5O<;<7W]M[Q.4NIU.!5DOQ:D2,)%I,@
M!,#P8YS;P)Y%:?L62M?5M1V=S]&W5SG(R&'!;#/69!DYG.7MCBP6<KU+LKNB
MN]B"1C?5Y,G(?7BY?\R+/,KJ?#D]UC:W/4J59QPF^I4JJIU9/?P0DEO(&\27
M+:7,[E1?Y39PX\]LTKRTP6+=:@I-TUTMUJ,JM&*V+CG"3]::T#78PX
M      (J><7X2^=ON/:_7:)$W/7[(L_^02]*)-GAQ^W+37TE'T)F1HQ^-U
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MG3QR[*\WJU>JHK>DONQKUG_DGT9?X">9-2KAFN<9'1HX[Z4KJM+#W,[:@O\
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MQ<,7U-,OIX<M*O)=&3SVXCPWF:5>-8K!]Q2QA26W\:3J33Z8SB^IDUB.2P@
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MCVFC^C]=Z/U]EBS?1V86U_8X+B=*:<Z;DL5&K3>%2C/#V%6$)+J.<G-G6
M   'K=+T/=.1L[5UC0]6SFW9^XY$@Q> QMG)6NU51'3S-KQO;5J1?&2:5611
MM17.<B(JGKY)D&=ZEOX97D%I7O,PGNITH2G+RO!/ABNF4L(Q6UM(\/4.IM/:
M2RR><ZFO;:QRNFMM2M4C3CCU+B:XI/=&$<92>R*;V%S_ (P_*B6&;';CY+W8
M9?;6.U7XJU^_[K%>U[7,CV_9J$J1R,^BO?4QLCFN16JMO^7$MV.5OA*<)T\Z
MYGSB\,)*PHSQ6/5<5X/!]M.BVGL;K;X&?'.3QN*I3JY!R?IRCCC&695X8/##
M:[6WFL4]V%6XBFMJ5#ULR[+#X?$:]BL?@\#B\?A<+B:D-#%XG%4Z^/QN.I5F
M)'7J4:-2.*M5K0QM1&L8UK6I\$+Q65E9Y=:4[#+Z5.A8T8*$*=.*A"$4L%&,
M8I1C%+<DDD9VW^87V:WM7,LSK5;C,*\W.I5JSE.I4G)XRE.<FY2DWM;;;9](
M^D^0          $<_(CQ;XE\F->;B>0<*L>:H0OCUW=</[-/:]>>Y7O]NI??
M%*RYC)))%66E99-5>J]Z,;*C)&QMS'Y4Z0YGY<K/45#"^IQ:HW-/"->CO>$9
MX-2@VVY4IJ4'CC@II24L<J>=&N>3^:N^TM<8Y=5DG7M*N,K:NMBQE!-.%1))
M1K4W&HDN%R<'*$L^'D1\O#GC@J:]E\5B9N4>/X%EFBVK3J%FSD*%.-O>LFRZ
MO']9RF(6*-KG231+;I,8G5T[57M3.WF/X<M?Z"G4O+2C+-=/1Q:KVT)2G"*V
MXUJ"XIT\%BW*/>4DEBZB>Q:F\J?%7RSYE4Z=C>UXY+JB6"=M=3C&$YO9A;W#
MX:=7%X*,)=U6;>"I-+%P*( +-@       FWX\^ W/7/\U#*18*7C_0++F22[
MUN-2>E7L5'?26;7<%(M?+;(Z1J+[<D38Z3GIVOLQJ3ERY\/O,#F%.G=PMWEV
MGI8-W5S%Q3CUT:3PJ5L?8N*5)O8ZL2NO-7Q.\LN5].K93N8YIJB":5G:RC.4
M9=5>LN*E;X>RC)RK)/&-&2-"OC;XC\2>,6%=6TO%NRFV7ZS(-@W[.1PV-ERZ
M=6R25:\K6>UA<,LK45M.JC(W=C'3+-(WW%T4Y9\G](<K;%T\DI=[F]2.%:[J
MI.M4Z7%/=2IXX84X8)X1<W.2XC*[F[STUUSCS%5=0UE1R.E-NA946XV]+H4I
M+'&M5PQ3JU,6L9*FJ<'P$>?FHX3,Y_QEH4<%B,GFKJ<H:K.M/$T+>2M)!'B-
MH;),M>G%-,D3'2-17=.B*Y.OQ(Z\5]C>YAROIT+"C5KU_P!*T'PTX2G+!4Z^
M+PBF\%BMN[:2KX*LQR_*^<-6YS.O1M[?]#7,>.K.-..+JV^"XIM+%X/!8X[&
M9SO]6/)7]GN\?]$\_P#Z/,V_^%M3_P!77_\ J]7_ )AK%_QEI#^M<M_UFC_S
MRT#Y3.G;=KWD9NEW/ZKL>#IR\*;'5CMYC!Y/&5I++]ZXXE979/=JP1/G?% ]
MR,1>Y6L<O3HBEI_"+DN<9=S)OJ^86ES0HO(ZT5*I2G"+D[JS:2<HI8X)O#?@
MF^@IKXXL_P BS7E/E]OE=[:7-Q'45"3C2K4ZDE%6=^G)QA)M13:6.&&+2Z4:
M%S18RM    !41\W77=@V+CKB&'7\%F<[-6W7.RV(L-B[N3D@C?@HV,DFCI03
MNB8YR=$5R(BJ4\\866YCF6F\GAEUO6N)QOJK:IPE-I=TMK44\%Y2]G@4S;*L
MIU9GU3-;FWMJ<\NHJ+JU(4U)JLVTG-I-X="*'_\ 5CR5_9[O'_1//_Z/*"_\
M+:G_ *NO_P#5ZO\ S#3#_C+2']:Y;_K-'_GEU?R?-8V77/\ :(_I#KV<P/US
M_5)]3_;6)OXOZW]7_P!9OUCZM]>KP>_['OL[^WKV][>O3JA=_P &V59GEG_$
M?Z2MJ]OQ_H_A[RG.GQ8?'<>'B2QPQ6.&[%8[S/'QZYSD^;_\*?HJ[MKKN_TG
MQ=U5A4X>+]'\/%P2?#Q<+PQPQP>&YEUA=XSQ             !#[R?\ "KB3
MR>HNO9RJ_5>0ZM7V,3R'@:U=,KVQ1.95H[#4>D<.R8>%_:J12NCL1-16P3PH
MY_=#7-/DAI#FE0=>_B[34<(84[RDEWFQ>;&M%X*M37XLFIQ6RG4AB\9ZY->(
M;7/)NY5MELU>Z5G/BJV-:4N[VO&4Z$EB[>JUCYT5*$F\:E.HU'#/=Y!^$///
MCO+=R&PZU)L^C5GO=%R!J,<^5P#*R+U;+FH61_M+67HU6HY;L4<"R+VQ2R_$
MSLYB<B]?\N)SN<QM7=9#%O"[MTZE)1ZZJ2XZ'1CWL8PQV1G/>:G<K/$9RRYK
M0IVN57BL]232QL;IJG6<NJBV^[N%O:[F4I\*QG3AN(@D.D\      '](HI9Y
M8X88Y)III&1111,=)+++(Y&1QQQL17/D>Y41$1%554_*$)5)*$$W-O!);6V]
MR2Z6S\9SA3@ZE1J-.*;;;P22VMMO8DEO98OXY?+5YNYEFHYW>J=GB'0'R0RR
MW]EHRQ[?F*BKWO;@=4G]FY![L:)VV<A]5A[9&R1-L(BL+(\MO#)KG6DZ=_GT
M)9/IYM-SK1:N*D>GNK=X26*W3K<$<&I053!HJ=S9\7G+KE_3J9;IJI#/M4)-
M*%O-.UI2W)UKE8PE@]].AWD\8N,W2;4C01P9X]<6>.VJ,U3C37HL<V9L+LUG
M[GMV]FV:W"UR-N9[,>U'-:<QTCUBA8D=6OWN2&*-JJBZ':#Y=:4Y<92LITQ;
M*FI8=[5EA*O7DO95:F"<M[X8K"$,6H0BFT9;\R>:FM.:V=O.]874JLHMJC0A
MC&WMXOV%&EBU''!<4VY5*F"=2<VDSMIW)'0             (<\Z^'^H\GR6
M]CU*6MIF[3+)-8E9 [^CV>L.17*[+4J[5DI6Y9.G=;KM5R]7.DBF<J*D@Z9U
M_?Y*HV=^G<9:MB6/OD%[5O>E^++L2E%$"<R.1&1ZQG/-LCE#+]0RQ<FE[Q6E
M_I81VPDWOJP3>]RA4>#55G(?$G(7%E_ZCNVMWL4R21T=3*-:EO"Y#IU5%HY:
MLLE*=ZL3N6/N29B+]-C5]";LIS[*L[I=YEM:,VEMCNG'W47M7EPP?0V4NU5H
M?5.C+GXOJ&TJ48MX1J>NI3]Q5CC!O#;PXJ:7KHH^QQ_SURQQDR.MJ>XY&MBX
MU],)D/:R^%1JKU<V''9..S!25ZI])U?V7K_?'Z,UTOD6<MSO[>#K/V<<83]6
M4<&_)+%=A]^F.9>M]'Q5')+^K"S7[C/"K2]2G44E#'I<.%]I*W7/F$;;5CCC
MVSC_  &:>G1K[&"RM_7GJU.B>XZ"[!L4;Y>GJJ-=&UR_#M3X<-><J;";;L;N
MK375.,:GWTZ?ZOJDUY3XH\\HQ4<[RNUN)=,J-2=!^7":KIOKP<4WNP1T:+YA
M6I+&U9N.=BCE5/ILBS&,EC:[\S9'P0N>G_"K&_W#R'RHO\?-NZ+C[B2_5?X3
MJX>*7(W%.IE-VI]*56FUZC:6/W$?/R7S#<.R)W['XPR5F96*C5R6S5:,3)%[
MD17-JXC(.E8WT7IU8KO5.J?$_=1Y3W#E_*+V"C[6FV_OSCA]\^6\\4]A&'\@
MR>M.IA^Z7$8)/]C2GBO56.[9O.&;?YT<Q[!'+6U^+7M*K2(]K9L70=D\JC'^
MBHZ[F9+E1'(ST1\56)Z*JJBHO3ITMARST_:M3NG5N9KHE+AC]R&#]1R:(XSW
MQ'Z]S2,J.5QM<OHO';3AWE3!^WJN4=W3&G%K>GCAA$S.;!L>WY5^3V',9?8L
MQ;<V-;>3N6LE=E5SU]N"-\[Y9$C1[^C(V=&MZ]&HGP.[MK2TL*'<VE.G1MX]
M$4HI=NS#U6_5(0S'-,USV]=YFE>O=W\WAQ5)RJ3>W8DY-O#%[(K8MR1*OA[P
MSY#W^2KEMQCGT#57+%*YV1KK_27)0*O<K,=AI>U]%)&)T]ZY[:-[FN9%,G5#
MA]0<P\IRI2H9>U=7VU>:_>XOVTUO\D,>IRB35H/D#JK4\X7N?*669*\'C4C_
M "BHNJ%)[88KV=7APQ3C"HL46N<=<9Z9Q7@(M=TO#Q8VFBLDN67+[^3RUIK5
M:MW*WWI[URR[JO3KTCB:O;&UC$1J0;FV<YCG=T[O,:CG4Z%NC%=48[DOOO>V
MWM+KZ5TAD&B\L65:?H1HT-\I;ZE27X]2;VREU>QBO-@HQ22]Z>6=,
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M9PS.]:OM2)8JK*/F4G_H(/'!]'>2QF_8\";B2M.&)K
M      .<<O\ &N&YAXQW?C+/HU,9N6OW<0ZPL:2NQ]U[4GQ.6AC541]G#9:"
M"W$B^GN0M.:UCIBRUGI:^TOF'\UO;>5/'#'@D]M.HE^-3J*-2/MHHZW0>K\P
MT#K'+M8Y7C\<R^ZA5X<<.."V5:3?1&K2<Z<O:S9C<W/4<[H.V[)I.STW8_8=
M4S>2P&9J+U<V+(8NU+4L>S(K6I/6D?%W12(G;+&YKV]6N13%W.LGO]/YO<Y'
MFL.[S&TKSI5(]4X2<7@^F+:QC+=*+36QF_FG\]RS4^1VFHLFJ*KE5];TZ]*7
M7"I%2CBNB23PE%[8R3B]J9YD\P]<   D9XL>06:\:^8M>Y$Q[;%S"*KL+NN#
M@?V_MW4<A+#^TZK&NDBC=?I/BCMTU>YK$MUX^]>Q7HLD<J.8E]RRUG;ZDMU*
M=C^:N:2?YVWFUQQ6U+CBTJE/%I=Y"./FXIQ/SJY6Y?S>T#=:4NG"GF/YVTK-
M?F;J"?=R>QO@FG*E5P3;I3GP^<HM:YM6V? [KK>#V[5LG6S.N[)BZ>9PN4J.
M5U>[C[\++%:9B.1LD;E8_HYCT:^-Z*UR(Y%1-@LJS3+\\RVAG&558ULMN:4:
ME.<=TH36,7UK8]J>#3Q32::,*LZR;,].YM<Y%G5&=OFUI6G2JTY>NA.#<9)]
M#VK8TVI+!Q;33/O'H'F         $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$F
MSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN=
M'U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?
M1MM\# ]R>8=(         >/WW=\'QSJ.;W+8I_9QF$IOL/8US$GN6'*D5/'5
M&O5K7W+]I[(HT543N>BJJ(BJGH97EMSF]_3R^T6-:I+#L2Z9/LBL6^Q'A:FU
M%EVE,CN,_P UEPV=O3<FMF,Y;HPCCOE.348KK>W!8LH"Y#WK-<D[EGMTS\B.
MR&<NNG]ACG.@HU(VMAH8VMW(B_5L?3C9$SJG5R-[G=7*JK:;*<LM\GR^EEUJ
MO>J4<,>F3WRD^V3Q;\N"V&8FJ=29AJW/[G4&9O\ E5S4XL%NA%;(4X^UA%**
MZ7AB]K9XP]$Y\   ][QAH>0Y,WW6=)QR2-?G,E##;LQM1RT,7#UL9;(KU16]
M*..BDD1%]'.:C?BJ'EYUF=+)LKK9E6PPI0;2_&D]D8^K)I??.ET=IJZU?J:S
MT]:XJ5S62E)>PIKSJD^KS(*4MN]I+>S0GB<70P>*QN%Q==E3&8BA4QF/JQ_R
M*U*C7CJU8&=?7MB@B:U/[A5&O7JW->=S7?%6J2<I/K<GBWZK9J38V5MEME1R
M^R@H6="E&G"*W1A"*C%+R))'T#]1]0             //;1J6J[OA[&O;GK>
M"VS VU:ZSAMCQ-#-8N=[$<D<DE'(P6*SI8^Y>UW;W-5>J*AYV:Y/E.>V4LNS
MJVM[O+Y^NIUJ<*L'AN;C-..*Z'ABN@]7)L]SK3E_#-=/W=S8YG#UM6A5G1J)
M/>E.G*,L'TK'!])7WR1\K#QAW5]BYK-7;.,,C*KY&IJF<6_AG3O_ )T^'VB#
M-JRNB]52*I/3:B_#HGH5XU+X4>5N>.5;*X7>57+Q?\GJ\=/%]=.NJNSVM.=-
M=6S86DTEXU.<FG8QH9Q.QSFT6"?QFCP5<%^+5MW1QE[:K"JWTXO:1%V'Y-F>
MBE<[4^=<1=@<Y%9#L.D7<7+"U?=ZL=9QNPYAEAS51GTDAB1W<[Z*=J=T/9CX
M+<PC-O*,^HSIO<JUK*#6_9Q0K5$^C;PQQQ>Q8;9VRKQ_Y9."6>::KTZJ6UT+
MR%1/=M4:E"DX].SBEA@MKQ?#X#_<]<X?VG<4_P#]S;O^K1SW^#377]:93]VX
M_B3I_P#'MRX_J;._N6O^T'L=>^3=N$\D:[7SAK6+A1(G3-U[3\IGI%7HY9HH
MWY+,:XUJ(J-1LBM7XJJL].UWM9=X+LYJ27Z6SVUI0V8]S;SJOM2XZE'LP>'3
MCALP?@9KX_LAIP?Z$TY>5JFW#O[JG171@VJ=*N^MN*:W)*6W%2MXZ^4]XX:G
M)!<W3(;KR=<C5CI*F6RK-=UY[F)U[F8[6HJ671'/7JYLF2E8J(B=.G=W2UIO
MPC\M<HE&MG=2^S2LL,8U*BHT=G5"BHU-^].M);EAOQA+5GC?YM9Y"5OIZEEV
M36[QPE2INO72?74N'.ENW.-"+3Q>.["PO1N.- XRQ"8+CS3=:TO$*K'24M;P
M]'%1V98T<UMBZZI#'+?M='KUEF=)(O5>KEZJ6+R'36G]+V?Q#3EE:V5GLQC1
MIQIJ373+A2<I>VDW)]+*K:DU;JC6-]^D]59A>9A?;<)W%6=5Q3]C#B;4([%Y
ML%&*P6"/:GMG/                 C#RYX;^.'-DMJ_N_&6%38+:R22[5K?
MO:MLDEF155UN[D,')3;F;"=5Z+?9:;_[/P(MUAR7Y:ZXG.XSS*Z'Z1GBW7HX
MT*SD_92G2<>\?[ZJB["9-"\_^;7+N$+73F<7'Z+A@E;7&%S;J*]C"%93[J/[
MRZ;[2 FZ_)ST2[++-QYS)M6N,57OCH[=KN*VUO54ZMA2]B;>GR0QH[T1SH9G
M(WXHY?5:^9YX,<@KR<].9U=VT=K4;BC3N/4XZ<K=I=KC)X=;VEGM.^/K4UO"
M-/56065W+8G.UKU+5^7@JQNDWV*4%CU+8N%9#Y.O+D<W;BN6N.+M?J_]+D*.
MS8R;HCE2-?8K8_+,ZN9ZN3W/HKZ)U^)P5QX,M81GA:9OELZ>W;.->#[-D85%
MNW[=G;O)+M?'SH6=/&]R/-J=79LA.WJ+=MVRG2>_=YNU;=FX_G2^3MS#),K<
MCROQK5K]G5):57:+\RO[F(C5@GQ6-8C.Q7+W>YUZHB=/7JGXT/!GK*4\+G-\
MLA3PWQC7F\?(Z<%NQVX]F&W%?E<>/C04:>-IDF;SJX[IRMX+#!],:E1XXX;.
M'=B\=F#[CIWR<--JR12[_P T[+G(^Y'2TM0UC%ZNYK?H?HFY',9#;O<^#OI_
M5F?%/HITZKW>2^##):4E+4.=W5>/3&WH0H>IQU)W&/3MX%Y-FV-\_P#'YJ"M
M!PTOIZSMIX;)W5Q4N.O:Z=*%KAT;.\>[?MV3UXF\)O&?AJ6K>U3C'#W\_4>D
ML6S[?[FVYV*PU.UMJE/FELT\/81OIW48*OHJ^G57=; :1Y'<L-%2C7RG*Z-3
M,(/%5[C&XJI_C1=7BC3?;2C#[[*RZX\1/.#F!"=MG><W%++)K!V]KA;47'\6
M:H\,JL<=N%:=3HZEA*PEDA(                                 _P"*
MB.16N1%:J*BHJ=45%]%147T5%0-)K![C_4VGBMY#[ECP-\7N7Y;60SG&U'6\
M_:[EDV/0IGZADEFDD62:U8I8UJ:]DKLSU57S7*-B5?[XAK5W('E7K*<[B^RR
MG;9A/?6M'\7GBWBY.,/>9R?3*I2G+M)ZT1XF><V@X0M<NS>I=Y7#=0O4KJG@
ME@HQG4]_IP2W0I5J<5U$%-O^3=KD\LLVA<X9O%P)U]C'[?J%'/RNZO3HDN9P
MV7UMD?9$J^J47=SD^#47T@7./!=EM2;GI_/:]*GT0N+>-5[^FI3J4<-G52>+
MZNBRF0^/[-J4(T]3Z<MZU3IG:W4Z*6SHI5:5PWB^NLL%TO#;Q>U\G?F1DRMH
M\J\96(.UO22U#M5.97?SD6"'#WV(U/R+[GK^9#B:W@SUI&>%#-LKE3ZY*O%_
M<5.:^^2%0\?&@)4\;G),XA5QW1=M-?==6#_R?5/UXOY.G*TTRMS7+O'N/@[F
M(DN+QFR9B96KW^XJP6ZN#8CF=&]J>YT=U7JK>B=?W6O@RU;.>%]G&74Z>S;"
M%:H^G'9*-)=6&W;MW8;?T7OCZT3"GCE^19K5JX/94J6])=&&V,JSV[<?-V;-
MCQV2#T?Y/'&&,DAFY"Y7W/;E8O?)4UK$8G2Z<KNO5(97W9MONOA1/1RQR0O=
M\45GP)$R+P::6M91GJ+-[V\:VN-&G3MHOL?$[B370\)1;WIK<19J/Q[ZRO(R
MIZ5R/+[!/8I7%6K=S7:E!6L$^E<49I;FI;RP3B3Q6\?^#UBL<<\9:]B<O"GT
M=EOQ3;!M*.5'I(Z'8L]-D<K29-[B]\=>6&%?1.Q$1J)8?2'*?E[H7"IIO*[:
MC>1_=IIU:_;A6JN=2...V,)1CV8)85;USSKYH\Q^*EJS.+JO82_]W@U0MNC#
M&A15.E-K#9*<92WOBQ;;D&2(18                  ?BR&.Q^7I6,=E:%+
M)X^W&Z&W0R%6"[2LPO3HZ*Q5LLD@FC<GQ:YJHI^RE6JT*BK4)2A5B\5*+::?
M6FMJ/GNK2UOK>5I>TJ=:UFL)0G%3A)/HE&2::[&B*F[^%7"NVOFM8JAD]'R$
MG<_W-9N(F.?*O7HLN'R4=ZG%"WK_ ,75^JIZ?%/7KW&6\QM1V"4*\H7-)?YQ
M>=AV3CPMOMEQ$*ZB\/?+W/)2K65*MEUT]N-O/WMOMI5%.*7M:?=_A(V9WY>N
MQQ/>NL\C82_&JN6./.X:_B'L3K]%CYL?8S;9%1/B]&-Z_P!ZGP.PMN:]G)+X
MY:5(/VDXS^])0^YB_*1)F7A:S:$F\HS:WJPZ%6I3I-=C<)5L?+@O(> G\"^:
MXI%9'DM!LM1$Z309W+MC=U1%5$2SKM>7JU?1>K4]?AU/5CS0TY)8N%U%]3A'
M]2HU]\YBIX:.84)\,:V6376JU7#_ "J$7]X^EC? +EJPYCLELNA8V%R_32*_
MG;]IG21K57V68"O6<BQ]7)^G^/1%Z=55/TUN:>106%&C=3E[F$5]WC;^\?7:
M>&/7%5IW=WEE&GTX3K3DMO4J,8O9BUY_4MF.SL.K_+WU^NZ*7<N0<MDT]'2T
MM<Q53#,:J=?T:9#(S9I\S'+TZN2O$O3JB=%^D<_>\UKJ2<<OM*<.VI)S_P F
M*AA^V?ZAWN3>%S*Z3C//\TKUNN%"G&DO)QU'5;7;P1?1VDN^/^">*>,ECGU'
M3L;4R;&]/VY>23+9SJJ='K%E,D^S9J-E_G,@6*-?[WT0X+-=3YYG.,;^XG*B
M_8+S8>K&.">'7+%]I.>F.6VBM'M5,CL*,+Q+\]/&K6[<*E1RE''I4'&/8=</
M!.Y                               !Q'D'QUX@Y+?-;V/4*4.7F5SGY
M[!N?A,P^5_7K/9L4/;AR4WTE];<<Z?\ !Z(=)E6K<_R9*G:7$G;KV$_/AAU)
M2VQ7N7$CO5'*K0FKY2KYM8TXWTM]:CC1JMOIE*&"J/\ ?(S(E[-\O7&2R22Z
M=R->IQ=7>W0V7#09%_KU5B.RN,LXQ&]OP7_F:]>O7TZ=%[NSYKUDE',+2,I?
MC4YN/^3)2],A#./"U9SFYY#FU2G#HA<4E4?\)3E3^"9R2_X"<OUU<M'8./\
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M:F6"$5%H0
M
M
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MDHQ2Z$DDD?L/UG[P
M
M
M                                    "NWYAGB2GD-QTS<M.HMDY:XY
MHVY\)'$UK9MLUM%=<R>I2.1.Z6ZQZ.LXSN54;962).U++WMKAXC.4']XNFUG
M634\=7Y;3DZ26^XH^NG;OKDGC.CCNGQ0V=ZY*UOA6YY_W5:L>09_5:T-FU6,
M:S>ZVN-D:=TNJ#6%.XPVNGPSVNC&+S"21OB>^*5CXY(WNCDCD:K'QO8JM>Q[
M'(CFO:Y.BHOJBF6LHRA)QDFI)X-/>GU,V1C*,XJ<&G!K%-;4T]S3Z4S_  ?X
M?D   ?[CD?$]DL3WQR1O;)')&Y6/C>Q4<Q['M5'->UR=45/5%/\ 8RE"2E%M
M23Q36]/K1^,HQG%PFDX-8-/:FGO372F7H^#/S(*\T&%X=\B<RD%F%E?%ZARI
MDYU]FVQO6*IB-\MRN_0VF-[(X<JY>R5.GUM6O1UB2^7(?Q+4YTZ&C.8]?AJQ
M2A;W\WLDMT:=U)[I+9&-=[)?NS33J2S:\27A)JTZEQK[E1;\5&3E4NLMIK;%
M[Y5;**WQ>V4[9;8O'N$XM4H7<QR,E8R6)[)(I&-DCDC<CV2,>B.8]CVJK7,<
MU>J*GHJ%YHRC.*G!IQ:Q36U-/I1G1*,H2<)IJ:>#3V--;TUT-'^S_3\0
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M3"DFXQZ&W*>"X\#OQRQ)P
M
M
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M#^34I+;1IR6#JR36*JU$\(K?"FWCYTVH6 $5EGP
M
M
M
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M]<>P>$14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J
M &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGX
MP_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2'D-QW_2^/\<N
M5W/9<3KM/MD=$N0M-98MK&WN?'0HQ^Y>R,Z-_P"3@CD>OYC[\ORO,<UJ]QEU
M&I6J=/"MBQ_&EZV*[9-(\+/M3Z?TO:_'=07E"UM\'AQRPE+#>H06,YOVL(R?
M85Y<L^>=FPVUA^(<.ZDQ4?#_ $PV*".2W^5OO8C JLM:%>J=S);CI>K5Z.KM
M4EC(N5\(.-QG]3B>_NJ;V>2<]C?:H8=DV59UOXEJU53L-"T'3CM7QJNDY>6E
M1VQ76I57+%/;2BRO3/[%G=JRUO.[)ELAF\Q>D]RUD<E9EM695^#6>Y*YW9#$
MWZ,<;>C(V(C6HC41"6+6TMK&A&VLZ<*=O%;(Q227W.E]+WM[7M*LYGFN99U?
M5,RS:O5N+^H\93J2<I/LQ>Y+<HK!16"226!\8^@^       L8\3?%B3*2XOE
M/DG']F(C6.]J6KWH&JN7=T[ZV=S%:9BHW%,54?5@<G6RY$E=TA1J31'KK6ZH
M1GDF3SQKOS:M1/UG7"#7LNB3]CZU>=CPVMY(\F)WLZ.L]6TL+%83MK>:_.O?
M&M5BU^;6^G!K&H\)OWO!5+2"%"Y8
M
M
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MF-%K&3P=1*/FSL^1$1$1$1$1.B(GHB(GP1$_(B$+EQ4DE@MQ_P!
M
M
M
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MR(L=+NEGVJU3NM0QPE"ELE1MWT/;LJU8[^/UD)>L3<54<XR-2QH
M
M
M
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M)*/\JDDJE>>$JU3W4L%A'':H048+?ACBWUP\$[D
M
M
M
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M#_0
M
M
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ME"X[JMY?,V=.\C^J*U5:Y%1R*J*BIT5%3T5%1?5%12/&FG@]Y**::Q6X_P"
M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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M18/2W*+06DG&ME]C"M?QW5KCWZICUQXEP0?;3A!G>CER2P
M
M
M
M                                       #G.X</<3<A*YV]\9Z#N$K
MD<GUC9-1P.9ML5Z='/AN7Z$]J"3I\',>UR?D4YK.=&Z1U%B\_P KR^]D^FM;
MTJDEVJ4X.2?:FF=9D&O=<:5P6FLXS.P@O8V]U6I1>'0XPFHM=C3781MV+Y=O
MA[LCGRS</T\39?TZ6-=V7<,$V/T8B]E&AGXL5ZMC3^57=TZJJ=%556-,R\.'
M)K,VYSR:%&J^FC6N*6&[="%54^CI@^GI;)<RGQ6\^\H2A3SZI7HKV->WM:V.
M_?.=!U.GHFNA;DD<=RORF/%O(=?JF0Y6P77LZ?LK;<--V]G7NZ?MO5,S_P ;
M_.Z]?^#H<9=^$3E5<_F:F;6^[\W<4W\+0J;^G[V!WUEXX^=%K^?I9)<[_P Y
M;55O_>;FENZ/OXGC[7R?.!7S.=2Y'Y>KUU1O9%:NZ9;F:J-3N5T\6GT6.17>
MJ(D:=$]/7XGBU?!MH!S;H9GG$:?5*5M)_=5O%?>/?H^/7F;&FE<91D,JO2XP
MNXKL\UW4W_E/U"SC9-*H;-H>5T"W;N5\;EM<DUN:[7]GZ]'5EI)26>)98I(/
MK"1IU]6*WK^3H7$R6O+)*]M7MTIRM7#AXMSX,,,<,-^&W# H3JK+J6K<MO\
M++V4J=+,(58S<,,8JKCCP\2:Q6.S%/M(@U_E^\5M<Y;>W<@S,[>C6U[>N57(
M[JGJY\FN6T<WIU].U/[I(\^:F>->]V]HGVJH_P#^XBOE+PP:+3??WV:2CA[&
M5"/WW0E^#U3TM#P4X.IJQ;#]SRO:B(Y+^P5HTD5'(Y7/_9>*QJHKD3M7M5J=
M%].B^I\E7F;J6IZSXO#W,'^5*1ZUKX;>7-!KO7F%?#\>O%8^7NZ=/R;,/N[3
MHF'\4N ,(K'5^.L=<E9ZK)F,AFLTDCO3U?!D\E:J?S4]$C1O_!ZKU\BXUSJJ
MYQ4[N<5[2,(??C%/[YU5AR4Y89=@Z654JDUTU9U:N/EC4J2CZG#AV;6=CP.G
M:CJS/;UG5M<UUG14[<'A,;BD5'=.Y%^HUH.O=T3KU^/Y3G[K,+^]>-Y7K57[
M><I>DV=]EN09%DT>')[*TM8_Z&C3I^A%;^D](?&>L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338455952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAR&#201; BIOSCIENCE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4139823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3655 Nobel Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-7655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,785,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338805104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,329,101<span></span>
</td>
<td class="nump">$ 34,669,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">572,466<span></span>
</td>
<td class="nump">1,703,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,069,622<span></span>
</td>
<td class="nump">6,665,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">272,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,243,289<span></span>
</td>
<td class="nump">43,038,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">45,785<span></span>
</td>
<td class="nump">64,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">920,880<span></span>
</td>
<td class="nump">722,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,209,954<span></span>
</td>
<td class="nump">43,826,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,541,115<span></span>
</td>
<td class="nump">2,027,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,193,799<span></span>
</td>
<td class="nump">10,894,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">13,694,085<span></span>
</td>
<td class="nump">18,303,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">271,825<span></span>
</td>
<td class="nump">398,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,700,824<span></span>
</td>
<td class="nump">31,623,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">1,205,206<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="nump">23,326<span></span>
</td>
<td class="nump">90,346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,929,356<span></span>
</td>
<td class="nump">32,714,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 240,000,000 shares authorized; 86,633,588 and 84,825,481 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">8,663<span></span>
</td>
<td class="nump">8,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(404,467)<span></span>
</td>
<td class="num">(351,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">155,555,775<span></span>
</td>
<td class="nump">152,529,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(157,879,373)<span></span>
</td>
<td class="num">(141,074,640)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(2,719,402)<span></span>
</td>
<td class="nump">11,112,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 23,209,954<span></span>
</td>
<td class="nump">$ 43,826,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457340711904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">240,000,000<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">86,633,588<span></span>
</td>
<td class="nump">84,825,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">86,633,588<span></span>
</td>
<td class="nump">84,825,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457340771104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License fee revenue<span></span>
</td>
<td class="text">License fee revenue<span></span>
</td>
<td class="text">License fee revenue<span></span>
</td>
<td class="text">License fee revenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,920,672<span></span>
</td>
<td class="nump">2,792,894<span></span>
</td>
<td class="nump">6,258,098<span></span>
</td>
<td class="nump">5,362,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,043,684<span></span>
</td>
<td class="nump">6,797,784<span></span>
</td>
<td class="nump">11,063,907<span></span>
</td>
<td class="nump">12,603,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_LicenseFeeExpense', window );">License fee expense</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,989,356<span></span>
</td>
<td class="nump">9,615,678<span></span>
</td>
<td class="nump">17,372,005<span></span>
</td>
<td class="nump">18,016,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(8,989,356)<span></span>
</td>
<td class="nump">384,322<span></span>
</td>
<td class="num">(17,372,005)<span></span>
</td>
<td class="num">(8,016,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">227,124<span></span>
</td>
<td class="nump">29,676<span></span>
</td>
<td class="nump">567,272<span></span>
</td>
<td class="nump">31,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,762,232)<span></span>
</td>
<td class="nump">413,998<span></span>
</td>
<td class="num">(16,804,733)<span></span>
</td>
<td class="num">(7,984,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(31,151)<span></span>
</td>
<td class="num">(135,869)<span></span>
</td>
<td class="num">(53,156)<span></span>
</td>
<td class="num">(145,019)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (8,793,383)<span></span>
</td>
<td class="nump">$ 278,129<span></span>
</td>
<td class="num">$ (16,857,889)<span></span>
</td>
<td class="num">$ (8,129,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) per common share - basic (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) per common share - diluted (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">86,403,117<span></span>
</td>
<td class="nump">84,682,765<span></span>
</td>
<td class="nump">86,976,129<span></span>
</td>
<td class="nump">84,682,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">86,403,117<span></span>
</td>
<td class="nump">85,369,424<span></span>
</td>
<td class="nump">86,976,129<span></span>
</td>
<td class="nump">84,682,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457334188512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 38,754,321<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">$ 149,027,802<span></span>
</td>
<td class="num">$ (154,973)<span></span>
</td>
<td class="num">$ (110,126,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">532,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,398,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,398,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(9,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">30,878,910<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">149,560,211<span></span>
</td>
<td class="num">(164,123)<span></span>
</td>
<td class="num">(118,525,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">38,754,321<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">149,027,802<span></span>
</td>
<td class="num">(154,973)<span></span>
</td>
<td class="num">(110,126,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(7,984,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(145,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,820,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">33,033,459<span></span>
</td>
<td class="nump">$ 8,482<span></span>
</td>
<td class="nump">151,436,543<span></span>
</td>
<td class="num">(299,992)<span></span>
</td>
<td class="num">(118,111,574)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">30,878,910<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">149,560,211<span></span>
</td>
<td class="num">(164,123)<span></span>
</td>
<td class="num">(118,525,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">537,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">1,218,750<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">1,218,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">120,149<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">120,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">413,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(135,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,820,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">33,033,459<span></span>
</td>
<td class="nump">$ 8,482<span></span>
</td>
<td class="nump">151,436,543<span></span>
</td>
<td class="num">(299,992)<span></span>
</td>
<td class="num">(118,111,574)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,825,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">11,112,110<span></span>
</td>
<td class="nump">$ 8,482<span></span>
</td>
<td class="nump">152,529,579<span></span>
</td>
<td class="num">(351,311)<span></span>
</td>
<td class="num">(141,074,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">624,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,353,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">1,299,375<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">1,299,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,042,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,042,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(22,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,178,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">4,971,600<span></span>
</td>
<td class="nump">$ 8,618<span></span>
</td>
<td class="nump">154,453,439<span></span>
</td>
<td class="num">(373,316)<span></span>
</td>
<td class="num">(149,117,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,825,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">11,112,110<span></span>
</td>
<td class="nump">$ 8,482<span></span>
</td>
<td class="nump">152,529,579<span></span>
</td>
<td class="num">(351,311)<span></span>
</td>
<td class="num">(141,074,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(16,804,733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(53,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,633,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(2,719,402)<span></span>
</td>
<td class="nump">$ 8,663<span></span>
</td>
<td class="nump">155,555,775<span></span>
</td>
<td class="num">(404,467)<span></span>
</td>
<td class="num">(157,879,373)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,178,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">4,971,600<span></span>
</td>
<td class="nump">$ 8,618<span></span>
</td>
<td class="nump">154,453,439<span></span>
</td>
<td class="num">(373,316)<span></span>
</td>
<td class="num">(149,117,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">650,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">452,195<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">452,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,762,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,762,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(31,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,633,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">$ (2,719,402)<span></span>
</td>
<td class="nump">$ 8,663<span></span>
</td>
<td class="nump">$ 155,555,775<span></span>
</td>
<td class="num">$ (404,467)<span></span>
</td>
<td class="num">$ (157,879,373)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338819728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,804,733)<span></span>
</td>
<td class="num">$ (7,984,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">19,123<span></span>
</td>
<td class="nump">10,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,274,807<span></span>
</td>
<td class="nump">1,069,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_NonCashLeaseExpense', window );">Non-cash operating lease cost</a></td>
<td class="num">(11,811)<span></span>
</td>
<td class="nump">9,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,130,694<span></span>
</td>
<td class="num">(992,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(1,403,634)<span></span>
</td>
<td class="num">(3,427,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(272,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(44,934)<span></span>
</td>
<td class="nump">91,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,513,162<span></span>
</td>
<td class="num">(988,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(6,700,216)<span></span>
</td>
<td class="nump">3,211,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_IncreaseDecreaseInDeferredGrantFunding', window );">Deferred grant funding</a></td>
<td class="num">(4,609,482)<span></span>
</td>
<td class="num">(1,791,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">205,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,703,918)<span></span>
</td>
<td class="num">(20,791,986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">452,195<span></span>
</td>
<td class="nump">1,218,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="nump">1,299,375<span></span>
</td>
<td class="nump">120,149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,751,570<span></span>
</td>
<td class="nump">1,338,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="num">(53,156)<span></span>
</td>
<td class="num">(145,019)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(21,005,504)<span></span>
</td>
<td class="num">(19,603,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">34,669,605<span></span>
</td>
<td class="nump">51,674,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">13,664,101<span></span>
</td>
<td class="nump">32,070,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">13,329,101<span></span>
</td>
<td class="nump">32,070,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other non-current assets</a></td>
<td class="nump">335,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">13,664,101<span></span>
</td>
<td class="nump">32,070,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for new operating lease liabilities, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,043,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInDeferredGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Grant Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInDeferredGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457343590640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate one segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, vaginal health, reproductive health, menopause, sexual health, and fertility, and aim to expand treatment options, enhance outcomes and improve ease of use for women.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio includes one FDA-approved product, drug and drug/device product candidates and potential product candidates in various stages of development.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's product, XACIATO&#8482; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. That agreement became effective in June 2022, and in July 2022, the Company received the $10.0&#160;million non-refundable and non-creditable payment due upon the effectiveness of the agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457341023024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, or the 2022 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash and all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has an aggregate of approximately $0.3 million in restricted cash related to (i) letters of credit established under real property leases for the Company's wholly owned subsidiary, Dare MB Inc., that serve as security for potential future default of lease payments, and (ii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or for usage for general obligations and are included in other non-current assets on the Company's consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had an accumulated deficit of approximately $157.9 million, cash and cash equivalents of approximately $13.3 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $13.7 million, and a working capital deficit of approximately $2.5 million. Substantially all of the Company's cash and cash equivalents at June&#160;30, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the six months ended June&#160;30, 2023, the Company incurred a net loss of approximately $16.8 million and had negative cash flow from operations of approximately $22.7 million. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2 to the consolidated financial statements included in the 2022 10-K. Since the date on which the 2022 10-K was filed with the U.S. Securities and Exchange Commission, or the SEC, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of June&#160;30, 2023 and December&#160;31, 2022. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of June&#160;30, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"></td><td style="width:216.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,238,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,238,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification Topic 606, or ASC 606, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products. As of June&#160;30, 2023, the Company has not recognized any collaboration revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has recognized $10.0 million in license fee revenue, all of which represents the upfront payment due under its license agreement for XACIATO. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of June&#160;30, 2023, the Company has not recognized any royalty revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. As of June&#160;30, 2023, the Company has not recognized any revenue associated with product supply arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. As of June&#160;30, 2023, the Company has not recognized any milestone revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer License. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million. The Company concluded that there was one significant performance obligation related to the $1.0&#160;million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $1.0 million payment is recorded as deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also be entitled to receive (a) milestone payments totaling up to $310.0 million related to the commercial sales of Ovaprene, if all such milestones are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, Strategic Agreements.)</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457344485664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">STRATEGIC AGREEMENTS</a></td>
<td class="text">STRATEGIC AGREEMENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Agreements for Product Commercialization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organon Exclusive License Agreement</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an exclusive license agreement with Organon, which became effective in June 2022, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. In July 2022, the Company received a $10.0 million non-refundable and non-creditable payment from Organon, which was recorded as license fee revenue. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement in effect as of June 30, 2023, the Company is entitled to receive tiered double-digit royalties based on net sales and up to $182.5 million in milestone payments as follows: $2.5 million following the first commercial sale of a licensed product in the United States; and up to $180.0 million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. Subsequent to June 30, 2023, the Company and Organon entered into an amendment to the license agreement, which changed some of the payment terms. (See Note 10, Subsequent Events.)</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the agreement, the Company concluded that the transaction price was $10.0 million and should not include the variable consideration related to unachieved development, regulatory, commercial milestones and future sales-based royalty payments. This consideration was determined to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal in cumulative revenue. The Company re-evaluates the transaction price at each reporting period as uncertain events are resolved and other changes in circumstances occur. For the quarter ended June&#160;30, 2023, no adjustments were made to the transaction price. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize any consideration related to sales-based payments, including milestones and royalties which relate predominantly to the license granted, at the later of (i) when or as the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer HealthCare License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $1.0 million upfront non-refundable license fee payment from Bayer and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million, referred to as the $20.0 million fee. After payment of the $20.0 million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S. Such license would be exclusive as to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of either the point in time the Company receives the $20.0 million fee, the license is transferred to Bayer and Bayer is able to use and benefit from the license or the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $1.0 million payment is recorded as long-term deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023  and December&#160;31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S. or 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $20.0 million fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Strategic Agreements for Pipeline Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hennepin License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a license agreement with Hennepin Life Sciences LLC, or Hennepin, under which the Company acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of health conditions including bacterial, fungal, and viral infections. Under the agreement, the Company received an exclusive, worldwide, royalty-bearing license to research, develop and commercialize the licensed technology. The Company is entitled to sublicense the rights granted to it under the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company agreed to make potential future payments and sales milestone payments of up to $6.25 million in the aggregate upon achieving certain development and regulatory milestones, and of up to $45.0 million in the aggregate upon achieving certain commercial sales milestones for each product covered by the licenses granted under the agreement, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Hennepin is eligible to receive tiered royalties in low single-digit to low double-digit percentages based on worldwide net sales of products and processes covered by the licenses granted under the agreement.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, no payments have been made under this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Dare MB Inc., or MBI, to secure the rights to develop a long-acting reversible contraception method, that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the merger agreement, the Company agreed to pay former MBI stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property the Company acquired in the merger; and (c) tiered royalty payments ranging from low single-digit to low double-digit percentages based on annual net sales of such products sold by the Company (but not by sublicensee) and a percentage of sublicense revenue related to such products. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, a total of $1.25 million of the contingent consideration became payable upon the achievement of certain of the funding and product development milestone events. In accordance with the terms of the merger agreement, the Company&#8217;s board of directors elected to pay a portion of these milestone payments in shares of the Company&#8217;s common stock, and in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 in cash to the stockholders&#8217; representative in satisfaction of the $1.25 million in milestone payments associated with milestones achieved in June 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TriLogic and MilanaPharm License Agreement / Hammock Assignment Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into an assignment agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and a first amendment to license agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. In December 2019, the Company entered into amendments to each of the Assignment Agreement and License Amendment. In September 2021, the Company entered into a second amendment to the License Agreement. In March 2022, the Company entered into a Consent, Waiver and Stand-By License Agreement with TriLogic, MilanaPharm and Organon, which further amended the License Agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License Agreement, the Company paid clinical and regulatory development milestones in the aggregate of $300,000 to MilanaPharm, the final payment of $250,000 was expensed in 2021. The Company may also pay MilanaPharm up to $500,000 upon the first commercial sale in the United States of the first licensed product for each vaginal and urological use, and up to $250,000 upon the first commercial sale in the United States of each successive licensed products for each vaginal or urological use. In addition, upon achievement of $50.0 million in cumulative worldwide net sales of licensed products the Company must pay MilanaPharm $1.0 million. MilanaPharm is also eligible to receive (a) a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions, and (b) high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm license agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan. Hammock is eligible to receive up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $850,000 of which has been paid as of June&#160;30, 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company acquired Pear Tree Pharmaceuticals, Inc., or Pear Tree, to secure exclusive, sublicensable, worldwide rights under certain patents and know-how to develop and commercialize a proprietary formulation of tamoxifen for vaginal administration. This acquisition led to the Company's DARE-VVA1 program. </span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the merger agreement, the Company agreed to pay the former stockholders of Pear Tree: (a) up to $15.5 million in the aggregate upon achieving certain clinical development and regulatory milestones by licensed products, and (b) up to $47.0 million in the aggregate upon achieving certain commercial milestones by licensed products. Additionally, the former stockholders of Pear Tree are eligible to receive tiered royalties based on single-digit to low double-digit percentages of annual net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, and a portion of royalties the Company receives from sublicensees. Both the milestone and royalty payments may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the merger agreement. Under the merger agreement, in addition to customary royalty reductions and offsets, royalty payments and payments based on income received from sublicensees of licensed products made by the Company to Pear Tree's licensors are creditable against all royalty and sublicense revenue share payments payable to the former stockholders of Pear Tree.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay licensors of Pear Tree (a) up to approximately $3.2 million in the aggregate upon achieving certain clinical development, regulatory and commercial milestones by each licensed product, and (b) semi-annual royalties based on a single-digit percentage of net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, or a portion of any royalties the Company or its affiliates receives from sublicensees, and a low double-digit percentage of all sublicensing fees or other lump sum payments or compensation the Company receives from sublicensees, subject to customary exclusions. The milestone payments to the licensors of Pear Tree may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the license agreements. Portions of certain milestone payments made to Pear Tree's licensors may be creditable against royalty payments due to Pear Tree's licensors. </span></div><div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc., or Catalent, under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement and will pay a $100,000 annual license maintenance fee on each anniversary of the date of the agreement. The annual maintenance fee will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. Catalent is eligible to receive up to (a) $13.5 million in the aggregate in payments based on the achievement of specified development and regulatory milestones, $1.0&#160;million of which has been paid as of June&#160;30, 2023; and (b) up to $30.3 million in the aggregate in payments based on the achievement of specified commercial sales milestones for each product or process covered by the licenses granted under the agreement. Additionally, Catalent is eligible to receive mid single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals USA, Inc., or Adare, for the development and potential exclusive worldwide license of injectable formulations of etonogestrel for contraceptive protection over 6-month and 12-month periods (which the Company refers to as DARE-204 and DARE-214, respectively). The agreement, as amended, provides the Company with an option to negotiate an exclusive, worldwide, royalty-bearing license, with rights to sublicense, for the programs if the Company funds the conduct of specified development work. The Company has no obligation to exercise its option. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SST License and Collaboration Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder and/or female sexual interest/arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SST will be eligible to receive payments of up to $18.0 million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and up to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST. Additionally, SST is eligible to receive tiered royalties based on percentages of annual net sales of licensed products in the single-digit to mid double-digits subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, the Company will pay ADVA-Tec (a) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones, $1.2&#160;million of which has been paid; and (b) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, ADVA-Tec is eligible to receive royalties based on aggregate annual net sales of Ovaprene in specified regions at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds, subject to customary reductions and offsets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company sublicenses its rights under the agreement, in lieu of royalty payments to ADVA-Tec, ADVA-Tec is eligible to receive a double-digit percentage of sublicense revenue received by the Company during the royalty term; provided, however, that for sublicense revenue the Company receives prior to the first commercial sale of a licensed product that represents an upfront payment or license fee due on or around the effective date of the sublicense, ADVA-Tec is eligible to receive a single-digit percentage of that sublicense revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457341243648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Increase in Authorized Shares of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, following the approval of the Company's stockholders at its annual meeting of stockholders, the Company amended its restated certificate of incorporation to increase the Company's authorized shares of common stock to 240,000,000. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2023 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a sales agreement with Stifel, Nicolaus &amp; Company, Incorporated, or Stifel, and Cantor Fitzgerald &amp; Co., or Cantor, to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which Stifel and Cantor act as the Company's agent. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement or such lower amount as the Company and Stifel and Cantor agree, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862), the base prospectus included therein, originally filed with the SEC on March 30, 2021 and declared effective by the SEC on April 7, 2021, the prospectus supplement dated March 31, 2023 relating to the offering of up to $50.0&#160;million of shares of the Company's common stock under the sales agreement, and any subsequent prospectus supplement related to the offering of shares of the Company's common stock under the sales agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, the Company sold 454,592 shares of common stock under this agreement and received aggregate gross proceeds of approximately $463,000 and incurred sales agent commissions and fees of approximately $11,000.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2021 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a sales agreement with SVB Securities LLC (formerly known as SVB Leerink LLC) to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold no shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2021 ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a sales agreement with SVB Securities LLC to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold no shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwritten public offering in February 2018, the Company issued to the investors in that offering, warrants exercisable through February 2023 with an initial exercise price of $3.00 per share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which was recorded in equity as of the grant date. The warrants included a price-based anti-dilution provision, which provided that, subject to certain limited exceptions, the exercise price of the warrants would be reduced each time the Company issued or sold (or was deemed to have issued or sold) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issued, sold or entered into any agreement to issue or sell securities at a price which varied or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders had the right to substitute such variable price for the exercise price of the warrant then in effect. In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively. During the six months ended June&#160;30, 2023, warrants to purchase 1,353,515 shares of common stock were exercised for gross proceeds of approximately $1.3 million and the remaining unexercised warrants expired on February 15, 2023. No warrants were exercised during the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had the following warrants outstanding:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335708720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was no stock-based compensation related to the ESPP for the six months ended June&#160;30, 2023 or June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, provided for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increased annually on the first day of each fiscal year by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2022, the number of authorized shares increased by 2,000,000 to 2,201,855. As a result of the approval of the 2022 Plan (as defined below) by the Company's stockholders on June 23, 2022, no further awards have been or will be granted under the Amended 2014 Plan. Outstanding awards previously granted under the Amended 2014 Plan continue to remain outstanding in accordance with their terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company's board of directors approved the Dar&#233; Bioscience, Inc. 2022 Stock Incentive Plan, or the 2022 Plan, which was subsequently approved by the Company's stockholders on June 23, 2022, and became effective as of that date. The 2022 Plan provides for the grant of stock-based incentive awards to employees, consultants, advisors, and directors. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock authorized for issuance under the 2022 Plan is (a) 10,117,305; plus (b) up to 6,144,682 shares subject to awards granted under the Amended 2014 Plan or the 2007 Stock Incentive Plan that expire, terminate or are otherwise forfeited on or after June 23, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Company's stock incentive plans and related information for the six months ended June&#160;30, 2023. The exercise price of all options granted during the six months ended June&#160;30, 2023 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of June&#160;30, 2023, unamortized stock-based compensation expense of approximately $5.6&#160;million will be amortized over a weighted average period of 2.47 years. The number of shares of common stock available for future awards granted under the 2022 Plan at June&#160;30, 2023 was 6,718,916. </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:376.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,612,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,769,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457341152848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASED PROPERTIES</a></td>
<td class="text">LEASED PROPERTIES<div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for two years such that the term now expires on August 31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts. The lease for that space commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for three years to December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The extension of the lease in February 2022 resulted in an increase in operating lease liabilities and ROU assets of approximately $1.0&#160;million. In September 2022, the landlord exercised its option to terminate the lease, resulting in the new lease term ending on December 31, 2023. The termination of the lease resulted in a reduction of operating lease liabilities and ROU assets of approximately $504,000 and $458,000, respectively, and a $46,000 gain on the modification of the lease which was included as a reduction to research and development expense for the year ended December 31, 2022. MBI entered into a new lease for general office space in June 2023 that will commence on December 1, 2023 and will create an obligation to pay approximately $1.4&#160;million over the lease period of three years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI previously leased warehouse space in Billerica, Massachusetts, under a lease that commenced on October 1, 2016 and terminated on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate consisting of the current prime rate plus 200 basis points for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, the Company reported operating lease <span style="-sec-ix-hidden:f-446">ROU assets</span> of approximately $276,000 in other non-current assets, approximately $272,000 in current portion of lease liabilities, and approximately $23,000 in lease liabilities long-term in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately $145,000 and $284,000 for the three and six months ended&#160;June&#160;30, 2023, respectively, and $150,000 and $340,000 for the three and six months ended  June&#160;30, 2022, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was approximately $105,000 and $209,000 for the three and six months ended&#160;June&#160;30, 2023, respectively, and $80,000 and  $203,000 for the three and six months ended June&#160;30, 2022, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. At June&#160;30, 2023, operating leases had a weighted average remaining lease term of 0.83 years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, future minimum lease payments under the Company's operating leases are as follows (does not include any minimum lease payments under the lease MBI entered in June 2023 because the lease does not commence until December 1, 2023):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:445.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457433554640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESCRADA with NICHD for the Pivotal Phase 3 Study of OvapreneIn July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#8217;s Contraceptive Clinical Trial Network with NICHD's contract research organization providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD is responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $5.0&#160;million to NICHD, $3.5&#160;million of which was paid in 2022. The Company's remaining obligation under the CRADA at June&#160;30, 2023 was $0.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457344483008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Awards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_GrantAwardTextBlock', window );">GRANT AWARDS</a></td>
<td class="text">GRANT AWARDS<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of DARE-PTB1, DARE-LARC1 and DARE-204/214. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-PTB1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $300,000 was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $2.0&#160;million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NICHD award of $721 during the three and six months ended June&#160;30, 2023, and $2,500 and $19,500 during the three and six months ended June&#160;30, 2022, respectively. At June&#160;30, 2023 the Company recorded a receivable for expenses incurred through such date that it believes are reimbursable under the grant of $721. No receivable was recorded at December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $300,000 was to be used to explore device insertion and removal in nonclinical studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $0 and $32,000 for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, and $27,800 and $193,000 for the three and six months ended June&#160;30, 2022, respectively. The Company recorded a receivable of approximately $33,000 at December&#160;31, 2022 for expenses incurred through such date that were subsequently reimbursed under the grant. No receivable was recorded at June&#160;30, 2023. The Company received aggregate reimbursements under the NICHD award of approximately $278,000 during the grant period, which ended in June 2023. No further funds are available under this award.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-204 and DARE-214</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company received a notice of award of a grant from NICHD of approximately $249,000 to support end-user research to better understand women's preferences for a long-acting injectable contraceptive method. The findings from the research will inform the Company's target product profile and guide its development priorities for DARE-204 and DARE-214. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $32,700 and $81,500 for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, with no such credits recorded in the same periods of the prior year. The Company recorded a receivable of approximately $33,040 and $24,000 at June&#160;30, 2023 and December&#160;31, 2022, respectively, for expenses incurred through such date that it believes is eligible for reimbursement under the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Dilutive Grant Funding</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 DARE-LBT Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company entered into an agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation, under which the Company was awarded $585,000 to support the development of DARE-LBT. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LBT, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the full amount of the award in November 2022. As of June&#160;30, 2023, the Company has recorded a deferred grant funding liability of approximately $544,000 in the Company's condensed consolidated balance sheets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 DARE-LARC1 Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into an agreement with the Foundation under which the Company was awarded up to $49.0&#160;million to support the development of DARE-LARC1. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LARC1, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The agreement supports technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in nonclinical proof of principle studies. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets.</span></div>The Company received an initial payment of approximately $11.5 million in 2021, and aggregate payments of approximately $12.4 million in 2022. As of June&#160;30, 2023, the Company has received a cumulative total of approximately $23.9 million in non-dilutive funding under the agreement and recorded a deferred grant funding liability of approximately $13.1 million in the Company's condensed consolidated balance sheets. Additional payments are contingent upon the DARE-LARC1 program&#8217;s achievement of specified development and reporting milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrantAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Award [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrantAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457433551120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share, or EPS, using the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted EPS is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Dilutive securities include the dilutive effect of in-the-money options and warrants, which is calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an option or warrant, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option or warrant is exercised are assumed to be used to repurchase shares in the current period</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities are excluded from the diluted EPS calculation if their effect is anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:541.50pt"><tr><td style="width:1.0pt"></td><td style="width:251.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,053,156&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417,533&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,476,719&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,111,889&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,476,719&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,798,548&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457341149328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Sales</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July and August 2023, the Company sold an aggregate of 1,151,578 shares of common stock under its ATM equity offering program and received aggregate gross proceeds of approximately $946,000 and incurred sales agent commissions and fees of approximately $22,000 (See Note 4, Stockholders' Equity).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Award</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2023, the Company received a notice of award of a grant from NICHD of approximately $385,000 to support preclinical development of a potential new therapeutic for the prevention of idiopathic preterm birth. The grant funds will support activities related to the conduct and completion of proof-of-concept target validation studies in collaboration with the University of South Florida, or USF, which are to occur over a 12-month period. The Company will track expenses eligible for reimbursement under the grant award and submit a detailed accounting of such expenses to receive payment of the grant funds. The amounts of any such payments will be recognized in the Company's statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the project period. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Financing</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Company obtained financing for certain director and officer and other liability insurance premiums. The agreement for such financing assigns to the lender a first priority lien on and a security interest in the financed insurance policies and any additional premium required in the financed insurance policies including (a) all returned or unearned premiums, (b) all additional cash contributions or collateral amounts assessed by the insurance companies in relation to the financed insurance policies and financed by the lender, (c) any credits generated by the financed insurance policies, (d) dividend payments, and (e) loss payments which reduce unearned premiums. If any circumstances exist in which premiums related to any financed insurance policy could become fully earned in the event of loss, the lender will be named a loss-payee with respect to such policy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total premiums, taxes and fees financed is approximately $0.8 million with an annual interest rate of approximately 8.0%. In consideration of the premium payment by the lender to the insurance companies or the agent or broker, the Company unconditionally promises to pay the lender the amount financed plus interest and other charges permitted under the agreement. The Company will pay the insurance financing through monthly installment payments through April 20, 2024. The amount financed will be recognized as an insurance financing payable in the Company's consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Exclusive License Agreement with Organon</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2023, the Company entered into an amendment to its exclusive license agreement with Organon to commercialize XACIATO. Under the amendment, Organon agreed to pay $1.0&#160;million to the Company as reimbursement for fees paid to the FDA in connection with the submission of the new drug application for XACIATO (known as PDUFA fees) and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, which will be recognized as license fee revenue in the third quarter of 2023. The Company received such amount in July 2023. The amount payable by Organon to the Company following the first commercial sale of a licensed product in the United States was revised to $1.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338546160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, or the 2022 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashThe Company considers cash and all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has an aggregate of approximately $0.3 million in restricted cash related to (i) letters of credit established under real property leases for the Company's wholly owned subsidiary, Dare MB Inc., that serve as security for potential future default of lease payments, and (ii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or for usage for general obligations and are included in other non-current assets on the Company's consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had an accumulated deficit of approximately $157.9 million, cash and cash equivalents of approximately $13.3 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $13.7 million, and a working capital deficit of approximately $2.5 million. Substantially all of the Company's cash and cash equivalents at June&#160;30, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the six months ended June&#160;30, 2023, the Company incurred a net loss of approximately $16.8 million and had negative cash flow from operations of approximately $22.7 million. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2 to the consolidated financial statements included in the 2022 10-K. Since the date on which the 2022 10-K was filed with the U.S. Securities and Exchange Commission, or the SEC, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification Topic 606, or ASC 606, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products. As of June&#160;30, 2023, the Company has not recognized any collaboration revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has recognized $10.0 million in license fee revenue, all of which represents the upfront payment due under its license agreement for XACIATO. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of June&#160;30, 2023, the Company has not recognized any royalty revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. As of June&#160;30, 2023, the Company has not recognized any revenue associated with product supply arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. As of June&#160;30, 2023, the Company has not recognized any milestone revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457341234800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of June&#160;30, 2023 and December&#160;31, 2022. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of June&#160;30, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"></td><td style="width:216.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,238,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,238,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457344506720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text">As of June&#160;30, 2023, the Company had the following warrants outstanding:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338654944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Company's stock incentive plans and related information for the six months ended June&#160;30, 2023. The exercise price of all options granted during the six months ended June&#160;30, 2023 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of June&#160;30, 2023, unamortized stock-based compensation expense of approximately $5.6&#160;million will be amortized over a weighted average period of 2.47 years. The number of shares of common stock available for future awards granted under the 2022 Plan at June&#160;30, 2023 was 6,718,916. </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:376.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,612,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,769,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457433358912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, future minimum lease payments under the Company's operating leases are as follows (does not include any minimum lease payments under the lease MBI entered in June 2023 because the lease does not commence until December 1, 2023):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:445.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457433554640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:541.50pt"><tr><td style="width:1.0pt"></td><td style="width:251.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,053,156&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470,219&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417,533&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,476,719&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,111,889&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,476,719&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,798,548&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457332969216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335815184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit related to lease of real property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,879,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,879,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,074,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,664,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,070,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,664,101<span></span>
</td>
<td class="nump">$ 32,070,612<span></span>
</td>
<td class="nump">34,669,605<span></span>
</td>
<td class="nump">$ 51,674,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,303,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_WorkingCapitalIncreaseDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,762,232<span></span>
</td>
<td class="nump">$ 8,042,501<span></span>
</td>
<td class="num">(413,998)<span></span>
</td>
<td class="nump">$ 8,398,670<span></span>
</td>
<td class="nump">16,804,733<span></span>
</td>
<td class="nump">7,984,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash flow from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PeriodofInsufficientCashandLiquidityRequirements', window );">Period of insufficient cash and liquidity requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember', window );">Bayer Healthcare License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_OrganonMember', window );">Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodofInsufficientCashandLiquidityRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of Insufficient Cash and Liquidity Requirements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodofInsufficientCashandLiquidityRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeeAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee, Amount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeeAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WorkingCapitalIncreaseDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital Increase (Deficit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WorkingCapitalIncreaseDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457340712384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 10,837,944<span></span>
</td>
<td class="nump">$ 33,238,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,837,944<span></span>
</td>
<td class="nump">33,238,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457328782448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Agreements (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember', window );">Upon Achievement of Specified Development and Regulatory Milestones | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination', window );">Payment of additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination', window );">Cash paid to stockholders' representative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsideration', window );">Asset acquisition, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember', window );">Bayer Healthcare License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember', window );">Hennepin License Agreement | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember', window );">Hennepin License Agreement | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Licensed Product or Process for Vaginal or Urological Use | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Maximum | Upon Achieving Certain Development Milestones | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Upon Achievement of Specified Development and Regulatory Milestones | Upon Achieving Certain Commercial Milestones | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement | Maximum | Upon Achieving Certain Clinical and Regulatory Development Milestones | Hammock Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember', window );">Merger Agreement | Upon Achieving Certain Clinical and Regulatory Development Milestones | Pear Tree Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember', window );">Merger Agreement | Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones | Pear Tree Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_PearTreePharmaceuticalsIncMember', window );">Pear Tree Pharmaceuticals, Inc. | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter', window );">Potential annual license maintenance fee payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_OrganonMember', window );">Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount', window );">First commercial sale amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount', window );">Sales based milestones amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember', window );">Catalent and MilanaPharm | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, First Commercial Sale Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, Sales Based Milestones Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Additional Consideration in Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentOfAdditionalConsiderationInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Stockholders' Representative in Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentsToStockholdersRepresentativeInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee Payments, Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeeAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee, Amount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeeAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_PearTreePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_PearTreePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_PearTreePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_PearTreePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335907440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity', window );">Estimated fair value of warrants recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_NumberOfCommonStockWarrantsExercised', window );">Number of common stock warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,353,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_March2023AtTheMarketSalesAgreementMember', window );">March 2023 At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_PercentageOfAggregateCommission', window );">Commission percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares of common stock for net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SaleOfStockBrokerageCommissionsExpense', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_October2021AtTheMarketSalesAgreementMember', window );">October 2021 At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember', window );">April 2021 At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SaleOfStockProspectusOfferingAmount', window );">Issued shares</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Warrants Recorded In Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_EstimatedFairValueOfWarrantsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Common Stock Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SaleOfStockBrokerageCommissionsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Brokerage Commissions Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SaleOfStockBrokerageCommissionsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SaleOfStockProspectusOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Prospectus Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SaleOfStockProspectusOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_March2023AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_March2023AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_October2021AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_October2021AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457334723760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants (in shares)</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember', window );">Warrants Expiring on April 4, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants (in shares)</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Apr.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ClassOfWarrantOrRightsWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335655584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_WeightedAverageAmortizationPeriod', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,186<span></span>
</td>
<td class="nump">$ 537,521<span></span>
</td>
<td class="nump">$ 1,274,807<span></span>
</td>
<td class="nump">$ 1,069,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual percentage increase in outstanding number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,201,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember', window );">Amended and Restated Two Thousand Fourteen Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,470,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,470,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,718,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,718,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember', window );">Amended and Restated Two Thousand Fourteen Stock Incentive Plan | 2022 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,117,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,144,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dare_TwoThousandTwentyTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dare_TwoThousandTwentyTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457338462656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details) - Amended and Restated Two Thousand Fourteen Stock Incentive Plan - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">6,612,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,857,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares) | shares</a></td>
<td class="nump">9,470,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">4,769,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335628928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Employee Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 650,186<span></span>
</td>
<td class="nump">$ 537,521<span></span>
</td>
<td class="nump">$ 1,274,807<span></span>
</td>
<td class="nump">$ 1,069,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">210,198<span></span>
</td>
<td class="nump">171,938<span></span>
</td>
<td class="nump">410,499<span></span>
</td>
<td class="nump">346,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 439,988<span></span>
</td>
<td class="nump">$ 365,583<span></span>
</td>
<td class="nump">$ 864,308<span></span>
</td>
<td class="nump">$ 723,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457333026832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Square footage of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (decrease) operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (504,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on early termination of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Non-cash lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate', window );">Incremental borrowing rate, amount over prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_MBIMember', window );">MBI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (decrease) operating lease liability</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_OperatingLeaseIncrementalBorrowingRatePrimeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate, Prime Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_OperatingLeaseIncrementalBorrowingRatePrimeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_MBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_MBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457344455008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leased Properties - Future Minimum Lease Payments (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 213,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">306,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: accreted interest</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 296,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457336310208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_NICHDMember', window );">NICHD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ResearchAndDevelopmentAgreementCommitmentAmount', window );">Total payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Other cost</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_CRADAMember', window );">CRADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentAgreementCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Agreement, Commitment, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentAgreementCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_NICHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_NICHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_CRADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_CRADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457326902448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Awards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">$ 13,694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,303,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member', window );">Grant, DARE-PTB1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_AdditionalPotentialFundingRelatedToGrantAward', window );">Additional potential grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_DARELARC1Member', window );">DARE-LARC1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="nump">278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 27,800<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantADARE204AndADARE214Member', window );">Grant, ADARE-204 and ADARE-214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="nump">33,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_DARELBT1Member', window );">DARE-LBT1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdditionalPotentialFundingRelatedToGrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Funding Related To Grant Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdditionalPotentialFundingRelatedToGrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromAwardOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Award Of Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromAwardOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReceivableForExpensesEligibleForReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable For Expenses Eligible For Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReceivableForExpensesEligibleForReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_DARELARC1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_DARELARC1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantADARE204AndADARE214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantADARE204AndADARE214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_DARELBT1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_DARELBT1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457334724016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">9,476,719<span></span>
</td>
<td class="nump">7,111,889<span></span>
</td>
<td class="nump">9,476,719<span></span>
</td>
<td class="nump">7,798,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">9,470,219<span></span>
</td>
<td class="nump">6,053,156<span></span>
</td>
<td class="nump">9,470,219<span></span>
</td>
<td class="nump">6,417,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">1,058,733<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">1,381,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140457335547280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Jul. 18, 2023</div></th>
<th class="th"><div>Jul. 04, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_OrganonMember', window );">Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount', window );">First commercial sale amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount', window );">Premiums, taxes and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_InsuranceFinancingInterestRate', window );">Interest rate on insurance financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses', window );">Reimburse amount, PDUFA fees and other manufacturing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount', window );">First commercial sale amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | NICHD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | July and August 2023 At The Market Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares of common stock for net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dare_SaleOfStockBrokerageCommissionsExpense', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_InsuranceFinancingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance Financing, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_InsuranceFinancingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_InsuranceFinancingPremiumsTaxesAndFeesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance Financing, Premiums, Taxes And Fees, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_InsuranceFinancingPremiumsTaxesAndFeesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, First Commercial Sale Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromAwardOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Award Of Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromAwardOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SaleOfStockBrokerageCommissionsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Brokerage Commissions Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SaleOfStockBrokerageCommissionsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_NICHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_NICHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_JulyAndAugust2023AtTheMarketSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_JulyAndAugust2023AtTheMarketSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>dare-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dare="http://darebioscience.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dare-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:HennepinLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:HennepinLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:LicensedProductOrProcessForVaginalOrUrologicalUseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:March2023AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:March2023AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:October2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:October2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dare:TwoThousandTwentyTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-07-01</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CRADAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantADARE204AndADARE214Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELBT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELBT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:JulyAndAugust2023AtTheMarketSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:NICHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-18</startDate>
            <endDate>2023-07-18</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-04</startDate>
            <endDate>2023-07-04</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dare:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-28">0001401914</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-94">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-95">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-96">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-7" id="f-97">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-446">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36395</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">DAR&#xc9; BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">20-4139823</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3655 Nobel Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-13">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">926-7655</dei:LocalPhoneNumber>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-15">92122</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">DARE</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">87785166</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-30" unitRef="usd">13329101</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-31" unitRef="usd">34669605</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-3" decimals="0" id="f-32" unitRef="usd">572466</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="0" id="f-33" unitRef="usd">1703160</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="0" id="f-34" unitRef="usd">8069622</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="0" id="f-35" unitRef="usd">6665988</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="0" id="f-36" unitRef="usd">272100</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="0" id="f-37" unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="0" id="f-38" unitRef="usd">22243289</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="0" id="f-39" unitRef="usd">43038753</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-40" unitRef="usd">45785</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-41" unitRef="usd">64908</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="0" id="f-42" unitRef="usd">920880</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="0" id="f-43" unitRef="usd">722722</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="0" id="f-44" unitRef="usd">23209954</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="0" id="f-45" unitRef="usd">43826383</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="0" id="f-46" unitRef="usd">6541115</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="0" id="f-47" unitRef="usd">2027953</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-48" unitRef="usd">4193799</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-49" unitRef="usd">10894016</us-gaap:AccruedLiabilitiesCurrent>
    <dare:DeferredGrantFundingCurrent contextRef="c-3" decimals="0" id="f-50" unitRef="usd">13694085</dare:DeferredGrantFundingCurrent>
    <dare:DeferredGrantFundingCurrent contextRef="c-4" decimals="0" id="f-51" unitRef="usd">18303567</dare:DeferredGrantFundingCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-52" unitRef="usd">271825</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="0" id="f-53" unitRef="usd">398391</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="0" id="f-54" unitRef="usd">24700824</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="0" id="f-55" unitRef="usd">31623927</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-56" unitRef="usd">1205206</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-57" unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-58" unitRef="usd">23326</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-59" unitRef="usd">90346</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="0" id="f-60" unitRef="usd">25929356</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="0" id="f-61" unitRef="usd">32714273</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-62" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-63" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-64"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-65"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-66" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-67" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-68" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="0" id="f-72" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="0" id="f-73" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-75"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-77" unitRef="shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">86633588</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">86633588</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">84825481</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">84825481</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="0" id="f-82" unitRef="usd">8663</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="0" id="f-83" unitRef="usd">8482</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="0" id="f-84" unitRef="usd">-404467</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="0" id="f-85" unitRef="usd">-351311</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="0" id="f-86" unitRef="usd">155555775</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="0" id="f-87" unitRef="usd">152529579</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="0" id="f-88" unitRef="usd">-157879373</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="0" id="f-89" unitRef="usd">-141074640</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-90" unitRef="usd">-2719402</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-91" unitRef="usd">11112110</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="0" id="f-92" unitRef="usd">23209954</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="0" id="f-93" unitRef="usd">43826383</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="0" id="f-98" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="0" id="f-99" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-100" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="0" id="f-101" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-6" decimals="0" id="f-102" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="0" id="f-103" unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="0" id="f-104" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="0" id="f-105" unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="0" id="f-106" unitRef="usd">2920672</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="0" id="f-107" unitRef="usd">2792894</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-108" unitRef="usd">6258098</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="0" id="f-109" unitRef="usd">5362881</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="0" id="f-110" unitRef="usd">6043684</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="0" id="f-111" unitRef="usd">6797784</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-112" unitRef="usd">11063907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="0" id="f-113" unitRef="usd">12603247</us-gaap:ResearchAndDevelopmentExpense>
    <dare:LicenseFeeExpense contextRef="c-6" decimals="0" id="f-114" unitRef="usd">25000</dare:LicenseFeeExpense>
    <dare:LicenseFeeExpense contextRef="c-7" decimals="0" id="f-115" unitRef="usd">25000</dare:LicenseFeeExpense>
    <dare:LicenseFeeExpense contextRef="c-1" decimals="0" id="f-116" unitRef="usd">50000</dare:LicenseFeeExpense>
    <dare:LicenseFeeExpense contextRef="c-5" decimals="0" id="f-117" unitRef="usd">50000</dare:LicenseFeeExpense>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="0" id="f-118" unitRef="usd">8989356</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="0" id="f-119" unitRef="usd">9615678</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-120" unitRef="usd">17372005</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="0" id="f-121" unitRef="usd">18016128</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="0" id="f-122" unitRef="usd">-8989356</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="0" id="f-123" unitRef="usd">384322</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-124" unitRef="usd">-17372005</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="0" id="f-125" unitRef="usd">-8016128</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="0" id="f-126" unitRef="usd">227124</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="0" id="f-127" unitRef="usd">29676</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-128" unitRef="usd">567272</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="0" id="f-129" unitRef="usd">31456</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-130" unitRef="usd">-8762232</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-131" unitRef="usd">413998</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-132" unitRef="usd">-16804733</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-133" unitRef="usd">-7984672</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="0" id="f-134" unitRef="usd">-31151</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="0" id="f-135" unitRef="usd">-135869</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-136" unitRef="usd">-53156</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="0" id="f-137" unitRef="usd">-145019</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="0" id="f-138" unitRef="usd">-8793383</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="0" id="f-139" unitRef="usd">278129</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-140" unitRef="usd">-16857889</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="0" id="f-141" unitRef="usd">-8129691</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-150" unitRef="shares">86403117</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-151" unitRef="shares">84682765</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-152" unitRef="shares">86976129</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-153" unitRef="shares">84682765</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-154" unitRef="shares">86403117</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-155" unitRef="shares">85369424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-156" unitRef="shares">86976129</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-157" unitRef="shares">84682765</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="INF" id="f-158" unitRef="shares">84825481</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="0" id="f-159" unitRef="usd">8482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="0" id="f-160" unitRef="usd">152529579</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="0" id="f-161" unitRef="usd">-351311</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="0" id="f-162" unitRef="usd">-141074640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-163" unitRef="usd">11112110</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="0" id="f-164" unitRef="usd">624621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="0" id="f-165" unitRef="usd">624621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="c-14"
      decimals="INF"
      id="f-166"
      unitRef="shares">1353515</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-14" decimals="0" id="f-167" unitRef="usd">136</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-12" decimals="0" id="f-168" unitRef="usd">1299239</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-13" decimals="0" id="f-169" unitRef="usd">1299375</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="0" id="f-170" unitRef="usd">-8042501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="0" id="f-171" unitRef="usd">-8042501</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="0" id="f-172" unitRef="usd">-22005</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="0" id="f-173" unitRef="usd">-22005</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-174"
      unitRef="shares">86178996</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="0" id="f-175" unitRef="usd">8618</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="0" id="f-176" unitRef="usd">154453439</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="0" id="f-177" unitRef="usd">-373316</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="0" id="f-178" unitRef="usd">-149117141</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="0" id="f-179" unitRef="usd">4971600</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="0" id="f-180" unitRef="usd">650186</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="0" id="f-181" unitRef="usd">650186</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="c-23"
      decimals="INF"
      id="f-182"
      unitRef="shares">454592</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-23" decimals="0" id="f-183" unitRef="usd">45</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-22" decimals="0" id="f-184" unitRef="usd">452150</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-6" decimals="0" id="f-185" unitRef="usd">452195</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="0" id="f-186" unitRef="usd">-8762232</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-187" unitRef="usd">-8762232</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-25" decimals="0" id="f-188" unitRef="usd">-31151</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="0" id="f-189" unitRef="usd">-31151</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-190"
      unitRef="shares">86633588</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-191" unitRef="usd">8663</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-192" unitRef="usd">155555775</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-193" unitRef="usd">-404467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="0" id="f-194" unitRef="usd">-157879373</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-195" unitRef="usd">-2719402</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-196"
      unitRef="shares">83944119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="0" id="f-197" unitRef="usd">8394</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="0" id="f-198" unitRef="usd">149027802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="0" id="f-199" unitRef="usd">-154973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="0" id="f-200" unitRef="usd">-110126902</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-201" unitRef="usd">38754321</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="0" id="f-202" unitRef="usd">532409</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="0" id="f-203" unitRef="usd">532409</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="0" id="f-204" unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="0" id="f-205" unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="0" id="f-206" unitRef="usd">-9150</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-36" decimals="0" id="f-207" unitRef="usd">-9150</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-208"
      unitRef="shares">83944119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="0" id="f-209" unitRef="usd">8394</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="0" id="f-210" unitRef="usd">149560211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="0" id="f-211" unitRef="usd">-164123</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="0" id="f-212" unitRef="usd">-118525572</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="0" id="f-213" unitRef="usd">30878910</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-44" decimals="0" id="f-214" unitRef="usd">537521</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="0" id="f-215" unitRef="usd">537521</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="c-45"
      decimals="INF"
      id="f-216"
      unitRef="shares">751040</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-45" decimals="0" id="f-217" unitRef="usd">75</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-44" decimals="0" id="f-218" unitRef="usd">1218675</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-7" decimals="0" id="f-219" unitRef="usd">1218750</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-45"
      decimals="INF"
      id="f-220"
      unitRef="shares">125699</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-45" decimals="0" id="f-221" unitRef="usd">13</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="0" id="f-222" unitRef="usd">120136</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="0" id="f-223" unitRef="usd">120149</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="0" id="f-224" unitRef="usd">413998</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-225" unitRef="usd">413998</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-47" decimals="0" id="f-226" unitRef="usd">-135869</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="0" id="f-227" unitRef="usd">-135869</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-228"
      unitRef="shares">84820858</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="0" id="f-229" unitRef="usd">8482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="0" id="f-230" unitRef="usd">151436543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="0" id="f-231" unitRef="usd">-299992</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="0" id="f-232" unitRef="usd">-118111574</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="0" id="f-233" unitRef="usd">33033459</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-234" unitRef="usd">-16804733</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-235" unitRef="usd">-7984672</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-236" unitRef="usd">19123</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="0" id="f-237" unitRef="usd">10546</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-238" unitRef="usd">1274807</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="0" id="f-239" unitRef="usd">1069930</us-gaap:ShareBasedCompensation>
    <dare:NonCashLeaseExpense contextRef="c-1" decimals="0" id="f-240" unitRef="usd">-11811</dare:NonCashLeaseExpense>
    <dare:NonCashLeaseExpense contextRef="c-5" decimals="0" id="f-241" unitRef="usd">9940</dare:NonCashLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-242" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="0" id="f-243" unitRef="usd">10000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="0" id="f-244" unitRef="usd">-1130694</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-5" decimals="0" id="f-245" unitRef="usd">992334</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="0" id="f-246" unitRef="usd">1403634</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-5" decimals="0" id="f-247" unitRef="usd">3427756</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="0" id="f-248" unitRef="usd">272100</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-5" decimals="0" id="f-249" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="0" id="f-250" unitRef="usd">44934</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-5" decimals="0" id="f-251" unitRef="usd">-91690</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="0" id="f-252" unitRef="usd">4513162</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="0" id="f-253" unitRef="usd">-988855</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="0" id="f-254" unitRef="usd">-6700216</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-5" decimals="0" id="f-255" unitRef="usd">3211123</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <dare:IncreaseDecreaseInDeferredGrantFunding contextRef="c-1" decimals="0" id="f-256" unitRef="usd">4609482</dare:IncreaseDecreaseInDeferredGrantFunding>
    <dare:IncreaseDecreaseInDeferredGrantFunding contextRef="c-5" decimals="0" id="f-257" unitRef="usd">1791598</dare:IncreaseDecreaseInDeferredGrantFunding>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="0" id="f-258" unitRef="usd">205206</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-5" decimals="0" id="f-259" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-260" unitRef="usd">-22703918</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="0" id="f-261" unitRef="usd">-20791986</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-262" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="0" id="f-263" unitRef="usd">5369</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-264" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="0" id="f-265" unitRef="usd">-5369</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-1" decimals="0" id="f-266" unitRef="usd">452195</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-5" decimals="0" id="f-267" unitRef="usd">1218750</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-1" decimals="0" id="f-268" unitRef="usd">1299375</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-5" decimals="0" id="f-269" unitRef="usd">120149</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-270" unitRef="usd">1751570</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="0" id="f-271" unitRef="usd">1338899</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-272" unitRef="usd">-53156</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="0" id="f-273" unitRef="usd">-145019</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-274" unitRef="usd">-21005504</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="0" id="f-275" unitRef="usd">-19603475</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-276" unitRef="usd">34669605</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="0" id="f-277" unitRef="usd">51674087</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-278" unitRef="usd">13664101</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-52" decimals="0" id="f-279" unitRef="usd">32070612</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-280" unitRef="usd">13329101</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-52" decimals="0" id="f-281" unitRef="usd">32070612</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="0" id="f-282" unitRef="usd">335000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-52" decimals="0" id="f-283" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-284" unitRef="usd">13664101</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-52" decimals="0" id="f-285" unitRef="usd">32070612</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-286" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="0" id="f-287" unitRef="usd">1043590</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-288">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dar&#xe9; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#x2019;s health. Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries operate one segment. In this report, the &#x201c;Company&#x201d; refers collectively to Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, vaginal health, reproductive health, menopause, sexual health, and fertility, and aim to expand treatment options, enhance outcomes and improve ease of use for women.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's portfolio includes one FDA-approved product, drug and drug/device product candidates and potential product candidates in various stages of development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's product, XACIATO&#x2122; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp;amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. That agreement became effective in June 2022, and in July 2022, the Company received the $10.0&#160;million non-refundable and non-creditable payment due upon the effectiveness of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-289"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-53" decimals="-5" id="f-290" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-291">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, or the 2022 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers cash and all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has an aggregate of approximately $0.3 million in restricted cash related to (i) letters of credit established under real property leases for the Company's wholly owned subsidiary, Dare MB Inc., that serve as security for potential future default of lease payments, and (ii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or for usage for general obligations and are included in other non-current assets on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company had an accumulated deficit of approximately $157.9 million, cash and cash equivalents of approximately $13.3 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $13.7 million, and a working capital deficit of approximately $2.5 million. Substantially all of the Company's cash and cash equivalents at June&#160;30, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the six months ended June&#160;30, 2023, the Company incurred a net loss of approximately $16.8 million and had negative cash flow from operations of approximately $22.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2 to the consolidated financial statements included in the 2022 10-K. Since the date on which the 2022 10-K was filed with the U.S. Securities and Exchange Commission, or the SEC, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of June&#160;30, 2023 and December&#160;31, 2022. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of June&#160;30, 2023 or December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:216.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,238,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,238,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Represents cash held in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification Topic 606, or ASC 606, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products. As of June&#160;30, 2023, the Company has not recognized any collaboration revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fee Revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has recognized $10.0 million in license fee revenue, all of which represents the upfront payment due under its license agreement for XACIATO. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of June&#160;30, 2023, the Company has not recognized any royalty revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of product for commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. As of June&#160;30, 2023, the Company has not recognized any revenue associated with product supply arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. As of June&#160;30, 2023, the Company has not recognized any milestone revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bayer License. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million. The Company concluded that there was one significant performance obligation related to the $1.0&#160;million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $1.0 million payment is recorded as deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will also be entitled to receive (a) milestone payments totaling up to $310.0 million related to the commercial sales of Ovaprene, if all such milestones are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, Strategic Agreements.)&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, or the 2022 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-293">Cash, Cash Equivalents and Restricted CashThe Company considers cash and all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has an aggregate of approximately $0.3 million in restricted cash related to (i) letters of credit established under real property leases for the Company's wholly owned subsidiary, Dare MB Inc., that serve as security for potential future default of lease payments, and (ii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or for usage for general obligations and are included in other non-current assets on the Company's consolidated balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-3" decimals="-5" id="f-294" unitRef="usd">300000</us-gaap:LettersOfCreditOutstandingAmount>
    <dare:GoingConcernPolicyTextBlock contextRef="c-1" id="f-295">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company had an accumulated deficit of approximately $157.9 million, cash and cash equivalents of approximately $13.3 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $13.7 million, and a working capital deficit of approximately $2.5 million. Substantially all of the Company's cash and cash equivalents at June&#160;30, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the six months ended June&#160;30, 2023, the Company incurred a net loss of approximately $16.8 million and had negative cash flow from operations of approximately $22.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2 to the consolidated financial statements included in the 2022 10-K. Since the date on which the 2022 10-K was filed with the U.S. Securities and Exchange Commission, or the SEC, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;</dare:GoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-296" unitRef="usd">-157900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-297" unitRef="usd">13300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dare:DeferredGrantFundingCurrent contextRef="c-3" decimals="-5" id="f-298" unitRef="usd">13700000</dare:DeferredGrantFundingCurrent>
    <dare:WorkingCapitalIncreaseDeficit contextRef="c-3" decimals="-5" id="f-299" unitRef="usd">-2500000</dare:WorkingCapitalIncreaseDeficit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-300" unitRef="usd">-16800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c-1" decimals="-5" id="f-301" unitRef="usd">-22700000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <dare:PeriodofInsufficientCashandLiquidityRequirements contextRef="c-1" id="f-302">P12M</dare:PeriodofInsufficientCashandLiquidityRequirements>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of June&#160;30, 2023 and December&#160;31, 2022. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of June&#160;30, 2023 or December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:216.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:7.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,238,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,238,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Represents cash held in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="0" id="f-305" unitRef="usd">10837944</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="0" id="f-306" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="0" id="f-307" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="0" id="f-308" unitRef="usd">10837944</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="0" id="f-309" unitRef="usd">33238658</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="0" id="f-310" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="0" id="f-311" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="0" id="f-312" unitRef="usd">33238658</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-313">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification Topic 606, or ASC 606, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products. As of June&#160;30, 2023, the Company has not recognized any collaboration revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fee Revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has recognized $10.0 million in license fee revenue, all of which represents the upfront payment due under its license agreement for XACIATO. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of June&#160;30, 2023, the Company has not recognized any royalty revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of product for commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. As of June&#160;30, 2023, the Company has not recognized any revenue associated with product supply arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. As of June&#160;30, 2023, the Company has not recognized any milestone revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-62" decimals="-5" id="f-314" unitRef="usd">10000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-315" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-316" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-317" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-318" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-319" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-320" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-321" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:MilestonePaymentsContingentAmount contextRef="c-63" decimals="-5" id="f-322" unitRef="usd">310000000</dare:MilestonePaymentsContingentAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-323">STRATEGIC AGREEMENTS&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Agreements for Product Commercialization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organon Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into an exclusive license agreement with Organon, which became effective in June 2022, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. In July 2022, the Company received a $10.0 million non-refundable and non-creditable payment from Organon, which was recorded as license fee revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement in effect as of June 30, 2023, the Company is entitled to receive tiered double-digit royalties based on net sales and up to $182.5 million in milestone payments as follows: $2.5 million following the first commercial sale of a licensed product in the United States; and up to $180.0 million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. Subsequent to June 30, 2023, the Company and Organon entered into an amendment to the license agreement, which changed some of the payment terms. (See Note 10, Subsequent Events.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the agreement, the Company concluded that the transaction price was $10.0 million and should not include the variable consideration related to unachieved development, regulatory, commercial milestones and future sales-based royalty payments. This consideration was determined to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal in cumulative revenue. The Company re-evaluates the transaction price at each reporting period as uncertain events are resolved and other changes in circumstances occur. For the quarter ended June&#160;30, 2023, no adjustments were made to the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize any consideration related to sales-based payments, including milestones and royalties which relate predominantly to the license granted, at the later of (i) when or as the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer HealthCare License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $1.0 million upfront non-refundable license fee payment from Bayer and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million, referred to as the $20.0 million fee. After payment of the $20.0 million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S. Such license would be exclusive as to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of either the point in time the Company receives the $20.0 million fee, the license is transferred to Bayer and Bayer is able to use and benefit from the license or the termination of the agreement. As of June&#160;30, 2023, neither of the foregoing had occurred. The $1.0 million payment is recorded as long-term deferred license revenue in the Company's consolidated balance sheets at June&#160;30, 2023  and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S. or 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $20.0 million fee if and when due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Strategic Agreements for Pipeline Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hennepin License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into a license agreement with Hennepin Life Sciences LLC, or Hennepin, under which the Company acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of health conditions including bacterial, fungal, and viral infections. Under the agreement, the Company received an exclusive, worldwide, royalty-bearing license to research, develop and commercialize the licensed technology. The Company is entitled to sublicense the rights granted to it under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, the Company agreed to make potential future payments and sales milestone payments of up to $6.25 million in the aggregate upon achieving certain development and regulatory milestones, and of up to $45.0 million in the aggregate upon achieving certain commercial sales milestones for each product covered by the licenses granted under the agreement, which may be paid, in the Company&#x2019;s sole discretion, in cash or shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Hennepin is eligible to receive tiered royalties in low single-digit to low double-digit percentages based on worldwide net sales of products and processes covered by the licenses granted under the agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, no payments have been made under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MBI Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company acquired Dare MB Inc., or MBI, to secure the rights to develop a long-acting reversible contraception method, that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the merger agreement, the Company agreed to pay former MBI stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property the Company acquired in the merger; and (c) tiered royalty payments ranging from low single-digit to low double-digit percentages based on annual net sales of such products sold by the Company (but not by sublicensee) and a percentage of sublicense revenue related to such products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, a total of $1.25 million of the contingent consideration became payable upon the achievement of certain of the funding and product development milestone events. In accordance with the terms of the merger agreement, the Company&#x2019;s board of directors elected to pay a portion of these milestone payments in shares of the Company&#x2019;s common stock, and in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 in cash to the stockholders&#x2019; representative in satisfaction of the $1.25 million in milestone payments associated with milestones achieved in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;TriLogic and MilanaPharm License Agreement / Hammock Assignment Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into an assignment agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and a first amendment to license agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. In December 2019, the Company entered into amendments to each of the Assignment Agreement and License Amendment. In September 2021, the Company entered into a second amendment to the License Agreement. In March 2022, the Company entered into a Consent, Waiver and Stand-By License Agreement with TriLogic, MilanaPharm and Organon, which further amended the License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the License Agreement, the Company paid clinical and regulatory development milestones in the aggregate of $300,000 to MilanaPharm, the final payment of $250,000 was expensed in 2021. The Company may also pay MilanaPharm up to $500,000 upon the first commercial sale in the United States of the first licensed product for each vaginal and urological use, and up to $250,000 upon the first commercial sale in the United States of each successive licensed products for each vaginal or urological use. In addition, upon achievement of $50.0 million in cumulative worldwide net sales of licensed products the Company must pay MilanaPharm $1.0 million. MilanaPharm is also eligible to receive (a) a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions, and (b) high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm license agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan. Hammock is eligible to receive up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $850,000 of which has been paid as of June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pear Tree Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company acquired Pear Tree Pharmaceuticals, Inc., or Pear Tree, to secure exclusive, sublicensable, worldwide rights under certain patents and know-how to develop and commercialize a proprietary formulation of tamoxifen for vaginal administration. This acquisition led to the Company's DARE-VVA1 program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the merger agreement, the Company agreed to pay the former stockholders of Pear Tree: (a) up to $15.5 million in the aggregate upon achieving certain clinical development and regulatory milestones by licensed products, and (b) up to $47.0 million in the aggregate upon achieving certain commercial milestones by licensed products. Additionally, the former stockholders of Pear Tree are eligible to receive tiered royalties based on single-digit to low double-digit percentages of annual net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, and a portion of royalties the Company receives from sublicensees. Both the milestone and royalty payments may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the merger agreement. Under the merger agreement, in addition to customary royalty reductions and offsets, royalty payments and payments based on income received from sublicensees of licensed products made by the Company to Pear Tree's licensors are creditable against all royalty and sublicense revenue share payments payable to the former stockholders of Pear Tree.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company agreed to pay licensors of Pear Tree (a) up to approximately $3.2 million in the aggregate upon achieving certain clinical development, regulatory and commercial milestones by each licensed product, and (b) semi-annual royalties based on a single-digit percentage of net sales of licensed products by the Company or its affiliates, subject to customary reductions and offsets, or a portion of any royalties the Company or its affiliates receives from sublicensees, and a low double-digit percentage of all sublicensing fees or other lump sum payments or compensation the Company receives from sublicensees, subject to customary exclusions. The milestone payments to the licensors of Pear Tree may be made, in the Company's sole discretion, in cash or in shares of its common stock in accordance with the terms of the license agreements. Portions of certain milestone payments made to Pear Tree's licensors may be creditable against royalty payments due to Pear Tree's licensors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Catalent JNP License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc., or Catalent, under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, the Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement and will pay a $100,000 annual license maintenance fee on each anniversary of the date of the agreement. The annual maintenance fee will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. Catalent is eligible to receive up to (a) $13.5 million in the aggregate in payments based on the achievement of specified development and regulatory milestones, $1.0&#160;million of which has been paid as of June&#160;30, 2023; and (b) up to $30.3 million in the aggregate in payments based on the achievement of specified commercial sales milestones for each product or process covered by the licenses granted under the agreement. Additionally, Catalent is eligible to receive mid single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adare Development and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals USA, Inc., or Adare, for the development and potential exclusive worldwide license of injectable formulations of etonogestrel for contraceptive protection over 6-month and 12-month periods (which the Company refers to as DARE-204 and DARE-214, respectively). The agreement, as amended, provides the Company with an option to negotiate an exclusive, worldwide, royalty-bearing license, with rights to sublicense, for the programs if the Company funds the conduct of specified development work. The Company has no obligation to exercise its option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SST License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;amp;&#160;Technologies-D&#160;LLC and Strategic Science &amp;amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder and/or female sexual interest/arousal disorder, or the Field of Use, SST&#x2019;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SST will be eligible to receive payments of up to $18.0 million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and up to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST. Additionally, SST is eligible to receive tiered royalties based on percentages of annual net sales of licensed products in the single-digit to mid double-digits subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ADVA-Tec License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, the Company will pay ADVA-Tec (a) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones, $1.2&#160;million of which has been paid; and (b) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, ADVA-Tec is eligible to receive royalties based on aggregate annual net sales of Ovaprene in specified regions at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds, subject to customary reductions and offsets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company sublicenses its rights under the agreement, in lieu of royalty payments to ADVA-Tec, ADVA-Tec is eligible to receive a double-digit percentage of sublicense revenue received by the Company during the royalty term; provided, however, that for sublicense revenue the Company receives prior to the first commercial sale of a licensed product that represents an upfront payment or license fee due on or around the effective date of the sublicense, ADVA-Tec is eligible to receive a single-digit percentage of that sublicense revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-64" decimals="-5" id="f-324" unitRef="usd">10000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:MilestonePaymentsContingentAmount contextRef="c-62" decimals="-5" id="f-325" unitRef="usd">182500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount contextRef="c-62" decimals="-5" id="f-326" unitRef="usd">2500000</dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount>
    <dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount contextRef="c-65" decimals="-5" id="f-327" unitRef="usd">180000000</dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-64" decimals="-5" id="f-328" unitRef="usd">10000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-329" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-330" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-331" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-332" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-333" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-334" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-335" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-336" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-63" decimals="-5" id="f-337" unitRef="usd">1000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:MilestonePaymentsContingentAmount contextRef="c-63" decimals="-5" id="f-338" unitRef="usd">310000000</dare:MilestonePaymentsContingentAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-5" id="f-339" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:MaximumPotentialMilestonePayments contextRef="c-66" decimals="-4" id="f-340" unitRef="usd">6250000</dare:MaximumPotentialMilestonePayments>
    <dare:MaximumPotentialMilestonePayments contextRef="c-67" decimals="-5" id="f-341" unitRef="usd">45000000</dare:MaximumPotentialMilestonePayments>
    <dare:ResearchAndDevelopmentMilestonePayment contextRef="c-68" decimals="-5" id="f-342" unitRef="usd">46500000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:AssetAcquisitionContingentConsiderationCurrent contextRef="c-69" decimals="-5" id="f-343" unitRef="usd">55000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:PaymentOfAdditionalConsiderationInBusinessCombination contextRef="c-70" decimals="-4" id="f-344" unitRef="usd">1250000</dare:PaymentOfAdditionalConsiderationInBusinessCombination>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-71" decimals="-3" id="f-345" unitRef="shares">700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <dare:PaymentsToStockholdersRepresentativeInBusinessCombination contextRef="c-71" decimals="-3" id="f-346" unitRef="usd">75000</dare:PaymentsToStockholdersRepresentativeInBusinessCombination>
    <dare:PaymentOfAdditionalConsiderationInBusinessCombination contextRef="c-70" decimals="-4" id="f-347" unitRef="usd">1250000</dare:PaymentOfAdditionalConsiderationInBusinessCombination>
    <dare:MilestonePaymentsContingentAmount contextRef="c-72" decimals="-3" id="f-348" unitRef="usd">300000</dare:MilestonePaymentsContingentAmount>
    <dare:AssetAcquisitionContingentConsideration contextRef="c-73" decimals="-3" id="f-349" unitRef="usd">250000</dare:AssetAcquisitionContingentConsideration>
    <dare:AssetAcquisitionContingentConsideration contextRef="c-74" decimals="-3" id="f-350" unitRef="usd">500000</dare:AssetAcquisitionContingentConsideration>
    <dare:MilestonePaymentsContingentAmount contextRef="c-75" decimals="-3" id="f-351" unitRef="usd">250000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount contextRef="c-76" decimals="-5" id="f-352" unitRef="usd">50000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount contextRef="c-77" decimals="-5" id="f-353" unitRef="usd">1000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount contextRef="c-78" decimals="-5" id="f-354" unitRef="usd">1100000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount contextRef="c-79" decimals="-3" id="f-355" unitRef="usd">850000</dare:MilestonePaymentsContingentAmount>
    <dare:MaximumPotentialMilestonePayments contextRef="c-80" decimals="-5" id="f-356" unitRef="usd">15500000</dare:MaximumPotentialMilestonePayments>
    <dare:MaximumPotentialMilestonePayments contextRef="c-81" decimals="-5" id="f-357" unitRef="usd">47000000</dare:MaximumPotentialMilestonePayments>
    <dare:ResearchAndDevelopmentMilestonePayment contextRef="c-82" decimals="-5" id="f-358" unitRef="usd">3200000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:UpfrontLicenseFeeAmountPaid contextRef="c-83" decimals="-3" id="f-359" unitRef="usd">250000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter contextRef="c-83" decimals="-3" id="f-360" unitRef="usd">100000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter>
    <dare:MaximumPotentialMilestonePayments contextRef="c-84" decimals="-5" id="f-361" unitRef="usd">13500000</dare:MaximumPotentialMilestonePayments>
    <dare:MilestonePaymentsContingentAmount contextRef="c-85" decimals="-5" id="f-362" unitRef="usd">1000000</dare:MilestonePaymentsContingentAmount>
    <dare:MaximumPotentialMilestonePayments contextRef="c-86" decimals="-5" id="f-363" unitRef="usd">30300000</dare:MaximumPotentialMilestonePayments>
    <dare:MilestonePaymentsContingentAmount contextRef="c-87" decimals="-5" id="f-364" unitRef="usd">18000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount contextRef="c-88" decimals="-5" id="f-365" unitRef="usd">100000000</dare:MilestonePaymentsContingentAmount>
    <dare:ResearchAndDevelopmentMilestonePayment contextRef="c-89" decimals="-5" id="f-366" unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:MilestonePaymentsContingentAmount contextRef="c-90" decimals="-5" id="f-367" unitRef="usd">1200000</dare:MilestonePaymentsContingentAmount>
    <dare:ResearchAndDevelopmentMilestonePayment contextRef="c-91" decimals="-5" id="f-368" unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:PercentageOfRoyaltyRate
      contextRef="c-92"
      decimals="INF"
      id="f-369"
      unitRef="number">0.01</dare:PercentageOfRoyaltyRate>
    <dare:PercentageOfRoyaltyRate
      contextRef="c-93"
      decimals="INF"
      id="f-370"
      unitRef="number">0.10</dare:PercentageOfRoyaltyRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-371">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Increase in Authorized Shares of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, following the approval of the Company's stockholders at its annual meeting of stockholders, the Company amended its restated certificate of incorporation to increase the Company's authorized shares of common stock to 240,000,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;March 2023 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company entered into a sales agreement with Stifel, Nicolaus &amp;amp; Company, Incorporated, or Stifel, and Cantor Fitzgerald &amp;amp; Co., or Cantor, to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which Stifel and Cantor act as the Company's agent. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement or such lower amount as the Company and Stifel and Cantor agree, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862), the base prospectus included therein, originally filed with the SEC on March 30, 2021 and declared effective by the SEC on April 7, 2021, the prospectus supplement dated March 31, 2023 relating to the offering of up to $50.0&#160;million of shares of the Company's common stock under the sales agreement, and any subsequent prospectus supplement related to the offering of shares of the Company's common stock under the sales agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2023, the Company sold 454,592 shares of common stock under this agreement and received aggregate gross proceeds of approximately $463,000 and incurred sales agent commissions and fees of approximately $11,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2021 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into a sales agreement with SVB Securities LLC (formerly known as SVB Leerink LLC) to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold no shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2021 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into a sales agreement with SVB Securities LLC to sell shares of its common stock from time to time through an ATM equity offering program under which SVB Securities acted as the Company's agent. The Company sold no shares of its common stock under the agreement during either of the six months ended June&#160;30, 2023 or 2022. The Company terminated the agreement in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with an underwritten public offering in February 2018, the Company issued to the investors in that offering, warrants exercisable through February 2023 with an initial exercise price of $3.00 per share.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which was recorded in equity as of the grant date. The warrants included a price-based anti-dilution provision, which provided that, subject to certain limited exceptions, the exercise price of the warrants would be reduced each time the Company issued or sold (or was deemed to have issued or sold) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issued, sold or entered into any agreement to issue or sell securities at a price which varied or may vary with the market price of the shares of the Company&#x2019;s common stock, the warrant holders had the right to substitute such variable price for the exercise price of the warrant then in effect. In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively. During the six months ended June&#160;30, 2023, warrants to purchase 1,353,515 shares of common stock were exercised for gross proceeds of approximately $1.3 million and the remaining unexercised warrants expired on February 15, 2023. No warrants were exercised during the six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company had the following warrants outstanding:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:169.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:19.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:18.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:118.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:18.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:157.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;04/04/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-94"
      decimals="INF"
      id="f-372"
      unitRef="shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <dare:PercentageOfAggregateCommission
      contextRef="c-95"
      decimals="INF"
      id="f-373"
      unitRef="number">0.03</dare:PercentageOfAggregateCommission>
    <dare:SaleOfStockProspectusOfferingAmount contextRef="c-96" decimals="-5" id="f-374" unitRef="usd">50000000</dare:SaleOfStockProspectusOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-375"
      unitRef="shares">454592</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-97" decimals="-3" id="f-376" unitRef="usd">463000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <dare:SaleOfStockBrokerageCommissionsExpense contextRef="c-97" decimals="-3" id="f-377" unitRef="usd">11000</dare:SaleOfStockBrokerageCommissionsExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-98"
      decimals="INF"
      id="f-378"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-99"
      decimals="INF"
      id="f-379"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-100"
      decimals="INF"
      id="f-380"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-381"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-102"
      decimals="2"
      id="f-382"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:EstimatedFairValueOfWarrantsRecordedInEquity contextRef="c-103" decimals="-5" id="f-383" unitRef="usd">3000000</dare:EstimatedFairValueOfWarrantsRecordedInEquity>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c-104"
      decimals="2"
      id="f-384"
      unitRef="usdPerShare">0.98</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c-105"
      decimals="2"
      id="f-385"
      unitRef="usdPerShare">0.96</us-gaap:WarrantExercisePriceDecrease>
    <dare:NumberOfCommonStockWarrantsExercised contextRef="c-1" decimals="INF" id="f-386" unitRef="shares">1353515</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-5" id="f-387" unitRef="usd">1300000</us-gaap:ProceedsFromWarrantExercises>
    <dare:NumberOfCommonStockWarrantsExercised contextRef="c-5" decimals="INF" id="f-388" unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-389">As of June&#160;30, 2023, the Company had the following warrants outstanding:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:169.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:19.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:18.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:118.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:18.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:157.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;04/04/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-106"
      decimals="INF"
      id="f-390"
      unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-106"
      decimals="INF"
      id="f-391"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="c-107" id="f-392">2026-04-04</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-3" decimals="INF" id="f-393" unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-394">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was no stock-based compensation related to the ESPP for the six months ended June&#160;30, 2023 or June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, provided for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increased annually on the first day of each fiscal year by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#x2019;s board of directors. On January 1, 2022, the number of authorized shares increased by 2,000,000 to 2,201,855. As a result of the approval of the 2022 Plan (as defined below) by the Company's stockholders on June 23, 2022, no further awards have been or will be granted under the Amended 2014 Plan. Outstanding awards previously granted under the Amended 2014 Plan continue to remain outstanding in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the Company's board of directors approved the Dar&#xe9; Bioscience, Inc. 2022 Stock Incentive Plan, or the 2022 Plan, which was subsequently approved by the Company's stockholders on June 23, 2022, and became effective as of that date. The 2022 Plan provides for the grant of stock-based incentive awards to employees, consultants, advisors, and directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock authorized for issuance under the 2022 Plan is (a) 10,117,305; plus (b) up to 6,144,682 shares subject to awards granted under the Amended 2014 Plan or the 2007 Stock Incentive Plan that expire, terminate or are otherwise forfeited on or after June 23, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Company's stock incentive plans and related information for the six months ended June&#160;30, 2023. The exercise price of all options granted during the six months ended June&#160;30, 2023 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of June&#160;30, 2023, unamortized stock-based compensation expense of approximately $5.6&#160;million will be amortized over a weighted average period of 2.47 years. The number of shares of common stock available for future awards granted under the 2022 Plan at June&#160;30, 2023 was 6,718,916. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:376.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,612,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,769,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:235.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="INF" id="f-395" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="INF" id="f-396" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-110"
      decimals="INF"
      id="f-397"
      unitRef="shares">2046885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-110"
      decimals="INF"
      id="f-398"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-111" decimals="2" id="f-399" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
      contextRef="c-112"
      decimals="INF"
      id="f-400"
      unitRef="shares">2000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-113"
      decimals="INF"
      id="f-401"
      unitRef="shares">2201855</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-114"
      decimals="INF"
      id="f-402"
      unitRef="shares">10117305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-403"
      unitRef="shares">6144682</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Company's stock incentive plans and related information for the six months ended June&#160;30, 2023. The exercise price of all options granted during the six months ended June&#160;30, 2023 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of June&#160;30, 2023, unamortized stock-based compensation expense of approximately $5.6&#160;million will be amortized over a weighted average period of 2.47 years. The number of shares of common stock available for future awards granted under the 2022 Plan at June&#160;30, 2023 was 6,718,916. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:376.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,612,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,769,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="c-3" decimals="-5" id="f-405" unitRef="usd">5600000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <dare:WeightedAverageAmortizationPeriod contextRef="c-1" id="f-406">P2Y5M19D</dare:WeightedAverageAmortizationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="INF"
      id="f-407"
      unitRef="shares">6718916</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-116"
      decimals="INF"
      id="f-408"
      unitRef="shares">6612554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-116"
      decimals="2"
      id="f-409"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-117"
      decimals="INF"
      id="f-410"
      unitRef="shares">2857665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-117"
      decimals="2"
      id="f-411"
      unitRef="usdPerShare">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-117"
      decimals="INF"
      id="f-412"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-117"
      id="f-413"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-414"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-117"
      id="f-415"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-416"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-117"
      id="f-417"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-115"
      decimals="INF"
      id="f-418"
      unitRef="shares">9470219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-115"
      decimals="2"
      id="f-419"
      unitRef="usdPerShare">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-115"
      decimals="INF"
      id="f-420"
      unitRef="shares">4769873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-115"
      decimals="2"
      id="f-421"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:235.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="0" id="f-423" unitRef="usd">210198</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="0" id="f-424" unitRef="usd">171938</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="0" id="f-425" unitRef="usd">410499</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="0" id="f-426" unitRef="usd">346552</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="0" id="f-427" unitRef="usd">439988</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="0" id="f-428" unitRef="usd">365583</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="0" id="f-429" unitRef="usd">864308</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="0" id="f-430" unitRef="usd">723378</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="0" id="f-431" unitRef="usd">650186</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="0" id="f-432" unitRef="usd">537521</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="0" id="f-433" unitRef="usd">1274807</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="0" id="f-434" unitRef="usd">1069930</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-435">LEASED PROPERTIES&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for two years such that the term now expires on August 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts. The lease for that space commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for three years to December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The extension of the lease in February 2022 resulted in an increase in operating lease liabilities and ROU assets of approximately $1.0&#160;million. In September 2022, the landlord exercised its option to terminate the lease, resulting in the new lease term ending on December 31, 2023. The termination of the lease resulted in a reduction of operating lease liabilities and ROU assets of approximately $504,000 and $458,000, respectively, and a $46,000 gain on the modification of the lease which was included as a reduction to research and development expense for the year ended December 31, 2022. MBI entered into a new lease for general office space in June 2023 that will commence on December 1, 2023 and will create an obligation to pay approximately $1.4&#160;million over the lease period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MBI previously leased warehouse space in Billerica, Massachusetts, under a lease that commenced on October 1, 2016 and terminated on March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate consisting of the current prime rate plus 200 basis points for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2023, the Company reported operating lease &lt;span style="-sec-ix-hidden:f-446"&gt;ROU assets&lt;/span&gt; of approximately $276,000 in other non-current assets, approximately $272,000 in current portion of lease liabilities, and approximately $23,000 in lease liabilities long-term in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease costs were approximately $145,000 and $284,000 for the three and six months ended&#160;June&#160;30, 2023, respectively, and $150,000 and $340,000 for the three and six months ended  June&#160;30, 2022, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities was approximately $105,000 and $209,000 for the three and six months ended&#160;June&#160;30, 2023, respectively, and $80,000 and  $203,000 for the three and six months ended June&#160;30, 2022, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. At June&#160;30, 2023, operating leases had a weighted average remaining lease term of 0.83 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, future minimum lease payments under the Company's operating leases are as follows (does not include any minimum lease payments under the lease MBI entered in June 2023 because the lease does not commence until December 1, 2023):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:445.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:NetRentableArea contextRef="c-130" decimals="0" id="f-436" unitRef="sqft">3169</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-131" id="f-437">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-132" id="f-438">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-133" decimals="-5" id="f-439" unitRef="usd">1000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-134" decimals="-3" id="f-440" unitRef="usd">-504000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <dare:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-134" decimals="-3" id="f-441" unitRef="usd">-458000</dare:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c-134" decimals="-3" id="f-442" unitRef="usd">46000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-135" decimals="-5" id="f-443" unitRef="usd">1400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-135" id="f-444">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dare:OperatingLeaseIncrementalBorrowingRatePrimeRate contextRef="c-136" decimals="4" id="f-445" unitRef="number">0.0200</dare:OperatingLeaseIncrementalBorrowingRatePrimeRate>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-447" unitRef="usd">276000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-448" unitRef="usd">272000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-449" unitRef="usd">23000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-450" unitRef="usd">145000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-451" unitRef="usd">284000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-3" id="f-452" unitRef="usd">150000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-453" unitRef="usd">340000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-454" unitRef="usd">105000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">209000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-456" unitRef="usd">80000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-457" unitRef="usd">203000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-458">P0Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-459">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, future minimum lease payments under the Company's operating leases are as follows (does not include any minimum lease payments under the lease MBI entered in June 2023 because the lease does not commence until December 1, 2023):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:445.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:63.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="0" id="f-460" unitRef="usd">213000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="0" id="f-461" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="0" id="f-462" unitRef="usd">306000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="0" id="f-463" unitRef="usd">10000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="0" id="f-464" unitRef="usd">296000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-465">COMMITMENTS AND CONTINGENCIESCRADA with NICHD for the Pivotal Phase 3 Study of OvapreneIn July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#x2019;s Contraceptive Clinical Trial Network with NICHD's contract research organization providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD is responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $5.0&#160;million to NICHD, $3.5&#160;million of which was paid in 2022. The Company's remaining obligation under the CRADA at June&#160;30, 2023 was $0.5&#160;million.</us-gaap:CommitmentsDisclosureTextBlock>
    <dare:ResearchAndDevelopmentAgreementCommitmentAmount contextRef="c-137" decimals="-5" id="f-466" unitRef="usd">5500000</dare:ResearchAndDevelopmentAgreementCommitmentAmount>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-138" decimals="-5" id="f-467" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-139" decimals="-5" id="f-468" unitRef="usd">3500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-140" decimals="-5" id="f-469" unitRef="usd">500000</us-gaap:RevenueRemainingPerformanceObligation>
    <dare:GrantAwardTextBlock contextRef="c-1" id="f-470">GRANT AWARDS&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NICHD Non-Dilutive Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of DARE-PTB1, DARE-LARC1 and DARE-204/214. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DARE-PTB1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $300,000 was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $2.0&#160;million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense for costs related to the NICHD award of $721 during the three and six months ended June&#160;30, 2023, and $2,500 and $19,500 during the three and six months ended June&#160;30, 2022, respectively. At June&#160;30, 2023 the Company recorded a receivable for expenses incurred through such date that it believes are reimbursable under the grant of $721. No receivable was recorded at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DARE-LARC1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $300,000 was to be used to explore device insertion and removal in nonclinical studies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense of approximately $0 and $32,000 for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, and $27,800 and $193,000 for the three and six months ended June&#160;30, 2022, respectively. The Company recorded a receivable of approximately $33,000 at December&#160;31, 2022 for expenses incurred through such date that were subsequently reimbursed under the grant. No receivable was recorded at June&#160;30, 2023. The Company received aggregate reimbursements under the NICHD award of approximately $278,000 during the grant period, which ended in June 2023. No further funds are available under this award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DARE-204 and DARE-214&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company received a notice of award of a grant from NICHD of approximately $249,000 to support end-user research to better understand women's preferences for a long-acting injectable contraceptive method. The findings from the research will inform the Company's target product profile and guide its development priorities for DARE-204 and DARE-214. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense of approximately $32,700 and $81,500 for costs related to the NICHD award during the three and six months ended June&#160;30, 2023, respectively, with no such credits recorded in the same periods of the prior year. The Company recorded a receivable of approximately $33,040 and $24,000 at June&#160;30, 2023 and December&#160;31, 2022, respectively, for expenses incurred through such date that it believes is eligible for reimbursement under the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Non-Dilutive Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022 DARE-LBT Grant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company entered into an agreement with the Bill &amp;amp; Melinda Gates Foundation, or the Foundation, under which the Company was awarded $585,000 to support the development of DARE-LBT. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LBT, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the full amount of the award in November 2022. As of June&#160;30, 2023, the Company has recorded a deferred grant funding liability of approximately $544,000 in the Company's condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 DARE-LARC1 Grant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into an agreement with the Foundation under which the Company was awarded up to $49.0&#160;million to support the development of DARE-LARC1. The Company is required to apply the funds it receives under the agreement solely toward direct costs for the development of DARE-LARC1, other than approximately 10% of such funds, which it may apply toward general overhead and administration expenses that support the entire operations of the Company. The agreement supports technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in nonclinical proof of principle studies. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Foundation. Any unspent funds and any funds spent that have not yet been depreciated or expensed are recorded as a deferred grant funding liability in the Company's condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;The Company received an initial payment of approximately $11.5 million in 2021, and aggregate payments of approximately $12.4 million in 2022. As of June&#160;30, 2023, the Company has received a cumulative total of approximately $23.9 million in non-dilutive funding under the agreement and recorded a deferred grant funding liability of approximately $13.1 million in the Company's condensed consolidated balance sheets. Additional payments are contingent upon the DARE-LARC1 program&#x2019;s achievement of specified development and reporting milestones.</dare:GrantAwardTextBlock>
    <dare:ProceedsFromAwardOfGrant contextRef="c-141" decimals="-3" id="f-471" unitRef="usd">300000</dare:ProceedsFromAwardOfGrant>
    <dare:AdditionalPotentialFundingRelatedToGrantAward contextRef="c-142" decimals="-5" id="f-472" unitRef="usd">2000000</dare:AdditionalPotentialFundingRelatedToGrantAward>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-143" decimals="0" id="f-473" unitRef="usd">721</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-144" decimals="0" id="f-474" unitRef="usd">721</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-145" decimals="-2" id="f-475" unitRef="usd">2500</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-146" decimals="-2" id="f-476" unitRef="usd">19500</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-147" decimals="0" id="f-477" unitRef="usd">721</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-148" decimals="INF" id="f-478" unitRef="usd">0</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ProceedsFromAwardOfGrant contextRef="c-149" decimals="-3" id="f-479" unitRef="usd">300000</dare:ProceedsFromAwardOfGrant>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-150" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-151" decimals="-3" id="f-481" unitRef="usd">32000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-152" decimals="-2" id="f-482" unitRef="usd">27800</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-153" decimals="-3" id="f-483" unitRef="usd">193000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-154" decimals="-3" id="f-484" unitRef="usd">33000</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-155" decimals="INF" id="f-485" unitRef="usd">0</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ProceedsFromAwardOfGrant contextRef="c-156" decimals="-3" id="f-486" unitRef="usd">278000</dare:ProceedsFromAwardOfGrant>
    <dare:ProceedsFromAwardOfGrant contextRef="c-157" decimals="-3" id="f-487" unitRef="usd">249000</dare:ProceedsFromAwardOfGrant>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-158" decimals="-2" id="f-488" unitRef="usd">32700</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="c-159" decimals="-2" id="f-489" unitRef="usd">81500</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-160" decimals="-1" id="f-490" unitRef="usd">33040</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ReceivableForExpensesEligibleForReimbursement contextRef="c-161" decimals="-3" id="f-491" unitRef="usd">24000</dare:ReceivableForExpensesEligibleForReimbursement>
    <us-gaap:GrantsReceivable contextRef="c-162" decimals="-3" id="f-492" unitRef="usd">585000</us-gaap:GrantsReceivable>
    <dare:DeferredGrantFundingCurrent contextRef="c-163" decimals="-3" id="f-493" unitRef="usd">544000</dare:DeferredGrantFundingCurrent>
    <us-gaap:GrantsReceivable contextRef="c-164" decimals="-5" id="f-494" unitRef="usd">49000000</us-gaap:GrantsReceivable>
    <dare:ProceedsFromAwardOfGrant contextRef="c-165" decimals="-5" id="f-495" unitRef="usd">11500000</dare:ProceedsFromAwardOfGrant>
    <dare:ProceedsFromAwardOfGrant contextRef="c-166" decimals="-5" id="f-496" unitRef="usd">12400000</dare:ProceedsFromAwardOfGrant>
    <dare:ProceedsFromAwardOfGrant contextRef="c-151" decimals="-5" id="f-497" unitRef="usd">23900000</dare:ProceedsFromAwardOfGrant>
    <dare:DeferredGrantFundingCurrent contextRef="c-155" decimals="-5" id="f-498" unitRef="usd">13100000</dare:DeferredGrantFundingCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-499">NET LOSS PER SHARE&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share, or EPS, using the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted EPS is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Dilutive securities include the dilutive effect of in-the-money options and warrants, which is calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an option or warrant, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option or warrant is exercised are assumed to be used to repurchase shares in the current period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities are excluded from the diluted EPS calculation if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:541.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:251.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,053,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,476,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,111,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,476,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,798,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted EPS for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:541.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:251.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,053,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,476,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,111,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,476,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,798,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-167" decimals="0" id="f-501" unitRef="shares">9470219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-168" decimals="0" id="f-502" unitRef="shares">6053156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-169" decimals="0" id="f-503" unitRef="shares">9470219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-170" decimals="0" id="f-504" unitRef="shares">6417533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-171" decimals="0" id="f-505" unitRef="shares">6500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-172" decimals="0" id="f-506" unitRef="shares">1058733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-173" decimals="0" id="f-507" unitRef="shares">6500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-174" decimals="0" id="f-508" unitRef="shares">1381015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-509" unitRef="shares">9476719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-510" unitRef="shares">7111889</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-511" unitRef="shares">9476719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-512" unitRef="shares">7798548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-513">SUBSEQUENT EVENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During July and August 2023, the Company sold an aggregate of 1,151,578 shares of common stock under its ATM equity offering program and received aggregate gross proceeds of approximately $946,000 and incurred sales agent commissions and fees of approximately $22,000 (See Note 4, Stockholders' Equity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NICHD Non-Dilutive Grant Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 28, 2023, the Company received a notice of award of a grant from NICHD of approximately $385,000 to support preclinical development of a potential new therapeutic for the prevention of idiopathic preterm birth. The grant funds will support activities related to the conduct and completion of proof-of-concept target validation studies in collaboration with the University of South Florida, or USF, which are to occur over a 12-month period. The Company will track expenses eligible for reimbursement under the grant award and submit a detailed accounting of such expenses to receive payment of the grant funds. The amounts of any such payments will be recognized in the Company's statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the project period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 18, 2023, the Company obtained financing for certain director and officer and other liability insurance premiums. The agreement for such financing assigns to the lender a first priority lien on and a security interest in the financed insurance policies and any additional premium required in the financed insurance policies including (a) all returned or unearned premiums, (b) all additional cash contributions or collateral amounts assessed by the insurance companies in relation to the financed insurance policies and financed by the lender, (c) any credits generated by the financed insurance policies, (d) dividend payments, and (e) loss payments which reduce unearned premiums. If any circumstances exist in which premiums related to any financed insurance policy could become fully earned in the event of loss, the lender will be named a loss-payee with respect to such policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total premiums, taxes and fees financed is approximately $0.8 million with an annual interest rate of approximately 8.0%. In consideration of the premium payment by the lender to the insurance companies or the agent or broker, the Company unconditionally promises to pay the lender the amount financed plus interest and other charges permitted under the agreement. The Company will pay the insurance financing through monthly installment payments through April 20, 2024. The amount financed will be recognized as an insurance financing payable in the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to Exclusive License Agreement with Organon&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2023, the Company entered into an amendment to its exclusive license agreement with Organon to commercialize XACIATO. Under the amendment, Organon agreed to pay $1.0&#160;million to the Company as reimbursement for fees paid to the FDA in connection with the submission of the new drug application for XACIATO (known as PDUFA fees) and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, which will be recognized as license fee revenue in the third quarter of 2023. The Company received such amount in July 2023. The amount payable by Organon to the Company following the first commercial sale of a licensed product in the United States was revised to $1.8&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-175"
      decimals="INF"
      id="f-514"
      unitRef="shares">1151578</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-175" decimals="-3" id="f-515" unitRef="usd">946000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <dare:SaleOfStockBrokerageCommissionsExpense contextRef="c-175" decimals="-3" id="f-516" unitRef="usd">22000</dare:SaleOfStockBrokerageCommissionsExpense>
    <dare:ProceedsFromAwardOfGrant contextRef="c-176" decimals="-3" id="f-517" unitRef="usd">385000</dare:ProceedsFromAwardOfGrant>
    <dare:InsuranceFinancingPremiumsTaxesAndFeesAmount contextRef="c-177" decimals="-5" id="f-518" unitRef="usd">800000</dare:InsuranceFinancingPremiumsTaxesAndFeesAmount>
    <dare:InsuranceFinancingInterestRate contextRef="c-177" decimals="3" id="f-519" unitRef="number">0.080</dare:InsuranceFinancingInterestRate>
    <dare:MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses contextRef="c-178" decimals="-5" id="f-520" unitRef="usd">1000000</dare:MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses>
    <dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount contextRef="c-178" decimals="-5" id="f-521" unitRef="usd">1800000</dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #N "E<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  [@ I7,$E!3NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VE!-'1[43PI""XHWD(RNQML_I",M/OVIG6WB^@#>,S,+]]\
M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7KDO"EN0O)*2K/M(>H](?:
M(S2<7X-#4D:1@AE8Q97(^LYHJ1,J"NF$-WK%Q\\T+#"C 0=TZ"F#J 6P?IX8
MC]/0P04PPPB3R]\%-"MQJ?Z)73K 3LDIVS4UCF,]MDNN["#@[>GQ95FWLCZ3
M\AK+KVPE'2-NV'GR:WMWOWU@?<.;MN(WE>#;ADLN9'O[/KO^\+L(NV#LSOYC
MX[-@W\&ON^B_ %!+ P04    "  [@ I7F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #N "E>(@C/;OP4  +\>   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9G];^(V&,?_%8N33IM42NP A3N*1--V8[MKN=)MNDW[P20&HDMBYCBE_>_W
M.$#2JYR'*#I^@;P]W_CCQR_?V*.M5-_2M1":/,=1DEZVUEIO/G0ZJ;\6,4_/
MY48D<&<I5<PUG*I5)]THP8,\*(XZS''ZG9B'26L\RJ_-U'@D,QV%B9@IDF9Q
MS-7+E8CD]K)%6X<+#^%JK<V%SGBTX2LQ%_J/S4S!6:=0"<)8)&DH$Z+$\K(U
MH1\\EYF _(D_0[%-7QT3@[*0\ILYF0:7+<>42$3"UT:"P]^3\$04&24HQW][
MT5;Q3A/X^OB@?IO# \R"I\*3T5]AH->7K4&+!&+)LT@_R.VO8@_4,WJ^C-+\
MEVQWSW:[+>)GJ9;Q/AA*$(?)[I\_[ROB50!C%0%L'\#>!-"J-[C[ #<'W94L
MQ[KFFH]'2FZ),D^#FCG(ZR:/!IHP,6F<:P5W0XC38T\^"45FD#'2)NF:*Y&.
M.AJ$S>V.OQ>YVHFP"I$^^2P3O4[)31*(X/OX#A2H*!4[E.J*H8*_9<DY<9TS
MPASF6LKCX>&3;'5.G*$M_+OBN$4EN;F>BU;2/Y-%JA6TNW]M-;13Z-H53&?\
MD&ZX+RY;T-M2H9Y$:_S^'>T['VUX/TCL.]AN =O%U,?7TL^@GVKR^+(1-E(\
MG#KM+S8D-*HA4J] ZM5#^I)QI86*7LB#V$BE;7BXE%:9K5(\-*HA7K_ Z]?#
MFPD5RL#T0@*#@35YN%+1[RH['AK?D/.BX+RHV3(5AWDDGP:J\XAK+7F46A.)
MAC4$'!2  [10-XD.]0NY#2-![K)X(90-#-=P'-IV^^ZP9X-#0QO"#0NX81VX
M![$*S3 *:;SCL;6-XCK7DX?W[YA#/Y*KZ?W<F][<>3=G9'KGG=N(4:V&Q-0I
M)U>G#O,T\:6"=LI-DSTC<PV=DTA%/)DE6KW ?V"MB"/JUS<V8CRH*?(K/T'K
M(#_R9S(-H+.&R]#/N9$6?422.>TN=8<#^XB$!S?E924OJ\,["0)03\\.!^03
M/$?N$WM><4FWW^N1.[D0$;E68'*MU*A$4^K2$%'4@N#4CUMII<8EYUD(O8+U
M'2ON*1P1+2T1Q4W-6US/G$$'?I3;Q(J*R\UY0JY#L;)5DX?'-D4MK1+%#<Y;
MU&*PFBGY%":^O4'CFM[$"GH*ST1+TT1QKY/G< *?OM7#+RXPZ VL6*>P2+3T
M2!0W-I^DSR,R6\L$\Q!'1(:LW[Z 4<C*=PJ'1$N+1&MYI*)]SF2J ?CO<%.=
M1UQQR"AC5M)3V"5:^B6*&YW'4(,/E$M"V4^+G\E<^)D"="LAKN3).(8)>*ZE
M_\T*>@J7Q$J7Q' ? W8^"),5F;_$"QG9^(X(@"6T6B$\K"E7:858+2OD94J9
MKY;=ITH."F-J9EUG.:+XU;HZX^%133E+"\1J6:!I I_6NV4Y\_G)#^!63ERQ
MBO,4IH>5IH?5,CWF\PR\.TR+*ZFLW?&(SIU,VMSW!<B 2+ 3M/*>PO6PTO6P
M6JYG'O,H(E=9"K=3>ZO%=:K63/"PIGBETV&UG,Y-+-3*],I?0$&O81:)-SRQ
MYQ47K%Q3P..:@I9.A^%&Y9#'M8 \8GBX3#7>*1P/*QT/P\W*89A]-<F!;<V7
MLLE]IL$>)&9ZL1+_("^SKX>=6B]7,_LG3^/!Q<6@1_O]4>?)QEBZ'H9[E$DL
MDB!?^[J-N!T%%ZA.WBE,#BM-#CNRFG-8T[L-4V-<OPJNR"U<M \TN%CE;L$I
M_(U;^AOWB#UYP[A?IJVD/"+WQ6I6\:"FC*77<>MY'<!4@#A- O%,?A?6<>:(
ME.,XM.O0(>U:.4_A==S2Z[BX,SF8N=?-%5MO/R+7;E/6=JD5](>:G<ZK+4(S
MX>4[IRGQS0KD;K>PN%KLSD[R/<E.^?AN:_<S-_-E2B*QA%#G_ (&/+7;+=V=
M:+G)-QP74FL9YX=KP0.AS -P?RFE/IR8%Q1[UN/_ 5!+ P04    "  [@ I7
M8P] */D%  "K%P  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U8;6_;
M-A#^*X17;!U@QWS1:^L8:!,,6[%U0;-NGQF)MH5*HDM13K-?OZ.L6+9(R=Z6
M $DD^^[X''F\YR$7CU)]J39":/2MR,OJ>K+1>OMF/J^2C2AX=26WHH1O5E(5
M7,.K6L^KK1(\;9R*?$XQ#N8%S\K)<M%\=J>6"UGK/"O%G4)5711</;T7N7R\
MGI#)\P>?LO5&FP_FR\66K\6]T)^W=PK>YH<H:5:(LLIDB91874_>D3<W-#(.
MC<6?F7BLCIZ12>5!RB_FY9?T>H(-(I&+1)L0'/[MQ(W(<Q,)<'QM@TX.8QK'
MX^?GZ#\UR4,R#[P2-S+_*TOUYGH235 J5KS.]2?Y^+-H$_)-O$3F5?,7/;:V
M>(*2NM*R:)T!09&5^__\6SL11P[$&W"@K0.]U(&U#JQ)=(^L2>N6:[Y<*/F(
ME+&&:.:AF9O&&[+)2K.,]UK!MQGXZ>6-+%-8%)$B>*IDGJ5<P\M[GO,R$>C>
M!*[0#'V^OT6O7_VXF&L8U+C.DW: ]_L!Z,  '^KR"C$\1113YG"_&7>_%0FX
MD\:=GKK/(=5#OO20+VWBL:%\:Z5$J1&O*DC,E<[>WW/[FUWUIMKR1%Q/8-M4
M0NW$9/G]=R3 ;UW)O5"PDU39(54V%GUYPZL-XF6*$O,@OM;9CN>0NS/K?:B@
M"66V_FY)&*,QP60QWQUG9!LR+PCB /L'PQ.TW@&M-XKV=[T1"AI#(@#F0RZ<
M*/<A_*/!_9#"\#V,MAD),8-I=4/T#Q#]48AW2FQYEB+Q;6NVC!.A;PT=89@=
M4[LG$&V[( C\.(K<$(,#Q.""64S.%GE@#4]#2C#NH;3-!J8P/. +1_'](37/
M+\ 7VO@H]1B-XAY"V]!CF$6AS]Q HP/0Z,Q: U,J_=1L(+-WML!=>HI*H5UX
M(QN&'T9^#ZQM%7@Q'ECR^( TOF#)2UG.SD]K; &(*8ZB_K+;9B&%^J!NH 1W
M7(,O6/UA>*W[R;(SBN/8]WH('98>BVC HH%U)T>$2"YBB#SC#UF>Z<R]T=LH
M+\03+Q7M-.>.%,DH$2W?)8FL@1G0EC^9YNM,F-K5ZWN$D'Z5.PR!O,-X:$N2
MCM#(.*,!3%6+\0;<ACBI#!*S,.YW#H<AP5'L81(,X.RHC(QSV:U8"2BB%*T5
MATI:U66:E6LG6@=5L0! 6+W#91E!J_.#< !N1VMDG->>*WXK52.MY0KE J3Q
MV2U@DQ@-240MZ+8=BR,6DP'@'=F1<;8[99-S:!V<YX481]1J+K8EB ?*8CHT
MU1W]D7'^.U2&$CM1UNZ-9G,:H=BGN"]S7(:X^1F V9$?&6>_7_O+CW)9KF=:
MJ,*)V"8V"NK1PFN;Q1C4XP#:C@#). /NR^#<\MND1OV8QK"!^C!M2P9U[=%P
MH('1C@#I. '>R*+(M%$2U5Z9RU)#9Q!E8N;X]4>I!0J=AZSQP&Z"0,X3R?\/
M=)I\1ZQTG%COM4R^;&2>"E7]T&@JD%>OX<B=)9EV)_VB'/M2T4[3/SIXCG,L
MG![:O5^9B9BB5_@*$V!<A>!<5HLI\J>P=<TOJC8<("!>ZXU4V=\B?8L^RE*@
MK*H,_YG2D;6N-!\D%FJ3<%_EC9J<)MDQ-#USYH0"!P8YRA ?Y_@640^/91D%
MTX"QJ1]%39*1-P4ZF7H1>39VSP#B&GVH2[%?KN?;AL;J%DZ4Q8-0[5?M3<(4
M&G"U%<T=4O[DG$!;'D1!P/ISZ+#RH@&A3#L!0<<%! B=NJCSYBI&[H]TLH"J
MW)C[LQUT9EFY[RYLD3#SL.<=:806M\.0^821 4ZFG9B@XV+B79IF1D5 1S:'
MY5E6HH1O,^C03L"V-""^^0G#OHIPFE*?QGX8#X#NA 0=%Q+'\]TV)"=:6QC,
M")SS0M"75F6X;#V"0R_PAK99)R/H)<?HZM\W5%LQS(#:0&_V[R<<EB#U"25D
M"'PG+NBXN+#HNMFG_R&9R+J*&C@M.BP'3HOSHYM4<XW]&U?KK 3Y(U;@BJ]"
MF!"UOQG>OVBY;2Y7'Z36LF@>-X)#$L8 OE])X/3VQ=S7'N[GE_\ 4$L#!!0
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M5%O.OK7@1@/7P7'NH)/GJ(4<$";6,9WN@(9-0-4XE)KJLT0'Q(T.X'@<L=&
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MC0+E#R,_ X>*JMHDR0*[*EEPJT^^*HTF"Z!Q$U U#J6F.GKV $APLL!,7C!
M%BPM+63!TFJ(+-A"6\F"K>$069B?/2VZ?7JX*"=%D5E[1?8@.OMO0J%5'1_(
M?7S3E/ON =*?RZ8IM]W+39:**JIM(/[^4);-CS?M,ZE/CT6__Q]02P,$%
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MOFLNMRS-F= "\'[#N3K>Z _TI^C+?P%02P,$%     @ .X *5^IW^6R9!0
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M(JS;* ]@3,14H *,)('>Z"$<?'?TN5:@5D]\P/<6HE@1B"^D]U2N="PKPJ;
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M>U">PX)R_*2)F#7Q&(36JF[B\#E6U]C<YZ[4B+JY%0<AK^Y"NI)@2&';K-L
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ME8XKY##T]-]P)^MKL'\$&K*'8ECT]E+9-PE@H:G_$#KOQFTGW':WW;&U/])
M%QX\+!H7,R-!")D6&V))%0))QR]7D!:SQ9'=?'JBI(U_H!Y2_,TI  JS*4XR
M@TVLLYB^?J#<O>S$LN0$!(J-BD6F5F99F-=(91P>@T(/UEV=2:\QT4)B''Q7
M)#R7OZ0QC%XJ7'J A[?8(+@+UN.O/VSK65$8TUM2+5DNQ>L /BD.ER* 0?H>
MKG"M6+$.R76]W9K +4SL+M6&8HXBFZM4YG%0:*1*4 J[BY]798JV@^(EW<Q?
M5LB38O\<6\.V!KL2!))&):K27H(2D*=*R^7PG2,M'+I;J(P0:VQO*4OK,W@6
M_F=WW-[XG0YH$:TU*33-!Y=G!\Y7/LQB)Q-BVBLR\/)+O:6%8.MU9("%-TB*
M,D/TBMNX:Q8FOVXA.ZO/+>ADL3MQ:S.4#(HL=W39_NGTNZ7P0@.(%K)C0X O
MM*4>" T.T XR0G3C,9,HD8+\6#ML8J%;!_N=X8\TS )P84Q,PM^&B(#(<\7P
MAD&L9 V)3<GK^I'([?E&-!/+CMJ 3+3[1(1*B;5!&-;>J)IHV['[9%7TL)T#
MFPSP@R1*@_89_>71;#Z%;#O]';1QS?YY4ZJJDD09*P:J-V('X_E)0J_K"P+1
MP6S@9]@/+1QX.-V7#XPE 3P+1T!1IEZO=<D8'03)'F?WEO#KM0"JY=)3K<EE
M-Z $Y#@(Y?46CH.1.QPY)+DM<FP40G+8OV@E!IL!#0A$;0J;]\0/,(>K&LK0
MUET -FP\\'($0'J*#.>F(--'3.-\!KNEM.S.1#D&Y21M*@&U-%\TND,B_?&"
M!>I VT;  $I]*W8RLJOKHB) *8FIT%6_#PY"R7@/4P%]0^#>A5H?,?3$&8IU
MBHY%Q_PXAP_R7%+41GR1K>C6^.2""9-3=T-E/3!@1<?S@/616H&DI=EM.U/K
M#K*6272^I(#IC,9Z?>^^V-J/8^9#ZMUOZ4W"R=FB<(PW](#+NH$_9,;$SC!7
MDRP+[8+!GY_+^.9)D(F3:X?*Y0O&R8.LG-34MK:0E1.9(NY**5I()D=(1<"5
M6.U#KFZWYCF@ ,8#Y@AC<SJB8-"J"7@5-);#@<C0'V#*=GR/S:KVR1!L?S_!
MML38$3$;5VDVJ1@9V04+9:($ _Y .6#$3N.66\"_'5.P]MW%.8HLG!047-^@
M+Q90RU)5#?-PHQ5-)<#%TF[P@YL,I?^Y79F]'3LL5P7YZ%JDAE]"O &U.G6J
M3JFBR%<G) ;5>LW2NLJU%MQPH<37%ZGX(C*V,*[1<FQM"<QJ> L];Q80^FS&
M5^<]Z!RJ8CP0#V%_O?*#DP?\HEWAL"O5C?6-%B &8R%)*C6"@*A:B4)3(_"5
M$U 98HE- 24<,S4<$02$@E,JRF@'PX0U42"@;VQ%XZR5,*LE4UGFNTV.$F8N
MHRN*.7=S*7,</5@\=-61)KU!VF92P)[Z(E;?GUW=<-W$TLWA^DG,'QXDM,T!
M;^8,>M&Q0F,Q"-*4PK#?#+!%DRPI'0HC:I(%5"TB\6_LPSIFF%88V:4EK4R.
MT:1%I,E0P384$#P3R&B2 ES6;4M0-(W)^6-K:0"%#3.>,9O#';/'K$'=@,3=
MS/;/$74#7?OH=<B6,=+WC@\;_LM;.)#&>+5SPMF,K98M!$X+Z)\*1+YT.83$
M[!R8A_/EE(QAO&ROMI(*_\"<AE'])/-<;J&T06I^7J^@LULK]6/,/!A\*:/+
M1$DNCWSX<,&)OOL:=L$%8&.C+4*5<+J:6J-SW&"5%<#6?HE^H"I?E5+8TDJ*
MU0>&F<-*L1DP\(U*RF)!UK3*=HDLBRS:%'F1B9HT&3WX\>.'AZTJ/K:-%"JX
MDL5YU3):<Y9#KF,,3@?PM(#]RY)Y,W*$%?U+DE[#AZB>M33GE#HLA(^4')M$
M)#@=B9MCB]CARLD"CD-S!]R$3I_HY"7>IZ\F$D/K,EGG=%BQVQN5 DCR_%F[
M4A#=@ A4]U=V>-V_4S#V21,3]&U1D3"40ICJ9E.+S]-NX;OY$G/98/-D,F]5
M]8V0*Z*:E>5K)H!P><-6!O=D)6&(,I#N9GKTN%.G/V2F?55\7Z1P:0]#;W/N
M8S79;,; -KC80$"W( 6I-.X0FV__\6P^>_IB(&<B^81>DS?K-4*MW\/ND[0*
M+ ]R)U] WWR6E"')]#!!=@4RKBQ5[)S9- $;MU*,;E67<'^/]C21,PCAS1%?
M*XK[HSB;U0*H2''W4.@8.RT:XUL+RB&I#LFE7C<(T>1FE(]OWD?G!(#:1##@
M\2^0AMGB?#K[/AZ&RK?$>#Z^P>W)A&$6X\3LIC(A]PA<-$1.0W<IHX;MF6*[
MLC7Z(&7;R&I=I+&I[@OHDK,Z_ ?/XZ(059B6A(:EEMD2#I 0H6;,+2(FYS=T
MNB93?]  ?3-?IMW/L8-?<KH%_/OM^>=W)Q_./U_,1I$"CK%R991]0 '%\Z&J
M9&T8*UP7&<;4SYE,.P=]$IS8&1:T(@_WM-DR29><ZZU,%%>1J?:#FV/OB0<!
MQ LFI';RQR$ZW&ERL:$B'FNE@9-AZT90*DKP+D/DS?G,T!GRH&E95#!:?^$I
M:LL_@W-#N,B*9F'V=G^''>+<G OX10&6ND?=4&Q=,7W"]29 R8<L]>VDNG5N
M$DYFS]!-4P%R-F&2%QH%26402:R)!AO9/IBQS0K0%J?&8[OLPH!+:HV=M6IO
MH:DUD<Z<71D2S$YH2K2NK'*X'WD,7Q14>\$C*:PA@2D37../QL>@5SI-\ZN'
M/@="+U9S>+ P,12/7 *"'/B1XEOU2ZUK\H,M5/)5@5Q3?\33Z32>3J?!7)3*
MA6.3V!860DB@6PDF6,<(A]'QT\<\DHMVMCX4/F-EI_-$WU!D&E#,B9(]P7/%
MGEF'<PQV$N@"4=\W@82G<^X(..AO 4A>E>H#-9:PX!]5)G+Q"6O?#'#[T^@G
M 3U !>>:"F-\L47]?6$"H>;9_C8=T0S130#L)"P&@DC-60]XD0].-.Z0"+'U
M4WL^$O8!C"0;?O5FLIC2C+XF;.I!TWJMN,$GT1M* $63-MDC3[O?^]J1 ,'P
M2KO>>'PK3&7(=J_8@X_OB2+,GGK!]FY=& L']\YEG7M'B4D$UFK#;7KZ&"$8
M(ZF'5XIA,PZW1L)+$5N5%;88"5#3^Q*35JL4R94JL<H+K?"43_(L+#+T67<S
MA6=P5BF(M^'A5HIF=%X6]6H=F9.0T68M>U9H4[6K,%$:7J2Q'E\D7^_2LE@A
MYTS+>N6R481+W$0@1,*.FHTG15>?WY\\G3]A6+>'M[%ACC0M9:.FON$2-V)5
M^]K)G#8;%4(,GZ]&K E2\J2+"=_OPP1G0;QV3E L\(U:[( SOM^/^9T2!-AM
M08C1[1@:<*"#.Q"Y790=X9^"-HLEO:SP_Y,WNP%4;>%0W-K H,O))5SNB-*Y
MX8BT(]1WP*7#A7#<<D=W70(Z2!AT/R,E3G-FHRCT$:PGMM4X\I+@L.IX_MC<
M38<N=.1HO<,%J$! 2C<1"@QO"#7EV+"=]Y:*]5!SG.=*_$2OG\XGS<[-N96N
M\7,N4@;M=6Y-]Y2$IP*%I(0RB!UI&]%: K5Q!_*T2IEQ6"GP/!$*:Q<7@B:I
MD92W+TEH01NJ_'4W)SPWF;2^H=R5MG,H@3?'%7O8/F<N6<;9R48V5:X.I[<G
MPF*Y5)EB_7)]),]MHS_[']T8\/F@#"4(*,N4*[RF@D>'445=$2MW1M/:OW;M
MWC6%?;4-;:Y*CQ1NC83Z]O1FH-'4)C<'[U"K.C'Q!,M0,-N=UCF,:P7QIB6(
M:P#P8RKC68Y-V*=-[UWN'PTW>8#W$.;Z/#LI*/0YRN2ZAX9EX!@N*D%]U2;:
M:,]=!BJ0[MA^6]#*N9]P6Y>Z%@;J17AKT[<$T1LEC9277!?M9'90;:Z7F=T-
M9>/H^)D%%(QA(H'O2F/4'FAMGD2?I"@16J3LEH0^BMT 1?=DK7ENG(/[>\(R
M44#QO#=1HAKW>^3;A&\K*E]])=IRLH8;[*W1BQ9W<6S%I4N@B5_54AJJXB$[
MW4#IU'Y:,1)Q*4D$FLEZMO^=K2C]_OOYC"8$,&S^DL*2/6L>RB*]9EM5IMGC
MR=T+SM[*#BHL$7+VP*.!*U?N>OKGZM&WS->M\QZB*#ZO/:@(["'T3E4E/J[L
MUY/Z0'M;Z!D[UMUSG-NJCC0+&6R[X)I94+?2-CEEX_3%@J9--RB[V4(^59:[
MA?Q^(U^KA-\JS/2*)>H>A:30P?H^I<;.9V\['.^MV91JNKT(73K14^KPUG--
MOK/_$,_;Z'>NRX8J8&2OP;LP8@4?H8H%M65;*?D<JE]A9%4W4KM"H$6MVQRE
MS:;;B-1(UW*M!H+:A;+CL\G\+\&CL'>P@_,=K!CLK&WP2<N-.K%^.D2:1AN+
ML=Z_UZ_Y&#AP:W;B0=?ND]=Q9W=X<0!E]H]QI5V:$H<IJF3U9DOOW :'GE3]
MV%!:9KOH#X*>$94T/-C8XD -L_5V0,\>_Y= U6.R6,0GLXTZ)'<#BW)O9PSC
M@5W4 "3T0"NMQ\>91!?@QMS!^_,OGT:Z,\"9L@/JL[>^1AE.%?!"=[G=G^%O
M]IE5>.I"F5ZK/MCM1[BM7FCHHZ66L6M6+&YRDPY2JNP&SP+.@94VXMK6@-B<
MLQK[XJR>/^.O%"8ML\Q>H..CV+4CF49B*MWSY]'<JP$KP>W?=UJR[8-T:_:I
M"P.JRLT;]XPH;MU>ZW_'VOZR;H_V@?;]VCU,3M2483HOG[J>V+#G/C"&H0J!
MJ>4CS1EL+C7M5/PB#9]H'<]L)<K&(S<1_>X!3)4QAB:E]TLHJ@V\RS'X!H=1
MLAVT.YCK[!V%$=?S;I"^"RGAZOFDBDX:6UV)$1V/$E;Q$2E]699\CEV4-[;#
MFH,6#T\/!("T-X\F!#B>G>W+<%0^P-7V'G ?V&W3ZNH]/+M^T<V+SJ:3L[]2
M_#NU\)@WQ\@1[]E\TLJY;MNT#51RG[K5W]!%\Y[>T)>U/^[OQL\V3'B/]2N^
M&WV2+EL8YD3VF"2XG7*XL/[1!I%NN9'VA>C^VXXE_VKZ:@9_'N'PN-[UC\*,
MV@GS1H).'2CZ[?(\B/E\3]P<LG4&;IKMAGXS(5"-RHDP"OM"BBOHF((X#+]
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M<AJRO]%BJ"F* )C,>YDNS*\D&< 6@A!W*A5"GVH.NMC*C+684Y34G5/SM1O
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MI/.FW6'%KO5DNL,$43  &/:K7#,I^WRDDP_M]G)]2>N4&]=XOG;M-3<R&*W
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M!B'MFA>G2W\SN-(.P>D?,\&A'&W ]U1KU[R0@/:J^/1/4$L#!!0    ( #N
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M=]+_XGR'+VMNQ*4J?I>YW9X-T@'+Q88WA?VF=G\5K3]3DI>IPKC_;.?7QM&
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M G=9E;9"_U,L3I+Y,$D2%GPS/SFC&_:C5-PWS<N0UR163UER)2G^T;W<9AK
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MC>W^&GWA2Q4(\R$.RE9+:IG>AF&).%>#P;3*A=-F"XF.*\Z-SV'+V^PI"5*
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M\H\9C:5H^ "]7VGMZ@4[: ;=T3]02P,$%     @ .X *5Z<'9]!M"   &!L
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MB< 732J^.@4'#( @* 8KQ)96'1R-1OW1:"16\)@28I5)Y Z!9*$:/V,P>C=
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MVVF1S6B'#"\*4&4T,NA$6X\1,>=A+5,RS+HR1?NMZ94)-Q:;J9;2J!LC&D[
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MO>)22C!U\ZJ6G!ZD1J8'F%V[-#_X--^VH=)\):P6:M+]X^Z?P+VR%->:"<H
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M,%Q2RT?C#6B_TMIM)SY ^R<R_@-02P,$%     @ .X *5[_.Y/'P @  ?@8
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M"%0V@.932;O0&K9 ]^3,_P%02P,$%     @ .X *5VBK=7-5 P  WQ   !D
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MQ64+I()CF>M%/C1S-6QT$!^G&Y_PSQ6N4_]U%T;WHI8GH#IA'+5A')T4QC5
M7^!Z(0\-G$E8:!(6F80M#<$Z:1VW:1W_[^?=V&1)F(2%)F&12=C2$*Q3$I.V
M)";F#\S)B2?8HM?V0Q-H$A:9A"T-P>H$V@<-6 DLU:TRE\FIB*A?;=O9MAN_
MT$WH;_,+]SQTC\Q'LGNOF^U?^+KU?XU9FA.."EA+4\[96#Y?6-U.UP-!-[K]
M6U$AFTE]F0%.@*D%\OZ:4K$?* /M;QK!3U!+ P04    "  [@ I7EKU:I&H'
M  "91   &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RUG&MOXS86AO\*
MX5TL6J =ZV)+=C8Q,(FL:Z<;-)CMA\5^T-BT+8PLN12=-/^^I*38ELUAY/9M
M/B2ZG>=0U'G%0QU%MR\E^UIM*.7D]VU>5'>##>>[F^&P6FSH-JT^E#M:B#VK
MDFU3+E;9>ECM&$V7M=$V'UJ&X0RW:58,9K?UMD<VNRWW/,\*^LA(M=]N4_9Z
M3_/RY6Y@#MXV_)*M-UQN&,YN=^F:/E'^>??(Q-KP0%EF6UI465D01E=W@X_F
M36+5!O41_\WH2W6R3.2I?"G+KW(E6MX-#-DBFM,%EXA4_'FF#S3/)4FTX[<6
M.CCXE(:GRV]TOSYY<3)?THH^E/FOV9)O[@:3 5G25;K/^2_E2TC;$QI+WJ+,
MJ_HW>6F/-09DL:]XN6V-10NV6='\37]O.^+$0'#4!E9K8)T;C+YA8+<&=E\/
MH]9@U-?#N#48]S5P6@.GKX';&KA]SV'2&DSZ>IBV!M.^!J;Q=N6,WB:'B]T$
M71,E=8AY*4]GMZQ\(4P>+WARH8[3VEY$5E9(23UQ)O9FPH[/[M,JJTBY(H^,
M5K3@:1/HQ9(\-2*3^YZR=9&MLD5:</)QL2CW!<^*-7DL\VR1T8K\2'Y.&4NE
M.,AW'N5IEE??BZV?GSSRW3^_OQURT5+I;[AH6W7?M,KZ1JM,\JDL^*8B\V))
MEPI[3V]OOV<?ZNT=C?U0]/"AFZVW;KZWM,!XGW\@MOD#L0S+4K3GX1WSM#B8
M&ZKN>,^[-#=J<UMA/M>;?TK9P;O*W._O777N07_O*O/PKYU[]-<:'^O-/;K0
M-C[I;VYJPM ^J-VN>?8W>.\)^7\_"0,2<;JM_J]2;4,?J>ER]+^I=NF"W@UV
M\F["GNE@]J]_F([Q;U7((V$>$C9'PGPD+$#"0B0L0L)B)"P!P3J"&QT$-]+1
M9S]1SBF38^B"T67&11::IYPN"2])3D4J*'>)5#@G.R;29,9?5;+3^KA6=DB8
MU\"<&B:S]^>9;<B?V^'SJ:"0/GTD+$#"PGZ]$2%]QDA8 H)UI#(^2&6LE8H8
MC_;;?:,.,2<2 Q)7:4$+N58+2)C7P,8G5]\<NQ-W:KOVF1R0;GTD+$#"PMX=
M$B'=QN,+%9HCTW!'SNA,B G(;2?<G4.X.]IP?TBK33W/6L@%^ML^>TYS,0&K
M5$&O15T;]$B8YUQ>8]MQ1'^;9S&/].H[ES=:RW -Q[2Z7@.DU[#ON49]FQ=?
M$NV1XTP=8WP6J9?$L>FX(V/B'@[L1*%[B$)7&X4>75$F,A.R9G).L-H72S$A
M4(6@EG-M"")AGJNZ+%/1-V>=.$=Z]9&P  D+^_9'A/0:NY=WW8EMV&/'/0ME
MD-=.N$\.X3[1AONO)?LJ)[R+=)=QD71K\@PMZ-IX1\*\R<7UM<:JI!OIU$?"
M B0L[-D=$=)IC(0E(%A'$=.#(J9:1?Q,.<G+2IEU:"VOE0 2YDTOKOG$=2S+
M/AM?Y].+F]+$&(GP.!NP_4O>CR/3GDXG9^F$@F=/)XY[%FOA)<]TA&?7/D]\
M+P]TIY.1XYXG"LC>2T"P3KR9QK'@8+R?^*YR8;9BY9;(IQYUT4$9@GK6M3$(
MI7E0VAQ*\Z&T $H+6]JIBBS+5=VRH7YC*"U!T;HJ.BG;F5H5/5*6E4OY]# K
MJOU*IC%B\MA,)N6L,L_$C'*9\5?"Y-R2T>VWYI9Z1U=+#$GSH+0YE.9#:0&4
M%KX3/*9%MG5]4_4@']J2&$I+4+2NZ*RCZ"S]T_QL08N*-H]MRCQ/OY3-V"5$
M]DR+/57J2\N\6E](FM?23F_%Y[,(J$-?X= T#,6]/X#Z#=\_T:AWTV)HTQ(4
MK1O3QXJPJ:U_S>[35\I(2-.<;Q8IH^0MR#^N&:U'#6500RO!4)H'I<VA-!]*
M"Z"T$$J+H+082DM0M*[DCC5A<_2WOH5A0NO!4)H'I<VA-!]*"Z"T$$J+H+08
M2DM0M*[XCE5F4U]F_KQ;,9'[B@E2,\RM*"6[-%.])'BO1UTM-$5A4I5?>%"W
M<RC-A]("*"V$TB(H+8;2$A2MJZ%CZ=K4UZ[_W#P(6L0V+TNGEC);]Z!^YU":
M#Z4%4%H(I4506@RE)2A:5TW'$KRIK\%_RG):\;*0X]!K_9CN!Z&J.B>4C_32
MK4P0E8J"UN3-RPJNK9X >U#'<RC-A]("*"V$TB(H+8;2$A2M*ZECF=_4U_G_
MP]9I419*T4 +^U":!Z7-H30?2@N@M!!*BZ"T&$I+4+2NKHXO"YC3O_?)!?25
M BC-@]+F4)H/I0506@BE15!:#*4E*%KW/PB/+TY8^A<GKGER85W6V-6YW(/>
MZ;4B@M+F4)H/I0506MC2QN]>KPCJ-X;2$A2M*Y#C.Q&6OJS]IR=2>NZUPQ*4
MYD%I<RC-A]("*"UL:=T7DM5OAD(=QU!:@J(UDAJ>?"A@2]FZ_I9%1>I$3CHY
MV7KX7L;'^BL19]OOS9L'4['=,V\"U?;0O(F:#Q8<W38?[?B4LG565"2G*]$$
MXX,K[H&L^0Y&L\++7?WY@B\EY^6V7MS0=$F9/$#L7Y4E?UN1#@Y?(YG] 5!+
M P04    "  [@ I7T(UE;2X#   ##@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6S-5UU/VS 4_2M6-DU, O+53]9&HJW0F&"JJ& /TQ[<]+:U<.QB
M.RW[][.3$!)(LR+RP$L3Q_><W'-\E-J#'1?W<@V@T&-$F1Q::Z4V9[8MPS5$
M6)[R#3 ]L^0BPDH/Q<J6&P%XD8 B:GN.T[$C3)@5#))G4Q$,>*PH83 52,91
MA,7?$5"^&UJN]?3@AJS6RCRP@\$&KV &ZG8S%7IDYRP+$@&3A#,D8#FTSMVS
ML>L90%)Q1V G"_?(2)ES?F\&EXNAY9B.@$*H# 76ERV,@5+#I/MXR$BM_)T&
M6+Q_8K](Q&LQ<RQAS.DOLE#KH=6ST *6.*;JAN^^0R:H;?A"3F7RBW99K6.A
M,):*1QE8=Q 1EE[Q8V9$ >"V]@"\#. ="O S@)\(33M+9$VPPL% \!T2IEJS
MF9O$FP2MU1!FEG&FA)XE&J>"$99$(KY$4P$2F,*IN6R!9NG"FKD963&R)"%F
M"IV'(8^9(FR%IIR2D(!$)^B",,Q"@BDZEQ*43!BN")X32I0IN8$(L(P%+)#A
MU^,P%L*PI!T<34!A0N570X:)0'>8QG",KE.4#HZ2QP74";J=3=#1YZ\#6VD;
MC!@[S"2/4LG>'LD_8G:*?.<8>8[G5\#']? )A!KN)G"O#+>U^?D*>/D*> F?
MOX>OJ':/>=<%ZYXM,%4_.1,OG/Q]I5^ +A5$\D^5.6DWK>INS%?C3&YP"$-K
M8Q(AMF %7SZY'>=;E54-D96,\W/C_#KV8(SE&L%#3+:8FGA4B4T9.@F#^:)M
M ]?I^=U^JS6PMT4AKPM]W_-[G78O+RPUV<J;;-4V>05;H,BMZJT6^-:%:(BL
MI+&=:VQ_J 2WFS2N(;*2<9W<N,Z[$YPRM/^?X->%]0GNYDUV#TBP5]5;+?"M
M"]$064EC+]?8^U )[C5I7$-D)>/ZN7']=R>X_RJ8SHOHUE64VG*=YVV-<T!J
MJ_[>1_7(M[K?%%M99V'[YGZHY&;M-&5>0VQE\YYW7F[M_N2@]&84G9KXUI:D
MK=F%';HY'EUCL2),(@I+C7%.NSK\(CUQI /%-\FF?<Z5/@(DMVM]2@-A"O3\
MDG/U-##G@/S<%_P#4$L#!!0    ( #N "E>8>S&C'AL  /<? @ 9    >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;,W=6U/;V)K&\:^B8J9F=E?U!'SBD$FH
MHJ/S<4E*>E],S85B!*C:EKQED>Q4]8<?V0C$"F*!Z?\N3U]TC/'Z+8'@7>*U
M'NG#]ZK^8WV3YXWVS^6B7'\\N&F:U?O#P_7\)E]FZW?5*B_;SUQ5]3)KV@_K
MZ\/UJLZSR^V@Y>)P?'1T?+C,BO+@_,/V.5&??ZANFT51YJ+6UK?+95;_^"U?
M5-\_'HP.[I](BNN;9O/$X?F'57:=IWGS927J]J/#!^6R6.;ENJA*K<ZO/AY<
MC-ZG9^/-@.TK?B_R[^M'C[7-E_*UJO[8?.!<?CPXVFQ1OLCGS8;(VG^^Y9_R
MQ6(CM=OQCPX]>)AS,_#QXWO=W'[Q[1?S-5OGGZK%WXO+YN;CP>F!=IE?9;>+
M)JF^VWGW!<TVWKQ:K+?_U[YWKSTZT.:WZZ9:=H/;+5@6Y=V_V3^[;\2C :TS
M/&#<#1C_/&#ZS(!)-V#RV@'3;L#TM0-FW8#9:P<<=P..7SO@I!MP\MH!I]V
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M@VHNJGFHYJ-:@&HAJD6H)E M1K4$U5)*D]>#/BX\4]_0]^VG_: A8%334<U
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M?B'XJGHZPBT7@F?5YI)%,2M4 WG\CG/Q_$(EV#R&9/X?4$L#!!0    ( #N
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MS4"8"?K[FG-UZ!@#]6-O]@]02P,$%     @ .X *5RG[@9O3 P  -Q$  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULQ5C;;N,V$/T50BV*72")[K?4
M-A!;ZG:++AK$V/:AZ ,CC6TADJB2M)WTZTM2LM:R%2/;$M@7FR+/.:.Y>*S1
M9$_H$]L </1<E36;&AO.FUO39-D&*LQN2 .U.%D16F$N+NG:9 T%G"M259J.
M905FA8O:F$W4WCV=3<B6ET4-]Q2Q;55A^C*'DNRGAFT<-AZ*]8;+#7,V:? :
MEL _-_=47)F]2EY44+."U(C":FK<V;>I;4F"0OQ>P)X=K9%TY9&0)WGQ,9\:
MEKPC*"'C4@*+KQTLH"REDKB/OSM1H[<IB<?K@_I/RGGAS"-FL"#E'T7.-U,C
M,E .*[PM^0/9_PR=0[[4RTC)U"?:=UC+0-F6<5)U9'$'55&WW_BY"\010>B,
M$YR.X)P2O%<(;D=PWVK!ZPC>6RWX'4&Y;K:^J\ EF./9A)(]HA(MU.1"15^Q
M1;R*6A;*DE-Q6@@>GRTYR9ZNYR+4.5J02M0?PRJ#UVC9U@XB*_0 &5G7Q3\"
M]"HA?99K$-@2<W'(28M%OS7RG*$/%-?=05HU)7D!8 C7.4H**LJ&4(;>)<!Q
M4;+WPOP!,U 1^Y^7"7KW_?N)R87[T@DSZUR=MZXZK[CJHD^DYAN&TCJ'?(2?
M7.8'%_BF"'L?>^<0^[ES4?"7;7V#7.L*.9;CCMS/XNUT9\R=_V<]_<_6!\%P
M^T)TE9[[6B%N,(7K1U57]_A%]"*.[J@HF37(]=6AOG)5,@O<%!R7LB*OT%U%
MM@+]YZ]"$GWD4+&_QJJCM>^-VY<-^98U.(.I(3HN [H#8_;#=W9@_3B6&IUB
MB4ZQ5)/8((E>GT3ODGK73=HD9L?- =KDC:6E50R4HOQ;V\T"W[*C8&+NC@-^
M#O/=T'?L(2PYA]E.Z$56.,2E(S@KB&/7ZG&# /A] /R+ 7@0(<4TVZ@BS6$G
M_H@;6;YCCE]4^MIZU"F6Z!1+-8D-TA'TZ0B^<5,)="91IUBB4RS5)#9(8M@G
M,=3>5%I%_^CG[=B6'4<G3>4<9H=V[)[ DG.89UM>')_TE'.8ZP6^[XRWE*AW
M/[KH_@>H@>)252C.Q2-@P3C%\O%ZS/&+6E];CSK%$IUBJ2:Q04+B/B'Q-VXJ
ML<XDZA1+=(JEFL0&2;2M+X./I;VM=)+'CPV>&\?1:5\9P;FB$T3N26,9P46!
MYUHG>ND(+G1<-XQ.6HMY- A60-=J F?"/5%U[:-XO]M/^7=JMCW9G]NW"WMD
M/Y%O!=3@^46^?:7P"=-U(::\$E;"E'43BCY(VRF]O>"D46/H(^%BJ%7+#> <
MJ 2(\Q4A_' A#?3O2F;_ E!+ P04    "  [@ I71"'>MF '   :/0  &0
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MU*K,+K6%@KBEKOLOCXB*&1U7=4[76NZQ\H*$V9 P!Q+F0L*\86MTZ_6MMKJ
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MGD3YYH+1&4ME _&]7-+S_D$FJ)9#C_\'4$L#!!0    ( #N "E?R2Z*C> (
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M#I?Z8P.$,=#[<\[5=F(<E)\OT6]02P,$%     @ .X *5XPGBN=V"   F60
M !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULO9U;;Z-&&(;_RLBMJJVT
M&S/@8YI82LSY4*VRW?:BZ@6Q)PXJ!A=PLOOO"Y@88R83T+[*7JP-YGO>@?$[
MS.&+N7J.DW_31\8R\FT;1NGUX#'+=I?#8;IZ9%L_O8AW+,H_>8B3K9_EF\EF
MF.X2YJ_+H&TXE"5I,MSZ03187)7[/B>+JWB?A4'$/B<DW6^W?O+]EH7Q\_6
M#EYVW 6;QZS8,5Q<[?P-^\*RK[O/2;XU/%+6P99%:1!')&$/UX,;>NG)DR*@
M/.+/@#VG)^])<2KW<?QOL6&MKP=242(6LE56(/S\Y8DM61@6I+P<_U70P5&S
M"#Q]_T+7RY//3^;>3]DR#O\*UMGC]6 V(&OVX._#["Y^-EEU0N."MXK#M/R?
M/%?'2@.RVJ=9O*V"\Q)L@^CPZG^K+L1)0,[A!\A5@'P>H+P2H%0!RGG Z)6
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M(IHL3D3KD!$C)O3V/C0A#4K3H#0=2C.@-!-*LZ T&TISH#2WHIV.1\:S<6M
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M>?A1='9.>JWRQKWL58]0+^?U#_"^B15EG+5<R(U1F"7-*[FA<[BV=%:4(%[
MFOSZBSMT?F^S!!/F8\("3%B(!&M8V:^L[.?TWI'9@/SSASZ#W"E(Y+]M!O<Q
M#<:$^9BP !,6(L$:!@\J@P?&=S6,A%1DSI,$Q#RB,9$T!D(3GC+5YJ^1UM5?
M3)B/"0LP86$!&^:P;&#W,O$&CC.V7UI\&U:^#8V^[;^8;5X9"5V]PH3YF+
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M4Q)%2>)' /,[B"(,@:<11S 'X %#HJAZ#^Z\C\+F/16N_\<W^@U02P,$%
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MA!MCGHB#BV(W'),CE^0+,)]]2$P9\3Z<T1*7_X+Z"36FCR2P/G;"<]M$)IA
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M.],[7.^GMLMN'HYUR_5W_'W&1_T+<PB0'!(DQPU(CEN0'&.0''<@.>Y!<CR
MY. CE" H1.4H2.4H3.4H4.4H5.4H6.4H7.4H8.4H9!4H9!4H9!4H9!4H9!4H
M9!4H9!4H9!4H9!4H9!4H9)4H9)4H9)4H9)4H9)4H9)4H9)4H9)7_2=8/K9=_
M_7NV79-:E<W!GW7_P&=?4$L! A0#%     @ .X *5P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  [
M@ I7,$E!3NX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  [@ I7F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #N "E>(@C/;
MOP4  +\>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  [@ I78P] */D%  "K%P  &
M@($"#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ .X *
M5[E;*, ! P  5PH  !@              ("!,10  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( #N "E=GR;H5!@8  $4<   8
M      " @6@7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  [@ I7R*/5&F *   B70  &               @(&D'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ .X *5UUK>N,=!P  41\  !@
M             ("!.B@  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( #N "E?J=_ELF04  "0,   8              " @8TO  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  [@ I7$+7)2;05  "$
M0   &               @(%<-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ .X *5X\R,9L?&   -U4  !@              ("!1DL
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #N "E=F/,P#
MXP<  #86   9              " @9MC  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ .X *5Y]X./!K!P  C1(  !D
M ("!M6L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  [
M@ I7QK32JQ<(  "W%0  &0              @(%7<P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #N "E?=T%^XMP0  /0*   9
M          " @:5[  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ .X *5Z<'9]!M"   &!L  !D              ("!DX   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  [@ I73&A1VF($   Q
M"@  &0              @($WB0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( #N "E>##?QMPP<  $02   9              " @="-
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ .X *5S01
M(H*^$@  )3@  !D              ("!RI4  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    "  [@ I7YAEBT7 #  #H!P  &0
M    @(&_J   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M #N "E<=%>!.=0(  %<%   9              " @6:L  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ .X *5ZSF583%!   ^PH  !D
M             ("!$J\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  [@ I7YKA6K\P"  !0!@  &0              @($.M   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #N "E>_SN3Q\ (
M 'X&   9              " @1&W  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ .X *5VBK=7-5 P  WQ   !D              ("!
M.+H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  [@ I7
MEKU:I&H'  "91   &0              @('$O0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( #N "E?0C65M+@,   ,.   9
M      " @67%  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ .X *5YA[,:,>&P  ]Q\" !D              ("!RL@  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  [@ I7?\RE^U '  #:3
M&0              @($?Y   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( #N "E=A:TDP)@,  ',+   9              " @:;K  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ .X *5R14,]<L
M!P  DD0  !D              ("! ^\  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  [@ I7RQ?%T<0#  #X#0  &0
M@(%F]@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #N
M"E<I^X&;TP,  #<1   9              " @6'Z  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ .X *5T0AWK9@!P  &CT  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( #N "E=VU*$^4 4  #PH   9
M  " @648 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M.X *5T;YIN4X P  \!,   T              ( ![!T! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  [@ I7EXJ[',     3 @  "P              @ %/
M(0$ 7W)E;',O+G)E;'-02P$"% ,4    "  [@ I70Z:\TFP#   <&0  #P
M            @ $X(@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ .X *
M5YD^HH1\ 0  EA8  !H              ( !T24! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ .X *5ZIG%&&8 0  "Q<  !,
M         ( !A2<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R
)#   3BD!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>205</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Strategic Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StrategicAgreements</Role>
      <ShortName>Strategic Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leased Properties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedProperties</Role>
      <ShortName>Leased Properties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Grant Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwards</Role>
      <ShortName>Grant Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - Leased Properties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesTables</Role>
      <ShortName>Leased Properties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedProperties</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - Strategic Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StrategicAgreementsDetails</Role>
      <ShortName>Strategic Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StrategicAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - Stock Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - Leased Properties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails</Role>
      <ShortName>Leased Properties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leased Properties - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/CommitmentsandContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - Grant Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwardsDetails</Role>
      <ShortName>Grant Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/GrantAwards</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dare-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dare-20230630.htm">dare-20230630.htm</File>
    <File>dare-20230630.xsd</File>
    <File>dare-20230630_cal.xml</File>
    <File>dare-20230630_def.xml</File>
    <File>dare-20230630_lab.xml</File>
    <File>dare-20230630_pre.xml</File>
    <File>ex31_by-laws.htm</File>
    <File>exhibit311_20230630.htm</File>
    <File>exhibit312_20230630.htm</File>
    <File>exhibit321_20230630.htm</File>
    <File>exhibit322_20230630.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dare-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="391">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dare-20230630.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 391,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "dare-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dare-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dare-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dare-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dare-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dare-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 360,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 5,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 10
   },
   "keyCustom": 39,
   "keyStandard": 166,
   "memberCustom": 38,
   "memberStandard": 17,
   "nsprefix": "dare",
   "nsuri": "http://darebioscience.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://darebioscience.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://darebioscience.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://darebioscience.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Leased Properties",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://darebioscience.com/role/LeasedProperties",
     "shortName": "Leased Properties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://darebioscience.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Grant Awards",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://darebioscience.com/role/GrantAwards",
     "shortName": "Grant Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://darebioscience.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://darebioscience.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://darebioscience.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-4",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://darebioscience.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - Leased Properties (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://darebioscience.com/role/LeasedPropertiesTables",
     "shortName": "Leased Properties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://darebioscience.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - Organization and Description of Business (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "dare:GoingConcernPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-57",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-57",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-6",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - Strategic Agreements (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://darebioscience.com/role/StrategicAgreementsDetails",
     "shortName": "Strategic Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-76",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dare:MilestonePaymentsContingentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-103",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dare:EstimatedFairValueOfWarrantsRecordedInEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - Stock Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "dare:WeightedAverageAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-116",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-117",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-126",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
     "shortName": "Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-118",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-130",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - Leased Properties - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
     "shortName": "Leased Properties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-130",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leased Properties - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-137",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dare:ResearchAndDevelopmentAgreementCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-137",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dare:ResearchAndDevelopmentAgreementCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dare:DeferredGrantFundingCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - Grant Awards (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://darebioscience.com/role/GrantAwardsDetails",
     "shortName": "Grant Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-141",
      "decimals": "-3",
      "lang": "en-US",
      "name": "dare:ProceedsFromAwardOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-6",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://darebioscience.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-6",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-62",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://darebioscience.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-177",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dare:InsuranceFinancingPremiumsTaxesAndFeesAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-6",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-6",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-30",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-36",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Strategic Agreements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://darebioscience.com/role/StrategicAgreements",
     "shortName": "Strategic Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "dare_ADVATecAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVA Tec agreement.",
        "label": "A D V A Tec Agreement [Member]",
        "terseLabel": "ADVA Tec Agreement"
       }
      }
     },
     "localname": "ADVATecAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AdditionalPotentialFundingRelatedToGrantAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Potential Funding Related To Grant Award",
        "label": "Additional Potential Funding Related To Grant Award",
        "terseLabel": "Additional potential grant funding"
       }
      }
     },
     "localname": "AdditionalPotentialFundingRelatedToGrantAward",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "label": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "terseLabel": "Issuance of common stock from the exercise of warrants (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan",
        "label": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "Amended and Restated Two Thousand Fourteen Stock Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_April2021AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April 2021 At The Market Sales Agreement",
        "label": "April 2021 At The Market Sales Agreement [Member]",
        "terseLabel": "April 2021 At The Market Sales Agreement"
       }
      }
     },
     "localname": "April2021AtTheMarketSalesAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AssetAcquisitionContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration",
        "label": "Asset Acquisition, Contingent Consideration",
        "terseLabel": "Asset acquisition, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsideration",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssetAcquisitionContingentConsiderationCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Current",
        "label": "Asset Acquisition, Contingent Consideration, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationCurrent",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssignmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement [Member]",
        "label": "Assignment Agreement [Member]",
        "terseLabel": "Assignment Agreement"
       }
      }
     },
     "localname": "AssignmentAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BayerHealthcareLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Healthcare License Agreement [Member]",
        "label": "Bayer Healthcare License Agreement [Member]",
        "terseLabel": "Bayer Healthcare License Agreement"
       }
      }
     },
     "localname": "BayerHealthcareLicenseAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CRADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRADA",
        "label": "CRADA [Member]",
        "terseLabel": "CRADA"
       }
      }
     },
     "localname": "CRADAMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CatalentAndMilanaPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalent and MilanaPharm",
        "label": "Catalent and MilanaPharm [Member]",
        "terseLabel": "Catalent and MilanaPharm"
       }
      }
     },
     "localname": "CatalentAndMilanaPharmMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ClassOfWarrantOrRightsWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights warrants expiration date.",
        "label": "Class Of Warrant Or Rights Warrants Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsWarrantsExpirationDate",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dare_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical And Regulatory Milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_DARELARC1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARE-LARC1",
        "label": "DARE-LARC1 [Member]",
        "terseLabel": "DARE-LARC1"
       }
      }
     },
     "localname": "DARELARC1Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_DARELBT1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARE-LBT1",
        "label": "DARE-LBT1 [Member]",
        "terseLabel": "DARE-LBT1"
       }
      }
     },
     "localname": "DARELBT1Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding Current",
        "label": "Deferred Grant Funding Current",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_EstimatedFairValueOfWarrantsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Fair Value Of Warrants Recorded In Equity",
        "label": "Estimated Fair Value Of Warrants Recorded In Equity",
        "terseLabel": "Estimated fair value of warrants recorded in equity"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrantsRecordedInEquity",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going Concern",
        "label": "Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dare_GrantADARE204AndADARE214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant, ADARE-204 and ADARE-214",
        "label": "Grant, ADARE-204 and ADARE-214 [Member]",
        "terseLabel": "Grant, ADARE-204 and ADARE-214"
       }
      }
     },
     "localname": "GrantADARE204AndADARE214Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_GrantAwardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Award [Text Block]",
        "label": "Grant Award [Text Block]",
        "terseLabel": "GRANT AWARDS"
       }
      }
     },
     "localname": "GrantAwardTextBlock",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dare_GrantDAREPTB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant, DARE-PTB1",
        "label": "Grant, DARE-PTB1 [Member]",
        "terseLabel": "Grant, DARE-PTB1"
       }
      }
     },
     "localname": "GrantDAREPTB1Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_HammockPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hammock Pharmaceuticals, Inc. [Member]",
        "label": "Hammock Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Hammock Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "HammockPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_HennepinLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hennepin License Agreement",
        "label": "Hennepin License Agreement [Member]",
        "terseLabel": "Hennepin License Agreement"
       }
      }
     },
     "localname": "HennepinLicenseAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_IncreaseDecreaseInDeferredGrantFunding": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Deferred Grant Funding",
        "label": "Increase (Decrease) In Deferred Grant Funding",
        "negatedTerseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantFunding",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right-of-Use Asset",
        "negatedTerseLabel": "Decrease in operating lease ROU assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_InsuranceFinancingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Financing, Interest Rate",
        "label": "Insurance Financing, Interest Rate",
        "terseLabel": "Interest rate on insurance financing"
       }
      }
     },
     "localname": "InsuranceFinancingInterestRate",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_InsuranceFinancingPremiumsTaxesAndFeesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Financing, Premiums, Taxes And Fees, Amount",
        "label": "Insurance Financing, Premiums, Taxes And Fees, Amount",
        "terseLabel": "Premiums, taxes and fees"
       }
      }
     },
     "localname": "InsuranceFinancingPremiumsTaxesAndFeesAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_JulyAndAugust2023AtTheMarketSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July and August 2023 At The Market Sales",
        "label": "July and August 2023 At The Market Sales [Member]",
        "terseLabel": "July and August 2023 At The Market Sales"
       }
      }
     },
     "localname": "JulyAndAugust2023AtTheMarketSalesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_JuniperPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juniper Pharmaceuticals, Inc. [Member]",
        "label": "Juniper Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Juniper Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "JuniperPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration Agreement [Member]",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseFeeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fee Expense",
        "label": "License Fee Expense",
        "terseLabel": "License fee expense"
       }
      }
     },
     "localname": "LicenseFeeExpense",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Product or Process for Vaginal or Urological Use",
        "label": "Licensed Product or Process for Vaginal or Urological Use [Member]",
        "terseLabel": "Licensed Product or Process for Vaginal or Urological Use"
       }
      }
     },
     "localname": "LicensedProductOrProcessForVaginalOrUrologicalUseMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MBI",
        "label": "MBI [Member]",
        "terseLabel": "MBI"
       }
      }
     },
     "localname": "MBIMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_March2023AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2023 At The Market Sales Agreement",
        "label": "March 2023 At The Market Sales Agreement [Member]",
        "terseLabel": "March 2023 At The Market Sales Agreement"
       }
      }
     },
     "localname": "March2023AtTheMarketSalesAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MaximumPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Potential Milestone Payments",
        "label": "Maximum Potential Milestone Payments",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "MaximumPotentialMilestonePayments",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement",
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MicrochipsBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Microchips Biotech, Inc. [Member]",
        "label": "Microchips Biotech, Inc. [Member]",
        "terseLabel": "Microchips Biotech, Inc."
       }
      }
     },
     "localname": "MicrochipsBiotechInc.Member",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilanaPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MilanaPharm [Member]",
        "label": "MilanaPharm [Member]",
        "terseLabel": "MilanaPharm"
       }
      }
     },
     "localname": "MilanaPharmMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilestonePaymentsContingentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments, contingent amount.",
        "label": "Milestone Payments, Contingent Amount",
        "terseLabel": "Milestone payments, contingent amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Amount, First Commercial Sale Amount",
        "label": "Milestone Payments, Contingent Amount, First Commercial Sale Amount",
        "terseLabel": "First commercial sale amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmountFirstCommercialSaleAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Amount, Sales Based Milestones Amount",
        "label": "Milestone Payments, Contingent Amount, Sales Based Milestones Amount",
        "terseLabel": "Sales based milestones amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmountSalesBasedMilestonesAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses",
        "label": "Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses",
        "terseLabel": "Reimburse amount, PDUFA fees and other manufacturing expenses"
       }
      }
     },
     "localname": "MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NICHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NICHD",
        "label": "NICHD [Member]",
        "terseLabel": "NICHD"
       }
      }
     },
     "localname": "NICHDMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/GrantAwardsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_NetProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of common stock and warrants.",
        "label": "Net Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NumberOfCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Common Stock Warrants Exercised",
        "label": "Number Of Common Stock Warrants Exercised",
        "terseLabel": "Number of common stock warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockWarrantsExercised",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_October2021AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2021 At The Market Sales Agreement",
        "label": "October 2021 At The Market Sales Agreement [Member]",
        "terseLabel": "October 2021 At The Market Sales Agreement"
       }
      }
     },
     "localname": "October2021AtTheMarketSalesAgreementMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_OperatingLeaseIncrementalBorrowingRatePrimeRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate, Prime Rate",
        "label": "Operating Lease, Incremental Borrowing Rate, Prime Rate",
        "terseLabel": "Incremental borrowing rate, amount over prime rate"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRatePrimeRate",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dare_OrganonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon",
        "label": "Organon [Member]",
        "terseLabel": "Organon"
       }
      }
     },
     "localname": "OrganonMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_PaymentOfAdditionalConsiderationInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Additional Consideration in Business Combination",
        "label": "Payment of Additional Consideration in Business Combination",
        "terseLabel": "Payment of additional consideration"
       }
      }
     },
     "localname": "PaymentOfAdditionalConsiderationInBusinessCombination",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PaymentsToStockholdersRepresentativeInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Stockholders' Representative in Business Combination",
        "label": "Payments to Stockholders' Representative in Business Combination",
        "terseLabel": "Cash paid to stockholders' representative"
       }
      }
     },
     "localname": "PaymentsToStockholdersRepresentativeInBusinessCombination",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PearTreePharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pear Tree Pharmaceuticals, Inc.",
        "label": "Pear Tree Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Pear Tree Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "PearTreePharmaceuticalsIncMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_PercentageOfAggregateCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate commission.",
        "label": "Percentage Of Aggregate Commission",
        "terseLabel": "Commission percent"
       }
      }
     },
     "localname": "PercentageOfAggregateCommission",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PercentageOfRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty rate.",
        "label": "Percentage Of Royalty Rate",
        "terseLabel": "Percentage of royalty rate"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRate",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PeriodofInsufficientCashandLiquidityRequirements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of Insufficient Cash and Liquidity Requirements",
        "label": "Period of Insufficient Cash and Liquidity Requirements",
        "terseLabel": "Period of insufficient cash and liquidity requirements"
       }
      }
     },
     "localname": "PeriodofInsufficientCashandLiquidityRequirements",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "label": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "terseLabel": "Potential annual license maintenance fee payments, thereafter"
       }
      }
     },
     "localname": "PotentialAnnualLicenseMaintenanceFeePaymentsThereafter",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ProceedsFromAwardOfGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Award Of Grant",
        "label": "Proceeds From Award Of Grant",
        "terseLabel": "Amount awarded for grant"
       }
      }
     },
     "localname": "ProceedsFromAwardOfGrant",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from the exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ReceivableForExpensesEligibleForReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable For Expenses Eligible For Reimbursement",
        "label": "Receivable For Expenses Eligible For Reimbursement",
        "terseLabel": "Receivable for expenses eligible for reimbursement"
       }
      }
     },
     "localname": "ReceivableForExpensesEligibleForReimbursement",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ResearchAndDevelopmentAgreementCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Agreement, Commitment, Amount",
        "label": "Research and Development Agreement, Commitment, Amount",
        "terseLabel": "Total payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAgreementCommitmentAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ResearchAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development milestone payment.",
        "label": "Research And Development Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMilestonePayment",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_SaleOfStockBrokerageCommissionsExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Brokerage Commissions Expense",
        "label": "Sale Of Stock, Brokerage Commissions Expense",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "SaleOfStockBrokerageCommissionsExpense",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_SaleOfStockProspectusOfferingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Prospectus Offering Amount",
        "label": "Sale Of Stock, Prospectus Offering Amount",
        "verboseLabel": "Issued shares"
       }
      }
     },
     "localname": "SaleOfStockProspectusOfferingAmount",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones [Member]",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.",
        "label": "Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]",
        "terseLabel": "Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company"
       }
      }
     },
     "localname": "StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_TwoThousandTwentyTwoStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Stock Incentive Plan",
        "label": "Two Thousand Twenty Two Stock Incentive Plan [Member]",
        "terseLabel": "2022 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoStockIncentivePlanMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UpfrontLicenseFeeAmountPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront License Fee, Amount Paid",
        "label": "Upfront License Fee, Amount Paid",
        "terseLabel": "Upfront license fee paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeeAmountPaid",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon achievement of specified development and regulatory milestones.",
        "label": "Upon Achievement Of Specified Development And Regulatory Milestones [Member]",
        "terseLabel": "Upon Achievement of Specified Development and Regulatory Milestones"
       }
      }
     },
     "localname": "UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "label": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Clinical and Regulatory Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones",
        "label": "Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Commercial Milestones [Member]",
        "label": "Upon Achieving Certain Commercial Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Commercial Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainCommercialMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Development Milestones [Member]",
        "label": "Upon Achieving Certain Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponReachingCertainWorldwideNetSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon reaching certain worldwide net sales milestones.",
        "label": "Upon Reaching Certain Worldwide Net Sales Milestones [Member]",
        "terseLabel": "Upon Reaching Certain Worldwide Net Sales Milestones"
       }
      }
     },
     "localname": "UponReachingCertainWorldwideNetSalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiring on april four two thousand twenty six.",
        "label": "Warrants Expiring On April Four Two Thousand Twenty Six [Member]",
        "terseLabel": "Warrants Expiring on April 4, 2026"
       }
      }
     },
     "localname": "WarrantsExpiringOnAprilFourTwoThousandTwentySixMember",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WeightedAverageAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Amortization Period",
        "label": "Weighted Average Amortization Period",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "WeightedAverageAmortizationPeriod",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_WorkingCapitalIncreaseDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital Increase (Deficit)",
        "label": "Working Capital Increase (Deficit)",
        "negatedLabel": "Working capital deficit"
       }
      }
     },
     "localname": "WorkingCapitalIncreaseDeficit",
     "nsuri": "http://darebioscience.com/20230630",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r165",
      "r170",
      "r296",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r204",
      "r304",
      "r340",
      "r353",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r425",
      "r428",
      "r435",
      "r441",
      "r476",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r204",
      "r304",
      "r340",
      "r353",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r425",
      "r428",
      "r435",
      "r441",
      "r476",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r142",
      "r306",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r416",
      "r429",
      "r440",
      "r458",
      "r472",
      "r473",
      "r477",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails",
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r142",
      "r306",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r416",
      "r429",
      "r440",
      "r458",
      "r472",
      "r473",
      "r477",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails",
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r204",
      "r232",
      "r233",
      "r234",
      "r303",
      "r304",
      "r340",
      "r353",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r425",
      "r428",
      "r435",
      "r441",
      "r444",
      "r471",
      "r476",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r204",
      "r232",
      "r233",
      "r234",
      "r303",
      "r304",
      "r340",
      "r353",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r425",
      "r428",
      "r435",
      "r441",
      "r444",
      "r471",
      "r476",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r165",
      "r170",
      "r296",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r46",
      "r84",
      "r327",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r6",
      "r19",
      "r256",
      "r259",
      "r293",
      "r341",
      "r342",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r351",
      "r466",
      "r467",
      "r468",
      "r506",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r29",
      "r30",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r7",
      "r25",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock from the exercise of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r236",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r68",
      "r83",
      "r102",
      "r131",
      "r136",
      "r140",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r251",
      "r253",
      "r272",
      "r323",
      "r375",
      "r439",
      "r451",
      "r474",
      "r475",
      "r511"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r79",
      "r87",
      "r102",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r251",
      "r253",
      "r272",
      "r439",
      "r474",
      "r475",
      "r511"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r249",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r249",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock issued to microchips capital stock holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r81",
      "r417"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r22",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r21",
      "r52",
      "r99"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the condensed consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r52"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Shares Underlying Outstanding Warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "STRATEGIC AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r36",
      "r324",
      "r362"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r466",
      "r467",
      "r506",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r40",
      "r363",
      "r381",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r326",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 240,000,000 shares authorized; 86,633,588 and 84,825,481 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r89",
      "r91",
      "r96",
      "r319",
      "r332"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r183",
      "r184",
      "r195"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Unamortized stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r4",
      "r24"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r205",
      "r209",
      "r237",
      "r238",
      "r239",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r119",
      "r121",
      "r123",
      "r124",
      "r125",
      "r129",
      "r263",
      "r264",
      "r320",
      "r333",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Income (loss) per common share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r121",
      "r123",
      "r124",
      "r125",
      "r129",
      "r263",
      "r264",
      "r320",
      "r333",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Income (loss) per common share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails",
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r7",
      "r77",
      "r92",
      "r93",
      "r94",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r130",
      "r146",
      "r147",
      "r182",
      "r240",
      "r241",
      "r242",
      "r247",
      "r248",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r293",
      "r341",
      "r342",
      "r343",
      "r351",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r34",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r267",
      "r300",
      "r301",
      "r302",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r166",
      "r197",
      "r202",
      "r267",
      "r300",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r166",
      "r197",
      "r202",
      "r267",
      "r301",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r267",
      "r302",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r300",
      "r301",
      "r302",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r265",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "terseLabel": "Gain on early termination of lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49",
      "r385"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "verboseLabel": "Initial payment"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r151",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r305",
      "r464"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r457",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Increase (decrease) operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total future minimum lease payments",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASED PROPERTIES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedProperties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit related to lease of real property"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r102",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r252",
      "r253",
      "r254",
      "r272",
      "r361",
      "r423",
      "r451",
      "r474",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r45",
      "r69",
      "r329",
      "r439",
      "r465",
      "r470",
      "r507"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r80",
      "r102",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r252",
      "r253",
      "r254",
      "r272",
      "r439",
      "r474",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fee revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r33",
      "r245",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "negatedLabel": "Cash flow from operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r54",
      "r70",
      "r78",
      "r88",
      "r90",
      "r94",
      "r102",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r122",
      "r131",
      "r135",
      "r139",
      "r141",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r264",
      "r272",
      "r331",
      "r383",
      "r399",
      "r400",
      "r424",
      "r450",
      "r474"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Square footage of office space"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r135",
      "r139",
      "r141",
      "r424"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r288",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r286",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r291",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r38",
      "r61",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r86",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r39",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r39",
      "r363",
      "r381",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39",
      "r325",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r85",
      "r148",
      "r149",
      "r418"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercises, gross"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r322",
      "r330",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r203",
      "r294",
      "r295",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r380",
      "r382",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r203",
      "r294",
      "r295",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r380",
      "r382",
      "r406",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r245",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Other cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r245",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Credits recorded to research and development expense for costs related to award"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r37",
      "r244",
      "r519"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r21",
      "r71",
      "r99"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in other non-current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r59",
      "r328",
      "r344",
      "r346",
      "r350",
      "r364",
      "r439"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r77",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r146",
      "r147",
      "r240",
      "r241",
      "r242",
      "r247",
      "r248",
      "r255",
      "r257",
      "r258",
      "r260",
      "r262",
      "r341",
      "r343",
      "r351",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r142",
      "r143",
      "r144",
      "r193",
      "r194",
      "r306"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r95",
      "r102",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r272",
      "r321",
      "r474"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r290",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right-of-use assets obtained in exchange for new operating lease liabilities, net"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares of common stock for net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity for Amended 2014 Plan and Related Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Options to purchase number of outstanding shares of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in usd per share)",
        "periodStartLabel": "Outstanding beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual percentage increase in outstanding number of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) of non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r7",
      "r16",
      "r77",
      "r92",
      "r93",
      "r94",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r130",
      "r146",
      "r147",
      "r182",
      "r240",
      "r241",
      "r242",
      "r247",
      "r248",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r293",
      "r341",
      "r342",
      "r343",
      "r351",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r130",
      "r306",
      "r349",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r130",
      "r306",
      "r349",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r59",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r16",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r56",
      "r365",
      "r381",
      "r402",
      "r403",
      "r439",
      "r451",
      "r465",
      "r470",
      "r507",
      "r522"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r101",
      "r167",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r261",
      "r404",
      "r405",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant, exercise price, decrease (in usd per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r442",
      "r443",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-1B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001401914-23-000045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001401914-23-000045-xbrl.zip
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MW3$:1%Q](F0X^D*/Q%UV<W9A:L3X)&_5LV=(,3?NZ=OQ<I?$H]N]UV3QW5X
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M^.JK-_#@:U\]TO7\K%D5"="DG_WFY->6?&O_@#36!Z11-5J% %+8C(8$Y(Z
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M./XJ\;VGX )/;:$1/# A79_F]W?#".91=4+?)\.87N0_?'*]>.B3MPLO\+V
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MQYYS@26MGK,&QAZQIFK4JU+A]8A80HZ[2A3LWHH6.:I-4#^I#]HSJPZX2>A
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MHY0$48;><XC]068LMXF1E=!;.C&L;F<+3:Q]?!&-8_"]0;,I+$,TO@PO5*<
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M>GZ@6ZV)=P*=76D#X#2SI3;K9EE =Z*Y[&_9$<8L"XH)T.RHY8 FTK+=,#K
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M@6FUGUPTF%J5=D,UZBU5L^>/ Y%@*CN85OO"18/)QI,JS09HI@5GGIQ&HD5
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M6:OK5ED&J]5:VG;8.L)@C5K+W,=@FU;QXJ7KM9:]'@T6KV6-D?I;4?+)M9D
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M2MO23=6V6P)%JB5R#F&W[P:<NHC .=T4AVQ.*@,+DCF2.9(YI\N<S7:<K]G
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M3P<M?7S+;(JG;.=<KHV6WS7"$J=AVA:GBY<8M#<YV9<9M*MUL55TN$(8+ZO
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M<@C(G[Y"F/QRTJF0FNI+?A(LATKY504K8=LISR=L*B_2QNZ<(E%8LL0SXL3
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M' BZ9<"@I(1-C/\ *8W(K*QYQ]Z0](<ZF2&CE/)HMGNR.F3$IQK-4;4RV*,
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MI8?4]EV%LZ_0>W5PEEP9N3>E$8<S<6]D0J(,ZU/ZG CD?Q^?G!U?7^0!M]X
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M]064K2@Z2#/$//3E(O)476:XFXFH?4%426]]FLI2!N8\;[+*%L?QEB[K(-E
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MU&<VH](O6+-9^56N<-U9G5_5@/ *>P^:S=6JT'_YMH-F:[?;#IK+MCT]KNU
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MUBVE>E#<L'1-+1NB#QQ.Z&<NCHBZ(:P;6.D=* PL9**  $613=7R0@@1JW_
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M\/J685DV@K(D>E,@M?,=^$ 4LRD%:/L/5E3 ?\]#*1>F&S)]/O;+=KARYLR
M--01(HG29[C]E=CFL#;'?Q=!<C$RKD2&7\ZBCPA:#4;\"<UEHE^NS#V(4##7
MI]=#HS0399NX!+\"*)42^E4<ICQ<E85G^90I"+5%E F1<)<>ISC((.*V 56?
MM;S.T.YI/\8B+OC*$#AQ "(0?3+XP>@3G%656(4&J5\6LX'=+.\'<S0#OG(%
MYJ R1)%V,D6U:3I#&838V3\)RSQ\<"H)BE]>H*EZAJ::^5R((AI+()_"3].'
M,PK^IM/TC%9QD>!_\4[/9[C<B]$5O8__NAR=U0R=M?>.P,5P@1>+I&9.$5.G
M]JGAA8ARMQ4[?A25/5&/%ZPX!JOJA&RN2Z_C*^N%EVH4%9G!C^ \ZT0Z<"+M
M\@-1D18IJ+.W+L1EAF-Y"C2&VP-E_^L4G6V!-#I<)(VJP"FR0R?L;E'54&W!
MZM27<\BW,2%UG01?$(>'2!]L3B_RO@'WC(L)*N<WYT\/. F8" PPV #]\E7D
MKU2Y$;KRW?EH3)[9>CZ+)8=#QP=.^HSRU*EKG']\;MG1N6+W2!^>C1Q1D3'3
MM\8O<S%75KQ!R9_A:_5MJH<?.!\Q96]-JY669Q$1\U"G> JW[-=U*DF(J[X$
M+T=:@7H8\JH?ZH7-)3D[TU5V<+I.8.Y37!HB/>9^>K%$"^=1$<"IR)_I0^'H
MG+)%*LSUV)4CBZ6T$PR5=%YV+8.(A>L:!MY-%*<!CCE1F4HQ=<B<$0G-5>G#
M /S)5,THM_*,?.9)/+NY=;CEIA*32WI2)=]X;6?[RC?)U*,KZ&\?ADE\XX?.
M,)G=J)3J Z)Z3E&"XV(KR48'G:XOS_8/&QTRU:3AV>5(*(_T]*=<D:*RCQBU
MFH<:ID[3'"&."U%)5X=. @^97FC+A-X\F: HB/9.^131E9446\*,9_/MN%P>
M/?7Q7HL8,R4,M#30G(/:EQCA'QY>%JWT:@K_N__QH40;9.20F[E "Q='Y8=4
MTYYBP_+5[JP.J0@YE8@B^P+(TE2];?D@2JGSDA83?RN[B(TYQNJ&:BLMHQ1K
M*ZO,=" [BVQ<*5-#860U/:VVN>:<S2T9-EIYBUBHU:[8(C:]8-^C2$XV%C-%
M$I@Y)?QQ]!-M+EHC:G;8>O[MMVM[1^VJ&UY0FUP&=*8=>OI& 1M-)ZV5WB)8
M-*.XJ$YR3:BTP_9SLD:[/H=NUCPX.IET-L!,K&6[#;,61>;\LGI_AB.=K.)/
MURXL\-?CR<YS%G.W&TB."THG+$2HBM1V\>!LP3W&:K<\OZYV*'/K239^* MZ
MU0XR&\%,,PJDLKH"[E*8$QNF.'<84BQ[[)M"M%P$6!JKO=$H" .B7BI6B2*N
M<6/K C]H17^M2K'LH#BD:6SZB6=3E&-*@F2X(UL#KP"[?@K8F*IV[[]W;D&M
M+PZ&EP!W2BA\:8+*%$WLKNFCW%YVC 7Q+->LE7&M#+@19;Y![6.%H$0S.6)(
M>&Z1_JI-G"7>*%K".GLWB-$A48YL;FAJ;@WD67E3S]5C9U/M4984-ZJN_4E,
M5=W4*35+TIG'!KAG?]0@,,'2#W1LH*):9QU=-2^CN'D!0E']^GKU:(60_6HF
MK[OBP?2>58FW]XZZ54H<MLS>CT9B(XO?JR@#V@494!Y$_.9["?B"OK]*;4\%
M1EAG"V4<.=$/)=%!'2<R)U =_M.?L2N K.B25G68(W&+*.S96-/$F^HJ8(R8
M[-^"CII;X^YEPB8J4**"^]XX_AF,_$AFPHAQ/1P#JR)NYS3@ 8-H')@[=L*"
M@/^K% O]_>_'=7PA:.WQ6\U0><U0_374#+5*:X;:I35#.\3S&Z@BDN[PLF2C
ME@5KEQ1U:\]9D=[N +FV%Z"\+U>1KI3_4@5$Z#<43&=CK*]S;O5G/;?#O:/6
MX88K^1<<SX&3K15?A@RI27FI0G+M[ZQ4,$2]KL52H:)7M,A/K.IEGM/#G"F^
M,!LIQ=.@<BBK)"F5/!FQOLX3&\1@JZ)*6B"P:#O? E'$KLPT/V3J/@H5"\$:
M=2IVXJPHL8*JYMY%'>&%/7.]1!XO(._[%PZU_.JIW#UW_[ \3:-_5? I6&"#
M]&H--?%N@$<P>8H(T;)*ZH\J%H_149M5JSHCL6(6,<I"(WV'5-QUI>8RYYP1
M$D9592N*5A/ \^9W/$TM;!NS$ >-IU%>-EIASNK.2>I2*%^CS%)_'.R+E"R+
M+U6B,L,=/:]4I:962ZB2""T5K,4X7[6H5=)ZB>BB_AJ5L/J<Z^;L>C@;3^#O
M8ZL5$M/@8\S!")SZ4H*_XDA,R)#3.*6C8:T(4H&'7E)-%()G*4[83/B&K0!-
MR:;4?(%R:2R;*A'(!94QG%4_9WU@<5U:]5(AD!-ORF"G?SO_]LJ:^R=)$'+L
M@^-5\\JC%@ZKL\_)BHVH7V=[_/6'=>C?+B+'5$2F/"??T[ZH7(=#*!)><17R
M6GP?<;X",V7JX:%E9\-.S7*E3=OEMCWF:LI!TK_AIR$($C\,Y1=8#>\J_!8&
MC,5B2_IW97+ J B/8'Y7VK( HJD]ZQ@UJ;$@8D5*<ESM6Y_Z<^QM8X@!N]8?
MN4G(  XKKVB&S2N5>#3:G!4AGU<>D1M-J! 4;?!JB]O*<H1<J^@/9J4P?@R.
M0\,UJ I_<R>D0P3'9+#)27WU,(45H0J&0].EWXA_2K&[50^O4\/.PHK#$U-1
M'=;8O)L.#F=-H,%9,M>A=)H#<Z(\-/\PA659J>$5 #8;87EM;]\@%:!CAT<&
MH\S!EB T(Z@M"/^8)-1W%B?W I%+]B0]'K]P8#UT7E8-U<1JUSYO]-?& T2=
M.MQP<Z7 6A"5^-QS>]"6A,=8[9@>-5=PY6-JE%<PL$5BM1:MDG#[\*@XXMRR
MEHV321/KZ Z:3THF*X&%\* D5.)K 3[D8I2+>'D,U[A.4<;3(U=@M508^#/=
M^9CW>+*J6BLCO>/5'%Y?1=?*O5BI<+8^CC%/.W^8U8_Y6IHE.RBWL9/E&#G/
M!HGC.F3&2G@5GI@JY%[4HV*<L+S@C_DT<CX9GUPN<>U\OSJV'#3ZC&L:$G(/
M-BA596/$+5H,(HRI>(+LKS+07+P(DB:^ 8&3^#R+PX*[N*.FB*E8?LBF3F=_
M#'^_I=?7&_(/'IR5.N^*('$T."*5L1&4HF[46HPV3/^HMUP:/,"PZ^'#>S&(
MRMI(7!EVDHMV2=6:.F9X5>3?Q%,,?*V,Q.;*A "-#F)XVER#Y-?3/ (F=L.F
MJLV6Q765/0 K^9%UPE!Y1G%N "'8V* 94/Q@1&W"Y0!O6?VRK'[C-63UR_/W
M6RO\KZZN==0-6?HD#D.O'TM+^:N0_I_]?B+3M.8K !,MH&2$?1 YP6\P5P5T
MT_E/;SSYP%;RM8X4^>G^)_Z=:C.L^*)C?\?E!D1[7@\N1HE7E*9P:]6@GA48
MECEQF2N;LL->E950G $%JXKG#BK7]<9'83J!A6#P)0G /PI,/P));):\7-\\
M5/UQ]+M[L,DR@TM&_A@K]5/_)_K3PX<49#)K+WC7;_ -^0#V79,QBCJ.T4$S
MN.)VKUKVF5X2SW#$\3!($:,_R3U8/J5J:G_+?URW8'X._)#@"[ZC:H$[T7@#
MP X4)LS5BET%(7"!-PI"YP26-W:=YD'G+S+5V?\9I*;MD\(SBZ9(XI%JWU[>
MB02"/8@8.,P8)A9:880133RDU"R(4E.P39JKD?AH/N- T^PS0IG;A<;T#48T
M6+V'F/' NT3>X-44/@9DC9$*T:7\+%_!/=,V2M87]&?PVY%,!,:J=EP@W$%P
MQUT(:!BIS^1[=H?.-U78L;/B"\6S"B&5N7>/A"WM/FLW10>+H;L;J>FI*(0N
M]OOID0V6X;AFEU/W62O'.VV*8#XQEBEXX:.B1DQ9(:9:6=EV+S 9CF-*@._H
MR-#]C> [M\$D=7(#J J<Z-I#]DJRI7JZF,0_@?[S$0]DB67!.W4X8ZV2*A5S
MS85/,*1B1QW2]:=$O(X)$15AA4]_/]X'NZ:D!7H']K0XEG"X#F*[.A0[0*!_
M567082^LG<@UD0(][K*Z>'W^]#U.1QKAN,- 8.ME '5849/KNF7%\X#WGJ8Z
MJX.UQ:V#S@H:XN72'KVY9=<;UYZ,7[16VN-1V8W>O"KI)R*#[J*!)RN1@;(:
MRC( MN&PLX(B:TYHOJ^P*<H*"O4YSITIA65GFJ7@"VP"8-Y"FP8\W\>3*3UW
M:#;T_>D]4F(ET44$ E>@NTQQZ-GYYVS275L9%Z-+?ODEO%L3$\Z$5]2$<[,+
MI/07XHE5U]3<T)H.:XP37+HH.CKP^Q/$[C&7A*-#P&^W[F9Z"^X\EB:O5K6Y
M"Q98A;62->V-<9F:+N+2[!;%>51NKE"("&=F;)9%[./-2]"5(I26][W+@#:J
M9I(%H9K_H/()0]>YC>\1\5MPO='<*7E^:?9O J2B>YTKYWUY!1>!WZ0! )%L
M"L-,X<%V50[Z-8PPCF$EZ9DN#_38>8O%QSRGQIE6N="U>,M"<!:B69V%P$6B
M2 KJ7J\S:!\V!_U:I]7P6EZ_UZSYAX?#7J_=.:S[_P>QD+<T=5$AP+IXK>B<
M1S?[H3^"E[<7B[1]_-"S>I6M S;ABO\KRNE\!GP;#'*JJ)X'7[4Q11EU]3R>
M^I^"=!#&Z2SQK^&['T/XC%%"]6*_YF$=GXS30"=(N,G,WSNZNKXX^:\_+[Y\
M.KV\4ABAI__]_>SZ?Y0"DR7F;J<BI<2O*'EQ8]5$T\O-J:NWR7<6%1W@W+/I
M;9S XX;.E:[,/^&J?+J9'2BFF -''3X(:MPH#L/X7BDNZOVY\S2$AM6]8'=-
M@;"FU@\I*/1]0C5'=6E]*M<^*^API-;!0J<8'!KR%&J?2@&!!DGGS+2VF;)K
M\<S=F*Z)/!3PBE#(O5:%):C8D>^>KIX)PE#(JJ6?A\ 8C1:5?I:6?S[*<WDY
M'N(I, J1L.D<7W]UKLBN?15)6K.S^0".M.-"-C88^:'KG <#'"J82DY5'D&A
M-J%\-!/!]%)?H(2W!T].G,_!]-\W?N*%0_UMU6"!?Q?D"2PHJ^XDXI&Q-'(^
M5J/G%6BHL^=-]V%C^W 7/_RINT>AO^NOKN.3]D%O@V<G2FE*)AK("[;7"\2,
M";H<Z][H<N3R]D2/%APP!@^\&.?OSF'F"K>NO:Q;=ZP<Y1/]UE+W#FLT2[P[
M$9,W29RF7&SH#U/5-I<Y>9J54%:F1TX -@^";Y#(2(G<N4E>OG# -P0X,@F!
MGE1()(3-A J6,#VP=%?V'I9;F\KK"=:\#8F4TPZW?CBB"(("%'%(Q/,.(^<S
M L->[3>==Y\#< O.XP.GV6SN-]JM;J?QGOD)_6(\0RK3FJGAF1Q03OR DJ>!
M'KX9A H&%K][=7J"KV$6E1K@.IT5D$'H(7L:#T;\-OD.]T =NA8TJ[6(=#:9
MA+P-ACR65]1EI#U[%SQV";^J>62];&=O7N4QRM*+$6F@;WJ%%_+"]8*0AZT*
M2+U"%+)T>D&>D P-Y:2@Y)+8Q4^!K?% RX\YEY^S#_1Q:]C=*,DG$UE(@Y\.
ME4-B-Q4R1]G(N4Q(!7E[55OH<($M9%%BV<"'L^@:,=+X92L;1VT<D-ERV[V2
MINX*<Z^L44S2 JK02 =$2V3U^@WOV9,J#M"P#BJ#Q'HIZ[IXU$EU< Q4LZJ#
M""V2P8SJLQ0G^-'44J\<0QP):,,3G$)>:GU,XA]P #>6LDU/656MO'?,GM3+
MK>?=-9XO!M-8H82_-O/9WML:!O3?/SI7"*L64*(#BQ7?,9X'$*M&E<=/??%1
M7_S C[Q_M$F,=["4]9M=GC>0,KF%QN]:XKG[9.)Y%/STA_O_]I.XC.>Z>T>K
M+K7W0DOM[1U%<4$TK#1.J,P@EAB_:B<?+:N3T<K'>$OV\C$]@--OI&C"O":P
MO<W'#*!Y87FF\ 76EV;;B*UC 2=L2)2]2C%5K]5>AOF[M97E5+U6?Z&UUM\$
MU18(*CNP[_S#2["4+=UA^52$6V<JN0?.GV(1$:5:C; (YO:@2/A'//(@NL,*
MFT2J3[VI?HSKW,O1J9XRAE\3066] 0A-K2L SN3F0NE" ]$Z6#S[Y)N?$/\5
M.3E39M(HA/%#+TTO1G+'%\DE'MRIO/L;OEK_,96_IO4RQFT@[EB9YS5!C#E<
MFN:'Y\L].D_YRL5(<T 7Y$"RF!AY <(-AS-=+Z#)@SM(-$'4VS0ZK(LDUO<?
MXXK6:\TY$;13M;[/L+2_X\K,98-+CKTS(,DYV;IJ**W;)(*H+G%C%8R5LHF\
M"AE(U+9IJ:$R6@HVL@S69Z;CH1ZSR#X7$L'?@OUA$$JI.]::I(&9SJ2*3XA3
M2R<EA,&8ABGX/V7ZO&3NB@R9N4)=!T\U2?A]A! 0RZ0@.S#*C3;$.^S!@<T.
M48&02&$DH<RGWC."-ALIU)5%-5+96;*:S9P0@0I@>U'ELN,T<XX2"W:",:PA
M8"K3!384C,?U$$ *K@@N.C<XI7S>A#Z]7,<N;\[E T"LA6Q/]T.V9Y\^3>\E
MB]"RUJ;JYN5JL7Z,#PW!5:@T3P?$.8>3O;I5!M!:5^VHK.^M-S183=*V# PU
MG4U]/C5<$$E\?JWJ9)Y+2/AS9.Z$#EK#DO4H0J6RU36W"@EO"7X@Y+U92I_H
MQ]AM6+DTFUB05KT95M^I[C)%[HM"^]4*JC5708D\RJBD3S[GP<OT4&OOJ';0
MZ\[10VK>QIK+;6]TN6U:;DE!N%YNME7_P%DU^JWO#C.*,S!.,:^TJC\P+W^H
M['^K(D I$74,*Y<$=+%0WFVVFVZ[7@(85!'WOO<30\,$J+39\'9%I;BZ^V_R
MEL_@F^;H8&44G"Z5P\\!P5'36Q)_+*V7</=ZZY;A.:&I#7&4-R_ 05F5#.:F
MD5<G@_F>8'?OZ+SH"5JB*'O9PU78HK$LMG%G^Z&-5ZRB&]R"P-:^>Z&>+F_K
M%ZOJL&TF7]S6[16KZHXKH*BROI12HJ;N2E\PSKC"H9SPR]_G%^*]%<)R(6QK
M=^ XJO%NLRRFC[&ZV+)1_5>BRZ/_AT%X]+4B), ^H45,4O]W]<,'L(@FH??P
M>Q#1T=*7/F07A\=PAT5Z(*UD@;16_K.<4+O>.&APE>TT@?\;JC?+ 1[4Z&^_
M38<E?^STZ+ K_S[WRW/_V /O_$D>W%6[W?2#L?-\QY;</EQ^R;\1=20Y.=6H
M,^40G@GRS?^[!RZ\YETJ]_Z],?GIE#)*GCJ9,#<CA;J+0BXD&:3"BGH[PP=8
M+(F "R/+B_%$.:DY^ZTY]<RAZH]V=NEHE!GDD%>PB>WO%&6<HBG*XOD3&-^9
M_9?S0KT]AQ?ZWN#'#77D[,NR!V!]CT8?1,!3='TRQ3!#,'34GE[TG!;K\9IE
MT2V?K.DLJM4N"_):++FJ=]:K[1UUW'9)M'<)HJZ\MQ6H_?7>_7\\Y@1W?O?K
M1636(O\U<AP]!#"NE24YMI;L=^G6*SS8VF$FS%!ZF:F)-"@=\XDZDVVYACD$
MQL[<'WH/^XBL;:X6G(A:ZS?X_^"B=BJ]S8VIJA']/W5OXETTX>JX]U8S[:NX
MV&45657S^9.IL>9&U9C<Z:/X^0F>L<T$(GV@6W+:.W92)(A^HS!%60BLY#>K
MMD1W]HY>10MR>T,MR*;9F,+<>L[6)?=HG,3I-"4;Y2.FWO1,C$((M5<R2+;7
MJFA,WO]X?'7ZR3FY^/KM]/SJ^/KLXGRMMF1^0<EK=Z@MF6ZS4:NWG-/Q)(P?
M?%]JE+ZIQ-:WT%LXCGM;(_G7)6GHA9O5&)JG5]^^N4[?'^# $=/=%5CYXQ8C
M>B+BM2Z+)!1Q Z?$Y4=3U6;&M71I@.GEOWF1*H@ZI%J,Q*=\\&KU*(N*M8]#
M8!5<@&$DF]5*^R/F)I)Z[?E^17&)BXJT-[_$SK)5CWC_DMC/#/K+=8DA+9@)
M"<N5.:Z1)-M>&7$L[?68);U4[?7$2\Q"9Q%J=N2/71<8J^U42POU-?HD_T67
M1BG"X=*K>"0@^ C"1(_$##KPAU">C)1#$ /01?AVJ9G)_X:XSAZ=9%.SAZ./
MJ$;!%V&'PS='(W#.$_[.,("78IVE*YB)43H+IYZ:S>L-[P(>K"B2"?]GU4A:
M?6&)=BG''Z-#<D,E2Q\?"@; ,6XM6R2]/E9"[Q 4H%MK==QN=_G"" LA B]7
MEW.94ND"/3CW5(@TY9(?PL$H8#SE<3 "#:51[W*U'O>C4]E% :1"H5D,!3@#
MOBCX=@SH!$XZS<K .KI1@"<AX[-D9 U\EZCS7?!^BRZ:I["DEEMZ+CWY*UYT
MERZZ A+#A5W/VW8Y#D"]7I];O+3VIFT( 6OG)(%D0%09C$"OMW?4JH81,,1C
ME0)4D3C^@$5W&.4A*0<'%-#83,$0&/I<ME^@8FUK]6,<OP8/UJ+FP+F(M-W#
M/>X--[>V>80-+UJ9,JM@ 3.7U%]\2?T*RLQ*HF]D_RFD'U.IMA*Q@G::1ZQK
MP,_4ZPN#0:;,Z,2;H&' &T+$S@1$U><X^3R;@JMV)L)NY3W5<4\@RMQNNRAI
M#YQC!-N'%X(2TD#_.;@@)!<6IN^HQG?$U.>'\?W[!:(TCL@@<[!>AJD.K/;1
M+&&H?E:65"I,5CLA^3,V17& 5T&T U5;_"0/ Y5^A_"+((67>(3V(QG2#DO0
M,DQ:7I@:)(STN\.&)5WI:[(A[>Z]AILCR:)$-*8 ?O*3E_SG_VHTFQ^<CT&<
M\GP4!LIV*@]*FZ":.URK%\#@8?!8C&7,CB*OH$%8\(153X%GMQ,8%M5CK@KF
MKVVG!GHOI1:K996ZVB1UL_;K<G!6VT@K68MN;5O3G'F0$GCWRLIA$3C92YOI
MK1H.\:RY]?JAVZP5M<<'1BDRB-4;/X&G5X^4/*FW6FZG6XU,8G6&"+\LHURT
M@*@=EHH09F(N;79--R9CM/KL7=YCH0UL:>13-X\@N&+!8U98O&&JEI:2MG>G
ME+0ZWKUKD>VKV7@LLZN9[-5(3U1@P?2A$.=?J^Z[5#;2^\1#4*^[QM12(7O1
MPH:=;)YBQU08EP.3&0X""H\<'I J/U+FALH96'(J9WU8IL $9%(J $L<APTB
MEJ;XJ!7BL&R3%+NP< R;!.&T %VIX:%)QI7&#[1:XC(-J?.:X%1P1@%>TSK(
M#:HH\Y\!!<;)E#WCJL"U0/,]LC&GHLE5Y^UD,%^&X+6/;)D%Z9? ZP<AW/L)
M(D6!41 -SV.&C5H93:Y5:V/JL=C;E0634XZ;.2R:^>HY3,<8'KLCE"B5JX&C
M6H[WJ5[F'_*48W[(,;^%CH!]_\RN@*T&OP-EV<4QK5H'_)Z#UF$^[4CAN#0?
MZ*LR"^^\(%3#<,&31=NCVB8P)B(H^@IJ7MEFJFI?>CZ;Z1!MIL-ZU^W5BV2Q
M),QM58/$[C0Y- \[3U38WVD^56'_$W5EK++@BGZ!WA+] J^C@/Q<RQCFRU^N
M@E[)<D>$.9G$<[H*-EE5/^=XL/)G"TJD,D'-J?/)'_A$+P).VZ@DE\8&*ZMK
M3LD!48YT"TYH98VYJ++ZI;-DK5H7-6JGWG#;[6(FJ;R\<)-5]'3;M>7O>I,%
MXD]+LUO"U(5^B,WM>J<X=%X#1)9--Y?5+3)ISIG(]%"4<2=.)COH5,%I;QUC
M;K*TOVP]8C,O8C/8X+,2W1_L?JVE'TMV^[I4X$+L[T=R%QU^>B;.^!\(5[*J
M$JQ3]KW;/G0[G6*N845>FT.^3Z7GEBWE_R7H<*Z@/WR<H$]7HL45A7T=N^,.
MZD7(FI<CP"?T?[99GFNXG<=X/+O/26M+= P ,HPM8VTQ.W#,P<Z3K %KU*HW
ML)>GVZ@W/FS(*MHBC^0QSUA7'OY,@]^C()14U*8EHL;O6E<HTE3)0EW_+VQL
MGF#@/ S]X6\Z.?]F>+Z$X?F9CW^6&.)>18ZU-B;'MMCB7.,9VRG'2BY[54G6
M?EI)MHMF%D$KOAE9+R&]#-##6M*K\V:%[9055KCL5:77X4O88=LFL7(9,JJ#
M5"45CS'"?M'LV*)ZDA?/CM6[>T<]MW58<QOUWH;,M*W)CBVPX1[M..Q< JQL
M8SO%9W.5S'S8]9?+<=4IQ]6JJO)[96'/;=-HI]9<G8UHM&RJ<2E@KI*_ONF\
M]>UZ?:'KZ;Q&;>^HY1YV>F[W\-&YB,U3PY;7C+P^K5BVL9WBQ!?4BA8SKJ@5
M&Y0,;&^J\F-C6E'#I>EF+QM&JZ+BNKF-O4+VC3H".;21_B %-G7E)W=PN14T
MQ!!(\-/%"">%W438N<"N.<&@%=N&&HU=;AN*X5X6=[%8,$QV-Y'I<+"[A;-=
MP30%C8^1!PGZ>&5#?"R#W:"CY3&8#OR'PB:,S2,3P%+LIO52F:21_KY3S00U
MU1"P<C-!H]G>@MK\G6LF>%OP"[5K+#/>H3*BV]NE;H7KV\3WG:_<EWB*?8G4
MKZ!\M$UT;^S4>5P%/Y<\C0H'OK'>9) GMW#SVW\DUN\.7.7<\,)K[3Z:VT/S
MBC?]=M,;BBB.1K718 <:R;#?EZ:XDX'NW_EA/$%[>V/]"J\WS++DEG<M %,,
MO&1@C&N;0 A>(K39!-9$5*&2\;8;[JC9I9CE&YN]7C;KO02;M?:.ZH=UM]=\
M8[,W-OL5V*Q1>PDV:^\=M4";M7J/+DUY8[,W-ML%-JN_!)MU]HZ:K8[;;A=1
M&K>1S5ZP'/,%Z.<//_(3+Y0)!N,@"M)I0EB2OW933"G[-%Z"?0Y!2S5[;J_[
M:&-PB_M<?EV::KX$375!)'?:;KN[3<W2;S2U*9IJO01-]?:.NIV6VZR]R:G7
M2%/M%Z"I9FWOZ+#1=)N'VT133YB+H/4<,D3U]MF*5(.TT=+57]C9?-R![+X\
MZ;R$/*GO'77:-;?>?72WQ 8O<S?B06\,_,; &08^? D&;NP=M9N';KM1?V/@
M-P9^8^#',/!+5! TFWM'=;=QV'*[M<,W%GYCX3<6?@P+OT1U0A.K$]Q:I^?V
MFAL&UGT1%EZB+:M\)A>>1U#W>IU!^[ YZ-<ZK8;7\OIP*O[AX;#7:W<.Z_[_
M:?7VJEM@9,/8<&0WQ2"IR-;VD4-_;^4" F4M2?NM]I/U))5W@'4.'+[NXO^N
MUOOUQ4]3W[_@1J+HY@M.@"UIX&JV]_38S^'Q5'Z'C\NV=7TY/;XZ_>1\N[SX
M=GIY?79Z5;S07)M:R?@N>7+)^\J'>LE5]K)7N96M9)E14CC%FD?BX&ST09Q,
MX@0'+-WZWO!?,R^9XH#+=]5MVO\:30MRJ3F_G./<AT]&Q'''B>^M+( PH>S6
M.\6J#2?%%<-N?)_'QM/X=@>.=N"_IVE .!]TR/,Z0QFHC)/"SR+GL]]/:,IR
M80RI0T71U!6'4P1QGK,?#;$>E[KI?D[A7_1YG .H!EF98YW/"LVEF &.R[_W
MPFMX0>FTI'N0D*D?F2,ZW#N:WL<\'ZDP-8G&5-,$0[WJ*+Z7<88TS?1X=@.4
MJ@97M'9W8.C7CV<N3K*ZC6FZ^SV./\8)K\$PP+NV;]D;_&L6\#4[Y_$=C^X
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MA=/<\;+#-YM+;0.I]F)T E_%ER^ER%NMN8K\8(=M1&>2^'=!/$N!A.BT@?!
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M=)9$C-@WBX#-\&=U!*[SKL\?L]X[\-);GC\3]&?"0 G+R"DA.2K)P)/G$2V
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M(FW[N@Q&%YNCZ"28O5$DE",GLNRA'L@H:_X.1 V_O9K2G!J>07L7"'C>4[+
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M "]_K >>E7Y%#SQ3*;,9C1(VBQ1^5Q&?^8DVM3&573NX.I QG,WE:A2VT2A
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M#];VZ684)H!H]B2521'(!H2-PGX$,83I.[1.!"[^+J _VX+2<Z;!V)?)4#B
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M#2DES#@%0%*(+"F+_2O;[7!#9GTX4"B=&I3'*4Y@')EE@C2Q 3B 3@R60DJ
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MN1]$ZA=0W9RVBTV,?-K3-TX2,'KU93;G(<58/&"TH'-.8J7V#!$(:02YFOK
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M8'NW,5?5ZV-98UA5,:Q%X;\[3"&LD:Q&LMV+G#66U=.4*W8WK6>B_)>?VO^
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MRF34(,7XS[61\DRN(8639MX-'_86Y$&!)2%\G!D@!'H70Z2D)48@X!.)'9U
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M#'"*B6H^:#&+%<M @,[T.^G'Q*R5VK<]/\_5B7HD'D /'Q-'R7TT(WG@X3V
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M--UUAJ:U-?:#)>,(70W&P"0^(\U6=B.PR)WR.B+1\JC,=09WE4,7/^=ORWL
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MRN4__O.?YU9\L]WLOFVWNL2=B#I#\J9:II0)RJ V4]"JV/<+$CV2(2K,AW+
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MZP0):VI0DO>3\=0@URDEI!4,V,U>>QJ^L&?$_D7.'MHI=[2*K$[/DP'NE=#
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MT*2 49O+2 Z5/_\>DEM$2 UB1<J1-:0PRQ)YG#85SW<EW89S'IJ%)M%M"(R
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MHT.9LZN/+"^*W,QE"AQ6>E&."Q=S2<>0#5V/<N_I-["9]G1)#EWV*[JZ#"Y
M*[#3)&:O.ICIPJ0)T!^[MK ,G9I9^!.I5"LG0@Z:6$+)I414=(]S<[(YC6EJ
M8O,W;I-@HQDM8[0;A8BPX-6ZNT!^G+!>GF*#1O64@BRU1>OU>LTC[_BH?9R#
MYV]R1[_ZV/$3CV%5"REP63T@E0O%Q_($ZC&"+27Q!EJG #,L;)R TL-P@I.
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M1=E>F/>:X(-D.7'^ 6H99HF4@$CJ.@7?5H<]"8]*N ]-X_4GZT\^U"<?U@*
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MQN?A5?-]X[\??_KIP]^:S=_.!C?6!;/]&7C2.N= )#C6(Y532T[!^L+X5_I
MK+Y+Y)CQ6;/Y49.=L_F"T\E46IU69S\J%GWE)P?'1_:1O3]N'H^/QLV#XPXT
MWQ\<[S=;^YW6NV/G .!X_._)R?L#TMD?VX?-EMW"8ON'A\W1^Z-6<SP^V.\
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MS%&2;8K*12--[&?LKSORX<!F>,97S(?NB/WC,W*GY&5U'L8W  L;O03%GK#
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MQ4'.OKV#+S#NU@T229.EAB2.>J;TJ601*4L@X6N9>32J=BY'/\I^ZD&5I3?
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M&JTW"AM\@ @C-.N/;Q ; R3KD-B<!)YCAI7R!AG/L00F1B63T+45A[4(/#P
M519*[79 URA],6W^1#I/KYV'[>NOGTO,^PG3/#$TE$A,Y2J&:XYP]YX$9;*R
M(E'/^E?D?7R\[QP&0W%VB,)58]_B@?C/KO')['CZ871Z-GO]M81VMO!^.HIP
M^<MV^=N6E: ,0U$E(EZ71BA.6V)9QCV/9J.STD*GVJ[3)Q'ZG>-H>T*JW6'H
M=3L;G9?[W#=^-/TO/YY?HQ WP3(&'J,+'IU0J7 5&(-'9JD_;3TCSE%+%*->
MF)15D/T"+-89]3N'QK!<'B S>DG7#=2^@C@%CYL@3Z6U4HPDRH VMN*2.!,3
MT3I#R:I3GM<NO?@0/=\Y-JJSO&*P=#?A"Z7ZFL?E K87Q*83%[1,#!AAIFQ?
M# D,7J*29*-W7()+M\N@K-@5^HSVG4M\&*X.<V4? 5);KA9OP;,]X0+GIX4E
M(G5)W;0<6,[CS#E(J3R>7K6-DX?H^<XQ49WE]_B[-FS^<6?&BS 72H550@K<
MBQ*>5,(GXK0NF8U)ILR-$J9OX-R] U04K!^/MVI35.#8?6[+9V6":?;W.&YP
MD_CUE]ET#E<?-I,9?)V]'G<7LK_^TL)I>5&GYJ TV@GF+'&4Z])2$<U>!Y2D
MQ)1D #[<EO7W57.PGMCNK1JX#OL&+#;7AXS#JQJX%O-75)U["N>&K!J8E50.
MB> N,R(]G@R>XBNNG#$F6VEBC?)E^U$UL(;\UF'8H%4#P;'(N<E$"5&:.)E(
M7/:6Y. ]I48+5.XJ2&Y?J@:NP_:550/7X=D +0D^SD,[2B,__7;-5]@ATP3-
M77*4..8RD:73AD\QD\1%,ERPC/.L[:9?1<QW?V+69?? -X#^'%_>S>WO0^%
MP<V/4[>;B.=*XGS@ZJ^B+ 8(9NY!*>Z(N#5*1X*P>,!%Y7"UB"Z+)M+@4G9,
M'0A:'@E[WAE8UA%!];1C?-19D=#1[-,9X+L_EU&1=_K.^Y!UH)JH9)!(JQFQ
M*@%1AD;PVJ-6="L??54V<L\1MQ]S6EM4S=!\KAU%=AQG#=* 9++'R+1> 3?,
M$Y.2(C(X3ZR,CBC4B!.-7@4G>L&A_YB'!8B!>%V]"^OGZ6C<BTAEJ3 2%2XH
M_<# XQX9H=393HD;ZV.B/?NR]ASQL. P")]7ZJ&#!Z=?)#8V]]TT',]G[<Q/
MTFAR6C5>?=U!!PIAWVCN&T:U/Q@-<.5<-BZKD*DA7)1L+&,C\3Y$$K+@-B>F
MG-]*;,:[:H'P]SW]&J]/@'F;<J0DB1*!1Z4EP3!+O+8J6QVD-6P;,[Y&TP[Z
M&]5#1:_PDZ<*8(C6CD\*CTG: AZUEDA16D9X",3FP AP;0-/WN?;Q9,//89I
M5U"J*JK:2M*]%+=7%^N?1XO0SE=^!B<4(N,ELL8HC<9D"$"\L92 4M;*X%'3
MR[T4I75&/0B #,OK 9QV]]*Z<%*&$*-401)M +=#")0$#Z5N";.@*(^1]>JC
MMNG.LI7+[EUM&NNS>M<7WP].I_-%058V&&V(\2R6=CJ)N! 4T3[9)"-8&K:B
MNNVR;$HM8??!T-I,'Z+]ZWV$+2W./J0-U3-X-5D[*G!21X!]8+$!][<,$"JT
MUBY&HI0$/ ,5DN@9)[S4XU B29.W8OGLLB?PUG&Q#M-K:Z,W="$TO8XGG7/I
M33.??OJK^736S%NTR3[]A<?4MX^CKTN_DHN<JJ@X 5NR6DN/6R=4Z=7&+?6<
M"6<>=<D\??@]T4^?(KUFJZQ?:1H/X=)[X=M2 NB\9"%U2O4@-2?6&Z6>TVZ#
MV57RTG4)HW?)N"KO]N+;U5?>^V]=69N__#1=Z<PT)$8U:CG&!$XD5X8XR1,)
M(L5D4'MFK+:'8G.J-SWNCL;==R#=3\I%VIQ.)8$A6,)Y5*71.Q";.*J&.I@8
MA&:F>JQX/\IV<'6Q7:3=/BH'$-@0L59/9=+-!/!K)4$@^13 >\("QYU=,EEV
M=D&$2X9S-%7R[;(;NUN=JR;QPX%UMS 8(@KHJ1,Z_MP5%KWFQE],\41;:5)0
MGEBN<*':J(GC75$#892,TD6W-Z?.JDG\Q/5683!$3.13)W2]PL^U675:X3+Z
MMR3!:<T%*OT)T 9@0I%0ZB_PH((5U!E'JU?!&' ^/]&^*W ,4<^E$!X>GUM8
ML9)O'E0XX5&3WDX62;]7R;_>4<4%(S0P3:0 7VK69(*SDU8KKCVKW5]X&_/Z
M,1?"/H%E@'YNUP)MEL6+%]1^@!:F7R"]::9OYK/Y%$IQ)C^)<*(DC3K@J84,
M9*B264N\\8*$2/%0\P)LJGZSORZ1/QQ4AQ7C )5Q7D&&Z?0FMZX6T_4R_E<=
M(>;X!UUUXE+6?_'FA%L1LTZ&&-"II*PPXG,*I0P+,@P/&:UJWP97(OV'P^@N
M1%Z[\LX_H3B[D=HO7<6IZ_7;%_O[B>$Y*NTC\39*I"X$8H4W) .7D6;K1>A7
M0_+1H7X8  W ^0%*\%QU)'F43>TJ/BUNXJ4$S:A7I4X=\DA3M N3483CYREG
MZZ*4M?7'6L1O*R!FUZKA3H2]+S$V[\=^4N+X%_TI0*"RX#P1I6ZS!$&)<Z#1
MK$LLZLBDZI?4ODY=F6OC[[X!T581<+O\S%,E,43_ER4MRZO@/M0,U3'H!B6[
MB:AYNF16B'@#M@XO;!638BD*$GTPN)?:TO@A"8*XID'G*$2JK89O0\B/1,<,
M)>-UN%D[!N9:M 6JW27^8@8P>7W^>=Q\ UC4^IY/XQGN987J92"&CMR+Z"D!
MBCN75*GH7LD2QZ@)X+S,K%^1R2<-OX,F*QL(K-DJMVMGNAZ==_$;78^@=E9N
MIJ_-X6("'>%O)\4;//IRG7+@P%0YYIP6:+L!+Q71N" &3[I N18@^L5*;43&
M]XN7[7%_@#-CH?/@E[O]T@6J(&M/F&6E,U',N%\R1P0'$%D+::RN'6-RG8 ?
M6W%\NBQV<1VYDA%7TYBD6VNLSYR&*NHRP'QVH\5N )-U;Q6W)>-=A(D\96[1
M\IQ8IB2KXJ"GPI/2S(VXE&5R("R8],/B]A'%?,]ANXYH!X#K#?5R<5=Y44)%
M:<>TIL5[BHHE&BTE(D42FKCDD8,)H?;=WDIB]M"]/;BLFR$$5=L"N!./CQ^L
M5#F3!XGK+"T*"$IO@93"C_C6TN0IA7 [&.AQP_#147]@Z PKH:WV[+S#SH_S
M\W,__=;D:^OA*.)T1K-ON9DN;2-.F2S3\\5&&A<3:<B,BXHT#9B?,13G]B>;
M0S"E<-_C)/B@<:U0M(H@9Z(C9<HXS:/AV]:6!L_FJ!B7^J$9C]\TT_++$P!-
M=0B"!%2<2MGZ1$)VC-@@(!@C@]KG&.5K,]G#<Z ND@<,5'XJ(/8INV1E^+7W
MDDK'.!$6[8"N*:45/A/&K;!64ZYR[5( /W(4?D5T#1Z9OPXT]C#CY!]=%NW;
M94S,/Z9-6]J01 ,LEIJ801*I(R_7!:4%:^+96V.9KGTY-\ T?N)]#^ QA/.W
M,TRZUJ^OYB7U>T';(G[UFKYZK<V2%#8XFDJ\CDM$,I6)M<81YT0PPE@#O'J
M_=I4_L3K\,(=*D-D R8BUS*,2JCUY3([D8XSH[TFI< ^D<X'X@"7F4Y G88L
MLZ[>5[K^-'X">@_@,4 *R*93NJH<=S4EI:05@CN<0\G;U0$7L3/EIAF4=919
M+_.>(?Z>:?Q$_![ 8X#DD_I60Y09G,NAU%_ ":G29%QS1E*2P:G 671[XW[J
M9U#N8A_I5( 2VK#D*FH"UD7G2'" &Z,)0 *WBJ#&"B*DH+3?OUWDUB2^HSUD
M/WQ0F\%@#TWR:POM5A++C=*\9;_.R_TZ)IJY2YQP5F))8P3B54K$2L<HS:"X
MW#>%<?U9_EP9^P6D?:HSL=Z,3[R007JI"4\X.1FU)4YPG'4.- J=#>HXW^=Z
M^8X6R990NIM%M1;$]BK$[%[/WX-3190%P<H!JQ2>M\D8XEA"XT'&@.=PZ5Q=
MO3_B]J;W<T5MNJ)V!+6]"CR^Y;;L-UO)HU5>9^*B82@5X4M+7$TL& K@@E%I
MZU9BU1G^7%M#KZWA +<+7_ICL[W'6_K@?(,!GB3.,L50_$JXIP0G)(G2!04:
MF+2]VC1O<X&M.<>?2VSH)38DZ';AOG]\2[GCH'WXS(X\<TDY41258$DM)UXD
M2H0.@'ADWNB]4P_7G.//13;\.38<Z/;[QN#!:5HK- /#B>8IEGL$(#9G3XP4
M-K*DG&:U6T[LQ)&QT]N%!R6 7&:NA-HKXTOX0> D)!E)TII2(9T2<8_O' YD
M4]L/?^L0D!E"RZZ64.P$V@04^6R3+!,!4SJ(>0)>.9DTM;YZ<],?L?#41IC>
MB;#WLO!4,BID"Y2DP%4)%!/$:0@$%YU6R04AW,_"4]40\%#AJ74D,7PMHC[4
M_"B%I]:2S,-%B9["UN&%'1D:W5085)/1&NARNT-@D6BC2P]Y106O?5.^!_GM
M0\EX'6[6+CRU66D;YY(T^'\TG$SI@!H9\:6A @2=A9 T"-.O-_#W75AH+0'6
M*RRT#O<'2!"[6>Z!4LFR5YX(53)XC$M(#*02,Q1*G![GM':ZRX$5%MI$,7BZ
M+/;J?N^!M/P^<_I96&BMPD)KP60;%5J>(N.]BOIX8&[2>9^T<\2J9(A4AA$;
M4R(TH=:@8@:?MN[AVAO<KE58:.]@NXYHMUI8"&CB4-JS!EGZ796[!FMB(MQF
M'Q0%+6WM,_G0"PNM)>O>A876$=1N.^I>UC3Y +$YG91V@?=_<=DC<UG29-9<
M3SOL0I7*AQ<<*>KNJ]$4(B*]':Y:S/ T;Z.:S)8Y7ZG:S"7X8?IE%&'%XEST
M7<57Q]>FN;BH?-FTI4?)A3O7H?FM(G4$>$FN4M(2[UDN/75RT$)J&FNW*JT\
MA2UU%085C&.F5)J"0*33D804T$*-QG*#FTO6M=.V][6K\"XQ^,06P^M(;X@B
M,)?6;1W>+2Q=)2D-1BH2=>D98Q,GSK R/:>IMZ!4JG[?/L1$MG7[M4^XW3TB
M]N5:[*95(J@1@<O24S.7ZT4)Q#'G"=?&*LF=CZQZ\_;]\G_M# \/^L+6D<OW
MXDOH,Z>?OK"U?&%KP60;3H6GR/A[P6^F7C-@CG@H/<!T5B1HQU"ST399'E*F
M6R\$MS>X7<L7MG>P74>T6_6%<>,BE%H15F5#9 BH4C/CB4U&9Y^21+WGIR]L
M.%GW]H6M(Z@!+)ZWD]B<(UEHFA4>O%MJ*]UJTSIZ*XISCF9+9,R>>%M\@88[
MH3+3EM7VX3] SD^-K[;,!K@+74':<@7U(6X@1>Y!PG:CD5438S]X;""# 4ZN
MAXE$4@RUT1(C#)0[+T5<Q!\QT(CD,R9=[9N<'0#D$=5G-_A8A_4#X*+TDL<'
MGN'Q^PJ^P+CY7&A<N@>71Z9AFB5A(P$!I64!+]V8@R849Z]8R$REVDUK>I"U
M?2VGHB";8:4P@.+R#YC U(^1PJ-TCJQN9R73ZPO<)))%%R)/CBBN\9@UW3'K
M#$G44,6$1V.B]FU +\(."2SU);&M#B#OH%/_IPVJ@[,1M$<I=4_UXSK=/-9Z
M?I6[U*?/J-*]YSMH6X".C%?0QNGH\W(:2U\\  <T:8JE(]&(LB#1@N<.C2@0
MP@1I=/5\BD=(VG0C^AUF'W!!%:W^: K^A&4FHS*:6"\HD6 I\<I8XGR623-/
M):U].MTB8?N;2TVIW]Y>-N'O .?.8JK'N+YP+4U.NSDC??"7'W^"Z?F) L&I
M9;B3,G X7WSE,W!4U$+V+C!.8^W$]4=(.BPXU.3_,';-=#'OQ;]O)S=)?3?R
M830>S;Z=!*FBR:@ZJ>A0A9<R$1\I(U0JD'@>BEB]FWEOX@X+,L/(I*+WI$N.
M>(S*#R4Y^#C_T<(1LFIVHHVV4H(BMFR&TD2*'/%H$7INC'7!TMOE"%<DHZPY
M\&%@8W"6#Y"#_0]DUKNF;8\G9:<;399>QH[4D\QXT*56((W6$ZF1"3Y81IS3
M.C"A<]"UU8Z'Z#D,E%3G_ "E>>X[$"]WM.751OMJ#B=(B\,Y:C2Y/%I@.2*)
M5//2$("ZG)@%73N$L"]MAX66020R0+V9^^@L^#[.+YL)&O%Q=B*9LL9S2R+S
MR 9%@7CN4*]R>!)RX11"?@N8N4G5X:-E RG<Q8G>2"VY25AW8A;\^O&+9CIM
M_BH](/RLU"@YA_+BA%)4HK(WQ;N#YIDJ9V30CN2L%?+":,W[]>)=<^## ,7@
M++\+#[/I-O*@SG3I<#S.;_#<G,21'[]OVM$BZ'=6KD+0L'\W:F<GQG*@08B2
M82+0L(=,K-2:A.)F1KR+:&IW!*U$^F%@;Y?RO M+.R@L3[*GPD#R).7 B&2T
M1!))1V@2F0N9E4IQFV#[@2"T%N_O L/5!<:E8O9R/ITBKD\<<*H]LT1(5,6D
M1,TLE/L0Z0QSH#S*9EADW*;HD*&Q$??O<=]M[-Y=0=[OS20N*>3<!^Y+MF+,
M@-L:CSAY-/>,%DPQE:.M7OGA4:)^"(@\40;WH&1C+^]-"DM8%Y+$+(^&DA!U
M1%LN<3SM8D!;3@8N>*#.U0[RO4O%(>-@;2[?(_B-X]MNDG1ARY]XC319ZHF+
MUB)9)3V_=%ADB@OP$)6EPYX9%Y0<,@">Q.U[0+"Q'_8F6;>J=GZ PK;KACP[
MX=3Y6++HH?1VD3)04C+=2==G-BM*6?7.0>O2>,C J2RA>R!5R8E[FQF+4&&&
MJ(X\LQ)RGI 1!N'N16FWH*00(B9K:WOV'R!G6TF@P[O<-N?VKE,S$XQP+J=^
M_'HR0P5I$1GJ.<VENPU+#OEB;" .K6UBA3+)*$-]?D@];2'^[;3Y\AP?O0 *
MOKC"QST#[BHLOYH,FSJ\K%FI$$E94'$1L]V#CAYQ\X_+]OJHVPV*WYC]347>
M#2E+1WWD420B2DEF:8NS5@5.LF36<1X,#P_9"?L@PQ5QZX.)<!V6U2X8^MN+
MMQ?QSBZ9Y$L'%BI<J5<8B"U9B"$RFQ3.@RG=ZV+C\I';T[DV8VFS,3\JQN&U
MT]G)AY+&M\ 7XSZ""R3:TA:G7+L'Q@+)8"%Y;JE+O>XG\:G7]")\=[6F;@QX
M**?=T[E8,>SIDH@EHOJ0L4YZ6!^AUE^)CY]U&S#_MO@VX%S%G?(V.:587 (=
M<=<O<5+!.&)=D,0X*;QB*7/1J^#-K@6XXJ"K+[]U&%99;K_YKZ/S^?D%D#B>
M5AX-7UOJ.\MDBVLE!$(=FE2*FJ!5KWR91R1W8]#M'8,;L;VIP;-M53-\V9R?
MCV:=N\Q/4@DD&>&T)_BU3>H-]GAJE2R6=:G?,'>E4VRNC7ET:\PKIP-UX'PN
M752TDT32J(BG)?? !>8 (@TQ]=(!^XRVD=YZ?P;?T>D4.M?#U?A'Y\U\,CNQ
MCG(G2S\A&C(J$27R.5M',E?)ZF %:NN]9K;FP%O4@0>1\@WE>$BF#Y#*LH+<
MJRH9%P%HGYKW,"WI8V^:Z?'L#*9M5\G@[>(^+OUCVK3MB2IU7(U%7FD1B10X
M+>]20C44 D\Q!Y-J)[Y4G<"A(''WTATD+?P+3.97KOLEQ1Z/C>,P'IUV =DG
MGGLT8(4BS)9&WYDI8JU+1#$0- EIO*]]-=^+L,.#5FUIU$ZF>8 %R_HKD$*F
M.A.:2U5U#24=.7DB7/"< M/9\DU/\JW<EVSA6*O*S%W?F13]_64Y?6'ZV4]G
MWRX['$4>DU2:EKR>$EK@/;&EPU%DQK/ O?&J5[6C1TR?^\;>ME=I *DV%;E;
MVS,!G^=X#OH6KFEB-TF\:&S4@\B:#JB^A&W?/;6Y#)MM"6!G:,D<' ,D,?&B
M$B4 M/NI(B8!YYJRC+K]]X^2!WQ@.P+).GRO?1WT^]N7__GJHG(?M1E<RL0;
MJG&FO)251@U9J" 8S4:$U"\!]]I#M^P+&X;G306&531W%Z?=AZ-71Q>-Y PW
MQ@5'O"S%;A"0)-"H2<@\E Q?'5*_F[QK#STXP3V58=NJW=.U]NBJ=6[BT;SG
M*54\F(]15ZG:SE&,1>SM[\T,BA;WKO&3]@-$&'WQ71K.A>XO&5!NG"51QD1D
M4))8EM$T"[@@#404;O5VA3UIVVA9OY\V$2"U;W!Y++JJYX[U)]IY9[,,!'@)
MZ(N@4'D%@Q,6DEF;@E+]/+6K1MA^P.0@PKZQYJMPL_;.?57"ZCU.'*T4/WXS
MGZ22!;EH^?.IN5IM)XIF*K4"@AL?4@K,$ >&$>JBTLHIJP/K)?>UACU$, S'
M]ZV5C;SF[/SG:';V!E(I5/>/Y@M,)]V9.6]GS3E,E_/ZU!SGW,+LAOOSQ$KA
MH\N>\! YD4YH8BDM,1:&646%$M43.X:;S8$!=<_$7]N+><6F-\UT64ZQ?3T>
MG8X6'WV T7F83]MNBB<4M6I6JH]P6UITXYY,',^<,,M-YH:"-J;7UK?6L >&
MJ('Y/D15H+()7YO_"=K928O,"%B&6S$7 0]KCO10M,A3YM3=#E3<O!+0+1H.
M#!156%VQ]$\'TE>087$_AT0MM["++%J/QC2 EH0FZ8NEC9-T4I)B?C-0N*79
M1TVCQP8Y,!E7Y>D Q7JNVA#<8$/' ^3%LAA#4<XN^+'PXD=@U)<\22]H(%*D
M2)!>0:BE@+J:DH97;S[S-%*WE5FTE:UB&^+:AZLT-!G3/,Z.I\NF&)T/F$?M
M+5.6<$YI2=!DQ)>5P[1F$JQ25/:J-/:(9_R^L7??)61 >3<5^5[YVF1)3YGK
MDJ+VHK1X#Z(J7JJM)&3[EVB;R^BNP"LQ>&O2ESE(E1PCECO$-\O%YZ\2;J1&
M2.N!F= K,WZ_I/[ I=B6A+X.7VM?@G7:T:NC#Z_??WK!+K*!9) R48'S\@SW
M,4Y+XUY&F-36NDAUM+&7QGG/P[=[MU*)YTU%AM5VJ192WAU]>'E!BX@I<1L,
M2<)R(BF>/XY!)"63"WPR*KO0SURX^>#O7G";,&J057=4*.)4EF8;W4LFEZ2E
M;)AWX DKG8ZE*J2!L42PH"V55B>]Q@)<.<YW+]**;*SM[NO0]N+3)=A$%II;
M-#IL:789N2%.\42X4X&"Y,;PGD;\C>=^]Q+<@$T5W6]WHANT DF# *)""7R)
M'H@W/!#CHZ6^]//3_3;1G86##""KIS)HI;.L<A3![S K=;W?P[3KYKA!),&*
M)U6))NA#9:V(@LELE$;C>6G@]!'B?#HJ;81>?XWC.3Z\7 R79I?SV;("^FL_
M+0'@EZ1=.4]4%#9DJX@Q2I:VEH[X$C/"9:#),I&XK^UWJD7[IJZZ#>E8)@=E
M9BT8'@FS0A')P9*@%#)0H\((,2E>W8U?A? =^(5W@=G;#K_M"WV C+!K7JS-
MIK-P;N&A 1Q'P6.CU"W/VI5D X\[OE 6CVL&LG8#X;HSV)I+>A\0O$/A[]J3
M74D.+[[=_X#.!R0]+E\3,EJ,Y:X0[7_BA,-73'H;HS$!:B^& :>S!W[VK8.T
M[HY?#2P#A%/=3]FUL.(^] W4R?LQVG;3S'MOP- +I!M*<A>(RR88/+_0!)7!
MEEQYCW3J6#QQQC(MI*#B()#V2%?P[Q9HZPAP ("]1B.^^0;P<=;$/X^[\ED7
M?@D3E:,LD""2(S+A&>"S2"1P2FU$92JRVK'Q*XG9%^/IJ7)KAF#Z (;./WV)
M#9U=)"8%-*M$CH3&B%:79DB'</A#!Z:8==[RVO69;Q!P8%)_.G.WE3ST<1Y:
M^->\]+3_TC5C>[K?;]6CJCC^>M%9R?-W:ZPKF]):ZHW(E$CO#9$2 O&1,R*$
MXQFL$^IVNMSF5OP*6C;V;_AB.72[T>_S@DY\4T[%]FW;SB&]G7Q"X+8^=O4K
M; @JB6B(5AZ7@#"&>,<,L3XZ'I1(5M?6.-:A;_N;1A6$W/$Z#"62(=QC5[2^
M;%!=2UV5^6:R".J"='R#V) =\YEJ4AIA$1F\(%Y'3;*SE#'E<GZP$O>&^'F<
MP,,#4&6AU+[!OT;IBVGS9]>,H*O"T1;-OUTF&IQ$&3U/5)&<2L:)\9IX7BC6
MR8'+#FSNE[K8;[SO' 9#<;;VY?[*W,IH@6E5\D4,;F>2HZ9E@U,$#.<NQ90D
MN%[BWI],U?H"KL*]VK?_OXW&T,Z:R65GFLN\H,5MSOM7?[PY>@-=D'E76.TW
M/YEGW(A0W9Z<7N05G5"KLN&,$\@%E5IQ$BQP9 J7'"3-+N9> *A#SR' 90>2
MJ9W><V<*EQ6:EM4CWXRF;5=2$J:E"6?9 I>7B%'%Y$J 6A"BY"U(@68U6.(T
M4AUBY,#[[2A/I^$@032,!"KF"G5DOYVT\VDIQ7>9<_!^"N>C^7G[R7_M$-\!
M?T&H8DDPJS-)3@MD3@RE [DC+)M(K339W?:JKH#*.J,> C@&XW+M_MUW"7U;
MZL0@LA>]HQ4S%J5)* /D @N:!(E;G/8B<6FS=CV##!\>YS!%_F1.#M"%^]9\
M%]>;7F2F-:I#U"(Y4@B*<X5(0DI"2:D@R.K)?_?0L:TPBF'LRTT9NR_!#;<G
M@G_6W?HHQHQF!G7F8A=+C<IT4%D21A/+PCLF1>W^<BM(V5E0P<8B?@0S3V'U
M '=@]Y"U=/?W(6R@^_R51.WF(K^*Z!Z'PP9\WRHPA);,.$C$*R-+/VY+/.#V
MB8J,\"E:GV7MJNY;!L0C]^W;Q<,Z[!X>!\L;O(P2LBXK@N:NPB-4:^*##B1%
MFH.R5+(\\ 70KJY)*PGJ8?$_@<M#W&T@4:,T\M-OUYRIBP9'3E(7DR$BE!@Y
M12,>A!I(E*"\C*7SVQ!;P+W$')2&L#F[*SJI[[N/\^?X\MKMR45+S1X4#J4L
M/$K=[K2&"N)\X&ZTHBR&.#@>IQ2W1Q:,5,0(-)*E+\UN8D1#C%EM;:965:^C
MMRNT]% I=@*6=410^_+S_\S'WTJZ[?QTWLZ*I(YFG\[@-S_]$V:%]'9Y# :6
M0&IMB:4Y$\F=Q?U4,J*3TR91RVWNUXBJYX [4"HJ"ZH9F,N5F[?>6R"#"N.X
M28[84CY/!A](P$\(+:"/('W(-?JX[E7%H%HJ116F5KP;?3B5N ]1/U YH+5D
MU*LRS%,8O+5R0$(E::CUQ(#'C4UD(#8'W'Q 2 O@-:6];(G]DOJZY8#J"WT=
MO@[9$R/8XD^/O!BQIA1)C,0%DTA1;*1043C1[SII#XL@K,7C5440UF%0Y8/W
MWG8MI6R-3]P2S7(H;BR<E F*B.QLS$(;)FH<O/O0]6J0@W=CIE:,&UFO,T@?
M(G_@9E=KR?!)?8R>(H#=M4;S$FU/YHBRT1,)U)6(%D824])Y$PR$7L',^XV2
M=9M=#0^2=?A>^V _GI[ZR67&5@@LRT@YB8%9(E6VQ D\N61,GKD8M+D=2[#B
M:+_QV'WMF[06WYLJ3%MYW#\Q^>F.QZSC$D Z?_ZZI RUI9K]Z\G\?!DP_V[4
MSGJD0*WAE2L#ME<+O R]7EY4A2G4JHO4MH!*86B[ELF5_92W'KZA+[8+:%T\
M\O=FT<9B4IOB^\?8?AKCO5*Y[1E]D"'KIAPN/RX_ NXC__%O_Q]02P,$%
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M'/?<Y*LMT9]FHC]3+J6KNC -GYCIE!;-4IF=+D],EZMT RJ59P#7S:Q_K%(
M@LQ,-\AI1DA4#%2T0+%J+DVW,XDD6JRH:CE=C333U; 4A]@9P("[;KV6-3+)
M0K]9(UM-.YAWNF2*,/W!ZB?M&6ZKTYPOZ$FTH-<]6D,&'V/2>(0B-"-/V1)'
MPW3%@ M:>)C7D_\6VS\I-JF .=K[-XD1%PC[3++4I/F4*:Q'(J>78T:X/P+8
MC 95$SHTC6)\!)34K(!1'L(%25WX"&B\/ W"M(*+U\6-1JV@?W2$9&-ZVJI
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M\2J1=0C;CQM$SB!<-3X<CS O$GTB01)TG1CZ"98H< 3L)U2BR!%1/]!C3)T
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MJBLZ@Q$] T@QG$2U((JJ$9)5BB0HV9=3+92@+$<VR2A ]0PE.<  "C84DP1
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M2BQ2B\)!&),141',,(7^J('U^_5H## 0"/2#/9T4K4PT/_[R2> !!#9+2>&
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MIR$5<@C5[!3U) -4R[5HIRD'WB-M:G*7:GOCKR78+;;<JN#!1@)*J-@RF 3
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M;_CFGGN\_O+O#WUV]=OH66]CP8Q7[7+H%<7WCK_KT&=N?.\?KQRW)C1_3>B
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MI6RP3^J^I(<0EXM=[ &3$8E=O[(_\W.+OL'U/?"330-ZO(M6@0:2SI> [1?
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M2+BNXSU8RN-%B?\TGJ6D.]_KP4-:5\X7,VV'Y9H<.2/-Q[9MR>)Y5>C."<:
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MQG9\]1B<_Q5E/G;'\&O2ZG:N6^-M#KG^; K*Z&!JIJ4CX5/2L]__#S3O[JY
M;%1\BEFY,@Z6A];GCG5PM1?/.FKH0B$>#*\1&]^_.Q'5N>>3"1"UGQA%6TN<
MXSB!@)\->^OO0Z$>W@;X\K?UVR?1G17YSI'JX;V:DBX;-5'3*@_>T!(W1*?7
M&!\M0RDJ/'>^VT!DPGYIVZZGDWXQI:\+QEXL+T===XJF1"\N^I=3\,"U/2X>
MMVI <GW*FJ$] >)&S+[U@!!+=&F*C+]QKQ/;]#@(YX['"#^@^#.;$[E8<)9K
MTJ&^.YZ_,XP0T;E^GB@Q6U&5WY>UYTK$IH-P :V[V[QV0KT;0>GLY8JE9! ?
M0-"#+GN"),:PJ3''HU96\\-S_73(//QI[;X9('WG\1D-',%W\;I9#TDCQM>.
M=9UHDK("?CTAJOFI+#$Z))\R,NZ16NL];[)&>C_AJ+B.F%'I/>TRR6G$6Y#?
MOJR#PF624G+5=7;VM7<1$!"1TMC:F=[U\].:[?O/MDYHO"E\;^FX=(T>FQK+
ML&G4,]<J/B[!;%I9N>2+A4LF(6]>DT7- YP747P(L+1:7.HNE<S":(FUX5($
MX**QAD292-E]>G9P*I9SIJEF?.4,7CQN02A74X; -UT+;8S:W4<'C9-$-WR2
MECCE?O[E/W?UI^ 3PE%[M]:GWOW3H61)?^QID]V>*M]59LF:-X='ZJ?V^Z?:
M3^;/C<\U=TM/Y(2_VO6P'EF%(NJ/O(Z5V2?0V8YCNML*FKR%#X'/D_[X-ZSY
M(=N;3^Q5B%EL:?(TY<:QN13@^-7?/H[5?>@P>* P2$E1?:OH#APUVCP2T$%Z
M!2@U]&X!&TO :*?T1>>G$GEK '%.=>-8,QW91'W8Y[*V+SN@'U)HJD.&K^KT
MIM<,"J"#!>.O6\"8\9GF:Z*&L]%S@9[MK)]&1$XP7KTASMU\4*?XBI$NZ]Q^
M_R6I8,9NNODOVWH7Y#,M_BM0YN%M'R.G*(&H$J3E,G]JY=>31DR?MQ1[NI$G
M0?@U&F[D08J6S#OCO?UEW-Q-TU"X1_)A<?4\0?JAY5P&U632$9AK/MO6;*0#
M5*M?(;",&^;OJ.;,8O^L0VE)KE?N)I4XE"N2!MKGUT;K@C=K<*6F6-4$3:1I
MT6AR;_2-PR^H?N1DP0B9%1+\\)1$QR&>!"C)H=2"/;V3\@9C8:RQ>"&& -JM
MJDR2L$6IJJZO)KBX7*?5DI1;?H[V3EH6PG%0Q=D6A0;UW=R^Q&:<$!;:OG$H
M*$;P(R3K4T@XJ1@;'N?E3?Y\IJSS/ :AXE1;JN/HCS 2C$H&-WS(^UG%ZH/"
M\YCE +DME9RBM25YO""A.+!@K'FC!1WF9R$5G;Q0O3B(:S:<G\IW%WY7 AK?
M0_YMH&M=YZZ)S0Z]J8 R;U&J&.LX!)R6?JUQQQVO_2YPX.>.0.S?F9B^<[SX
M,5#.IT.BWBJQTZ045NU\Q4NSU-K8TE^%3]386=%51[75FGMGO1(?7_706S,.
M63OR6Z=TG2!2;?:2Z<-A350@63$_ A L-HUD&ZWK2D"Z-&_ 8RU;BO4V/:8+
M&S55P 6\PNIZGQ?=WE;&?2@$E#Z6<CD9'!,9!:/'3//\"38N\T^2*((1\*C6
MUZR^.>\_V7_DJ ^[>R4V)[+5WH7>/K>K7/OA!76^@(;Z.$+023:?*S8M#DQ#
M.;@B+$<(SYX:2FQLRJX#_!59"C^7XZ[<\%UM>_+S6]-[L3 6' >^3 "MUY%Y
M=K8QR"B!I9N2O-+,"D6'2<;&6$!B(A7\+77"BRK%)+I5U9\*#X;\_1]D^*LO
M@O QP^B/D?YW!8LWTL;'0H1L*M9L<]RP X;,M2K$.#A%SSE2!S>?$#WV**$8
MR4U78-7,5.O.O)EF8]$[5)._&YMR<,D$T>C50-EG_+%?X4J0ZI==&P.ZZ;#N
MG>YX800H"L=@T%5.(3RGH$CEH*/0"?L\%?;6I[<"LK_H^YR6#BU=RD)9K!L,
M#)8P/TX@%\4+V@A '-ZCXH;=S,H>+*"5-_P3:"FG:/KKP*=R^:E!=R*KO%K'
MJQH\8D9WS96R0D86'2^9I/8%36.2W92\E"8AR+FC(P7/4:*V>\H-A4?5N#?&
ML3"[T7O_L%5PYGW(]);T-&?1LF1>,' =3E;KR])V"Y%R6TO>K:DTDZZZ):O2
M6^K6/3[C".6?&F1Y^II>Z^9L@:BGQ*DD5T+CN)9O[[U#,(PVVZ2M@"$Q2^(#
MXRA'3M1S^2T[Y9; )L5DYZ6AXN'$L1NE]K-PXT"P7JUQ;<:-?R\"/^G4?SFW
MV*^:R0PO')0YRVI"?-O9[L653U.@.UIVM8B5T5.?1SG,S'8?I7_6NAGRP[GH
M4!BUR/6=T$67[]& XLQ/L9S+_1,Z!:?NV[,.>G. 1R_^I/I\P]TV="?LX^CZ
M6$C#6F"]J106$VD@^*'BMJJ\R% $0W*RQKUU_C79\K/.<B?_) IF!('<NSO@
MY^?FZ&:\MY<G:FG\!K.LB/N6_7("C -%J***$X&"Y&QM+';:+@#0TI(,H).)
M.BRK+5+?&#\,NZ8C6@,PQ'/D37C\Z(SHZT_3?)J*[_;BNS5#CIZKS@_5> ,O
M66?9JX_:%*-8?GZ4)S=?N:Q//P ^RS@SXI%V )J;*=<<S0G-F_=1X@<@@@;Z
MA9XC)64H@QZE-G?/JO;1)E6B?O\UI:NDL ?U$N,KRB_H5LWX&Z<C1L8Y;E*<
M0V7M\*0J*G[0IC,H"0KG!@-RB??S4GTWZCG_.(]94-P'/9W'/)FN>R3;!Y-T
M[+:]7C3[=4D;IH!I&%\:(5P-'X 9[8^&Z\W&Z;,^:,A_\UDU,6WL0/:VDFY]
MR4XR #T&B% W]A/KSA7GB8*I-"G>2\K0_:XGR\E%$^)2FY%I:K:U.2*#!VCZ
M(:*KE1Z8V&W@)12KWGY+?=&QS$[X>H?=@'AUVT&PY;"=559SHIZKVQGY=*<]
M8ZR42MO4]0^XZ&\9],$DB\ILQ?U$K.E#.W?+9Y1U;4%<^DP=PG&R@4<U*"N>
MMIY!"*(W2.8+GJ=A2F \NJU*M N<(N43@SDE86IC#AJ14LOBN%@WMX="*Q/-
M)Y[S)'5FD@5>M!+]@L !CDT6F'OX3V8XEV:$AX14G#^?T2I6,::[S) 8?/PY
M.UZR$VE:MC[]^=):>2926FW2K=L/OJ6PLN$CW,VV?NTC=?T!?&]^"ZT195@G
MA>V#9]?0+ N=S_\=]41G^A^<4'QX-7L98U;:J*=L/3_&:UMF#;.5A@U$UB7<
MUPI3&R3A/4@# O:E Z9L/Z0P4X+#//'OJ*R?JD]WX>J2#,\B=IWVP?2G(8#!
M'OY2%T@-^#BV2)0H>3K)+WH4K<%12%FHFA6I*ONT="&HG968+6_V$NIBRL5Y
MW>=.Z=1&Q?=IW5X+V"#P@0ND-Z$8>,FDC1W A65\9"A,%INFU![3[]!8;P7L
M[DKQ\DYCL1SS%<SHA1 YT7TER2 /ODS1VGKE+P5'WA#E4V7_O+(QZOP[;(O-
M;Q:]?'_2]:[HA=!"$OQCVH\OKM*VS]2TA$R^YE1U_D 3;O<Z9W/\350\;:E6
M>#,=$/=;F,B:GRMUZ2"9:'*7S:H[Z$X6X7=9(D8EW^6.6F15RX!^"6^[E[&4
MAO)0A#GY[4"P.O,>6C75!++DY&,0(]2YW S/V(?;*A/:J[@A9!71 SM3O&C;
M_$^QVYP=\#^^?8H0X>VTX&)]SH('0F@B;4MJV+$P(*2/OGZ+ N7'"FI [ZGF
M$C9#!I\L^+Z/ R0G#-:M(I^CW1<"1$I."@L#I9)65Z%*G-80*%>[ZRMP^++8
MRUTDLAJF5/5:ME3S4= BK!,KW.ZT2AL)V$V2*.B&QW$)^YAJ+17:?XQI;2B8
MOU(1]X(FU%0ZJ_"<5]ARI,SW8]HMUANC]9K\/#^(&[7#5C^-(B#%/[Y".7CI
M#(/Z2&M$(C&_='',+\[(3E>B6Q2<D_KY&WL)/^(X_G&L"5\C8)^/R'!2F7:T
M5>Y=-ZGIE8)WX2W) HLJ?1Z< ,-MMXORT= WFYK_N0U_]0\)?NC=/(W[(9@N
M6YO?_T0]A5W&@E8\DDBRRBHX=C5+;@(VU%8HE&N+0WBX4=J@WQCFME..J9Z-
MY9D1O4K1X1$*@QFC0Z,#"\LUO!:%LAEC4E[ZIMWKK9%&X7X Z1!']K>X?QRU
MS7T?5/%>KEZZSFI$MH&Q6W$T/;(?Q>? 6:2VX&.?F>OGJK16NE+\E%[D33#9
M0@TT,'R SHS:&$G4YEW%\C%CGL?9@,V8&?;!V@P7IZ;'!T*.W5^?@H4;J/YH
MJO_AQV9(WG3[F/+I^ >&K'F1G0C ZNU1'\LWT]AMY]@?UR56SZEKV@SV4U8Z
MS>XFA_2;F7?,37$-74]%8HBK AG7>'[L@YBION(^\CWB&JE!;&J66TU-0MMO
MWL0X<ROIV/3QXD(,RLTE>SZ7:"/:B^0S/C9FLP6E[ P63.P30%<G::%N>;/"
MY)KFSM,% ^8(H2__UMD<$'UWV[+50D^J3K'\?#7KC+KL\T:;6,/AG7D&5WXC
M*IX@*W9/1I'K^]T?=JK^T&K!*FW J1W>'AL$4"BSV\ZKYJR0KY7P^/RM"[9G
M<0*Y@G_2Q[]EN;N*AHG?$;YXUVD.I;5_4=C@4?'F#.DS[3%9@:W^@?W'1!$S
M(M, N5=X3E Q*M;VSI5N37<*"C.T,Y/O18"KN@M^[<,#T$9O'U51IMN.H<T2
M4 UN@DC/_D9?I"'Z,\DO8W+X!1Z L2*H-'3)0&VA*_J*._H5"F'N)YL?@^Z%
M3;]IKW @E[#CU'#H.AI-MOZ-/3FE\R<S+:Y@?;/;+!]D 8&+MKJ^&>V^C9-^
M^\)9(9=,/4'Q7AI:!$=3^K.AE-O!XZGNLFTFQ"IJAHNJ;S!?-IASAYI5?^RS
MTYF\ES^21: 9X8)ZQ!+:](.&-V B7U9?(/&0_'G3VNF&K92?YY(MI\7UW:+8
MYVUCZZ,6EO;O%.8/AW)+"C<K3M59%<J/\AAP\F-/$2!8CMMD,85Z0/@5+8L
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MH(ZGIA_N8U'6?A6PMG#6'/C\>R#.,_V.&N^D?5.!VB*EB<S,DZ[4<$:UK4Y
MFQ?O^NA'QQG78"/%R("*!'X>>P,0M* ORK;LN"_H7O076[&G<>UO=JH\CF-]
M3 ]-\V,ID.C4&Y!Q>M#O>--?=;ZN+8_D5RJ:^M;YY$@T4^YA')^EP&GAOCJ_
MA9O8LM6S_5U'\F6][7)/H864Z:0@#'U21U E(X#S8L,E(BK]AD7@9"]W0M[+
M4\/_SK+^_P'']UWI^E7_OBWPF/=YCUHYXPY@6M;/5V&+N#)O@Y^*()JXC[RU
MT#&X?PD40EP^W^@AX1W3]RMOA@V ,Y,VV@-#DLRQ8^/S"-ZD ;"#G\7M4\K0
M:FQ)CY.4,DD1R7AF#M( 1SL%5!.0(EB7NBDSN?O/4T8K:CR5+*>W7&G@G&V)
M;RI=]"1R. +(>NH=[(9,'M2WM0_0?5*)"7';R3>]H=\UHJQ)KR-^B)8=4*5*
MR_).+PGW"K4'(2V]L?18'G-B;<^H]GY'4;7<=P&C11:67V:WGP=:715UJ&+(
MX47=S>%0F+"?CI2?C<LX  1C+D^O0XF5-/J J<BB$,S9,8^[V_;STZ -LG;,
M87*;]#GQZL+7\E#N Z$>A527=U5EU;V$F1O+6\7V8 '?O, &FQN2Y_^.F?CO
MC7.),KC]UK'<SOP[Z1?WS(#%(+O(!W:(9@O'U-4175X7!#X;]_%CCLFYLS+X
M?8E1,2W:M7H;*$FH/GR4-C)^0L.""2^',)R "OBCY+];A,D_6ZJK30126N2G
M;%YF"6'\CZ!\C>MEFHCTFK/EE?U2DS[WGWKRC5GD2^;$AK9@W?W0XV*%/ET9
M5QEJ%"B ,%<#Z%HR%F(.PV<6/=UD&W(9"'>_ID>TVB3_DS%*$EQ^M2.]/>GR
M)HJ@"THK6,Q>9=:I)Z5(Y%=L%DPWG,C3JRS;>]L@F:Y HZ2.P<['>U<?[TGY
M&B0GU[S:G$U!Y9:IB;F&HA/LZ5:KQ[':OJU1[2:;L&:ZN6T"#K>_BL.PTKE[
M3)#Z1QFK,:M'Z4$>\^E9OYR*T<R-L0)(D(RU,K<6NHHCGGEI7A''EPXUMWA4
MOCF_U$=R-"TMQYO")@J94K$>*N6].7\'G5GX9B(:4Q?S!'9=FRAJS8;W](!)
M+I&5KC-D!8D:G%^1+JR^8GY*/G9UIO3%&(%"MW$SE2Z97HYW1H;"K/U.8:<$
M[COF_>&-9X$YP=Z.L3)(9UX3A/":\WWY10'1@* ^'B774J]5A4TVCXBO9GXH
M??R[QB>YUS<V%YAZ!E*B0!?IEHZP#&FNO=18WXPN#]K<YJO:XU5:)+V_WFG0
M2_>11^N?O8P@1\K"AEZ34+Z/T0 JBU=N+'&JY"^KXATYS,&47H 4.E:68*B(
M9A<+>TP2*0= A*M9DZ?TB",3L0"3Y%8G+=5&(>0=Z!"^6+X0YVRIF>F5%:N5
MRFAU=2.+E@*,HR?6P&-)*3AC#'M,14%?ZK6NT6R!&$W?LSWW U4=+=3HAI_6
M27#3@ZR2V<YU)8,0'@&0@XF@G8OBE;FKL^[_#HM0=1^CQWU:F!D'Y9X^9GP?
M?*]^<O:6+F P=2X1Q0M\H??W(/_BO\M*Y7^T@X>YV23*Y9U-[+/JD^"UX=&;
M]')-J<4#=()WN2*9@SH]+F41K&#O-VB&IY=Z>_;"$/ [YDSJGM'HI058<K :
M&XX?0>[81L_&J_$!:VF&SIP<UZF3I0LC=8N'B'5Y3,TN-UBO:<K*UO6I5F?N
M;:J_:QP X?.H>GL;*YS[@T4PU$Y]J[]BX<E8<.DDM'/$U-P"MZI4]$$X-(O>
M]_)0@ZB\ZE@1(P$RU;\E8((1-T-_]_O:/VU_'#\Z<>@C4;K: Z!5=  X=A&H
M! @R' TN$G= \V^FI'4:;"DHI?*SU<%[S,&]TLN=JO0GK0U9Q2(@5FMYR:Q4
M@+]&>?;9Q&"0/<3M=U5<':0?8@; X7 '$,C/VP8" ;<H,CJV)%:!$ASSE_^U
MY7_YOC,_,!WTG6O%/LS-H*O^UDTV8S@/9LW,'F\4;R<1.!)J6.KH4V?!:C7V
MN2/W/61UB9XXI0K*KMNYWGO'QB2"%";18]CYRX:;HYAHIQ-5 :8@6E5NI!^=
MU,FI]XIH1=]NZ9%R'BKQVWG+5,TU)P? K[52#?EJV#AOBX=/WS'8-H4+<P^:
M9][;:>AQ$]I%W3BS!$'&^G#AUQ7#GO9WPZH'HA#B7,*U;QSB$V0BCQP0BDQ(
ML*L9N:(0W, P8&5BE?;#Y%VLK>))/EG&\0JN #+W_I'(H^0VC+IE6Z%,=(?8
M-G [P[:O7P=)!#D!X@L*\ YDQPB>"0"X!M]47">? ZA]/ 7X#)P5N:HLI232
M_2KR/[@6$+-8U]7XOM,JY.N1_UG09!4T@Z]3R>RAN\'X7F!'UD%!FZPY?BKO
M>F!L]5_QD$TD/Q&A1F<M 0=;KAIH%^UO&MF 9J;'3/%!IG*IY, J866<.49$
MS\@+N &<2YZPGODET% ?T6><"UW-KI3N):PX[CM>FX(.UL8^6I-G7AL)'W88
MH0P9$"($PJJ.DEI.(Y>DSR9F6FA,CLO]NJP+]$#+-&<8)5/IHF_WPYEXT0^6
MJ32;KYP"NVD+EWH+"0<_6"[+3NX&S(39A^%(8S]8: 8U6E67U OT9876V]"^
MB[I/30<"I!"=NT$3&T<A:7X^Z^[Z^;-W359#]'^P_/:#Y6M W*7M9/#SAN.^
M#LN+&8%.Y6.U\9X/,9'J5LJ>'IV\'MK_VNE&>T<F_6")^,$R^PHOV:,I<ZK?
M=(PA\[CM-1Q_N!HPV<8;S(OZ/M?Y(=[<]NM.[>Y2RBW"ED2HO3KJ"\IA/^<^
MMU4JM6I*$OKY6*+A5*3$VNY04S)+W&A%N#<5KHK>&9[9DNE%B:15UOL0U"=W
M1(KJ0E3K^/_(SUCMLN=ZJG^BT9A&P0_'4(QC9G2RY@R4AW-$(A49B9>L/LYR
M*X/#EFD0V3A6(S$=-RVJVYM#K#M(_QHM:0J&FX67&$>\G8\,J\OK(MHMG;=7
M3.;5.^QY=-H!=^K/925O0Z_/3,8Y"=G@2CM'@CU5A"PF1R=2BW/7*]3H*!H4
M)62Q=^-@&I$U0?Y>."F*;7V6IL&VW'E-]TIE%!:L/]IO""]N;&;J_,D,>5<^
M6!?"@XB_H2!.[D1![V22F;$+67NUK"9SC._AINT?LV4$_WU;_[Q286LL5,"3
MB95C9#GVN#%N]9DL,[<87F.! WY+1V]M\P/#UNMNFV^WI <_3[;P,2W+H2,S
M!R[L,,HMIFQSH_8Z4L=M?6% U)I"0:[\^K+E:QB& *B %:YV:PYW[YH+EOV$
M1O]\&*"QF'#?OSW!Q_H=HSK^#[+QFG*H:JOEG[)[LB]^L&1-]C-0SN\MOKYB
MGLKU=_:(&_7\(G>H<I]O,5W-^X.XZUEV6QCWL/$'=C55L/6\H3>N!Y%OL*\'
MI.IS@EA;,6J[[NW3]4O"0Z345@OX6\-(PL';YA6%M7P=9:PGQ+OMMH[T%5.,
MIFA-[L#OC;-++0^=ZW0U*O5Q<-:ZW@]_T(HJHUI5Z[$(W<RR;C.1BJ[# I45
M7[AX8=04FXS@89'/WMW<QB^+DL!OO5(Y1=J2(VD;-,P'B&D>G]-1\R[HP4;X
MPUKZ'=-C3V8"8,6XKD=B/JAXKMRO1D\!Z>DS&&,]50\%;Z*YMM=S@%L/3VXG
M=_U7,'%(S/&=^6(D\&$F%Y<$^.N1K@28LA#LI2O$SMO]8$'[;WF^&\X$_4W8
MHVX,Y4:B#//1.]D/P7=R7F! P*+,#OE#>=H8#3IH/ZT6W*O2\&&Q\_O1FIS7
M903K7*1E%GNW5I%Y_<?AA):;U7K)%M5E"O>Z?]6N_KSO7MW]NZX?)H79$K6!
M0CN#VE_K6?3G&8AP#X5Q8?FF#SQVO-K#KCC*;\_&ELQ_Q9DIG OL+L&,\1EP
M?]V'PT,&):_?'6. [FV$BC:9N:G.IS1XLY@.D5?ZCTF!A;L< 7=Q1>,4-;8
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M!Y-H9]6&SZ>C8>VC'V,R.15/;\)&?20!RK2JAN+S5:^I&^P+A]3LW!LY%DH
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MAZ\.A!]^^3EKY]AW-U_K6P[+6!#LE-HU N8=OAFPQ9D"V<I?QL>_G*:;F.(
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M7D[&R"\Q3L,RM2H^ST)-LQV_P$,&)*-QSLQ ]8B+("4+*9JO+4(LKW I.@7
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MW_=?6PZX/ISN$XOA*C-@QRF6?)%0<HQ5+2+/*TE)E$_]PNYM=(6R2A]2(48
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M"GF%GHE<?]?P[B3U,3.K@<$&4)^AJKG;KM\J*FQ,H\;%;][RV(-UF$"57+.
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M<&LIB@CY^)M5\&0L7!"+CNW!I[0-M_5(N/H^.<B$11\.$<5M!G]H"H8_8-_
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M9N^\,*/^7F2'=S"FD 1]9."H.QM.*KT*WW9[DG$49&VNO.+;YAWB:DU+,N3
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M1#\@6E7<7:NDA"'48-HK7M<5WCF4?T[/2YC5,=TV!'B+=:Z66'+';(=;/LF
MQ"JW_YZ*;'SD(9^U!Y7>/C 6</4&(7MM#JKD6.NPYA@HO/LX]91\,S;=K'J'
M&71GG*7Z6SMS[-:,WCFG%$@RT-];^)W[@O\C6QC"_49$4HOU\@\<I?_50+<Y
M>E=["O^JL> =IPD3H7Z.JY.T!K5N)&3J0^'D:()=@O8R;6=/;<IZR)?R"_*
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MA=]QS^U;^\+";\9&SP'&[VP8@V\L*@\$4PY&,Q'3FNLEL''%0)4-VUBG7L:
M$S!!UUG6W(N(&];6#9!UTG;G%S!6Y?=[,K%0B6N7_NS4",-<#:>*AG].YHJ5
M"YZ*",M4G&XK7@6--S*CA!3H7]0?+4T$OUU7?\W$1"I);;L-7>8^;RE:?UXY
MD-!,6HG3@;^^EUNS5)"UFD[S,!C"X4/VEU<G'D]0:^9[")Y:O5^_\UYO"?7L
MF@NF]=+:*0[910,@(QAOEUT?*1'@N>&V'1P1N./=["7T]K;^J]__%KU/J3<[
M6FBX9NA*EQE>HSH<1!,OVW_G?NHY[G?D/NNMO0"%\^N3%MHTT-V3 H/.0#+.
MI3&6_$ = WE!\>,_%\JPEA(>V([UYX+9&G!I=%NL)\V'7:<F_)3.X%R4+/:S
M;:&U[QC4*.MAYVA T,N3*?;S1UG<_&B%P9@",;< %M+QL^,K[-RG2O%P7JH>
M'\3 NH2W:%-[L_.+)6)<X0@T:7,XVDY)>'#);8R:!_6"%(<\"#K[=?<.FY14
MC6>:H0@55E/>>JK OATC/OE$K(*_U.!-^;2@JUU\N#F0,=:?P6FHN/!8=_#T
M<FU&TA$I<!BC GA'W_:N_\P[X+R>.M'[Z%]+X$>,)O3\L?EPT#C'7T?BT^>N
M]&@Q1L"'&:3F64!T=&W9EQO)JYM/'W9FY[>U$/9"V3R(4PG BM/6QD?+3B<N
M*;^7%EXPA;AX*8CG4A^1L!(FJ0!_7*O(++$)97:@@%C9>MHU-KI13.CIZ<K^
MUILL:E+IJ2X& 47=\5ERGWHWGJ)FMFJ<'- ZFR6@@C 7?M\=&RVXH"52,9X"
MA8_PR7G4)Z;!TZB*(W]ULBA\2NS>NQ/HJ5C8A8#@EOY,--:,P1DU<.V](]DI
M2.!!"7?M4//!QK/E7(9B+'B^<[.%]\\=)938LUOS:^)CZ7WVWKJA*EFO*9%"
M\5-<G77OH\XT);F([3FF46H'*[]3AMC_8OI1.=B[9=#7-?XL^T_3XE7+NMJS
M-(2#R#C5+2#,_57YD6HI3@ 5WPEI5\2@;H/'T9W'SV@9)[I6\ZF<Q5D8#O'E
M\=KD.U.K ^X$D9) $3'O,H^4&HYB@>X&J--8SIP[I[]:'F"6W#4UJ\J>>W):
M;4B!C%U+8_*U:5=)@'XZ4+$Z4&$OAJ:3>6@*(>(V%&!,[);,%^S=>:%WB?5$
M)-(D%BCID+ZLL7AWYV%@=#"'(1WMMI2&EM-ZJF(N3-YN#E MP])\ K*YQ =3
M(&\7\*K"N&:YQ%L1 '>U;P\*)4B*%A=,*:,V3XK,E45%&E7O-'O?>.;SQ +.
M*9=&33>5I*F:/AI4J;U@JMMEL1Q(TE>Z(L0PBX$K+QM^)VFC[6P>@?&!Z[[)
M%;;@C_OB;H&0\:V*78O1D*K)>#7C\W14I4+?,^]Y@L+^FAZMR+3E0!IO-OI-
MJ4!V$OQQS%T])S38?^'J\-ME@(&',T79X!Y0L\W8;5WWIY5>F8Q79 -XGF]'
M8# ALF79S/9&ZUJF]31S8I/?0NV+9*=*N;&LT?Y_+5?UC4G2C)^MW<N)2OBV
MP_ZZX^T(E;1&N41.JRC5^A0/C0)<K&"Q4QB1J)F,_/L &[.GO7URT.OOQ:K[
MR@$Q*;9077]WP[TGUSJ/(2R7JJK>6%NNT"T?NA;*9=AJ)9F@/*@[]2*#;Z9%
MAY%Q8(?6^8<'.@^G6GK\=ZLDG(.;4Y7Z3'L4G[F,EU=*F6 D$*B1(EX7O01:
MZ:H %_59=28O8)^R%+VAJA !+#;E)&T0ZFA6S8\H@=%M@:DWC6.##OTP[T2&
M6CW")D6:[NV1$O0;;$@#=VVJO]:XQ):ZFZUY8J[U2K #!KW\5V:VH62":._#
M:69D/!UF^E$-26EXH15M.WW$77;!9%?=4PFY&3[DW? 'X9M41^ZY>G@'[#N*
M%ZPZC_S$I2K_9^??A^7\#WI>=C2?VQTG7C 1-\],I+W?))SU7C"]C]AO\[Y@
M6F'YCF,CMHW.)R"/X<^G_VF'WR^89"%"J<GUMF/%CCA5*APA-40/=12 IH!-
MFO5<\OOZBE868B3M!+RZRG,P]*+^[T0)\&W.\9D!:*=X@U2AO'N]V*<^BOO(
M#<NUZOKDLVI2<UZ3!L*R_^H8@TLZDVI^Z/NB6RX&5EHPM:%:+%L%#W#8$!W$
MQK=A3&P]U<O3GGL^>'!FSECET_3-1W3:NH3?11PZ!*R\/JRA^5\?U_R,=K1'
M&'N,8"!F-58*$)HU@</NB>Z"9DUA-SG8OK!^T1&(#?1A3T![@WOPQ)!%MM,.
MR;[<!]'LOB6I9C78;H_N9\%XF4(#,BFIN:<VYVBIWHX01Z_#(:<*S;*X#<,<
MRCZM,:2YTYLG2Y M#!'3+H<=!4$/BO1\&?M\%6#=,H-21B-9N9#CC?04.O+;
MK&S'[<8&&\HSW4>I6*[D18XXUVMY(EW2>0!)^1/31R$'79N2]814NR$T]VI(
M.=;DC@6 _8$P9Y-!CC'2K3@J82KL2M>_/&"Q/J\K1.GZLB7D,?WY<!"OW<V5
MQ/'J4HL:!P..]68 &F FVJXQ?K"8Y;3,\QR>^&$1)\"U**R&VX?HY)2ICL6:
M@,V/07SLHB_IXYG)CO>:1+M,/#=BO*];CV38FL<.A"1]4HV)2AE,V5A4K3;Q
MB9*),[/G4 'X9KQXY\BVG9QN,<L>EP[\]8*I?K6Y_SRB+^*K9/>WZT\CYI*2
M[*@<]U>JM%J3VH^4%Z?W;:M.UK';V(&6T,[0Y_W.Q"!UW=72J2Y&F3Q1N>O%
MDEI2?LW'CM$8M!A1Z4!I$-F:EMZ&70!I9FBQ\N3T2"U;6$[;#->5F,C/LKOY
MQF%51-K$IPYKY!-W[(YT%^,M':UE&[H);J/6@VBKI,#*3[IL<PLJ6F&3]_*G
M'82#-5%__JTKYLW="Z8GR/.Z@AU)$?;-OVRR;7L[VOQACK"5\7MUWRG:1[/.
MQX+ZQ_3J=^5=/0,F==5=8AHH!]S323TGY+J/V_&O(&_6,1>P"B@>7Q4O2RI8
M,G<+7P3W886',<8 3:N"V"Q>F';(K4>.2W9I_$V;"A=,.54VAR3BXX]$==^7
M7FHU5E,,NB/@&\B8FQ=;1\OA+7DD&YCNQ(K7=_3U.*50YU)8[4B[=38F#XJ?
MK(PLHX,!8PP;E7#G^[%&'$2@H:KL^6T1[U$N9-CE453+UYG_ ISI$_,='[>]
M.=;AL ZJD_B+,)[K7DMXQ0AA:I8H5^OJ1B4Y.NR8*ZNAQ\BN UX+%4T)1+\H
M;9[*/,*.7EU/36)G%%/C!3Z-X;CD=*<6J_/\F8%L8%OW+&<-M+IL*,PNFI--
MZ/<FIP/RV]LE\P+^195?4'FQN>WBF663'6/Q]4#44CQ,:3*U9@-"YJ:852B!
MY3T\W6VIH?*BCSL/1(H@]WWMTT9=[(+1+LFR=?*+8?X0MIG*=;3^]T=3J;%A
M+'=?8<QIA>XAU$;\O&G>#?@-1-,PR%VF_RTWD"NQFY^_9-GY65T6&03JPN'P
M*V9UX[6IARAO:'@ 0=_PV&F\N8/XA8N0Y!QPS&<,3;**4"1580$:]W ^QH8'
M]3)AGN6;]T67_U'! &<_VMSNOWO!E*180BUUHG1%, X;-E)GT@S/3,]FD\)W
M?9>-55+?W&]8M?,IGW[ULM\U;=I\?N=3B)S*K1L1KY).%*NPVC4_-G!,_/VZ
M6[P=5JBP7=VQO54 M9WXLDRY8R&PB52X2A89-](+$PLT43$=,,5K,H=P&I[M
MU/=%V=_8<V^S\,\]6U@I N."N+ ">85^"QM/K2]SU[D-&6T[BS1<"V\+E84\
M56?]DOC%V86@)MSN7#IZ[==T!4BW/$QY59PG#N1>XK1?U%1(X1CHE4QVUF6\
MR7R-9O[8Z@^0M?LCWSG2*C#8<ZU@V"0OS!N47_4]=$APK?D@3PN^"M^"L0.-
MYQ'6OD5'U#8C7K;@#P)+V2;]ID8XAKLX:PXQ<3IZE<-,)U3*\<0/QF[]PEE!
M]OE4@ZUZT .EOTYF#KZ<4XI"LL3_'/IV!?<**BGL7""J,$7-15F4V%MI>EK,
M?DT>\IF,LW&.NO%__3[*).+;6?S,5=CWY^XTK+W$S/8=)0N:DV/=7!)K%/+5
MI->5')SJ]12 ]5T,Y ,Y*4?,_TG_JPDTO>8R=T@L2WIL?2&M55U1<Z155YK$
M6=C[S9K7OGAC<WVQ/?5%!,>?U.'E04\?X2.2F,IP@M. UMDO7[-+?/*M_6I^
M; T,Z?;/7ZS"I/[P^^'28(A (E]_A+!">[AK6V(=1?6VJURY3F#F4'=AO=O8
MT/C&XML(F!B?7HS$81193J+D&7B8?3ZRS=FNM_VLE\?^RBA"#[2OO%4&N_W9
M\;^559CP=AF0C^MOVWGX)B%*JFU_=%C 4_*T01Y!MC$I3^TJ8CY,YRS+*1(G
M>7 ?T.P:H,Y!7!"Y(\NQVXJS50'QO%$&*ZJ) V%494])0GK>A8.QGV>@QD4E
M&6 5=G.4Q) 8_FIQ[; P\_9I,L;.Y1S=F58C]QOM^V?/]SU&\ES(74GZ$(K^
M;+E5"]"\^_('08_27NXD2IF.P.V.QL079\N@PB=%4.,DA(4^0-+;4-W4MG!=
MR]9=OEBD;ZK>;*E/2C9V+-.IU.U ?LOEZ]'[<&Q7J'7[1*S.0"UOO_$75[I3
MF*IY7<3]2S5B-[5!NMT)'46E&K=!M[=Q_G;1E2%J+XPI(:92P\E<,^3R/%#>
MFK.RL'*PO::(YG#_8J/M<BR"@R!G*PS+#DZ=IOZ9<?#BW1A62P@0*F>4IR^'
MX7W0^?N_E/B_X3 MG_L"59<&CDP_RDF@^&L<KRBR<!60A9Y'M3'L?TVYM((>
M'#+H*\WFB[Z#R\D1XWV8V'W!I.^N9AU S,<5=N.CLK.&UD+5-0MY=QTUOR,F
M%7BZR^T@,*H<8U02W\!F:DN<]]W1J>>[_'-*7,_?.Y@0K0^J8ZN95_)/$W/-
MR[N31R7#^-#+R1TCW[+Y][7!XEM;YOL73$<A?N+F#?5'C(+J+_/,-O*T-8?J
MQFZ8O&NBI4%7L&OJ=I&XS2%J87S*+/6G?3?=[ NFKTG"7 ;_2 _:F_)G$4;\
M1]PN0]O;NNOMS(3Q"A5(1QVZW/[/4N+<MT[VK&'KFYK!2WC4NH=W::?M1.)!
MD5[?!N2"*9CKQ]6'E?J+9EK)5E7O%PNQD>J0>V)?87GQHL(*P@DW+\W.+J9+
M)Y_UEO<7YU(?^R (*X873$JX><3SN\JUK"\(43<ZG[RP4)DK,U1GI62Y5WY.
M(:4/=EZ.V6T[<GT3!"%V7Q]XAD"*.B3B: H=,11@[(J3$,!?U PE1O3!WQTR
ME!\R^CD=;FKD:.3NPAC$ TG*5(Q(7]Q<'J=.?FYZJSRU+7TL?63@0"$L0RUO
M+4BCRJ+3HGG-:LH\!<J2C"/H+]&)5$X70I3 V!)=UX K4&:)H4&VHIOC<KZE
MF;M%(%W,Y$*+BPH8YA1'D\SY!KFW)K&VMWZNS$^'.AHJ)KQ5Z=R9?)H\00_N
MO6?C#/9S!1!4O- JK6W&02^IHFMN^5DWY ==2L]T=K+-=Q+B?^TWM1HAK_[
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MT\;Y+M%0X:VAQC(!<;\2X5ZY_]G'6_0)6454USA(N4N:;<C:U/!A^D3/A^/
MO\#UOHN\)=HG]>M42>!ZPA.R6,UZ(]89BSZBPC= ?M37.^V2+#<#=?SV;?:
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M5N4_B3,"U#F$Y!Z%A3N%A6;9=[4K/A-&QZSL\RXUK*(%P'MBL=-+-Y0DYN7
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MZ7_4!;=XLMN#-,T&?:W,@]&DLH^!9K5M FL.92C:1/N"V+YY"=FDB1\?DF/
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M=!U"HLX\V<EM$W81GINLR;5HX&5+Z=;".X\2W629F"[]M>68.?Y7EH[;Z5T
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MK6W=D[4U1 [$LCC.,!*Y^/Z3'VE*8Y69^82%S>PV5#C*)>4S ZL7#Z +.8/
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M'N$G32K?$[_DRMO;6 ';&B1K[$HZ5&Z=JO.KJ%C7!W@D0\ND+#;LO;ND3*U
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M&=,:-@)%I93PHJK!X3J"]; 1V+8E:X]H0NJ.3*W9<I-9_YHKSO7T2FS[C$_
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MXFBK:/PM::VO4BG]Z0_*B_-Z[=ZW+X:V#&5&>N/!*D-V>J)OSAN\W [;Z!W
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M#TP5/:T*@T1Y9IL'LJZ!E##\$ZF=PVWO\8D=C%B,CC"8)L2S0A%_0M9.4[[
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MPF!0B _2T-86E:P3"G H_FQQZE1<4TOQT3^NDNM#E7+"?&U,\>TG]@\$#!7
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MSK(TI4D&TTSE$/.80BYB 5.=XH2RB&GDE&C:L;^AK5W'0K)G&W=!@L9D^]\
M"8AHQZO.L:CL3FY_.,+285SVJ]W]<%3=)3+[\IL?=3G9.I]IO0U3K$YP%]=E
MD-HHCS#"+(ZAS'(&,<L)Y%(IF"F<499PA=S*:;EU-S2:60ELLQ&4$E^M8S46
M=2"?5T7H<W@[&+M!4>R86M8 WJT 7(L+KL,#Z%58.R"0O977=O@BCU=U]ZVQ
M[0C0F4K;YUKIL]ZVHT8[5;==WVK!P7\\SZ;WBHE'T^!;-5^P\?2OL_E$?A]+
M]4DM/C/3]WXJ?Z$2%7%N&-E6HXU9#"D5&.I4J4SF/!+:O<Y(&PF&QM16!] H
M 6HMP$H-8/0 I2+M<OVW&B0'+N\:^H[IO0WJ;38I6L'OL1)T/0P]+0[E<,R;
MX1#U<'Q?#<?4#$=1#L?32IE0:\4E$)Y</EHUW-^*<HG>6XO,10VU6'?*T&]6
MJ'>J^M\/T^W0\.J&N?ZC4-=%H1:CE&6<$K/DR)S8-.?(%HXQ_Q29HE&,(H*(
M;.)C'AQ7'D\96D2_//2P]C32V]"(=3W92?FK^]L_ +.R^ZPVOD/CL-!T@70_
M:TPC.?BID?UG\&$*=NZ=5!DKX$S#/^RQH-6A0\ ]EI8.@>]I50D_ 'XK2TL$
M3RXJOFWVMYZTU'9K*6G;1MLJ-KN5%>W]E7?C0DQFQ7*N'M2/Q1NCW]]&L=2:
M)#J#,6$$8IH9KX61&&J=QD3+/(H)\2MPX]CST+R5SP^W;__O?[O]^.[F_O/_
M^$>2Q/D_@9O_]<>'A__P+8+C"KW;GG4G@':\/C0E6*ULH!0N:/$<3T""U=5Q
M[;?GDCN><.Q7X_%MH!TG&8/9YF._F\^^&?-9OGDQ7"<W:/!:+,;?Q@M[-PZG
M*A:QLI6BE;%K62HACV,$\X3R-"*I&9IDM)@MV,2-E-R[]F*EE0#=S23KK9=5
M-)8V%GC+F&4KH?T(RF,<W!BJ&W0[IB@+;%FAHA';QEW_]$>%\L\;EM3U>9B]
M*<P?L4 <YM%QKR3F#\@NB[5HH1V-'3#D; KR3[,J^_AT4=IOQ2C)$JQPFL(H
M2VU^-H4AH30S'!;E29SPC-#8PS?W['Z@;GE5QV$ZF\):6B]'W'<(W.@K)**O
MYWZ;I:$"=RUWY?$%I"U/I )QEFNOO1*6)Q2[;.7[>HN]Q']C3T_&:+M[9/,G
M\QDM%[9RJJV1\$N]%Q_I%$D4<9C3+($X00A2B2U5<<1C;GX9:>?SJG.]#<W;
MJ^4%.P*7J5(\-JG.@NRP#1@2NHZ)YQ1JO[0Y1#J+G\>N7D@<>]K&NQ!/OST[
M5WQ.;M*=;:2_73E7?;:VX9Q?:F<</IC7;O7&O;KK'V/KSF)%K!68Y[& .$X8
M)$9=F!$4BS0F3"JOK#H'>QD:PVY</?FFMBZXVCCLS7]7=LOBD4W!]DM?K%Z>
M-:@/CX";)7@QKAW3;_>0>IN$)R$+9  >[J-7<^^DFKO&W>F'0WF=33&LOXX7
MCV^7Q6+VI.8?QXR/)^/%RR@7,DUBF4#*>0XQ8QA2)#%,%=5:BB36J5,![);]
M#XV,WC71U'/U34V7GA6L?,%OZW<&@_1U_,]5Z;_O1G[0*' %5BITZ8DZ8=>9
M1WJZ]U?V3)V@.>^ANC73PE.]4VS^,%=JWRBKG0!%>1S)B$&52VGLIYQ"C@VW
M"8)2GLB<\\2]TM:YWH9&759>8 4^["5X.%MG<79P5D.BUS%+G0&NC;MZ%D$/
M=S4DDCVYJVT_13\_U168DW[JV4;Z\U-=]=GR4YU?:EW*>KMF]DZE[/5&Y$BG
M611C6]R*V9*G"4DAP[&$44JT2N(XE\C+>77O>FA,O%';OCR2'4_%9"GK8]D@
M!QL>P^)F8W8#=L?$O8%S>4);YKZQ/VP(?K5QSA&T>K0G7.%*0[MVW'?=9T]
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MDIRH&"-(*,HA5LRXK%F<0&2+(G"!4>I6!\FCSZ&1XX:<8"5HJSAO%\#=#,;
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M)UPD,O/AP;,]#HWS&O' <R6?']F=!]B-V(+"UC&)-;*"GQII?[9VWPK(NS-
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MGSNA<W;5;##QY(]U=C6HTV6C]*%G9?6.CS(%[^?+U83'2N%,$,!YDNMM9\P
M5IDAB\0QA&FF4NC$)G[<Q=CLQ9?Y#%27*W41@G[I/B>0M#,-U^$3V" <51HP
M\H6J+;"K>Y!Z E4';UA#8%?![KH!>T]ZJDC\:;E<2S&A,%<IUDY!FII;<E)
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M/JN%^ZLLG[[K+?RM=@WID[S[*1>\7,JO"ZWJ)):94B@7@*>9 "A)]7)#DQ3
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MC["-]V=%*A$FH)!QHK=,B0($4>U^8$(94S26BEIOF?;;'MLD-](!(Y[#[N
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MY@:P!> XQ]_ZS;[!EL_/Y:HFCI^)39P5+^5R2S^_"65!2!J&]QRD,%< 28@
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MS-:PF=U4_ZTJV#=*5KN9Q0:"ZO>.L5;#?B)VAG"\ Q_8RKZO1KG* MC1R%S
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M+.8_I/BZ, OH(4/^[?-<_]M_5'<([UZ;9UZK8O7_+OFJ\J-QSEE:2 8H3@A
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MG_[UO[3_HO]C*K7^ZW_Y?U!+ P04    "  [@ I7,Z[\,QEC  #R5P0 %0
M &1A<F4M,C R,S V,S!?<')E+GAM;.R]:9>;.8XN^+U_14[-UT$E]Z5/=]_C
MM-/5ON-,>VQ7UYWYHL,%M'4K0G)+"J==OWY *?95"U^]M+OK9&6&(\(BEH<@
M  +@O_R/KZ<G/WW!Q7(ZG_WKG_B?V9]^PEF:Y^GLX[_^Z:\?7H+[T__XMW_Z
MIW_Y/P#^UR_O7O_T8I[.3G&V^NGY L,*\T]_3%>??EI]PI_^-E_\??HE_/3V
M)*S*?'$*\&_KO_9\_OG;8OKQT^HGP82\^+6+GR[^67F33)(%?#$%E!<(3GD)
M3 IF?5:(OOQ?'__9J2!D21I88O1K4FN(SC H14F!Z)*)FP\]F<[^_L_U7S$L
M\2=B;[9<__%?__1IM?K\SS___,<??_SY:UR<_'F^^/BS8$S^?/';?SK_]:]W
M?O\/N?YM[KW_>?W3RU]=3N_[1?I8_O/_^NWU^_0)3P-,9\M5F*6ZP'+ZS\OU
M-U_/4UBMI?XD73\]^!OU3W#Q:U"_!5R Y'_^NLQ_^K=_^NFGC3@6\Q-\A^6G
M^M^_OGMUN60."XS3^3)-2>GXYS0__;G^RL_/YP2)M^%C)7C] :MOG_%?_[2<
MGGX^N?S>IP66?_U3_0BHFF5&LKKL_WGUEW^^HN#S I<$FS7'K^D;YY]15]N7
M&ORZPEG&#9\7ZYS,TXU?.JE2GB\N_N9)B'BR_NXDXW2R_N1G<;E:A+2:&(S)
MZZC!<.8(8DQ#L(5!MEG+Y+,NN=QDOA*^),K72EEB^O/'^9>?Z8-_K@*I7ZPE
MLY;*G>4VTMF/[HM=^(%^=V*RS#F&"(P6 Z55!B>* (LIB)2\L=H?1/;UU6Y2
M?5VKSQ;II_DBXX+,R,5R89%N:/@N@,]_X^?/I/O9"M*GZ4F^^-ME,3]MH:O5
MO('D-FHA<O_T$W%=<+' _'JCE0>96W-&5,?Y$M>_VT+G_\]96*QP<?+M'7Z>
M+U83FZ,P7'I0%BVHK *$8 .D@E$RKD5 U43]MQ;>"@FB?R0<(L^]04$+-H3$
M6UQ,Y_G767Y!1_*DQ&P2]X%DP1,H(>AH]8I.2I.2(<6ZDDT30-Q8=BLXR/[A
ML+\L.P'#AT68+:=5\.> %J9@]4>@,)>K@Y4A1(D0E3(&59#!B#;GPZV5MX*$
MZA\2!TET9%3\.EM-5]]>3D_P][/3B(N)Q2(LH1F"KK0S2V=>HB,P,"+<&^Z8
MCP>AX?:*6Z% ]XN"@R38A?;?X<=I%<)L]7LXQ4F01:J2'&1&8982W%' 18%5
ME,((*[@@*AH@X.:J6Z' ](Z" R39!1)>46B_(!.V%OQ[DC\^GY_-5HMOS^<9
M)UF@TLX$* 1Q4%$0Q$O*@"XS'M$%JT(#8#Q*Q%8XL;WCI)V<NX#-A_#U52;Q
M3<MTD[,XMX1$*]?,..!(]D\58LG+DL$[*3F+)F;7PI(\L/Q64'&]0Z6%;+L
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M\MIN>H%EFJ:K"<\A^?HD"L/ZHBMWGK9.46!3O<1F%&P\.BA\'W@]3=6XH=]
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MQ8^FP0X\O7-NKV;OQ,RC*D'6J?I$O_3D83!44#+%WZE.SDFM1S3<IF'<W.R
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MF2]1@:UC>KAA2?#6S?M[9N>'[$ <,3V_BP(.3*K^.LM#)>>MSC%KJP&CI.W
M23!1*@Y<%45[1$J66U=:[9F<'[2W<,SL_"XJ: JDX_?)/ _+3R]/YG\,\S3$
MU:<?JP_F 7[:][U<+G3U,K0W!;$V5<5ZE4W1*<28+8%(H1-6V9A;.]./T=,@
M4JB?^78Q_S(ER?WR[:\D]E>SRTEAS^A@_[)YR_JRR8,7B4(F*.CK(>XCN!#7
M+T.E2!)PM'_:AQ,[4ME)"<2A"+HGP!A27=V%KB)HC9('X#I*DA6/X)%. ,_K
M(^P\AN#&#UT'@]'0VGXT>MU%]!W@YD9BO-XJSM+T!&^P]&&^JS11B<!<TI!8
M)&D:A1!4=A"X+C9Z-%ZT+A4<@H]QBS".C.+1@=#!9GB!M'*:KE4\$:BRJB6Z
MW-2@6[@,WA@#%(<;Z2,K3+7N!+J^_K@F='PTS!NII@-874R5NEG8,5$424FL
MCV4S75^,X@H<RQ1(%<S>!,\B:]W><3\EX]JY[J#60%UC5]C\/I]5B;VNZ8&+
M";,AHP@A,\AE_51[)OJEXV!#%L(8RYF[=2@_4"YSSX>/6\C5#8*:R+X#@W4W
MPW0IJ?-:B:N!5M8'X2.Y'+K>\#GB,3(3P12O360\)],Z(;<]=>.69'4#RX'5
MVB5@GZ4T/R/)D]QQ^F7=KB,<:BL* ]IMB0RX)*]!T+]$= *%(K?!M(Y*MJ&K
MMYZ!-IAX$GH'*FAWT/D-Z&;XL:9%/PQI+.LMX!5?RPDZE;)QME[8U>'N(4*,
M,8"6I21AH\+F;P ]355O+09'PMU!RCD4=0,![NT"/X=IOO VBG;&"!?JZ%H#
M"BWM(PP)&*)5TBKF>.O XBF:>JOT/Q+8#E!,IU#;5#BL:QA6]4'1U7)B.?K:
MD5@;FBDP<O4='J<$9%ZB#P6)K>$;.^_2U5L]_C'MV_X*ZOY<I? JW>".Q<A<
M,+6SGMQBE=&21YP2)*E#"LE@U .\(;\-:;V5UQ\3@0>IJ6<07OBM;\.WM=/J
M,9,SX20X5>\FDQ40K"D4VK.2N6;1EM9]'D\2U5O1_)%#BGU4TVL0NS@C.J8A
M3D_6>8 )2I^T% ZXMY)<B.3)EK,"I7#%H]7U98)CP.T67;T5P1\/<8<H:.PT
M\5V&7IQ3\9?:"?7R;%,ZR$2N4[0\Y*0=R:Q.:T./X*U-%+$K+N)VC9;;K==;
MW7M3+ TE]YZ/S.?SV5I@?YNN/CT_6Z[FI[BXV#+?)MD6'NJ<)69M),? <G#)
M<-"11^E5*M&VGD2U(XF]U:\?R;BU4UL'A^OVU123$ITN+CL0*IOZ>DN"D ,#
MK[1B26?N5&M ;D_=N(F4XU=6#:&T#M[X>H"S5[,ON'Q D":C%YP<6<V%)T$:
M#='$.IDN:)>MD-;RX\#R$2H[F<]VI/K15NKJP#Y2S'31'9_^\VRZ0.*5MMGJ
MV]L3\DB>S7*M_O]<?V4B8_11TS[.AH)X51(#IYF@KXA=X8VQS9^9WIZZ+BM/
MF^%D?A2E]>-+;B_/B>=&,T]L95_'CW'RDR.BAE!TM*@T1M/ZTF-[ZKJL)!T*
ME0,IK=]3^^5T%F;I?D%:9[,OY/FP>MNC,@KPR3 PTC!N'<M9X7%@^0B5XSJ5
MQSZU6ZEK[.P-L4>L)<2\?$E"K8,9B"\D*=X[?FF2ZE E"MG 1U1UHHTA%]DD
ML,Q)4PSJ8F[=TSU4 +C;PET>R<U ,#^21L9&VTZ,.19)A$C'AY.2C@\;(5B!
MX%D)F#5MX-NC"QZ 6G.<'?N0'01G@^FB@T!D>SE.;-!2%:\@B4+R*Y$X0Y(?
M<ZS4%WA=^X*^[:GK,E'3&HT#*ZT#E^_74C"19_+KU_0IS#[B._)5WJP+O.O_
M:WSU)9S@NHZ1Y#A-%/[4'] &O/F-:[\Y0>4T-R: SE72P3D(D1R;1'M31Z^=
M4*TS.0.P,6Y]S6!.X]@*[\ $'\3L9B;8W=N$=')6+[6NBW4CZHD)/D?&%$CK
M'2C+ [C$$PAK@LD^<V%:SSDZ+H?CU@$-ME,ZADD'!\=A%D/FZ(O@!8PW-3(H
M"4+!"#PI%R43W.;6V:SA#X/!*H[ZA/A.2NQFCOUA+'MA:1MJ!UYX!(7:@Z<@
M%@1MS_H4FX^I]9"3X7$[6-U2I[C=18F=C H[B.%+D8O,S+J[-Q=/H;*FPR9:
M$6C_9L:*4%AR5^C=*7\[6,54GRC>2ZF=.-_$UVUN*+Y>++Z19[1Y[H&K:#.7
MK ;KQ)2P",&P#,)9]+(HQYL736U%V+BYWA$ <P]DVVJO TC>D>$M]JYJ_8FS
M6FI3,EB=16TUB>"TUA R,9D+9R6TKH;?GKIQ$\3C@W,@/7: T,/\G>R#377"
MM&880"6EZ\!I"T70F85$KKI=W_P=.*V#I9;'Q_'QM-U!'N']V>?/)VOW*IQ<
MN%>O9F6^.-UH_%*@VA5A(H(0S!%;,D%D5D,R-J"W0KCF#]=O2=JXY=.#>:=#
M**8#4_IN^O$3R>JO2UPW[KV)F^>,7\TN4G(OYXO+ MSUD)NKFG"1).VBH,'Y
MVM]<;(#HB>DL2L[)JHBI^:/2^Y,[\JS3(>!S^\ _DBZ;P;;YB.<WBX]A-OW'
M^I/"++_ 95I,UZ^4S,LO9TN2QG*OX<Y;?6ZCL<Z[\]!HH//UA:]&2F\>+'A[
MC:$WY?RB-YQ<39N^!' 23B(7"H(BV"K!/;BD/6B14[;)F51:&X4FA!_\*L@A
M1+R8+M/)?'FVP ^DS%_H<_\^D2DJIC&!D(5.+";IL/)T8GF3M%#1)(&MKXU;
M\S"NR3T^GN^\#S(F)OJUTK^$Y70Y+]<E0(;N_=GI:5A\FY?WTX^S:9FF6M.^
M:?&N;T^1[%*ML]G#>A^T7B.KWH[G1M;^[C*7D'=,%D=^,C@5ZV N1\%:(:]
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MW@%X[L:]X?Y0]WQO&$Y;0"=1*P,+*&]M?4C1@TB2!\5STJ'YLYZ[D3BNI]P
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M'']_%BF&GX;%MUJ>]*:L3>!Z%]AHA,^>_&9>L_SUF;:04X$L9+9"\D)R:>S
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MG!EJ+N(.S,_ZW5K,RSJMYM9>6$Z$)'D8Z4#F]8O>K)[+/I"D!"JE QW2K>/
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M*U,\*T:HBTHKIZP.K!-F#EIV6$O4/Y#ZT\$(CL)G+U+_/5U]/X=4IKS_UOR
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M)T,K[_I]M)R<-GWXW<UYXD5F6CM%J T8E E!B8\024A)*(F'39#5GS8^0L?
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MG355!#B&K,E#"WMQ>V-O+?5&9(I1F\<S$V6#5I8S(H0KAZG#@[GG;.W%025
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MI#\/,G%C91U^;9A4X8-!E$RB+(?!Y<Y0!CA<_.F\2+)1,H]3> K>0S_,R?3
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MH?-=VU4^-",A*J80/**FC#@@:>[OP9")LV9,V[']N0/#-*23QO!3)SX%CY[
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M3_B+ESWOVVK>-RK18$IC2YAWW*_<ZI4S,0FR5Y("F7&R# ,WI;/EYR@?%%Y
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M)3.\2AI!<"T4QK7ST8**F'BH*1/L!SL,F0+[?QY<':#-*TA5$O<+C4$Z1SB
ML-+CCV4EKB[.]<;!=2L7,;-;F[C&R2 Z.L5A'3W;&YL=[3S%/.%L1"571R]/
M3@<4G!>^</=Q[H^_0=O0380]-Q[W!.TI?54V"79I]M^Y0RPT^XXHAA JIRT@
MF[0%9.\M^OIE;NB <2$M0=O[C\K>(0KKDL-\GSCLW<*N_BQUR8J'QJIOY,U%
M&GH_Y!Z,X/KK_')'Y'/OB-SC.]A;]I[(M_%$0FY'_0T@+--S/!BA-:G9S^6J
M%L-MV4UJ$-;AI[@8N(#38Q VXO,X*4$-]Z0J,G KOK''TUBYK?)X=MQVWKCQ
M?'3 ^%%W Q$]BX&^PXMX+RPR30<_;!TV\>G75%=2."S=!C#E(#F9D!'IB1;4
M>([8S]IJ]L2J<(I/&D1WC2XU"+0:EF!,20\CKS\26"<%.;CD$S0&6@9'%01R
M96:["F6G;KV)WBZUJ%-NF>%"M<;\1GE&:&?K=KBRA/+BK?S A+<8PN7J##05
M]T;[9#@CC/V\/WV^^/3A<R5X\ A_/F^EG4:OC3>MFU87"YWG> 1R&^:-H=:T
M^U5S?NN6A.NW_?C#T?/#5XR5[_36UO&@I<^OEG7JL;';Q^*F-YY&TIV5AG^S
M<1H.C(ZFOBR$OK5]7D@+!$Y04Z7$+&OF[!J$[T3)1D;NZR/">?-FLPSS_!-'
M#:0=[[Z7ZF Z H*<,Q\!>8#U?AD^BT&MB3N- [N[A4FK!E%^FRF7IQ#)FU4&
MQ@*:COAS^G[/L6[1\A4K[\,"3N^CD_'3$Z<=HQLJW3>-/ )K*FVZ#:/P<DZ*
M&)_(]:O:K#3KH,')SG+X9_YW7)+6B5EF!PNP;LZ>A1]#YO ?,M_*.CN?_TAF
ML#;SHTJY&EU%*(13<H/41)-G-$<R)3QZ0;S$5")!(2OG^<X;D2)@LF5TH&M1
M41[BV<L=5UX;UUX2#U]/>4T67&C QFD\0X"^WA>6](.V8/M.EQ.9XYWB\\(G
MR0T75LA]EMKS[6JBS:K@>?ST"&S55FW +"NF*41I2Y5&) >V4:FV-._X[&'[
ML_=TYFB9P9=P2D<7\+AJ&;WW'[4O>H58]MK7COE=D1,SR:I8DXVTR%C#L5I'
MEFL-:=SSPT6]R#L.E6:0T8OKE.@4Q*HU&.CUKH=".K8%J[(X+?W&VOIGO'!E
M57!>D%O Y(N4@YFV$JC'%?>XXAY7W(8K/JW!7'M<<8\K]BT8K]?2:JW-5I\J
M%ZFQ&R8JKDP_05;1)I--O6(*+CQ5GU4Q0I6-QU4"$P OA^U'=)WAB4FJKIT(
M?O@@&()U/<,S4M-UV4:%:#;G,VU;2MRF8&8^/)BFZ%IE)M M/\M'\)P"P]=U
MXC(^!^4I+A; VDV.S03GN6<RMXR?%XCK/$FGT/ +O3I\HNA8(>=IRW(Q8W?'
MI&S#]P;[)IF!(X HG'39]81:42]3M+E3E9+P;#QP<+*318'GKN!D\?T&/!3X
MJ[3NF:2R9SIL8WP_-+JP BQL=T5[#@%C*#C-:Y'+XW#]U[VS9'[ ZN+>F*%1
MH5F_=[&_[U?F6B\+HS>N%6=P):O-:L=ZCEKM*=/-LL4P)"F<JO%U*/@^A$%$
M$PS36SDNL0A\S-PH^AGM<8NX2*BL7R9F^J&.L VJ:K_01BAT3IF+EIUAC!48
MZ@4'KG%U2 &0ZP)*$CN#CDTB^LLM7>UKN[YP^V)JU]XP2H[Y,1JY9K#9_.:6
M0N(9?O2 (NU")*I0/4=SW2^7R=OA8QP<Z#K\KLA'BF'=1O>T#),P3<B6L.2=
MI^^N6QQ1P?E-GAKN&&]4E):83)(T<7#LWB\TV0)]E11Z3UG8!C/DC"T'S][K
M?:\7DHR(;6PX5M#U'ZKJ%AL6A2=E&CXAU\>4M(V.SGSST>LGT^#YV2#R#@>;
MZ[K9V25HPRDNL?=>,],7\&6FBK1#R R.L<:EN6JN?E11 CP+.;.$^'(V3_,E
M-U/2(QF@697*D@S!"@&U1= $.U3JYX8GN_?YOI "O7%?MM^-.8UU\Z(N$3,G
M7ZWZ51(JNH&#-$"H8/9Z6/Q,7!)J+>==34<D7 A#SY33$K(='-BN"8*(T%-J
M7ST)'%&,$]39( ];Y=Y)<%T>T5$I$9F"VM/1OBMP8803$/5XJ:VQU_P(TD67
MLOM*'77H+F4)7NH<:I[CS32M=CJASIKUH\ J>MQ8?,J)PJ;&F3 0K?$))%!0
M9' 89]BSND"@&4&$LZ5]S9(Q)4(MTGD!&T/H=7Q;=*BTY@NS;_$.X-6=%ZC>
ME1"S#&=)Y4)#??R=VST1$],*EF_")F0]VOD0XID;#VAJC$)W1-/K)@^F:TQX
M<<:+S UT%B-,IJ(?+BH*%%];WT]'NF:D8:'4)Q:JXEG./#5:_AOC*$WF)7A9
MP+02($R]!XZT1'=:RO YACFB<K]-P?E 89_1I5LSU'57 W**UL]U$<^G@G$-
M*XTN?=$K@9U5 C>;U@&'!R_62,G&'J>3MC."@LJ<1&C1T=9F[RRZAO-W+M8)
M?H_R+PUY_&X\[? _X_.X+;G]5MYFD GW4,6ZFBIZ_N(_].WJ9//6N_!OM(IA
MW+-SA/-1"ZMC4=%9#N-0DPF*JC3IKMM=3N(4O]8=AZ11-WHY-@A/3)%+U@#L
M2Y_&3X]>MKG@I#-?^X#^3LP#X9=-D]T)F;#:\J!^NUYQ<!,C9OP#KW%OX8$C
M-9S1\*W*Z:),<1(.3I&3.E*=65J?.)-^Y&_4TH17=EI/;%Q-F%Y;5DU81C,X
M.V;!DX-Y"]E@-VR375QKJ!8X[[ZBZ,2GC'-.YTX'R,/M=>*#?+=B985*TF!Y
MJPWKEOIP!!/&OS6GW'#TNJ>;-'B.OHVG)PK;TC8;S>V^4K\^+*,^:. 1E6@+
MF!^U.X!M84IKK]6M+WES6#E3*1IU*<J7;12T[$P[Z?I2F#;&#55F+,C8UELZ
MC=IHYVKK2;K(4[$E]P1VF MA<PA!^KX$K1K6\_V&0M:SD%M"0C79KNTW^ NE
M ?^CO-B/6:2R1B9JHV:T&SBJ[FRD8'S(";S@SH,3/TJ3F;FB+B^=0M_GK?N\
M=9^W;LM;/^OSUGW>NM/XM+:$>VA?POD9G1Z>RGG]P70BB:Z>_K>IYK\X-Z91
MP%%47-JDPZ^%NDY*I%#6%?S-HC&\D7FR26"L,+K,0<RI6:]"UM)AVZ??9[SY
MO"O>_%:LATM[E.EH\\"X;C$[.8KZJV#\!/:!JO%E#NKN.9DNQAZH55R[EBM8
M7 ^<,K\.E OF4FMU@UB?7X]LL0NM8UZ6VJ 6'127QS.EFYSEM9MWE.+CI_6X
MEX]X%O@O =]-\[<!EW%BY;%$T+YVU$E)'P^<:GRRIYVLJ%O'AD4;.K ),A%3
MIO_IWDU"*9Y+@E+P:SJQZ@2_NN(J28QLG+5B1:V[[[ZBD'FYTY5":M-N_^I*
MH7\B"X/LZ@U6"IVUR*K=\36ZCY8=']]12D5K"%Y'."DDSJTY*6K5D),HHXKA
MN%@.$%AC0JFN1V/ PU0Y[/DSYJO$+W#N#EG85B_%@@<(LR O,S;STI%[?91V
M-UVL=]*@,\?"FO$F.CH!S^^((GKEY$X'F+7#B*;I0\ORV[Z3NOU$E0\$593*
ML6HX.(;+P>HPZ9<Q;^QYGC'_T&'-"5 PZ:!%O2!ROTXT$8C4DK%Z#^]UK];H
ME0 ZP84.A9'BTK&PS##$OJE-@F1ZY4XQ_4'L5B&IFF,@1%=]K;EWX&"B<,-$
MVDDX=Y"H!%,9.-_P()K#,IA$]]#$VITAAF)D+"S0>B3C_7M9W';I^D*)VJ<&
M;7X/$<_6Y2*[@$F?Y5&:9]=T%E<$,<-1U/(\P=@?%E&/]S$A-EA5DL442'4\
MCQA_8B4,EUK:F4-*T^I\,^:D>Q9NCT3F-F\5;8NIM7EI6H$5+6+H6GCN=:R)
MK<*[+@X19-B,M3?G*QL ]M.X-J--0;S6Q)Y %$/I[3$9NS!/!@#+:>ZW;*OW
MCANX?!A.?'>LXC$:$25U]&03DX !L>!W/00J-XBJ<8AAMGQ*/8G439(ORG0I
M>>V*B5YQ7/;F. ?DK&.,M"SSLA96)7&EU#A]IV[=)FZ[;,1.-FW$/CMXOJ*A
M\0>M6\\IG^BV0/4]CXW8MI>9X;G0^JL.]F[:>R$ANG_S=]!6/,PB[V:K"2%D
MA; Y@UK")UB2Q^:N(5E;=4ZQ;BAUNBH0'5C=[PIC :"/VZ98/]S(*)\CD:>>
M52@Q9ME*&ITZ+1H?+VY2#8JVM'>0*714#_M9\C5@ RT@*->O-L>-GG@P36M0
M 1[:RKX6VY',.\E9@[I93:M,*:/(C'S8W2X3UD$*EB23%C"8TP$GF.+%-2EE
M43!6<22%_JWEJOSU\;[#>X,D5^!/D,GC;OR0O.IW@"_S\.6K]C>Q]\T7SL=9
MA"$]]5A2[*H2"0R%L!CM=0OU>*64P2O9_:%!R.Y33'450!<)J%__;+]%)FM*
MI!X=U?U1SRA0%;!/]X59-!P),$W=3+;9ZQEG)Z$3S^UK9 F<FBW]Z&4U[M[2
M%M:24B(#U31&5Q&=$L?G;9JS?4.Z.]@XUYNV<58'ZOZN^Y*^9K]HN9DX'0B%
M!FKHB)AU-P;:/#8 %1\5XV-<G&A.8_MV!\,T\:JA(V9X,+AZ<M/E@$B*X5\9
MQ200A)](X'TIJ2)Z-)9R8-Z7?#P,)S$/8'RM&/2:C -]0.-V%ZC#Z6P7D![(
MT ,9'CV0X7D/9-@](,-FL\=X%FSVW#XZ/7A^W'UNGUF*RP^N%X&6U1^PF&-C
M0;(+<.[0?N;4-(+BQ-I_C'3 ^X(AB0,Y3:\4 1R=7Y8[W:CV^]N \?;;@&9O
MX$M_+S4!__"1)!^:2)(SC239( DDV&77Q*_ VW7-IN'AZ'Z@O6[QQ5TFW)%H
MNU)CW4VW ?&W<66%91F^:$#*W5O96]3#VOP4\N*<\+.UAC&E%(\PU>;',5V"
M6V<@N'K:ZN48@:7(K&'/W>X=7FE6.%*U'S!][RO=PG$Y%QNEO0H/&!4LK1W&
MHT\8,4!%*$WK1^P?#Z3\QR'4HXX18X74 EZ6Q010/0BX=W>-.FBI0 P#=-RP
M"L/7F4:=@QO^Y$QBVTV!U)>72%GTXJ +A3ARBIIX35$P3@1;8=\&TV+GJ@YP
M&6TW+EJZSV'86$,KO ]#- F%\VA(%'I@ I$1DM-H#@=-%6WK\YWB5$K)N*6I
MM&,X.XVA4[P?;WLFV9G-DDI?AW0Q!<D8P@DHW%-_QQS7FN:WLFD$>&\K E;J
MJP'/2S#^NA8-'Y; X\E3UIO"0"W7G:J>( 6#+,RSZ4X36.*N=Q\1'I\S?CDG
MA L$ISGQP;D?\(J'29KP&^, ZIU7JN7&DV2\ .4.^F>\H,IYCH@ZZ0@.]?^V
M3Q$R7A/>!/9OW%2#^J["<:JLC&%(,-IYO.2%094QRXQB<0MN,M@Q>,[<93^&
M-U<M55!++3>*=VPCL#AT5)+ W6%'D)XXW^?M64_T=%1OZL_@.*'X2DQ\4##:
M";P+4@FZVH4_Q>AT!0L&,Q:D3T!%(^<.%W9B>%6H9Z\7R9@(SLM!K1K<BQ2%
M+W$W!W'FZ(HF@Q@1)28G-.Z%%D6U!IZ(-;FITEQ5]46))]KG+8.G #5L BX\
MW>W8ZG#'[.HWBR)+RFETK@IBK'I'6\[!>&_&BJ[M.-1K^AAFM6[]3#?HB@I!
MPQ4=.$38XB-)$7(S1;J[64RVOJ6.)&O&]*JTSO:Q'&E2DK5.ZA*&4P[JOR@H
MM><4)&A58!H@6CUG[A(M2FO&!.8)KU7/4T,?Y2XZ4U<W&MO4H5$L.RVCHTW+
M*-<GKP54ML*Z:9D\Z]#PGG"L S)F-Y/K0DO''>S*A!S=)QRY\T'?!G_L0BV_
M&'[<(XZW ''LOHAM!!S[&^5QXXW1@[]7>=KOP:I;#U;E>%><AJ&J^EL7Z(58
M&@0RZ;TPEH(<AJT-I&LP_,/VQ21& 4Q!$UBEAE$<4DDE^J:([^N&*NZT,;4#
M_:$^J#^M_.@R5M23;_/LZ<B :#=B5;W-';/*G,0F?]!I:+40GA)U3-P(0@T\
M[*5]J X%!S!L2GV2,H1Y&N-9'.8RH89%2>8.M GD;.0/)-1?,[VT\S>-$S-!
M+3K2O"_A3R=PZ(!&HW 4=B4QGAP3]_9,&CT I0>@M )07O0 E-T#H'S7D]VE
MII! .S<V)$0V<V[5,[=K*GEV;T"/3[GK ]I#4TK E$Y(;N!]S>4+\.THY=ZP
M]=8$=8M>GVM@WPKKDS,CZ_-J!#2"2];#+2>9,:$# .UM!BVWGXD[ 7\ZVGKX
MTV^&][J*SABT\7?=,OR=38!=.$4V/8#IP0*8_J8R56"7B<W$:]GAK6.'U@0*
M4><<4D3&X34Z<Y1GXX7.<O.G5N.9,Z+F 3NJV<"DVGX;@#RM.6PS6 UN0N"-
M#2$Z+5DX9N-VL^>:/3=$7:@JW_> 1(8BN_ B,H&LBS#BV%J]-1;F"QX"/V=Z
MFS5O[P=; D%8 <\0)8XP7TUS0J]@G=DMN91A#NW S4"!3.M-A6 Y:[Q$)LPT
M(>1%PUXXYG"Y?QMG7@.J;4M6QFH%!G"R'W!/F\^4;JI>%2B=^F0*(/K"-X<<
MH%6<AHPC4\KX4TO]G/B^=9(NCVE]R&]4?::&\#?<0)?QM35P4JY#4E8HPJ&I
M+Q0V&.V5^PLG6F#8<^?"AN^E4L5."R0J9YKT7:,S.GEL=5.8^HOSFC/YP(A
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M%B"0<?B.L88<.%.SRV&-6JH',D8TE4<ETJL$'+.Q7AHQ.R1K,Z)LDRZJTRQ
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MMQ+R*!?LAL9&.8DJ2<HZ?$7*G!]V^/JGK=_L']A4V$TC<] =@C:X*9@B\4[
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M,:[005;@D^LM0V MZMHR6F!>]#Z/G^^OB(;;HH@0E= \65;)^9V<RDZNQ :
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M<ON;UK\'IQX[I&],6<YE -&B5,TZT)6Z<!:7HP7>?!!-%*&#R![(%'C6X"^
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M..(==:4%^U.[/[7[4[OUU#X^[$_MX*G]EV$^7L)_IM4L_?7_ U!+ P04
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M&B<(."5'2BL_IPAOT[ $5R8/0R5P\4G5E=P4B\?':D)%:0N$FN.(-(X1*FP
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MA@,PSC?Q>T_UNP%?19PJ3QT>,VZ0-C+!A@X6RN9%.E59*FR"B$&O;X08T&$
MZ,H)>C8N"$^F4I0;WZ+8:=5S(,V/2YH]R8K?8AB76A0.#?1[8*V#Y.#W%"O$
M-$(4I/*IT5.@4"B7X^IU2UO)(Y@4VLP!2V>9"9I(/@$8 N>[Q(FMK3#PPI&<
M1=F?OK1\$.0.%S"<\[@MQWBW3XZCB_8P:C?"2:8M#W^L[IGZW-#K8JY[U8IZ
MWQ3<85CXG0.F#8ZD(5V?Q"M[T<GQ.6YC_MQX^&=]U[X\U>I^\G&F NVGA]2B
M-OPKUR'<QU==BC\Z_=V?X;M,02H^+.#T2P@(]VN2I]4C/7I+?C'3*O1]LP6$
M:RM7STX6QO$+K(/PEL84UDY3+GV \=1>-I$C=(32O]SD*=AHED=?.)M9?89C
MHF=\//5_4$L#!!0    ( #N "E?M<XI!:P0  !L0   7    97AH:6)I=#,R
M,5\R,#(S,#8S,"YH=&W=6&UOXD80_MY?,25J+I$,V :2@$DDCA UIS;D M&U
MGZK%N\;;,[N^W742^NL[N[9S)"2ZZ-1+>T4(8>9EG^?9F?&:86I6V<DP982>
M_##\L=F$4QD7*R8,Q(H1PR@4FHLE?*!,?X1FL_(:RWRM^#(U$/IA!SY(]9'?
MD-)NN,G829UGV"ZOAVVWR' AZ?ID2/D-<'K<X'&/= Z"(QKZ">V2;K??ZY,P
M"<EA/SA<Q*S[1]# 4'0O8[199^RXL>*BF3*[_N PS$UTRZE)!X'O_]1P?B?#
M1 J#BRD,+K^6.;8R&79GFB3C2S%P?!IE:&V.92;58,=WK\A:F@E9\6P]>#-2
MG&1O/$V$;FJF>%*:-?^+(1($Y2YO*Y08G7'!:M1!:*%.[E*^X 8Z82N AT W
MR1*U1+Y&YAB&>3<@QR@P4Z^*>3RYFI^?G8]'\_/I!5Q>7\VN1Q=SF$\A.(+K
MUJPU;L%L,G;6H-/SO>>)_;M$1C,8G4XOYY/3!RS^HVAK2?O^ 4S/8/[S!&:C
MJ[>CB\FL.?WME\GO,!K/K27T_?"K:NG/0AN>K+\1J^Z3K,X%Q%((%ALN!=QR
MDX))&;POB$*!LS5<L5PJ V@\DVH%@=]\#S*!4Z)V=\).)X*W7.J8,Q$S#\Y%
MW((]FV!WYR@,_6@L5SD1:W<51/N02.7R)US')(-/Y3+ !,4Y]ZX0;'<G./"C
M#A:M'6L>$(V^&1KOH<U87"AN.-- !(7)79P2L60X$%<KKK6E@6_K27%Z0LH4
M0[R;H$I*-2;/^1:(0&G<!48]F)&%XH+ KXBNB&,.[V0JM!0>7"JF.;7#V:X]
M3CE+$ $B,OR&P31)>(QT<#V;LR+O.0R+-: )]Q>!>Y 72A<$TQBYV;7E-I0:
ME*UK4F(\ZX4YX*.0MZ@%DMUFN+O3.XJ^F[+;"_9AC@2JZDJ*#$LM1KTRNZ_W
M>ZW8IX(K9N]BVJKZ2* ]L@]84$%OC^[7HF^4QWUIC&)CS4&_TT69^I';O.]&
MJK"4B@MLGA5Q?8HM:PAZ4OS5L:YU)-SV;(Y5:B7SK)ED&6 8LTA04)VCAMJK
MNE 0$=O?,2'E+K65!KV*K%1<YDRY-?6CJFZ]6,!75>L4F9:M,"J6N%M5J53S
M9!OS/X,M?!&V$LM+9.L]++OZ7&3((F.U^T(J'%E-A)R17+-!_26B7.<960^X
M<!!<4%0E7TACY,KEO['3"(=PM89;KC17A[E.O]7W._8\9_ 09VB]<'74:[FC
M7MO0;5O_"".?-_NMX-[6=KE5[5#KU75E@X'(2F.Y'3<ZC=HG)Y3B@7C@0^"\
M-O-\*2;,[VS4IK@92[;%D'GCJ;VIY M>KZC]LG"ZAY%VG\_>FQZ=LE^@255
MKDUS9"(S3J&F\%6"O9XB7U3A6]7$ZU%\T5'C?\1W+\<=C7F.=R-V3U.6-/>W
M>;;=7-N:Y$\\<6ZT<;5@#\=+E$OM[G@#Q3)B%]MZAOW<**[K_<\A9('=4ICG
M0Q[-"_]^8#S[1%Q]E@_G;?>GP-]02P,$%     @ .X *5T(SXSQ>!   #Q
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MASR:&N[=V'CV+;CZ+%_(V_8? 7\!4$L! A0#%     @ .X *5[Y ]BFE- $
MTI@, !$              ( !     &1A<F4M,C R,S V,S N:'1M4$L! A0#
M%     @ .X *5Z:QZ/:P#P  H9X  !$              ( !U#0! &1A<F4M
M,C R,S V,S N>'-D4$L! A0#%     @ .X *5XSG*]RE$   FI0  !4
M         ( !LT0! &1A<F4M,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M #N "E<7-:5U'$   -BX @ 5              "  8M5 0!D87)E+3(P,C,P
M-C,P7V1E9BYX;6Q02P$"% ,4    "  [@ I7-<<)2?Z@ 0!B_P$ %
M        @ ':E0$ 9&%R92TR,#(S,#8S,%]G,2YJ<&=02P$"% ,4    "  [
M@ I7RZ+1EH>G  !L!@< %0              @ $*-P, 9&%R92TR,#(S,#8S
M,%]L86(N>&UL4$L! A0#%     @ .X *5S.N_#,98P  \E<$ !4
M     ( !Q-X# &1A<F4M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    ( #N
M"E=O\(6:$V   #IQ P 0              "  1!"! !E>#,Q7V)Y+6QA=W,N
M:'1M4$L! A0#%     @ .X *5RY9S]GW!P  F3L  !<              ( !
M4:($ &5X:&EB:70S,3%?,C R,S V,S N:'1M4$L! A0#%     @ .X *5ZB[
M9T/9!P  I3H  !<              ( !?:H$ &5X:&EB:70S,3)?,C R,S V
M,S N:'1M4$L! A0#%     @ .X *5^USBD%K!   &Q   !<
M ( !B[($ &5X:&EB:70S,C%?,C R,S V,S N:'1M4$L! A0#%     @ .X *
M5T(SXSQ>!   #Q   !<              ( !*[<$ &5X:&EB:70S,C)?,C R
?,S V,S N:'1M4$L%!@     ,  P '@,  +Z[!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
